Company Name,Company Description,Logo Path,Original Link,Country,Founded,Industry,Sector,Employees,CEO,Address,Phone,Website,Ticker Symbol,Exchange,Fiscal Year,Reporting Currency,CIK Code,CUSIP Number,ISIN Number,SIC Code,IPO Date,Stock Type,Employer ID,IPO Price,Share Class
Haleon plc,"Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues.
The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.",Data/company_logos_stock_analysis\Haleon_plc_logo.svg,https://stockanalysis.com/stocks/hln/,United Kingdom,2022,Drug Manufacturers - Specialty & Generic,Healthcare,"25,408",Brian McNamara,"The Heights, Building 5, First Floor
Weybridge, KT13 0NY
United Kingdom",44 1932 822000,haleon.com,HLN,NYSE,January - December,GBP,0001900304,405552100,US4055521003,2844,,,,,
Zoetis Inc.,"Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally.
The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives.
In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health.
It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health.
Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.",Data/company_logos_stock_analysis\Zoetis_Inc._logo.svg,https://stockanalysis.com/stocks/zts/,United States,1952,Drug Manufacturers - Specialty & Generic,Healthcare,"14,100",Kristin Peck,"10 Sylvan Way
Parsippany, New Jersey 07054
United States",973 822 7000,zoetis.com,ZTS,NYSE,January - December,USD,0001555280,98978V103,US98978V1035,2834,"Feb 1, 2013",Common Stock,46-0696167,,
Vertex Pharmaceuticals Incorporated,"Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial.
Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics.
Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy.
Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.",Data/company_logos_stock_analysis\Vertex_Pharmaceuticals_Incorporated_logo.svg,https://stockanalysis.com/stocks/vrtx/,United States,1989,Biotechnology,Healthcare,"5,400",Reshma Kewalramani,"50 Northern Avenue
Boston, Massachusetts 02210
United States",617 341 6100,vrtx.com,VRTX,NASDAQ,January - December,USD,0000875320,92532F100,US92532F1003,2834,"Jul 24, 1991",,04-3039129,,
BioNTech SE,"BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.
The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors.
It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases.
It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa’s mrna vaccine ecosystem.
BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.",Data/company_logos_stock_analysis\BioNTech_SE_logo.svg,https://stockanalysis.com/stocks/bntx/,Germany,2008,Biotechnology,Healthcare,"6,133",Ugur Sahin,"An der Goldgrube 12
Mainz, 55131
Germany",49 6131 9084 0,biontech.de,BNTX,NASDAQ,January - December,EUR,0001776985,09075V102,US09075V1026,2836,"Oct 10, 2019",,,$15.00,
"BeiGene, Ltd.","BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors.
The company’s clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK‑targeting chimeric degradation activation compound active against wild‑type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor.
It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.","Data/company_logos_stock_analysis\BeiGene,_Ltd._logo.svg",https://stockanalysis.com/stocks/onc/,Cayman Islands,2010,Biotechnology,Healthcare,"10,600",John Oyler,"94 Solaris Avenue
Camana Bay, KY1-1108
Cayman Islands",345-949-4123,beigene.com,ONC,NASDAQ,January - December,CNY,0001651308,,,2834,,,98-1209416,,
Takeda Pharmaceutical Company Limited,"Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.
It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr.
Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr.
Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences.
The company was founded in 1781 and is headquartered in Tokyo, Japan.",Data/company_logos_stock_analysis\Takeda_Pharmaceutical_Company_Limited_logo.svg,https://stockanalysis.com/stocks/tak/,Japan,1781,Drug Manufacturers - Specialty & Generic,Healthcare,"49,281",Christophe Weber,"1-1, Nihonbashi-Honcho 2-chome, Chuo-ku
Tokyo, 103-8668
Japan",81 3 3278-2111,takeda.com,TAK,NYSE,April - March,JPY,0001395064,874060205,US8740602052,2834,,,,,
argenx SE,"argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.
It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH.
It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services.
argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.",Data/company_logos_stock_analysis\argenx_SE_logo.svg,https://stockanalysis.com/stocks/argx/,Netherlands,2008,Biotechnology,Healthcare,"1,148",Timothy Van Hauwermeiren,"Laarderhoogtweg 25
Amsterdam, 1101EB
Netherlands",31 10 703 8441,argenx.com,ARGX,NASDAQ,January - December,USD,0001697862,04016X101,NL0010832176,2836,"May 18, 2017",,,,
Teva Pharmaceutical Industries Limited,"Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.
The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM.
In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder.
The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names.
It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH.
The company was founded in 1901 and is based in Tel Aviv, Israel.",Data/company_logos_stock_analysis\Teva_Pharmaceutical_Industries_Limited_logo.svg,https://stockanalysis.com/stocks/teva/,Israel,1901,Drug Manufacturers - Specialty & Generic,Healthcare,"37,851",Richard Francis,"124 Dvora HaNevi’a Street
Tel Aviv, 6944020
Israel",972 3 914 8213,tevapharm.com,TEVA,NYSE,January - December,USD,0000818686,881624209,US8816242098,2834,,,,,
"Alnylam Pharmaceuticals, Inc.","Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.
Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial.
Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran.
It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Alnylam_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/alny/,United States,2002,Biotechnology,Healthcare,"2,100",Yvonne Greenstreet,"675 West Kendall Street, Henri A. Termeer Square
Cambridge, Massachusetts 02142
United States",617 551 8200,alnylam.com,ALNY,NASDAQ,January - December,USD,0001178670,02043Q107,US02043Q1076,2834,"May 28, 2004",Common Stock,77-0602661,,
"Regeneron Pharmaceuticals, Inc.","Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.
It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies.
The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","Data/company_logos_stock_analysis\Regeneron_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/regn/,United States,1988,Biotechnology,Healthcare,"13,450",Leonard Schleifer,"777 Old Saw Mill River Road
Tarrytown, New York 10591-6707
United States",914 847 7000,regeneron.com,REGN,NASDAQ,January - December,USD,0000872589,75886F107,US75886F1075,2834,"Apr 2, 1991",Common Stock,13-3444607,,
Royalty Pharma plc,"Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies.
In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes.
The company was founded in 1996 and is based in New York, New York.",Data/company_logos_stock_analysis\Royalty_Pharma_plc_logo.svg,https://stockanalysis.com/stocks/rprx/,United States,1996,Biotechnology,Healthcare,89,Pablo Legorreta,"110 East 59th Street
New York, New York 10022
United States",212 883 0200,royaltypharma.com,RPRX,NASDAQ,January - December,USD,0001802768,G7709Q104,GB00BMVP7Y09,2834,"Jun 16, 2020",,,$28.00,Class A Shares
United Therapeutics Corporation,"United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products.
It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag.
The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.",Data/company_logos_stock_analysis\United_Therapeutics_Corporation_logo.svg,https://stockanalysis.com/stocks/uthr/,United States,1996,Biotechnology,Healthcare,"1,168",Martine Rothblatt,"1000 Spring Street
Silver Spring, Maryland 20910
United States",301 608 9292,unither.com,UTHR,NASDAQ,January - December,USD,0001082554,91307C102,US91307C1027,2834,"Jun 17, 1999",,52-1984749,,
"Moderna, Inc.","Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Moderna,_Inc._logo.svg",https://stockanalysis.com/stocks/mrna/,United States,2010,Biotechnology,Healthcare,"5,600",Stephane Bancel,"200 Technology Square
Cambridge, Massachusetts 02139
United States",617 714 6500,modernatx.com,MRNA,NASDAQ,January - December,USD,0001682852,60770K107,US60770K1079,2836,"Dec 7, 2018",Common Stock,81-3467528,,
Genmab A/S,"Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.
In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease.
It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.
It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S.
Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.",,https://stockanalysis.com/stocks/gmab/,Denmark,1999,Biotechnology,Healthcare,"2,204",Jan G.J. de Winkel,"Carl Jacobsens Vej 30, Valby
Copenhagen, 2500
Denmark",45 70 20 27 28,genmab.com,GMAB,NASDAQ,January - December,DKK,0001434265,372303206,US3723032062,2834,,,,,
"Neurocrine Biosciences, Inc.","Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications.
The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Neurocrine_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/nbix/,United States,1992,Drug Manufacturers - Specialty & Generic,Healthcare,"1,400",Kyle Gano,"12780 El Camino Real
San Diego, California 92130
United States",858 617 7600,neurocrine.com,NBIX,NASDAQ,January - December,USD,0000914475,64125C109,US64125C1099,2836,"May 23, 1996",Common Stock,33-0525145,,
Viatris Inc.,"Viatris Inc. operates as a healthcare company worldwide.
The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.
It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions.
The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.
It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names.
The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.",Data/company_logos_stock_analysis\Viatris_Inc._logo.svg,https://stockanalysis.com/stocks/vtrs/,United States,1961,Drug Manufacturers - Specialty & Generic,Healthcare,"38,000",Scott Smith,"1000 Mylan Boulevard
Canonsburg, Pennsylvania 15317
United States",724 514 1800,viatris.com,VTRS,NASDAQ,January - December,USD,0001792044,92556V106,US92556V1061,2834,,Common Stock,83-4364296,,
Incyte Corporation,"Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.
The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors.
The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460.
It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib.
The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers.
The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003.
Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.",Data/company_logos_stock_analysis\Incyte_Corporation_logo.svg,https://stockanalysis.com/stocks/incy/,United States,1991,Biotechnology,Healthcare,"2,524",Herve Hoppenot,"1801 Augustine Cut-Off
Wilmington, Delaware 19803
United States",302 498 6700,incyte.com,INCY,NASDAQ,January - December,USD,0000879169,45337C102,US45337C1027,8731,"Nov 4, 1993",,94-3136539,,
Summit Therapeutics Inc.,"Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom.
The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab.
The company was founded in 2003 and is headquartered in Miami, Florida.",Data/company_logos_stock_analysis\Summit_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/smmt/,United States,2003,Biotechnology,Healthcare,105,Robert W. Duggan,"601 Brickell Key Drive, Suite 1000
Miami, Florida 33131
United States",650 460 8308,summittxinc.com,SMMT,NASDAQ,January - December,USD,0001599298,86627T108,US86627T1088,2834,,,37-1979717,,
Dr. Reddy's Laboratories Limited,"Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.
It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments.
The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products.
This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements.
The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services.
The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology.
Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.",Data/company_logos_stock_analysis\Dr._Reddy's_Laboratories_Limited_logo.svg,https://stockanalysis.com/stocks/rdy/,India,1984,Drug Manufacturers - Specialty & Generic,Healthcare,"27,048",Erez Israeli,"8-2-337, Road No. 3, Banjara Hills
Hyderabad, 500034
India",91 40 4900 2900,drreddys.com,RDY,NYSE,April - March,INR,0001135951,256135203,US2561352038,2834,,,,,
BioMarin Pharmaceutical Inc.,"BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions.
Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A.
The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally.
It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation.
The company was incorporated in 1996 and is headquartered in San Rafael, California.",Data/company_logos_stock_analysis\BioMarin_Pharmaceutical_Inc._logo.svg,https://stockanalysis.com/stocks/bmrn/,United States,1996,Biotechnology,Healthcare,"3,401",Alexander Hardy,"770 Lindaro Street
San Rafael, California 94901
United States",415 506 6700,biomarin.com,BMRN,NASDAQ,January - December,USD,0001048477,09061G101,US09061G1013,2834,"Jul 23, 1999",Common Stock,68-0397820,,
"Sarepta Therapeutics, Inc.","Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio.
The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Sarepta_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/srpt/,United States,1980,Biotechnology,Healthcare,"1,314",Douglas Ingram,"215 First Street, Suite 415
Cambridge, Massachusetts 02142
United States",617 274 4000,sarepta.com,SRPT,NASDAQ,January - December,USD,0000873303,803607100,US8036071004,2834,"Jun 3, 1997",Common Stock,93-0797222,,
Bio-Techne Corporation,"Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.
The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications.
The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease.
The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.
Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.",Data/company_logos_stock_analysis\Bio-Techne_Corporation_logo.svg,https://stockanalysis.com/stocks/tech/,United States,1976,Biotechnology,Healthcare,"3,050",Kim Kelderman,"614 McKinley Place N.E.
Minneapolis, Minnesota 55413
United States",612 379 8854,bio-techne.com,TECH,NASDAQ,July - June,USD,0000842023,09073M104,US09073M1045,2836,"Feb 9, 1989",Common Stock,41-1427402,,
Insmed Incorporated,"Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.
The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.",Data/company_logos_stock_analysis\Insmed_Incorporated_logo.svg,https://stockanalysis.com/stocks/insm/,United States,1988,Biotechnology,Healthcare,912,William Lewis,"700 US Highway 202/206
Bridgewater, New Jersey 08807
United States",908 977 9900,insmed.com,INSM,NASDAQ,January - December,USD,0001104506,457669307,US4576693075,2834,"Jun 1, 2000",Common Stock,54-1972729,,
"Intra-Cellular Therapies, Inc.","Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications.
In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson’s disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders.
Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.","Data/company_logos_stock_analysis\Intra-Cellular_Therapies,_Inc._logo.svg",https://stockanalysis.com/stocks/itci/,United States,2002,Drug Manufacturers - Specialty & Generic,Healthcare,610,Sharon Mates,"430 East 29th Street
New York, New York 10016
United States",646 440 9333,intracellulartherapies.com,ITCI,NASDAQ,January - December,USD,0001567514,46116X101,US46116X1019,2834,,Common Stock,36-4742850,,
"Vaxcyte, Inc.","Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases.
Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease.
The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020.
Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.","Data/company_logos_stock_analysis\Vaxcyte,_Inc._logo.svg",https://stockanalysis.com/stocks/pcvx/,United States,2013,Biotechnology,Healthcare,254,Grant Pickering,"825 Industrial Road, Suite 300
San Carlos, California 94070
United States",650 837 0111,vaxcyte.com,PCVX,NASDAQ,January - December,USD,0001649094,92243G108,US92243G1085,2836,"Jun 12, 2020",Common Stock,46-4233385,$16.00,
Roivant Sciences Ltd.,"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.
The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases.
The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform.
It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis.
The company was founded in 2014 and is based in London, the United Kingdom.",Data/company_logos_stock_analysis\Roivant_Sciences_Ltd._logo.svg,https://stockanalysis.com/stocks/roiv/,United Kingdom,2014,Biotechnology,Healthcare,908,Matthew Gline,"50 Broadway, 7th Floor
London, SW1H 0DB
United Kingdom",44 20 7400 3347,roivant.com,ROIV,NASDAQ,April - March,USD,0001635088,G76279101,BMG762791017,2834,,,98-1173944,,
"Revolution Medicines, Inc.","Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets.
The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial.
Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.","Data/company_logos_stock_analysis\Revolution_Medicines,_Inc._logo.svg",https://stockanalysis.com/stocks/rvmd/,United States,2014,Biotechnology,Healthcare,378,Mark Goldsmith,"700 Saginaw Drive
Redwood City, California 94063
United States",650 481 6801,revmed.com,RVMD,NASDAQ,January - December,USD,0001628171,76155X100,US76155X1000,2836,"Feb 13, 2020",Common Stock,47-2029180,$17.00,
Ascendis Pharma A/S,"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs.
It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.",,https://stockanalysis.com/stocks/asnd/,Denmark,2006,Biotechnology,Healthcare,879,Jan Mikkelsen,"Tuborg Boulevard 12
Hellerup, 2900
Denmark",45 70 22 22 44,ascendispharma.com,ASND,NASDAQ,January - December,EUR,0001612042,04351P101,US04351P1012,2834,"Jan 28, 2015",,,,
"Madrigal Pharmaceuticals, Inc.","Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.
Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
The company is headquartered in West Conshohocken, Pennsylvania.","Data/company_logos_stock_analysis\Madrigal_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/mdgl/,United States,2011,Biotechnology,Healthcare,376,William Sibold,"Four Tower Bridge, Suite 200
West Conshohocken, Pennsylvania 19428
United States",267 824 2827,madrigalpharma.com,MDGL,NASDAQ,January - December,USD,0001157601,558868105,US5588681057,2834,,Common Stock,,,
"Exelixis, Inc.","Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.
It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload.
It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F.
Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V.
and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000.
Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.","Data/company_logos_stock_analysis\Exelixis,_Inc._logo.svg",https://stockanalysis.com/stocks/exel/,United States,1994,Biotechnology,Healthcare,"1,310",Michael Morrissey,"1851 Harbor Bay Parkway
Alameda, California 94502
United States",650 837 7000,exelixis.com,EXEL,NASDAQ,January - December,USD,0000939767,30161Q104,US30161Q1040,2836,"Apr 7, 2000",Common Stock,04-3257395,,
Jazz Pharmaceuticals plc,"Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally.
The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders.
The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders.
The company was incorporated in 2003 and is headquartered in Dublin, Ireland.",Data/company_logos_stock_analysis\Jazz_Pharmaceuticals_plc_logo.svg,https://stockanalysis.com/stocks/jazz/,Ireland,2003,Biotechnology,Healthcare,"2,800",Bruce Cozadd,"Waterloo Exchange, Fifth Floor
Dublin, D04 E5W7
Ireland",353 1 634 7800,jazzpharma.com,JAZZ,NASDAQ,January - December,USD,0001232524,G50871105,IE00B4Q5ZN47,2834,"Jun 1, 2007",Common Stock,98-1032470,,
"Halozyme Therapeutics, Inc.","Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.
The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma.
In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis.
Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy.
Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Halozyme_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/halo/,United States,1998,Biotechnology,Healthcare,373,Helen Torley,"12390 El Camino Real
San Diego, California 92130
United States",858 794 8889,halozyme.com,HALO,NASDAQ,January - December,USD,0001159036,40637H109,US40637H1095,2836,,Common Stock,88-0488686,,
"Lantheus Holdings, Inc.","Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer.
In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;.
It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC.
The company was founded in 1956 and is based in Bedford, Massachusetts.","Data/company_logos_stock_analysis\Lantheus_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/lnth/,United States,1956,Drug Manufacturers - Specialty & Generic,Healthcare,834,Brian Markison,"201 Burlington Road, South Building
Bedford, Massachusetts 01730
United States",978 671 8001,lantheus.com,LNTH,NASDAQ,January - December,USD,0001521036,516544103,US5165441032,2835,"Jun 25, 2015",Common Stock,35-2318913,,
Legend Biotech Corporation,"Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.
Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.
It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel.
The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.",Data/company_logos_stock_analysis\Legend_Biotech_Corporation_logo.svg,https://stockanalysis.com/stocks/legn/,United States,2014,Biotechnology,Healthcare,"1,826",Ying Huang,"2101 Cottontail Lane
Somerset, New Jersey 08873
United States",732 317 5050,legendbiotech.com,LEGN,NASDAQ,January - December,USD,0001801198,52490G102,US52490G1022,2834,"Jun 5, 2020",,,$23.00,
Blueprint Medicines Corporation,"Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.
The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.
In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers.
It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011.
Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Blueprint_Medicines_Corporation_logo.svg,https://stockanalysis.com/stocks/bpmc/,United States,2008,Biotechnology,Healthcare,655,Kathryn Haviland,"45 Sidney Street
Cambridge, Massachusetts 02139
United States",617 374 7580,blueprintmedicines.com,BPMC,NASDAQ,January - December,USD,0001597264,09627Y109,US09627Y1091,2834,"Apr 30, 2015",Common Stock,,,
Elanco Animal Health Incorporated,"Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals.
It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations.
Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.",Data/company_logos_stock_analysis\Elanco_Animal_Health_Incorporated_logo.svg,https://stockanalysis.com/stocks/elan/,United States,1954,Drug Manufacturers - Specialty & Generic,Healthcare,"9,800",Jeffrey Simmons,"2500 Innovation Way
Greenfield, Indiana 46140
United States",877 352 6261,elanco.com,ELAN,NYSE,January - December,USD,0001739104,28414H103,US28414H1032,2834,"Sep 20, 2018",Common Stock,82-5497352,,
"Cytokinetics, Incorporated","Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.
It develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
The company’s drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy.
The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy.
Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Cytokinetics,_Incorporated_logo.svg",https://stockanalysis.com/stocks/cytk/,United States,1997,Biotechnology,Healthcare,423,Robert Blum,"350 Oyster Point Boulevard
South San Francisco, California 94080
United States",650 624 3000,cytokinetics.com,CYTK,NASDAQ,January - December,USD,0001061983,23282W605,US23282W6057,2834,"Apr 29, 2004",Common Stock,94-3291317,,
"BridgeBio Pharma, Inc.","BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.","Data/company_logos_stock_analysis\BridgeBio_Pharma,_Inc._logo.svg",https://stockanalysis.com/stocks/bbio/,United States,2015,Biotechnology,Healthcare,556,Neil Kumar,"3160 Porter Drive, Suite 250
Palo Alto, California 94304
United States",650 391 9740,bridgebio.com,BBIO,NASDAQ,January - December,USD,0001743881,10806X102,US10806X1028,2834,"Jun 27, 2019",Common Stock,,$17.00,
"Nuvalent, Inc.","Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.
The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Nuvalent,_Inc._logo.svg",https://stockanalysis.com/stocks/nuvl/,United States,2017,Biotechnology,Healthcare,92,James Porter,"One Broadway, 14th Floor
Cambridge, Massachusetts 02142
United States",857 357 7000,nuvalent.com,NUVL,NASDAQ,January - December,USD,0001861560,670703107,US6707031075,2834,"Jul 29, 2021",Common Stock,,$17.00,Class A Shares
"Ionis Pharmaceuticals, Inc.","Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus.
In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2.
It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics.
The company was incorporated in 1989 and is based in Carlsbad, California.","Data/company_logos_stock_analysis\Ionis_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/ions/,United States,1989,Biotechnology,Healthcare,927,Brett Monia,"2855 Gazelle Court
Carlsbad, California 92010
United States",760 931 9200,ionispharma.com,IONS,NASDAQ,January - December,USD,0000874015,462222100,US4622221004,2834,"May 17, 1991",Common Stock,33-0336973,,
Alkermes plc,"Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder.
It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.
The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.
Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.",Data/company_logos_stock_analysis\Alkermes_plc_logo.svg,https://stockanalysis.com/stocks/alks/,Ireland,1987,Drug Manufacturers - Specialty & Generic,Healthcare,"2,100",Richard Pops,"Connaught House, 1 Burlington Road
Dublin, D04 C5Y6
Ireland",353 1 772 8000,alkermes.com,ALKS,NASDAQ,January - December,USD,0001520262,G01767105,IE00B56GVS15,2834,"Jul 16, 1991",,98-1007018,,
"Krystal Biotech, Inc.","Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States.
It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.","Data/company_logos_stock_analysis\Krystal_Biotech,_Inc._logo.svg",https://stockanalysis.com/stocks/krys/,United States,2015,Biotechnology,Healthcare,229,Krish Krishnan,"2100 Wharton Street, Suite 701
Pittsburgh, Pennsylvania 15203
United States",412 586 5830,krystalbio.com,KRYS,NASDAQ,January - December,USD,0001711279,501147102,US5011471027,2836,"Sep 20, 2017",Common Stock,82-1080209,,
"ADMA Biologics, Inc.","ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S.
pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities.
The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.
ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.","Data/company_logos_stock_analysis\ADMA_Biologics,_Inc._logo.svg",https://stockanalysis.com/stocks/adma/,United States,2004,Biotechnology,Healthcare,624,Adam Grossman,"465 State Route 17
Ramsey, New Jersey 07446
United States",201 478 5552,admabiologics.com,ADMA,NASDAQ,January - December,USD,0001368514,000899104,US0008991046,2836,,Common Stock,56-2590442,,
"Viking Therapeutics, Inc.","Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
The company was incorporated in 2012 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Viking_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/vktx/,United States,2012,Biotechnology,Healthcare,27,Brian Lian,"9920 Pacific Heights Boulevard, Suite 350
San Diego, California 92121
United States",858 704 4660,vikingtherapeutics.com,VKTX,NASDAQ,January - December,USD,0001607678,92686J106,US92686J1060,2834,"Apr 29, 2015",Common Stock,46-1073877,,
"TG Therapeutics, Inc.","TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A.
for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies.
TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.","Data/company_logos_stock_analysis\TG_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/tgtx/,United States,1993,Biotechnology,Healthcare,264,Michael Weiss,"3020 Carrington Mill Blvd., Suite 475
Morrisville, North Carolina 27560
United States",212 554 4484,tgtherapeutics.com,TGTX,NASDAQ,January - December,USD,0001001316,88322Q108,US88322Q1085,2834,"Dec 14, 1995",Common Stock,36-3898269,,
Alvotech,"Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product.
Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.",Data/company_logos_stock_analysis\Alvotech_logo.svg,https://stockanalysis.com/stocks/alvo/,Luxembourg,2013,Drug Manufacturers - Specialty & Generic,Healthcare,999,Robert Wessman,"9, Rue de Bitbourg
Luxembourg City, 1273
Luxembourg",,alvotech.com,ALVO,NASDAQ,January - December,USD,0001898416,L01800108,LU2458332611,2836,,,98-1629342,,
Ultragenyx Pharmaceutical Inc.,"Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally.
Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
The company’s products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.
Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.",Data/company_logos_stock_analysis\Ultragenyx_Pharmaceutical_Inc._logo.svg,https://stockanalysis.com/stocks/rare/,United States,2010,Biotechnology,Healthcare,"1,276",Emil Kakkis,"60 Leveroni Court
Novato, California 94949
United States",415 483 8800,ultragenyx.com,RARE,NASDAQ,January - December,USD,0001515673,90400D108,US90400D1081,2834,"Jan 31, 2014",Common Stock,27-2546083,,
Corcept Therapeutics Incorporated,"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing’s syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.
In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial.
The company was incorporated in 1998 and is headquartered in Menlo Park, California.",Data/company_logos_stock_analysis\Corcept_Therapeutics_Incorporated_logo.svg,https://stockanalysis.com/stocks/cort/,United States,1998,Biotechnology,Healthcare,352,Joseph Belanoff,"149 Commonwealth Drive
Menlo Park, California 94025
United States",650 327 3270,corcept.com,CORT,NASDAQ,January - December,USD,0001088856,218352102,US2183521028,2834,,Common Stock,77-0487658,,
"Axsome Therapeutics, Inc.","Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder.
Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation.
The company was incorporated in 2012 and is based in New York, New York.","Data/company_logos_stock_analysis\Axsome_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/axsm/,United States,2012,Biotechnology,Healthcare,545,Herriot Tabuteau,"One World Trade Center, 22nd Floor
New York, New York 10007
United States",212 332 3241,axsome.com,AXSM,NASDAQ,January - December,USD,0001579428,05464T104,US05464T1043,2834,"Nov 19, 2015",Common Stock,45-4241907,,
"Crinetics Pharmaceuticals, Inc.","Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
The company’s lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.
It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing’s disease.
In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves’ disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity.
Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Crinetics_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/crnx/,United States,2008,Biotechnology,Healthcare,290,R. Struthers,"6055 Lusk Boulevard
San Diego, California 92121
United States",858 450 6464,crinetics.com,CRNX,NASDAQ,January - December,USD,0001658247,22663K107,US22663K1079,2834,"Jul 18, 2018",Common Stock,26-3744114,,
Scholar Rock Holding Corporation,"Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia.
Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Scholar_Rock_Holding_Corporation_logo.svg,https://stockanalysis.com/stocks/srrk/,United States,2012,Biotechnology,Healthcare,150,Jay Backstrom,"301 Binney Street, 3rd Floor
Cambridge, Massachusetts 02142
United States",857 259 3860,scholarrock.com,SRRK,NASDAQ,January - December,USD,0001727196,80706P103,US80706P1030,2836,"May 24, 2018",Common Stock,82-3750435,,
"Arcellx, Inc.","Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
In addition, the company’s preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs.
It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel.
The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016.
Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.","Data/company_logos_stock_analysis\Arcellx,_Inc._logo.svg",https://stockanalysis.com/stocks/aclx/,United States,2015,Biotechnology,Healthcare,130,Rami Elghandour,"800 Bridge Parkway
Redwood City, California 94065
United States",240 327 0603,arcellx.com,ACLX,NASDAQ,January - December,USD,0001786205,03940C100,US03940C1009,2836,"Feb 4, 2022",,47-2855917,$15.00,
Biohaven Ltd.,"Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide.
The company’s pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson’s disease, sclerosis, and amyloid-related imaging abnormalities.
It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy.
In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin’s lymphoma.
It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022.
Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.",Data/company_logos_stock_analysis\Biohaven_Ltd._logo.svg,https://stockanalysis.com/stocks/bhvn/,United States,2013,Biotechnology,Healthcare,239,Vladimir Coric,"215 Church Street
New Haven, Connecticut 06510
United States",203 404 0410,biohaven.com,BHVN,NYSE,January - December,USD,0001935979,G11196105,VGG1110E1079,2834,"May 4, 2017",,,,
Prestige Consumer Healthcare Inc.,"Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally.
The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
It offers analgesic powders under the BC and Goody's brand; diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and Debrox for ear wax removal.
The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; Dramamine for motion sickness relief; enemas and other laxative products under the Fleet brand name; Gaviscon for upset stomach; cough drops under the Luden's brand; Monistat for yeast infections in women; Nix for lice and parasite treatments; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; TheraTears for dry eyes; nasal saline sprays and washes under the Fess brand name; and Hydralyte for oral rehydration.
It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels.
The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018.
Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.",Data/company_logos_stock_analysis\Prestige_Consumer_Healthcare_Inc._logo.svg,https://stockanalysis.com/stocks/pbh/,United States,1996,Drug Manufacturers - Specialty & Generic,Healthcare,570,Ronald Lombardi,"660 White Plains Road, Suite 250
Tarrytown, New York 10591
United States",914 524 6800,prestigebrands.com,PBH,NYSE,April - March,USD,0001295947,74112D101,US74112D1019,2834,"Feb 10, 2005",Common Stock,20-1297589,,
"Rhythm Pharmaceuticals, Inc.","Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders.
The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.
Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Rhythm_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/rytm/,United States,2008,Biotechnology,Healthcare,226,David Meeker,"222 Berkeley Street, 12th Floor
Boston, Massachusetts 02116
United States",857 264 4280,rhythmtx.com,RYTM,NASDAQ,January - December,USD,0001649904,76243J105,US76243J1051,2834,"Oct 5, 2017",Common Stock,46-2159271,,
"Avidity Biosciences, Inc.","Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics.
It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics.
The company’s lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.
Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial.
The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Avidity_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/rna/,United States,2012,Biotechnology,Healthcare,253,Sarah Boyce,"10578 Science Center Drive, Suite 125
San Diego, California 92121
United States",858 401 7900,aviditybiosciences.com,RNA,NASDAQ,January - December,USD,0001574111,05370A108,US05370A1088,2834,"Jun 12, 2020",Common Stock,,$18.00,
Verona Pharma plc,"Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.
The company’s product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler.
Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.",Data/company_logos_stock_analysis\Verona_Pharma_plc_logo.svg,https://stockanalysis.com/stocks/vrna/,United Kingdom,2005,Biotechnology,Healthcare,79,David Zaccardelli,"3 More London Riverside
London, SE1 2RE
United Kingdom",44 20 3283 4200,veronapharma.com,VRNA,NASDAQ,January - December,USD,0001657312,925050106,US9250501064,2834,"Apr 27, 2017",,,,
"Immunovant, Inc.","Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia.
Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","Data/company_logos_stock_analysis\Immunovant,_Inc._logo.svg",https://stockanalysis.com/stocks/imvt/,United States,,Biotechnology,Healthcare,207,Peter Salzmann,"320 West 37th Street, 6th Floor
New York, New York 10018
United States",(917) 580-3099,immunovant.com,IMVT,NASDAQ,April - March,USD,0001764013,45258J102,US45258J1025,2836,,,83-2771572,,
"Apellis Pharmaceuticals, Inc.","Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development.
It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases.
The company was incorporated in 2009 and is based in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Apellis_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/apls/,United States,2009,Biotechnology,Healthcare,706,Cedric Francois,"100 Fifth Avenue
Waltham, Massachusetts 02451
United States",617 977 5700,apellis.com,APLS,NASDAQ,January - December,USD,0001492422,03753U106,US03753U1060,2834,"Nov 9, 2017",Common Stock,27-1537290,,
"PTC Therapeutics, Inc.","PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally.
The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis.
The company distributes its products through third-party distributors. It has collaborations with F.
Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program.
PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.","Data/company_logos_stock_analysis\PTC_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ptct/,United States,1998,Biotechnology,Healthcare,"1,055",Matthew Klein,"100 Corporate Court
South Plainfield, New Jersey 07080
United States",908 222 7000,ptcbio.com,PTCT,NASDAQ,January - December,USD,0001070081,69366J200,US69366J2006,2834,"Jun 20, 2013",Common Stock,04-3416587,,
CRISPR Therapeutics AG,"CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA.
The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.
The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells.
It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D.
It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics.
CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.",Data/company_logos_stock_analysis\CRISPR_Therapeutics_AG_logo.svg,https://stockanalysis.com/stocks/crsp/,Switzerland,2013,Biotechnology,Healthcare,407,Samarth Kulkarni,"Baarerstrasse 14
Zug, 6300
Switzerland",41 41 561 32 77,crisprtx.com,CRSP,NASDAQ,January - December,USD,0001674416,H17182108,CH0334081137,2836,"Oct 19, 2016",,47-3173478,,
Perrigo Company plc,"Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products.
The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands.
It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies.
The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013.
Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.",Data/company_logos_stock_analysis\Perrigo_Company_plc_logo.svg,https://stockanalysis.com/stocks/prgo/,Ireland,1887,Drug Manufacturers - Specialty & Generic,Healthcare,"9,140",Patrick Lockwood-Taylor,"The Sharp Building, Hogan Place
Dublin, D02 TY74
Ireland",353 1 709 4000,perrigo.com,PRGO,NYSE,January - December,USD,0001585364,G97822103,IE00BGH1M568,2834,"Dec 16, 1991",,,,
Merus N.V.,"Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers.
The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.",Data/company_logos_stock_analysis\Merus_N.V._logo.svg,https://stockanalysis.com/stocks/mrus/,Netherlands,2003,Biotechnology,Healthcare,229,Sven Lundberg,"Uppsalalaan 17, 3rd & 4th floor
Utrecht, 3584 CT
Netherlands",31 30 253 8800,merus.nl,MRUS,NASDAQ,January - December,USD,0001651311,N5749R100,NL0011606264,2834,"May 19, 2016",Common Stock,,,
Vericel Corporation,"Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America.
The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Vericel_Corporation_logo.svg,https://stockanalysis.com/stocks/vcel/,United States,1989,Biotechnology,Healthcare,314,Dominick Colangelo,"64 Sidney Street
Cambridge, Massachusetts 02139
United States",617 588 5555,vcel.com,VCEL,NASDAQ,January - December,USD,0000887359,92346J108,US92346J1088,2836,"Feb 4, 1997",Common Stock,94-3096597,,
Xenon Pharmaceuticals Inc.,"Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada.
Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy.
Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.",Data/company_logos_stock_analysis\Xenon_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/xene/,Canada,1996,Biotechnology,Healthcare,259,Ian Mortimer,"3650 Gilmore Way, Suite 200
Burnaby, BC V5G 4W8
Canada",604 484 3300,xenon-pharma.com,XENE,NASDAQ,January - December,USD,0001582313,98420N105,CA98420N1050,2834,"Nov 5, 2014",,98-0661854,,
MoonLake Immunotherapeutics,"MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.
It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis.
MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.",Data/company_logos_stock_analysis\MoonLake_Immunotherapeutics_logo.svg,https://stockanalysis.com/stocks/mltx/,Switzerland,2021,Biotechnology,Healthcare,50,Jorge da Silva,"Dorfstrasse 29
Zug, 6300
Switzerland",41 415108022,moonlaketx.com,MLTX,NASDAQ,January - December,USD,0001821586,61559X104,KY61559X1045,2834,,,,,Class A Shares
Bausch Health Companies Inc.,"Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.
It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally.
The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States.
The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products.
The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018.
Bausch Health Companies Inc. is headquartered in Laval, Canada.",Data/company_logos_stock_analysis\Bausch_Health_Companies_Inc._logo.svg,https://stockanalysis.com/stocks/bhc/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,"20,270",Thomas Appio,"2150 St. ElzEar Boulevard West
Laval, QC H7L 4A8
Canada",514 744 6792,bauschhealth.com,BHC,NYSE,January - December,USD,0000885590,071734107,CA0717341071,2834,,,,,
"SpringWorks Therapeutics, Inc.","SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.
Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas.
In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations.
The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib.
It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor.
The company was founded in 2017 and is headquartered in Stamford, Connecticut.","Data/company_logos_stock_analysis\SpringWorks_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/swtx/,United States,2017,Biotechnology,Healthcare,305,Saqib Islam,"100 Washington Boulevard
Stamford, Connecticut 06902
United States",203 883 9490,springworkstx.com,SWTX,NASDAQ,January - December,USD,0000813619,85205L107,US85205L1070,3081,"Sep 13, 2019",Common Stock,94-2551470,$18.00,
ACADIA Pharmaceuticals Inc.,"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States.
The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer’s disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.
It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS.
The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997.
ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.",Data/company_logos_stock_analysis\ACADIA_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/acad/,United States,1993,Biotechnology,Healthcare,598,Catherine Owen Adams,"12830 El Camino Real, Suite 400
San Diego, California 92130
United States",858 558 2871,acadia.com,ACAD,NASDAQ,January - December,USD,0001070494,004225108,US0042251084,2834,"May 27, 2004",Common Stock,06-1376651,,
Denali Therapeutics Inc.,"Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States.
The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases.
It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs.
The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015.
Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.",Data/company_logos_stock_analysis\Denali_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/dnli/,United States,2013,Biotechnology,Healthcare,445,Ryan Watts,"161 Oyster Point Boulevard
South San Francisco, California 94080
United States",650 866 8548,denalitherapeutics.com,DNLI,NASDAQ,January - December,USD,0001714899,24823R105,US24823R1059,2836,"Dec 8, 2017",Common Stock,46-3872213,,
"Janux Therapeutics, Inc.","Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer.
The company’s clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates.
Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Janux_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/janx/,United States,2017,Biotechnology,Healthcare,64,David Campbell,"10955 Vista Sorrento Parkway, Suite 200
San Diego, California 92130
United States",858 751 4493,januxrx.com,JANX,NASDAQ,January - December,USD,0001817713,47103J105,US47103J1051,2834,"Jun 11, 2021",Common Stock,82-2289112,$17.00,
"Amicus Therapeutics, Inc.","Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.","Data/company_logos_stock_analysis\Amicus_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/fold/,United States,2002,Biotechnology,Healthcare,517,Bradley Campbell,"47 Hulfish Street
Princeton, New Jersey 08542
United States",609 662 2000,amicusrx.com,FOLD,NASDAQ,January - December,USD,0001178879,03152W109,US03152W1099,2834,"May 31, 2007",Common Stock,20-0422823,,
"Catalyst Pharmaceuticals, Inc.","Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type.
It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.
The company was founded in 2002 and is based in Coral Gables, Florida.","Data/company_logos_stock_analysis\Catalyst_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/cprx/,United States,2002,Biotechnology,Healthcare,167,Richard John Daly,"355 Alhambra Circle, Suite 801
Coral Gables, Florida 33134
United States",305 420 3200,catalystpharma.com,CPRX,NASDAQ,January - December,USD,0001369568,14888U101,US14888U1016,2834,"Nov 8, 2006",Common Stock,,,
NewAmsterdam Pharma Company N.V.,"NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.",Data/company_logos_stock_analysis\NewAmsterdam_Pharma_Company_N.V._logo.svg,https://stockanalysis.com/stocks/nams/,Netherlands,2019,Biotechnology,Healthcare,29,Michael Davidson,"Gooimeer 2-35
Naarden, 1411 DC
Netherlands",31 35 206 2971,newamsterdampharma.com,NAMS,NASDAQ,January - December,USD,0001936258,,NL00150012L7,2834,,,,,
HUTCHMED (China) Limited,"HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally.
The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.
In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton’s tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms.
It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021.
HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.",Data/company_logos_stock_analysis\HUTCHMED_(China)_Limited_logo.svg,https://stockanalysis.com/stocks/hcm/,Hong Kong,2000,Drug Manufacturers - Specialty & Generic,Healthcare,"1,988",Wei-Guo Su,"Cheung Kong Center, 48th floor
Hong Kong
Hong Kong",852 2121 8200,hutch-med.com,HCM,NASDAQ,January - December,USD,0001648257,44842L103,US44842L1035,2834,,,,,
"Kymera Therapeutics, Inc.","Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.
It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.","Data/company_logos_stock_analysis\Kymera_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/kymr/,United States,2015,Biotechnology,Healthcare,187,Nello Mainolfi,"200 Arsenal Yards Boulevard, Suite 230
Watertown, Massachusetts 02472
United States",857 285 5300,kymeratx.com,KYMR,NASDAQ,January - December,USD,0001815442,501575104,US5015751044,2836,"Aug 21, 2020",Common Stock,81-2992166,$20.00,
Zai Lab Limited,"Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions.
It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO.
The company was incorporated in 2013 and is headquartered in Shanghai, China.",Data/company_logos_stock_analysis\Zai_Lab_Limited_logo.svg,https://stockanalysis.com/stocks/zlab/,China,2013,Biotechnology,Healthcare,"2,175",Ying Du,"Jinchuang Plaza, Building 1, Fourth Floor
Shanghai, 201210
China",86 21 6163 2588,zailaboratory.com,ZLAB,NASDAQ,January - December,USD,0001704292,98887Q104,US98887Q1040,2834,"Sep 20, 2017",,,,
"Amneal Pharmaceuticals, Inc.","Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson’s disease, and endocrine disorders.
This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson’s disease.
The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs.
This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers.
It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies.
The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018.
Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.","Data/company_logos_stock_analysis\Amneal_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/amrx/,United States,2002,Drug Manufacturers - Specialty & Generic,Healthcare,"7,850",Chirag K. Patel,"400 Crossing Boulevard, 3rd Floor
Bridgewater, New Jersey 08807
United States",908 947 3120,amneal.com,AMRX,NASDAQ,January - December,USD,0001723128,03168L105,US03168L1052,2834,,,,,Class A Shares
"Vera Therapeutics, Inc.","Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases.
Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections.
The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020.
Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.","Data/company_logos_stock_analysis\Vera_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/vera/,United States,2016,Biotechnology,Healthcare,51,Marshall Fordyce,"8000 Marina Boulevard, Suite 120
Brisbane, California 94005
United States",650 770 0077,veratx.com,VERA,NASDAQ,January - December,USD,0001831828,92337R101,US92337R1014,2834,"May 14, 2021",Common Stock,81-2744449,$11.00,Class A Shares
"Arrowhead Pharmaceuticals, Inc.","Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
The company’s product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B.
In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials.
Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial.
Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No.
3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.","Data/company_logos_stock_analysis\Arrowhead_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/arwr/,United States,2003,Biotechnology,Healthcare,609,Christopher Anzalone,"177 East Colorado Boulevard, Suite 700
Pasadena, California 91105
United States",626 304 3400,arrowheadpharma.com,ARWR,NASDAQ,October - September,USD,0000879407,04280A100,US04280A1007,2834,"Jun 16, 1993",Common Stock,46-0408024,,
"Edgewise Therapeutics, Inc.","Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials.
In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.
Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.","Data/company_logos_stock_analysis\Edgewise_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ewtx/,United States,2017,Biotechnology,Healthcare,88,Kevin Koch,"1715 38th Street
Boulder, Colorado 80301
United States",720 262 7002,edgewisetx.com,EWTX,NASDAQ,January - December,USD,0001710072,28036F105,US28036F1057,2834,"Mar 26, 2021",Common Stock,82-1725586,$16.00,
"Protagonist Therapeutics, Inc.","Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113.
Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.","Data/company_logos_stock_analysis\Protagonist_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ptgx/,United States,2006,Biotechnology,Healthcare,112,Dinesh Patel,"7707 Gateway Boulevard, Suite 140
Newark, California 94560-1160
United States",510 474 0170,protagonist-inc.com,PTGX,NASDAQ,January - December,USD,0001377121,74366E102,US74366E1029,2834,"Aug 11, 2016",Common Stock,98-0505495,,
Beam Therapeutics Inc.,"Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.
Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Beam_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/beam/,United States,2017,Biotechnology,Healthcare,436,John Evans,"238 Main Street, 9th Floor
Cambridge, Massachusetts 02142-1016
United States",857 327 8775,beamtx.com,BEAM,NASDAQ,January - December,USD,0000789073,07373V105,US07373V1052,2080,"Feb 6, 2020",Common Stock,13-3295276,$17.00,
"IDEAYA Biosciences, Inc.","IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester.
IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\IDEAYA_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/idya/,United States,2015,Biotechnology,Healthcare,124,Yujiro Hata,"7000 Shoreline Court, Suite 350
South San Francisco, California 94080
United States",650 443 6209,ideayabio.com,IDYA,NASDAQ,January - December,USD,0001676725,45166A102,US45166A1025,2834,"May 23, 2019",Common Stock,47-4268251,$10.00,
"Apogee Therapeutics, Inc.","Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.
The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.
Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Apogee_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/apge/,United States,2022,Biotechnology,Healthcare,91,Michael Henderson,"221 Crescent Street, Building 17
Waltham, Massachusetts 02453
United States",650 394 5230,apogeetherapeutics.com,APGE,NASDAQ,January - December,USD,0001974640,03770N101,US03770N1019,2836,"Jul 14, 2023",,93-4958665,$17.00,
"Supernus Pharmaceuticals, Inc.","Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
The company’s commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients.
In addition, the company’s product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage.
It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors.
Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.","Data/company_logos_stock_analysis\Supernus_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/supn/,United States,2005,Drug Manufacturers - Specialty & Generic,Healthcare,652,Jack Khattar,"9715 Key West Avenue
Rockville, Maryland 20850
United States",301 838 2500,supernus.com,SUPN,NASDAQ,January - December,USD,0001356576,868459108,US8684591089,2834,"May 1, 2012",Common Stock,,,
Centessa Pharmaceuticals plc,"Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients.
Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.
In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs.
Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.",Data/company_logos_stock_analysis\Centessa_Pharmaceuticals_plc_logo.svg,https://stockanalysis.com/stocks/cnta/,United Kingdom,2020,Biotechnology,Healthcare,76,Saurabh Saha,"1 Ashley Road, 3rd Floor
Altrincham, WA14 2DT
United Kingdom",,centessa.com,CNTA,NASDAQ,January - December,USD,0001847903,152309100,US1523091007,2834,"May 28, 2021",,,$20.00,
"Tarsus Pharmaceuticals, Inc.","Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States.
The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.
In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention.
Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.","Data/company_logos_stock_analysis\Tarsus_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/tars/,United States,2016,Biotechnology,Healthcare,244,Bobak Azamian,"15440 Laguna Canyon Road, Suite 160
Irvine, California 92618
United States",949 409 1801,tarsusrx.com,TARS,NASDAQ,January - December,USD,0001819790,87650L103,US87650L1035,2836,"Oct 16, 2020",Common Stock,81-4717861,$16.00,
"CG Oncology, Inc.","CG Oncology, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer.
The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients.
CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020.
CG Oncology, Inc. was founded in 2010 and is based in Irvine, California.","Data/company_logos_stock_analysis\CG_Oncology,_Inc._logo.svg",https://stockanalysis.com/stocks/cgon/,United States,2010,Biotechnology,Healthcare,61,Arthur Kuan,"400 Spectrum Center Drive, Suite 2040
Irvine, California 92618
United States",949 409 3700,cgoncology.com,CGON,NASDAQ,January - December,USD,0001991792,,US1569441009,2836,"Jan 25, 2024",Common Stock,37-1611499,$19.00,
Ligand Pharmaceuticals Incorporated,"Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.
Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19.
In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications.
The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International.
Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.",Data/company_logos_stock_analysis\Ligand_Pharmaceuticals_Incorporated_logo.svg,https://stockanalysis.com/stocks/lgnd/,United States,1987,Biotechnology,Healthcare,58,Todd Davis,"555 Heritage Drive, Suite 200
Jupiter, Florida 33458
United States",858 550 7500,ligand.com,LGND,NASDAQ,January - December,USD,0000886163,53220K504,US53220K5048,2834,"Nov 18, 1992",Common Stock,77-0160744,,
"Mirum Pharmaceuticals, Inc.","Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis.
In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases.
The company was incorporated in 2018 and is headquartered in Foster City, California.","Data/company_logos_stock_analysis\Mirum_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/mirm/,United States,2018,Biotechnology,Healthcare,264,Christopher Peetz,"950 Tower Lane, Suite 1050
Foster City, California 94404
United States",650 667 4085,mirumpharma.com,MIRM,NASDAQ,January - December,USD,0001759425,604749101,US6047491013,2834,"Jul 18, 2019",Common Stock,83-1281555,$15.00,
Mesoblast Limited,"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.
It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy.
It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain.
The company was incorporated in 2004 and is headquartered in Melbourne, Australia.",Data/company_logos_stock_analysis\Mesoblast_Limited_logo.svg,https://stockanalysis.com/stocks/meso/,Australia,2004,Biotechnology,Healthcare,73,Silviu Itescu,"55 Collins Street, Level 38
Melbourne, VIC 3000
Australia",61 3 9639 6036,mesoblast.com,MESO,NASDAQ,July - June,USD,0001345099,590717104,US5907174016,2836,,,,,
"Recursion Pharmaceuticals, Inc.","Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited.
Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.","Data/company_logos_stock_analysis\Recursion_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/rxrx/,United States,2013,Biotechnology,Healthcare,500,Christopher Gibson,"41 South Rio Grande Street
Salt Lake City, Utah 84101
United States",385 269 0203,recursion.com,RXRX,NASDAQ,January - December,USD,0001601830,75629V104,US75629V1044,2836,"Apr 16, 2021",Common Stock,46-4099738,$18.00,Class A Shares
"Iovance Biotherapeutics, Inc.","Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers.
The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H.
Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH.
The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017.
Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.","Data/company_logos_stock_analysis\Iovance_Biotherapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/iova/,United States,2007,Biotechnology,Healthcare,557,Frederick Vogt,"825 Industrial Road, Suite 400
San Carlos, California 94070
United States",650 260 7120,iovance.com,IOVA,NASDAQ,January - December,USD,0001425205,462260100,US4622601007,2836,,,75-3254381,,
"Agios Pharmaceuticals, Inc.","Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.
Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Agios_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/agio/,United States,2007,Biotechnology,Healthcare,386,Brian Goff,"88 Sidney Street
Cambridge, Massachusetts 02139
United States",617 649 8600,agios.com,AGIO,NASDAQ,January - December,USD,0001439222,00847X104,US00847X1046,2834,"Jul 24, 2013",Common Stock,,,
"Harmony Biosciences Holdings, Inc.","Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.
Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.","Data/company_logos_stock_analysis\Harmony_Biosciences_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/hrmy/,United States,2017,Biotechnology,Healthcare,246,Jeffrey Dayno,"630 West Germantown Pike, Suite 215
Plymouth Meeting, Pennsylvania 19462
United States",484 539 9800,harmonybiosciences.com,HRMY,NASDAQ,January - December,USD,0001802665,413197104,US4131971040,2834,"Aug 19, 2020",Common Stock,82-2279923,$24.00,
Geron Corporation,"Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
The company was incorporated in 1990 and is headquartered in Foster City, California.",Data/company_logos_stock_analysis\Geron_Corporation_logo.svg,https://stockanalysis.com/stocks/gern/,United States,1990,Biotechnology,Healthcare,141,John Scarlett,"919 East Hillsdale Boulevard, Suite 250
Foster City, California 94404
United States",650 473 7700,geron.com,GERN,NASDAQ,January - December,USD,0000886744,374163103,US3741631036,2834,"Jun 30, 1996",Common Stock,75-2287752,,
"Soleno Therapeutics, Inc.","Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.","Data/company_logos_stock_analysis\Soleno_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/slno/,United States,1999,Biotechnology,Healthcare,33,Anish Bhatnagar,"203 Redwood Shores Parkway, Suite 500
Redwood City, California 94065
United States",650 213 8444,soleno.life,SLNO,NASDAQ,January - December,USD,0001484565,834203200,US8342033094,3845,"Nov 13, 2014",Common Stock,77-0523891,,
Wave Life Sciences Ltd.,"Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington’s disease (HD).
The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD.
Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.",Data/company_logos_stock_analysis\Wave_Life_Sciences_Ltd._logo.svg,https://stockanalysis.com/stocks/wve/,Singapore,2012,Biotechnology,Healthcare,268,Paul B. Bolno,"Marina One East Tower, 7 Straits View No.12-00
Singapore, 018936
Singapore",65 6236 3388,wavelifesciences.com,WVE,NASDAQ,January - December,USD,0001631574,Y95308105,SG9999014716,2834,"Nov 11, 2015",,,,
"Akero Therapeutics, Inc.","Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States.
The company’s lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases.
The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018.
Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Akero_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/akro/,United States,2017,Biotechnology,Healthcare,56,Andrew Cheng,"601 Gateway Boulevard, Suite 350
South San Francisco, California 94080
United States",650 487 6488,akerotx.com,AKRO,NASDAQ,January - December,USD,0001744659,00973Y108,US00973Y1082,2834,"Jun 20, 2019",Common Stock,,$16.00,
"Amphastar Pharmaceuticals, Inc.","Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures.
In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging.
Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions.
The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.","Data/company_logos_stock_analysis\Amphastar_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/amph/,United States,1996,Drug Manufacturers - Specialty & Generic,Healthcare,"1,761",Yongfeng Zhang,"11570 6th Street
Rancho Cucamonga, California 91730
United States",909 980 9484,amphastar.com,AMPH,NASDAQ,January - December,USD,0001297184,03209R103,US03209R1032,2834,"Jun 25, 2014",Common Stock,33-0702205,,
"Belite Bio, Inc","Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes.
Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.","Data/company_logos_stock_analysis\Belite_Bio,_Inc_logo.svg",https://stockanalysis.com/stocks/blte/,United States,2018,Biotechnology,Healthcare,20,Yu-Hsin Lin,"12750 High Bluff Drive, Suite 475
San Diego, California 92130
United States",858 246 6240,belitebio.com,BLTE,NASDAQ,January - December,USD,0001889109,07782B104,US07782B1044,2834,"Apr 29, 2022",,,$6.00,
"ImmunityBio, Inc.","ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.
Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
The company’s platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme.
Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.","Data/company_logos_stock_analysis\ImmunityBio,_Inc._logo.svg",https://stockanalysis.com/stocks/ibrx/,United States,2014,Biotechnology,Healthcare,628,Richard Adcock,"3530 John Hopkins Court
San Diego, California 92121
United States",844 696 5235,immunitybio.com,IBRX,NASDAQ,January - December,USD,0001326110,45256X103,US45256X1037,2836,,Common Stock,43-1979754,,
Galapagos NV,"Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.",Data/company_logos_stock_analysis\Galapagos_NV_logo.svg,https://stockanalysis.com/stocks/glpg/,Belgium,1999,Biotechnology,Healthcare,"1,123",Paulus Stoffels,"Generaal De Wittelaan L11 A3
Mechelen, 2800
Belgium",32 1 534 29 00,glpg.com,GLPG,NASDAQ,January - December,EUR,0001421876,36315X101,US36315X1019,2834,"May 6, 2005",,,,
"Disc Medicine, Inc.","Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders.
The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases.
Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.","Data/company_logos_stock_analysis\Disc_Medicine,_Inc._logo.svg",https://stockanalysis.com/stocks/iron/,United States,2017,Biotechnology,Healthcare,74,John Quisel,"321 Arsenal Street, Suite 101
Watertown, Massachusetts 02472
United States",617 674 9274,discmedicine.com,IRON,NASDAQ,January - December,USD,0001816736,,US2546041011,2834,,Common Stock,85-1613057,,
MannKind Corporation,"MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.
It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
The company’s product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).
In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis.
Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India.
MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.",Data/company_logos_stock_analysis\MannKind_Corporation_logo.svg,https://stockanalysis.com/stocks/mnkd/,United States,1991,Biotechnology,Healthcare,414,Michael Castagna,"1 Casper Street
Danbury, Connecticut 06810
United States",818 661 5000,mannkindcorp.com,MNKD,NASDAQ,January - December,USD,0000899460,56400P706,US56400P7069,2834,"Jul 28, 2004",Common Stock,13-3607736,,
"Vir Biotechnology, Inc.","Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV).
The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases.
It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.","Data/company_logos_stock_analysis\Vir_Biotechnology,_Inc._logo.svg",https://stockanalysis.com/stocks/vir/,United States,2016,Biotechnology,Healthcare,587,Marianne De Backer,"1800 Owens Street, Suite 900
San Francisco, California 94158
United States",415 906 4324,vir.bio,VIR,NASDAQ,January - December,USD,0001706431,92764N102,US92764N1028,2836,"Oct 11, 2019",Common Stock,81-2730369,$20.00,
Dynavax Technologies Corporation,"Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E.
Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996.
The company was incorporated in 1996 and is headquartered in Emeryville, California.",Data/company_logos_stock_analysis\Dynavax_Technologies_Corporation_logo.svg,https://stockanalysis.com/stocks/dvax/,United States,1996,Drug Manufacturers - Specialty & Generic,Healthcare,408,Ryan Spencer,"2100 Powell Street, Suite 720
EmeryVille, California 94608
United States",510 848 5100,dynavax.com,DVAX,NASDAQ,January - December,USD,0001029142,268158201,US2681582019,2834,"Feb 19, 2004",Common Stock,33-0728374,,
"Celldex Therapeutics, Inc.","Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity.
It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.","Data/company_logos_stock_analysis\Celldex_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/cldx/,United States,1983,Biotechnology,Healthcare,160,Anthony Marucci,"Perryville III Building, Suite 220
Hampton, New Jersey 08827
United States",908 200 7500,celldex.com,CLDX,NASDAQ,January - December,USD,0000744218,15117B202,US15117B2025,2835,"Mar 10, 2008",Common Stock,13-3191702,,
Fortrea Holdings Inc.,"Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process.
The company offers delivery models that include full service, functional service provider, and hybrid service structures.
It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services.
The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.",Data/company_logos_stock_analysis\Fortrea_Holdings_Inc._logo.svg,https://stockanalysis.com/stocks/ftre/,United States,1996,Biotechnology,Healthcare,"18,000",Thomas Pike,"8 Moore Drive
Durham, North Carolina 27709
United States",877 495 0816,fortrea.com,FTRE,NASDAQ,January - December,USD,0001965040,34965K107,US34965K1079,8071,,Common Stock,92-2796441,,
"Arcutis Biotherapeutics, Inc.","Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis.
The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.
Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.","Data/company_logos_stock_analysis\Arcutis_Biotherapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/arqt/,United States,2016,Biotechnology,Healthcare,296,Todd Watanabe,"3027 Townsgate Road, Suite 300
Westlake Village, California 91361
United States",805 418 5006,arcutis.com,ARQT,NASDAQ,January - December,USD,0001787306,03969K108,US03969K1088,2834,"Jan 31, 2020",Common Stock,81-2974255,$17.00,
"Travere Therapeutics, Inc.","Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases.
Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
The company’s clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.
It has a cooperative research and development agreement with National Institutes of Health’s National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome.
The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020.
Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Travere_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/tvtx/,United States,2008,Biotechnology,Healthcare,380,Eric Dube,"3611 Valley Centre Drive, Suite 300
San Diego, California 92130
United States",888 969 7879,travere.com,TVTX,NASDAQ,January - December,USD,0001438533,89422G107,US89422G1076,2834,,Common Stock,26-2383102,,
Evotec SE,"Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.
It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases.
The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.",Data/company_logos_stock_analysis\Evotec_SE_logo.svg,https://stockanalysis.com/stocks/evo/,Germany,1993,Drug Manufacturers - Specialty & Generic,Healthcare,"5,061",Christian Wojczewski,"Essener Bogen 7
Hamburg, 22419
Germany",49 40 560 81 0,evotec.com,EVO,NASDAQ,January - December,EUR,0001412558,30050E105,US30050E1055,2834,"Nov 4, 2021",,,$26.16,
"Dyne Therapeutics, Inc.","Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Dyne_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/dyn/,United States,1984,Biotechnology,Healthcare,141,John Cox,"1560 Trapelo Road
Waltham, Massachusetts 02451
United States",781 786 8230,dyne-tx.com,DYN,NASDAQ,January - December,USD,0001379895,26818M108,US26818M1080,4911,"Sep 17, 2020",Common Stock,20-5653152,$19.00,
"BioCryst Pharmaceuticals, Inc.","BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases.
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.","Data/company_logos_stock_analysis\BioCryst_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/bcrx/,United States,1986,Biotechnology,Healthcare,536,Jon Stonehouse,"4505 Emperor Boulevard, Suite 200
Durham, North Carolina 27703
United States",919 859 1302,biocryst.com,BCRX,NASDAQ,January - December,USD,0000882796,09058V103,US09058V1035,2836,"Mar 3, 1994",Common Stock,62-1413174,,
"Novavax, Inc.","Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.
It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.","Data/company_logos_stock_analysis\Novavax,_Inc._logo.svg",https://stockanalysis.com/stocks/nvax/,United States,1987,Biotechnology,Healthcare,"1,543",John Jacobs,"700 Quince Orchard Road
Gaithersburg, Maryland 20878
United States",240 268 2000,novavax.com,NVAX,NASDAQ,January - December,USD,0001000694,670002401,US6700024010,2836,"Dec 5, 1995",Common Stock,22-2816046,,
Immunocore Holdings plc,"Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.
It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma.
Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial.
Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.",Data/company_logos_stock_analysis\Immunocore_Holdings_plc_logo.svg,https://stockanalysis.com/stocks/imcr/,United Kingdom,2008,Biotechnology,Healthcare,497,Bahija Jallal,"92 Park Drive, Milton Park
Abingdon, OX14 4RY
United Kingdom",44 12 3543 8600,immunocore.com,IMCR,NASDAQ,January - December,USD,0001671927,45258D105,US45258D1054,2836,"Feb 5, 2021",,,$26.00,
Indivior PLC,"Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.
The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder.
The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults.
In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics.
Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose.
It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder.
The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.",Data/company_logos_stock_analysis\Indivior_PLC_logo.svg,https://stockanalysis.com/stocks/indv/,United States,1994,Drug Manufacturers - Specialty & Generic,Healthcare,"1,164",Mark Crossley,"10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
United States",804 379 1090,indivior.com,INDV,NASDAQ,January - December,USD,0001625297,,GB00BN4HT335,2834,,,,,
Structure Therapeutics Inc.,"Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs.
The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF.
The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.",Data/company_logos_stock_analysis\Structure_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/gpcr/,United States,2016,Biotechnology,Healthcare,93,Raymond Stevens,"601 Gateway Boulevard, Suite 900
South San Francisco, California 94080
United States",650 457 1978,structuretx.com,GPCR,NASDAQ,January - December,USD,0001888886,86366E106,US86366E1064,2834,"Feb 3, 2023",,98-1480821,$15.00,
"Viridian Therapeutics, Inc.","Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases.
The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease.
The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Viridian_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/vrdn/,United States,2006,Biotechnology,Healthcare,94,Stephen Mahoney,"221 Crescent Street, Suite 401
Waltham, Massachusetts 02453
United States",617 272 4600,viridiantherapeutics.com,VRDN,NASDAQ,January - December,USD,0001590750,92790C104,US92790C1045,8071,,Common Stock,47-1187261,,
"Kiniksa Pharmaceuticals International, plc","Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024.
The company was incorporated in 2015 and is based in London, the United Kingdom.","Data/company_logos_stock_analysis\Kiniksa_Pharmaceuticals_International,_plc_logo.svg",https://stockanalysis.com/stocks/knsa/,United Kingdom,2015,Drug Manufacturers - Specialty & Generic,Healthcare,297,Sanj Patel,"23 Old Bond Street, Floor 3
London, WIS 4PZ
United Kingdom",781 431 9100,kiniksa.com,KNSA,NASDAQ,January - December,USD,0001730430,G5269C101,BMG5269C1010,2834,"May 24, 2018",,,,Class A Shares
"Spyre Therapeutics, Inc.","Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).
It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease).
The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-α4β7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies.
In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-α4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs.
The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023.
Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Spyre_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/syre/,United States,2013,Biotechnology,Healthcare,30,Cameron Turtle,"221 Crescent Street, Building 23
Waltham, Massachusetts 02453
United States",617 651 5940,spyre.com,SYRE,NASDAQ,January - December,USD,0001636282,00773J202,US00773J2024,2834,"Apr 7, 2016",Common Stock,46-4312787,,
"Harrow, Inc.","Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis.
In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop.
Further, the company has collaboration with Asembia to enhance provider and patient experience through nationwide digital services and hub support for harrow’s branded eyecare products.
The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023.
Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.","Data/company_logos_stock_analysis\Harrow,_Inc._logo.svg",https://stockanalysis.com/stocks/hrow/,United States,1998,Drug Manufacturers - Specialty & Generic,Healthcare,315,Mark Baum,"102 Woodmont Boulevard, Suite 610
Nashville, Tennessee 37205
United States",615 733 4730,harrow.com,HROW,NASDAQ,January - December,USD,0001360214,415858109,US4158581094,2834,,Common Stock,45-0567010,,
"Ocular Therapeutix, Inc.","Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States.
The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.
In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications.
The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC.
Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.","Data/company_logos_stock_analysis\Ocular_Therapeutix,_Inc._logo.svg",https://stockanalysis.com/stocks/ocul/,United States,2006,Biotechnology,Healthcare,267,Pravin Dugel,"15 Crosby Drive
Bedford, Massachusetts 01730
United States",781 357 4000,ocutx.com,OCUL,NASDAQ,January - December,USD,0001393434,67576A100,US67576A1007,2834,"Jul 25, 2014",Common Stock,,,
"Arcus Biosciences, Inc.","Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
The company’s pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease.
In addition, the company’s preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor.
It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases.
Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.","Data/company_logos_stock_analysis\Arcus_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/rcus/,United States,2015,Biotechnology,Healthcare,577,Terry Rosen,"3928 Point Eden Way
Hayward, California 94545
United States",510 694 6200,arcusbio.com,RCUS,NYSE,January - December,USD,0001724521,03969F109,US03969F1093,2834,"Mar 15, 2018",Common Stock,47-3898435,,
"Nurix Therapeutics, Inc.","Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases.
The company develops NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
It is also developing NX‑0479/GS‑6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates.
The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018.
Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.","Data/company_logos_stock_analysis\Nurix_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/nrix/,United States,2009,Biotechnology,Healthcare,284,Arthur Sands,"1700 Owens Street, Suite 205
San Francisco, California 94158
United States",415 660 5320,nurixtx.com,NRIX,NASDAQ,December - November,USD,0001549595,67080M103,US67080M1036,2834,"Jul 24, 2020",Common Stock,27-0838048,$19.00,
"Arvinas, Inc.","Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial.
Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG.
The company was founded in 2013 and is based in New Haven, Connecticut.","Data/company_logos_stock_analysis\Arvinas,_Inc._logo.svg",https://stockanalysis.com/stocks/arvn/,United States,2015,Biotechnology,Healthcare,445,John Houston,"5 Science Park, 395 Winchester Avenue
New Haven, Connecticut 06511
United States",203 535 1456,arvinas.com,ARVN,NASDAQ,January - December,USD,0001655759,04335A105,US04335A1051,2834,"Sep 27, 2018",Common Stock,47-2566120,,
"Xencor, Inc.","Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases.
The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types.
The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors.
In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus.
The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer’s disease, and depression.
It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.","Data/company_logos_stock_analysis\Xencor,_Inc._logo.svg",https://stockanalysis.com/stocks/xncr/,United States,1997,Biotechnology,Healthcare,280,Bassil Dahiyat,"465 North Halstead Street, Suite 200
Pasadena, California 91107
United States",626 305 5900,xencor.com,XNCR,NASDAQ,January - December,USD,0001326732,98401F105,US98401F1057,2834,"Dec 3, 2013",Common Stock,20-1622502,,
"MiMedx Group, Inc.","MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.
The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.
Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications.
The company’s products have applications in the areas of wound care, burn, surgical sectors of healthcare.
The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States.
MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.","Data/company_logos_stock_analysis\MiMedx_Group,_Inc._logo.svg",https://stockanalysis.com/stocks/mdxg/,United States,2006,Biotechnology,Healthcare,895,Joseph Capper,"1775 West Oak Commons Court, NE
Marietta, Georgia 30062
United States",770 651 9100,mimedx.com,MDXG,NASDAQ,January - December,USD,0001376339,602496101,US6024961012,3841,,Common Stock,26-2792552,,
"Maravai LifeSciences Holdings, Inc.","Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.
The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology.
The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services.
This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services.
The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies.
The company was incorporated in 2020 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Maravai_LifeSciences_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/mrvi/,United States,2020,Biotechnology,Healthcare,650,William Martin,"10770 Wateridge Circle, Suite 200
San Diego, California 92121
United States",858 546 0004,maravai.com,MRVI,NASDAQ,January - December,USD,0001823239,56600D107,US56600D1072,2834,"Nov 20, 2020",Common Stock,,$27.00,Class A Shares
"Ardelyx, Inc.","Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.
The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.
It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder.
The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories.
The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Ardelyx,_Inc._logo.svg",https://stockanalysis.com/stocks/ardx/,United States,2007,Biotechnology,Healthcare,267,Michael Raab,"400 Fifth Avenue, Suite 210
Waltham, Massachusetts 02451
United States",510 745 1700,ardelyx.com,ARDX,NASDAQ,January - December,USD,0001437402,039697107,US0396971071,2834,"Jun 19, 2014",Common Stock,,,
"Day One Biopharmaceuticals, Inc.","Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers.
Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2.
Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.","Data/company_logos_stock_analysis\Day_One_Biopharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/dawn/,United States,2018,Biotechnology,Healthcare,155,Jeremy Bender,"2000 Sierra Point Parkway, Suite 501
Brisbane, California 94005
United States",650 484 0899,dayonebio.com,DAWN,NASDAQ,January - December,USD,0001845337,23954D109,US23954D1090,2834,"May 27, 2021",Common Stock,83-2415215,$16.00,
"Praxis Precision Medicines, Inc.","Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.
It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF.
It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs.
The company was incorporated in 2015 and is based in Boston, Massachusetts.","Data/company_logos_stock_analysis\Praxis_Precision_Medicines,_Inc._logo.svg",https://stockanalysis.com/stocks/prax/,United States,2015,Biotechnology,Healthcare,82,Marcio De'Souza,"99 High Street, 30th Floor
Boston, Massachusetts 02110
United States",617 300 8460,praxismedicines.com,PRAX,NASDAQ,January - December,USD,0001689548,74006W108,US74006W2070,2834,"Oct 16, 2020",Common Stock,,$19.00,
Aurinia Pharmaceuticals Inc.,"Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States.
It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.",Data/company_logos_stock_analysis\Aurinia_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/auph/,Canada,1993,Biotechnology,Healthcare,300,Peter Greenleaf,"118 Avenue , 14315, Suite 140
Edmonton, AB T5L 4S6
Canada",250 744 2487,auriniapharma.com,AUPH,NASDAQ,January - December,USD,0001600620,05156V102,CA05156V1022,2834,"Jan 26, 1999",,98-1231763,,
BGM Group Ltd.,"BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China.
It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient.
The company also provides licorice products, such as Gan Di Xin, a medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions.
In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes.
Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil’s chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth.
BGM Group Ltd. is based in Chengdu, China.",Data/company_logos_stock_analysis\BGM_Group_Ltd._logo.svg,https://stockanalysis.com/stocks/bgm/,China,2019,Drug Manufacturers - Specialty & Generic,Healthcare,298,Chen Xin,"No. 152 Hongliang East 1st Street, No. 1703, Tianfu New District
Chengdu, 610200
China",86 28 6477 5180,bgmgroupltd.com,BGM,NASDAQ,October - September,USD,0001779578,,,2834,"Jan 12, 2021",,,,
"Syndax Pharmaceuticals, Inc.","Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat.
Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Syndax_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/sndx/,United States,2005,Biotechnology,Healthcare,184,Michael Metzger,"35 Gatehouse Drive, Building D
Waltham, Massachusetts 02451
United States",781 419 1400,syndax.com,SNDX,NASDAQ,January - December,USD,0001395937,87164F105,US87164F1057,2834,"Mar 3, 2016",Common Stock,32-0162505,,
"Tilray Brands, Inc.","Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally.
The company operates through four segments: Beverage Alcohol, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products.
The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Hiball Energy, Redhook Brewery, Square Mile Cider, Widmer Brothers Brewing, Runner’s High Brewing Company, Happy Flower, and Fresh Hemp Foods brands.
It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers.
The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022.
Tilray Brands, Inc. is headquartered in Leamington, Canada.","Data/company_logos_stock_analysis\Tilray_Brands,_Inc._logo.svg",https://stockanalysis.com/stocks/tlry/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,"2,650",Irwin Simon,"265 Talbot Street West
Leamington, ON N8H 5L4
Canada",844 845 7291,tilray.com,TLRY,NASDAQ,June - May,USD,0001731348,88688T100,US88688T1007,2833,"Jul 19, 2018",,82-4310622,,
"ARS Pharmaceuticals, Inc.","ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions.
The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis.
It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\ARS_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/spry/,United States,2015,Biotechnology,Healthcare,26,Richard Lowenthal,"11682 El Camino Real, Suite 120
San Diego, California 92130
United States",858 771 9307,ars-pharma.com,SPRY,NASDAQ,January - December,USD,0001671858,82835W108,US82835W1080,2834,,Common Stock,81-1489190,,
"Innoviva, Inc.","Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally.
The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea.
Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.
The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016.
Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.","Data/company_logos_stock_analysis\Innoviva,_Inc._logo.svg",https://stockanalysis.com/stocks/inva/,United States,1996,Biotechnology,Healthcare,112,Pavel Raifeld,"1350 Old Bayshore Highway, Suite 400
Burlingame, California 94010
United States",650 238 9600,inva.com,INVA,NASDAQ,January - December,USD,0001080014,45781M101,US45781M1018,2834,"Oct 5, 2004",,94-3265960,,
"ANI Pharmaceuticals, Inc.","ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals.
ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.","Data/company_logos_stock_analysis\ANI_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/anip/,United States,2001,Drug Manufacturers - Specialty & Generic,Healthcare,642,Nikhil Lalwani,"210 Main Street West
Baudette, Minnesota 56623
United States",218 634 3500,anipharmaceuticals.com,ANIP,NASDAQ,January - December,USD,0001023024,00182C103,US00182C1036,2834,,Common Stock,58-2301143,,
"Enliven Therapeutics, Inc.","Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
The company is headquartered in Boulder, Colorado.","Data/company_logos_stock_analysis\Enliven_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/elvn/,United States,2016,Biotechnology,Healthcare,46,Samuel Kintz,"6200 Lookout Road
Boulder, Colorado 80301
United States",720 647 8519,enliventherapeutics.com,ELVN,NASDAQ,January - December,USD,0001672619,29337E102,US29337E1029,2834,"Mar 12, 2020",,81-1523849,$16.00,
"Collegium Pharmaceutical, Inc.","Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.","Data/company_logos_stock_analysis\Collegium_Pharmaceutical,_Inc._logo.svg",https://stockanalysis.com/stocks/coll/,United States,2002,Drug Manufacturers - Specialty & Generic,Healthcare,197,Vikram Karnani,"100 Technology Center Drive, Suite 300
Stoughton, Massachusetts 02072
United States",781 713 3699,collegiumpharma.com,COLL,NASDAQ,January - December,USD,0001267565,19459J104,US19459J1043,2834,"May 7, 2015",Common Stock,,,
"Intellia Therapeutics, Inc.","Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics.
The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.
In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system.
It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer.
Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Intellia_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ntla/,United States,2014,Biotechnology,Healthcare,526,John Leonard,"40 Erie Street, Suite 130
Cambridge, Massachusetts 02139
United States",857 285 6200,intelliatx.com,NTLA,NASDAQ,January - December,USD,0001652130,45826J105,US45826J1051,2835,"May 6, 2016",Common Stock,36-4785571,,
Liquidia Corporation,"Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion.
The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD.
Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.",Data/company_logos_stock_analysis\Liquidia_Corporation_logo.svg,https://stockanalysis.com/stocks/lqda/,United States,2004,Biotechnology,Healthcare,145,Roger Jeffs,"419 Davis Drive, Suite 100
Morrisville, North Carolina 27560
United States",919 328 4400,liquidia.com,LQDA,NASDAQ,January - December,USD,0001330436,53635D202,US53635D2027,3841,"Jul 26, 2018",Common Stock,,,
Pharvaris N.V.,"Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases.
The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE).
It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.",Data/company_logos_stock_analysis\Pharvaris_N.V._logo.svg,https://stockanalysis.com/stocks/phvs/,Netherlands,2015,Biotechnology,Healthcare,82,Berndt Axel Modig,"Emmy Noetherweg 2
Leiden, 2333 BK
Netherlands",31 71 203 6410,pharvaris.com,PHVS,NASDAQ,January - December,EUR,0001830487,N69605108,NL00150005Y4,2834,"Feb 5, 2021",,,$20.00,
Adaptive Biotechnologies Corporation,"Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD).
The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications.
Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test.
The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011.
Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.",Data/company_logos_stock_analysis\Adaptive_Biotechnologies_Corporation_logo.svg,https://stockanalysis.com/stocks/adpt/,United States,2009,Biotechnology,Healthcare,709,Chad Robins,"1165 Eastlake Avenue East
Seattle, Washington 98109
United States",206 659 0067,adaptivebiotech.com,ADPT,NASDAQ,January - December,USD,0001478320,00650F109,US00650F1093,2836,"Jun 27, 2019",Common Stock,27-0907024,$20.00,
"Rocket Pharmaceuticals, Inc.","Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases.
It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy.
It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.","Data/company_logos_stock_analysis\Rocket_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/rckt/,United States,1999,Biotechnology,Healthcare,268,Gaurav Shah,"9 Cedarbrook Drive
Cranbury, New Jersey 08512
United States",609 659 8001,rocketpharma.com,RCKT,NASDAQ,January - December,USD,0001281895,77313F106,US77313F1066,2834,,Common Stock,,,
"Pacira BioSciences, Inc.","Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.
It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product.
The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.
Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.","Data/company_logos_stock_analysis\Pacira_BioSciences,_Inc._logo.svg",https://stockanalysis.com/stocks/pcrx/,United States,2006,Drug Manufacturers - Specialty & Generic,Healthcare,712,Frank Lee,"5401 West Kennedy Boulevard, Suite 890
Tampa, Florida 33609
United States",813 553 6680,pacira.com,PCRX,NASDAQ,January - December,USD,0001396814,695127100,US6951271005,2834,"Feb 3, 2011",Common Stock,51-0619477,,
Anavex Life Sciences Corp.,"Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States.
The company’s lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer’s disease and Parkinson’s disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer’s disease.
Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer.
Anavex Life Sciences Corp.was incorporated in 2004 and is headquartered in New York, New York.",Data/company_logos_stock_analysis\Anavex_Life_Sciences_Corp._logo.svg,https://stockanalysis.com/stocks/avxl/,United States,2004,Biotechnology,Healthcare,40,Christopher Missling,"630 5th Avenue, 20th Floor
New York, New York 10111
United States",844 689 3939,anavex.com,AVXL,NASDAQ,October - September,USD,0001314052,032797300,US0327973006,2836,,,98-0608404,,
CureVac N.V.,"CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer.
CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.",Data/company_logos_stock_analysis\CureVac_N.V._logo.svg,https://stockanalysis.com/stocks/cvac/,Germany,2000,Biotechnology,Healthcare,"1,172",Alexander Zehnder,"Friedrich-Miescher-Strasse 15
Tübingen, 72076
Germany",49 7071 9883 0,curevac.com,CVAC,NASDAQ,January - December,EUR,0001809122,N2451R105,NL0015436031,2834,"Aug 14, 2020",Common Stock,,$16.00,
Nuvation Bio Inc.,"Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology.
The company’s lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.
The company was founded in 2018 and is headquartered in New York, New York.",Data/company_logos_stock_analysis\Nuvation_Bio_Inc._logo.svg,https://stockanalysis.com/stocks/nuvb/,United States,2018,Biotechnology,Healthcare,51,David Hung,"1500 Broadway, Suite 1401
New York, New York 10036
United States",332 208 6102,nuvationbio.com,NUVB,NYSE,January - December,USD,0001811063,67080N101,US67080N1019,2834,,Common Stock,85-0862255,,Class A Shares
Bicycle Therapeutics plc,"Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors.
In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease.
Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas.
It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV.
Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.",Data/company_logos_stock_analysis\Bicycle_Therapeutics_plc_logo.svg,https://stockanalysis.com/stocks/bcyc/,United Kingdom,2009,Biotechnology,Healthcare,284,Kevin Lee,"Portway Building, Blocks A & B
Cambridge, CB21 6GS
United Kingdom",44 1223 261 503,bicycletherapeutics.com,BCYC,NASDAQ,January - December,USD,0001761612,088786108,US0887861088,2834,"May 23, 2019",,,$14.00,
Zymeworks Inc.,"Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas.
Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.",Data/company_logos_stock_analysis\Zymeworks_Inc._logo.svg,https://stockanalysis.com/stocks/zyme/,United States,2003,Biotechnology,Healthcare,278,Kenneth Galbraith,"108 Patriot Drive, Suite A
Middletown, Delaware 19709
United States",302 274 8744,zymeworks.com,ZYME,NASDAQ,January - December,USD,0001403752,98985W102,US98985Y1082,2834,"Apr 28, 2017",,,,
Oculis Holding AG,"Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases.
The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
The company is based in Zug, Switzerland.",Data/company_logos_stock_analysis\Oculis_Holding_AG_logo.svg,https://stockanalysis.com/stocks/ocs/,Switzerland,2003,Biotechnology,Healthcare,36,Riad Sherif,"Bahnhofstrasse 7
Zug, 6300
Switzerland",41 41 711 9325,oculis.com,OCS,NASDAQ,January - December,CHF,0001953530,,CH1242303498,2834,,,,,
"Cogent Biosciences, Inc.","Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib.
The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020.
Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Cogent_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/cogt/,United States,2014,Biotechnology,Healthcare,164,Andrew Robbins,"275 Wyman Street, 3rd Floor
Waltham, Massachusetts 02451
United States",617 945 5576,cogentbio.com,COGT,NASDAQ,January - December,USD,0001622229,19240Q201,US19240Q2012,2834,"Mar 29, 2018",Common Stock,46-5308248,,
AbCellera Biologics Inc.,"AbCellera Biologics Inc. builds an engine for antibody drug discovery and development.
Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies.
The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners.
The company was incorporated in 2012 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\AbCellera_Biologics_Inc._logo.svg,https://stockanalysis.com/stocks/abcl/,Canada,2012,Biotechnology,Healthcare,586,Carl Hansen,"2215 Yukon Street
Vancouver, BC V5Y 0A1
Canada",604 559 9005,abcellera.com,ABCL,NASDAQ,January - December,USD,0001703057,00288U106,CA00288U1066,2834,"Dec 11, 2020",,,$20.00,
"Gyre Therapeutics, Inc.","Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease.
The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis.
In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension.
The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.","Data/company_logos_stock_analysis\Gyre_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/gyre/,United States,2002,Biotechnology,Healthcare,593,Han Ying,"12770 High Bluff Drive, Suite 150
San Diego, California 92130
United States",619-949-3681,gyretx.com,GYRE,NASDAQ,January - December,USD,0001124105,,US4037831033,2834,,Common Stock,56-2020050,,
Phibro Animal Health Corporation,"Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally.
It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers.
In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers.
Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals.
Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries.
It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors.
The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003.
Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.",Data/company_logos_stock_analysis\Phibro_Animal_Health_Corporation_logo.svg,https://stockanalysis.com/stocks/pahc/,United States,1946,Drug Manufacturers - Specialty & Generic,Healthcare,"1,940",Jack Bendheim,"Glenpointe Centre East, 3rd Floor
Teaneck, New Jersey 07666-6712
United States",201 329 7300,pahc.com,PAHC,NASDAQ,July - June,USD,0001069899,71742Q106,US71742Q1067,2834,"Apr 11, 2014",Common Stock,13-1840497,,Class A Shares
"ArriVent BioPharma, Inc.","ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States.
It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.
It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib.
The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.","Data/company_logos_stock_analysis\ArriVent_BioPharma,_Inc._logo.svg",https://stockanalysis.com/stocks/avbp/,United States,2021,Biotechnology,Healthcare,40,Zhengbin Yao,"18 Campus Boulevard, Suite 100
Newtown Square, Pennsylvania 19073
United States",628 277 4836,arrivent.com,AVBP,NASDAQ,January - December,USD,0001868279,,US04272N1028,2834,"Jan 26, 2024",Common Stock,,$18.00,
"Replimune Group, Inc.","Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer.
The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors.
The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells.
Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.","Data/company_logos_stock_analysis\Replimune_Group,_Inc._logo.svg",https://stockanalysis.com/stocks/repl/,United States,2015,Biotechnology,Healthcare,331,Sushil Patel,"500 Unicorn Park Drive, Suite 303
Woburn, Massachusetts 01801
United States",781 222 9600,replimune.com,REPL,NASDAQ,April - March,USD,0001737953,76029N106,US76029N1063,2836,"Jul 20, 2018",Common Stock,82-2082553,,
"Tyra Biosciences, Inc.","Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors.
The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma.
The company was incorporated in 2018 and is headquartered in Carlsbad, California.","Data/company_logos_stock_analysis\Tyra_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/tyra/,United States,2018,Biotechnology,Healthcare,49,Todd Harris,"2656 State Street
Carlsbad, California 92008
United States",619 728 4760,tyra.bio,TYRA,NASDAQ,January - December,USD,0001863127,90240B106,US90240B1061,2834,"Sep 15, 2021",Common Stock,83-1476348,$16.00,
"Sana Biotechnology, Inc.","Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines.
It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
The company’s product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin’s lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others.
It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence.
The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.
The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018.
Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.","Data/company_logos_stock_analysis\Sana_Biotechnology,_Inc._logo.svg",https://stockanalysis.com/stocks/sana/,United States,2018,Biotechnology,Healthcare,328,Steven Harr,"188 East Blaine Street, Suite 400
Seattle, Washington 98102
United States",206 701 7914,sana.com,SANA,NASDAQ,January - December,USD,0001770121,799566104,US7995661045,2836,"Feb 4, 2021",Common Stock,,$25.00,
"Septerna, Inc.","Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves’ disease and thyroid eye disease.
It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes.
Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021.
The company was incorporated in 2019 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Septerna,_Inc._logo.svg",https://stockanalysis.com/stocks/sepn/,United States,2022,Biotechnology,Healthcare,68,Jeffrey Finer,"250 East Grand Avenue
South San Francisco, California 94080
United States",650 338 3533,septerna.com,SEPN,NASDAQ,January - December,USD,0001984086,81734D104,US81734D1046,2834,"Oct 25, 2024",Common Stock,84-3891440,$18.00,
"Avid Bioservices, Inc.","Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States.
It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services.
The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018.
Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.","Data/company_logos_stock_analysis\Avid_Bioservices,_Inc._logo.svg",https://stockanalysis.com/stocks/cdmo/,United States,1981,Biotechnology,Healthcare,371,Nicholas Green,"14191 Myford Road
Tustin, California 92780
United States",714 508 6100,avidbio.com,CDMO,NASDAQ,May - April,USD,0000704562,05368M106,US05368M1062,2834,,Common Stock,95-3698422,,
Bicara Therapeutics Inc.,"Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors.
Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
The company was incorporated in 2018 and is based in Boston, Massachusetts.",Data/company_logos_stock_analysis\Bicara_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/bcax/,United States,2018,Biotechnology,Healthcare,32,Claire Mazumdar Clemon,"116 Huntington Avenue, Suite 703
Boston, Massachusetts 02116
United States",617 468 4219,bicara.com,BCAX,NASDAQ,January - December,USD,0002023658,,US0554771032,2834,"Sep 13, 2024",Common Stock,,$18.00,
Immatics N.V.,"Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.
The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial.
The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications.
Immatics N.V. is headquartered in Tübingen, Germany.",Data/company_logos_stock_analysis\Immatics_N.V._logo.svg,https://stockanalysis.com/stocks/imtx/,Germany,,Biotechnology,Healthcare,535,Harpreet Singh,"Paul-Ehrlich-Strasse 15
Tübingen, 72076
Germany",49 7071 5397 0,immatics.com,IMTX,NASDAQ,January - December,EUR,0001809196,N44445109,NL0015285941,2836,,,,,
"89bio, Inc.","89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.
The company was incorporated in 2018 and is headquartered in San Francisco, California.","Data/company_logos_stock_analysis\89bio,_Inc._logo.svg",https://stockanalysis.com/stocks/etnb/,United States,2018,Biotechnology,Healthcare,70,Rohan Palekar,"142 Sansome Street, Second Floor
San Francisco, California 94104
United States",415 432 9270,89bio.com,ETNB,NASDAQ,January - December,USD,0001785173,282559103,US2825591033,2834,"Nov 11, 2019",Common Stock,83-1114349,$16.00,
Avadel Pharmaceuticals plc,"Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.
Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy.
The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.",Data/company_logos_stock_analysis\Avadel_Pharmaceuticals_plc_logo.svg,https://stockanalysis.com/stocks/avdl/,Ireland,2015,Drug Manufacturers - Specialty & Generic,Healthcare,154,Gregory Divis,"10 Earlsfort Terrace
Dublin, 2
Ireland",353 1 901 5201,avadel.com,AVDL,NASDAQ,January - December,USD,0001012477,05337M104,US05337M1045,2834,"Jun 7, 1996",,,,
"Relay Therapeutics, Inc.","Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Kα inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.
In addition, it has collaboration and license agreements with D. E.
Shaw Research, LLC to research certain biological targets through the use of D. E.
Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971.
The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015.
Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Relay_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/rlay/,United States,2015,Biotechnology,Healthcare,323,Sanjiv Patel,"399 Binney Street, 2nd Floor
Cambridge, Massachusetts 02139
United States",617 370 8837,relaytx.com,RLAY,NASDAQ,January - December,USD,0001812364,75943R102,US75943R1023,2836,"Jul 16, 2020",Common Stock,,$20.00,
Cronos Group Inc.,"Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany.
It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands.
Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.",Data/company_logos_stock_analysis\Cronos_Group_Inc._logo.svg,https://stockanalysis.com/stocks/cron/,Canada,2012,Drug Manufacturers - Specialty & Generic,Healthcare,356,Michael Gorenstein,"111 Peter Street, Suite 300
Toronto, ON M5V 2H1
Canada",416 504 0004,thecronosgroup.com,CRON,NASDAQ,January - December,USD,0001603447,22717L101,CA22717L1013,,,,,,
"Upstream Bio, Inc.","Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders.
It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor.
The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Upstream_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/upb/,United States,2021,Biotechnology,Healthcare,38,E. Sutherland,"890 Winter Street, Suite 200
Waltham, Massachusetts 02451
United States",781 208 2466,upstreambio.com,UPB,NASDAQ,January - December,USD,0002022626,,US91678A1079,2834,"Oct 11, 2024",,,$17.00,
"Dianthus Therapeutics, Inc.","Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.","Data/company_logos_stock_analysis\Dianthus_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/dnth/,United States,2015,Biotechnology,Healthcare,53,Marino Garcia,"7 Times Square, 43rd Floor
New York, New York 10036
United States",929 999 4055,dianthustx.com,DNTH,NASDAQ,January - December,USD,0001690585,252828108,US2528281080,2834,,Common Stock,,,
Prothena Corporation plc,"Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.
The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.
Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis.
Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target α-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43.
The company was incorporated in 2012 and is based in Dublin, Ireland.",Data/company_logos_stock_analysis\Prothena_Corporation_plc_logo.svg,https://stockanalysis.com/stocks/prta/,Ireland,2012,Biotechnology,Healthcare,173,Gene Kinney,"77 Sir John Rogerson’s Quay, Block C
Dublin, D02 VK60
Ireland",353 1 236 2500,prothena.com,PRTA,NASDAQ,January - December,USD,0001559053,G72800108,IE00B91XRN20,2834,,,,,
"Pliant Therapeutics, Inc.","Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.
The company’s lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
It also develops PLN-1474, an oral, small-molecule selective inhibitor of αvß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins αvß8 and αvß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies.
Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.","Data/company_logos_stock_analysis\Pliant_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/plrx/,United States,2015,Biotechnology,Healthcare,158,Bernard Coulie,"260 Littlefield Avenue
South San Francisco, California 94080
United States",650 481 6770,pliantrx.com,PLRX,NASDAQ,January - December,USD,0001746473,729139105,US7291391057,2834,"Jun 3, 2020",Common Stock,47-4272481,$16.00,
CorMedix Inc.,"CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States.
Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.
CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.",Data/company_logos_stock_analysis\CorMedix_Inc._logo.svg,https://stockanalysis.com/stocks/crmd/,United States,2006,Biotechnology,Healthcare,83,Joseph Todisco,"300 Connell Drive, Suite 4200
Berkeley Heights, New Jersey 07922
United States",908 517 9500,cormedix.com,CRMD,NASDAQ,January - December,USD,0001410098,21900C308,US21900C3088,2834,"Mar 25, 2010",Common Stock,,,Class A Shares
"Erasca, Inc.","Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.
It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors.
In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme.
The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds.
Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Erasca,_Inc._logo.svg",https://stockanalysis.com/stocks/eras/,United States,2018,Biotechnology,Healthcare,126,Jonathan Lim,"3115 Merryfield Row, Suite 300
San Diego, California 92121
United States",858 465 6511,erasca.com,ERAS,NASDAQ,January - December,USD,0001761918,29479A108,US29479A1088,2834,"Jul 16, 2021",Common Stock,83-1217027,$16.00,
"Immunome, Inc.","Immunome, Inc., a biotechnology company, develops targeted cancer therapies.
The company’s clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.","Data/company_logos_stock_analysis\Immunome,_Inc._logo.svg",https://stockanalysis.com/stocks/imnm/,United States,2006,Biotechnology,Healthcare,55,Clay Siegall,"18702 N. Creek Parkway, Suite 100
Bothell, Washington 98011
United States",610 321 3700,immunome.com,IMNM,NASDAQ,January - December,USD,0001472012,45257U108,US45257U1088,2834,"Oct 2, 2020",Common Stock,77-0694340,$12.00,
"Cullinan Therapeutics, Inc.","Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States.
The company’s lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors.
Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
In addition, the company’s development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma.
It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib.
Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024.
Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Cullinan_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/cgem/,United States,2016,Biotechnology,Healthcare,85,Nadim Ahmed,"One Main Street, Suite 1350
Cambridge, Massachusetts 02142
United States",617 410 4650,cullinantherapeutics.com,CGEM,NASDAQ,January - December,USD,0001789972,230031106,US2300311063,2836,"Jan 8, 2021",Common Stock,81-3867811,$21.00,
"LENZ Therapeutics, Inc.","LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States.
Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia.
The company is headquartered in Del Mar, California.","Data/company_logos_stock_analysis\LENZ_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/lenz/,United States,2019,Biotechnology,Healthcare,,Evert Schimmelpennink,"445 Marine View Avenue, Suite 320
Del Mar, California 92014
United States",(858) 925-7000,lenz-tx.com,LENZ,NASDAQ,January - December,USD,0001815776,,US52635N1037,2836,"Jun 25, 2021",Common Stock,84-4867570,$17.00,
"Evolus, Inc.","Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe.
The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown.
It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.","Data/company_logos_stock_analysis\Evolus,_Inc._logo.svg",https://stockanalysis.com/stocks/eols/,United States,2012,Drug Manufacturers - Specialty & Generic,Healthcare,273,David Moatazedi,"520 Newport Center Drive, Suite 1200
Newport Beach, California 92660
United States",949 284 4555,evolus.com,EOLS,NASDAQ,January - December,USD,0001570562,30052C107,US30052C1071,2834,"Feb 8, 2018",Common Stock,46-1385614,,
"Ironwood Pharmaceuticals, Inc.","Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.
The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis.
The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008.
Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Ironwood_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/irwd/,United States,1998,Drug Manufacturers - Specialty & Generic,Healthcare,267,Thomas McCourt,"100 Summer Street, Suite 2300
Boston, Massachusetts 02110
United States",617 621 7722,ironwoodpharma.com,IRWD,NASDAQ,January - December,USD,0001446847,46333X108,US46333X1081,2834,"Feb 3, 2010",Common Stock,04-3404176,,Class A Shares
Pharming Group N.V.,"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE.
The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105.
Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.",Data/company_logos_stock_analysis\Pharming_Group_N.V._logo.svg,https://stockanalysis.com/stocks/phar/,Netherlands,1988,Biotechnology,Healthcare,382,Sijmen de Vries,"Darwinweg 24
Leiden, 2333 CR
Netherlands",31 71 524 7400,pharming.com,PHAR,NASDAQ,January - December,USD,0001828316,71716E105,US71716E1055,2834,,,,,
uniQure N.V.,"uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases.
It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B.
The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease.
In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease.
The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.",Data/company_logos_stock_analysis\uniQure_N.V._logo.svg,https://stockanalysis.com/stocks/qure/,Netherlands,1998,Biotechnology,Healthcare,480,Matthew Kapusta,"Paasheuvelweg 25
Amsterdam, 1105 BP
Netherlands",31 20 240 6000,uniqure.com,QURE,NASDAQ,January - December,USD,0001590560,N90064101,NL0010696654,2834,"Jun 20, 2007",,,,
Arbutus Biopharma Corporation,"Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States.
Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.
It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300.
The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015.
Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",Data/company_logos_stock_analysis\Arbutus_Biopharma_Corporation_logo.svg,https://stockanalysis.com/stocks/abus/,United States,,Biotechnology,Healthcare,73,Michael McElhaugh,"701 Veterans Circle
Warminster, Pennsylvania 18974
United States",267 469 0914,arbutusbio.com,ABUS,NASDAQ,January - December,USD,0001447028,03879J100,CA03879J1003,2834,,,98-0597776,,
Autolus Therapeutics plc,"Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases.
The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma.
Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.",Data/company_logos_stock_analysis\Autolus_Therapeutics_plc_logo.svg,https://stockanalysis.com/stocks/autl/,United Kingdom,2014,Biotechnology,Healthcare,471,Christian Itin,"The Mediaworks, 191 Wood Lane
London, W12 7FP
United Kingdom",44 20 3829 6230,autolus.com,AUTL,NASDAQ,January - December,USD,0001730463,05280R100,US05280R1005,2836,"Jun 22, 2018",,,,
"CARGO Therapeutics, Inc.","CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients.
The company’s lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets.
The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022.
CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.","Data/company_logos_stock_analysis\CARGO_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/crgx/,United States,2021,Biotechnology,Healthcare,116,Gina Chapman,"1900 Alameda De Las Pulgas, Suite 350
San Mateo, California 94403
United States",650 379 6143,cargo-tx.com,CRGX,NASDAQ,January - December,USD,0001966494,14179K101,US14179K1016,2836,"Nov 10, 2023",Common Stock,84-4080422,$15.00,
"Capricor Therapeutics, Inc.","Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs.
The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD).
It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases.
In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions.
It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation.
The company was founded in 2005 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Capricor_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/capr/,United States,2005,Biotechnology,Healthcare,102,Linda Marbán,"10865 Road to the Cure, Suite 150
San Diego, California 92121
United States",858 727 1755,capricor.com,CAPR,NASDAQ,January - December,USD,0001133869,14070B309,US14070B3096,2834,,Common Stock,,,
"Humacyte, Inc.","Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.
The company was founded in 2004 and is headquartered in Durham, North Carolina.","Data/company_logos_stock_analysis\Humacyte,_Inc._logo.svg",https://stockanalysis.com/stocks/huma/,United States,2004,Biotechnology,Healthcare,185,Laura Niklason,"2525 East North Carolina Highway 54
Durham, North Carolina 27713
United States",919 313 9633,humacyte.com,HUMA,NASDAQ,January - December,USD,0001818382,44486Q103,US44486Q1031,2836,,Common Stock,85-1763759,,
"Tectonic Therapeutic, Inc.","Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs).
It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
The company’s pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators.
Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.","Data/company_logos_stock_analysis\Tectonic_Therapeutic,_Inc._logo.svg",https://stockanalysis.com/stocks/tecx/,United States,2019,Biotechnology,Healthcare,44,Alise Reicin,"490 Arsenal Way, Suite 210
Watertown, Massachusetts 02472
United States",,tectonictx.com,TECX,NASDAQ,January - December,USD,0001681087,,US8789721086,2836,"Jun 21, 2018",Common Stock,81-0710585,,
"EyePoint Pharmaceuticals, Inc.","EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).
The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases.
The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018.
EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.","Data/company_logos_stock_analysis\EyePoint_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/eypt/,United States,1987,Biotechnology,Healthcare,121,Jay Duker,"480 Pleasant Street, Suite A-210
Watertown, Massachusetts 02472
United States",617 926 5000,eyepointpharma.com,EYPT,NASDAQ,January - December,USD,0001314102,30233G209,US30233G2093,3826,"Jan 27, 2005",Common Stock,26-2774444,,
"Keros Therapeutics, Inc.","Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
The company’s lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases.
In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050.
Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.","Data/company_logos_stock_analysis\Keros_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/kros/,United States,2015,Biotechnology,Healthcare,136,Jasbir Seehra,"1050 Waltham Street, Suite 302
Lexington, Massachusetts 02421
United States",617 314 6297,kerostx.com,KROS,NASDAQ,January - December,USD,0001664710,492327101,US4923271013,2834,"Apr 8, 2020",Common Stock,81-1173868,$16.00,
Savara Inc.,"Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Savara Inc. is headquartered in Langhorne, Pennsylvania.",Data/company_logos_stock_analysis\Savara_Inc._logo.svg,https://stockanalysis.com/stocks/svra/,United States,,Biotechnology,Healthcare,37,Matthew Pauls,"1717 Langhorne Newtown Road, Suite 300
Langhorne, Pennsylvania 19047
United States",512 614 1848,savarapharma.com,SVRA,NASDAQ,January - December,USD,0001160308,805111101,US8051111016,2834,,Common Stock,84-1318182,,
"Kura Oncology, Inc.","Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies.
The company was founded in 2014 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Kura_Oncology,_Inc._logo.svg",https://stockanalysis.com/stocks/kura/,United States,2014,Biotechnology,Healthcare,142,Troy Wilson,"12730 High Bluff Drive, Suite 400
San Diego, California 92130
United States",858 500 8800,kuraoncology.com,KURA,NASDAQ,January - December,USD,0001422143,50127T109,US50127T1097,2834,,Common Stock,61-1547851,,
Opthea Limited,"Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States.
Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
The company’s lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema.
It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015.
Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.",Data/company_logos_stock_analysis\Opthea_Limited_logo.svg,https://stockanalysis.com/stocks/opt/,Australia,1984,Biotechnology,Healthcare,33,Frederic Guerard,"650 Chapel Street, Suite 0403, Level 4
South Yarra, VIC 3141
Australia",61 3 9826 0399,opthea.com,OPT,NASDAQ,July - June,USD,0001815620,68386J208,US68386J2087,2836,"Oct 16, 2020",,,$13.50,
Mereo BioPharma Group plc,"Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.
In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency.
The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab.
Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.",Data/company_logos_stock_analysis\Mereo_BioPharma_Group_plc_logo.svg,https://stockanalysis.com/stocks/mreo/,United Kingdom,2015,Biotechnology,Healthcare,33,Denise Scots-Knight,"One Cavendish Place, 4th Floor
London, W1G 0QF
United Kingdom",44 33 3023 7300,mereobiopharma.com,MREO,NASDAQ,January - December,USD,0001719714,589492107,US5894921072,2834,,,,,
"ORIC Pharmaceuticals, Inc.","ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States.
Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers.
It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\ORIC_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/oric/,United States,2014,Biotechnology,Healthcare,100,Jacob Chacko,"240 East Grand Avenue, 2nd Floor
South San Francisco, California 94080
United States",650 388 5600,oricpharma.com,ORIC,NASDAQ,January - December,USD,0001796280,68622P109,US68622P1093,2834,"Apr 24, 2020",Common Stock,47-1787157,$16.00,
"Rapport Therapeutics, Inc.","Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders.
Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders.
Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Rapport_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/rapp/,United States,2022,Biotechnology,Healthcare,58,Abraham Ceesay,"1325 Boylston Street, Suite 401
Boston, Massachusetts 02215
United States",857 321 8020,rapportrx.com,RAPP,NASDAQ,January - December,USD,0002012593,,US75383L1026,2834,"Jun 7, 2024",Common Stock,88-0724208,$17.00,
Emergent BioSolutions Inc.,"Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.
The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.
It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector.
In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections.
Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services.
The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.",Data/company_logos_stock_analysis\Emergent_BioSolutions_Inc._logo.svg,https://stockanalysis.com/stocks/ebs/,United States,1998,Drug Manufacturers - Specialty & Generic,Healthcare,"1,600",Joseph Papa,"400 Professional Drive, Suite 400
Gaithersburg, Maryland 20879
United States",240 631 3200,emergentbiosolutions.com,EBS,NYSE,January - December,USD,0001367644,29089Q105,US29089Q1058,2834,"Nov 15, 2006",Common Stock,14-1902018,,
"Ginkgo Bioworks Holdings, Inc.","Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States.
Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum.
It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Ginkgo_Bioworks_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/dna/,United States,2008,Biotechnology,Healthcare,"1,218",Jason Kelly,"27 Drydock Avenue, 8th Floor
Boston, Massachusetts 02210
United States",877 422 5362,ginkgobioworks.com,DNA,NYSE,January - December,USD,0001830214,37611X100,US37611X1000,2836,,Common Stock,87-2652913,,Class A Shares
"Annexon, Inc.","Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications.
In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis.
The company was incorporated in 2011 and is headquartered in Brisbane, California.","Data/company_logos_stock_analysis\Annexon,_Inc._logo.svg",https://stockanalysis.com/stocks/annx/,United States,2011,Biotechnology,Healthcare,71,Douglas Love,"1400 Sierra Point Parkway, Building C
Brisbane, California 94005
United States",650 822 5500,annexonbio.com,ANNX,NASDAQ,January - December,USD,0001528115,03589W102,US03589W1027,2834,"Jul 24, 2020",Common Stock,27-5414423,$17.00,
Omeros Corporation,"Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders.
The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders.
In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers.
Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.",Data/company_logos_stock_analysis\Omeros_Corporation_logo.svg,https://stockanalysis.com/stocks/omer/,United States,1994,Biotechnology,Healthcare,198,Gregory Demopulos,"The Omeros Building, 201 Elliott Avenue West
Seattle, Washington 98119
United States",206 676 5000,omeros.com,OMER,NASDAQ,January - December,USD,0001285819,682143102,US6821431029,2834,"Oct 8, 2009",Common Stock,91-1663741,,
"Entrada Therapeutics, Inc.","Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.
Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy.
Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701.
The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017.
Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Entrada_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/trda/,United States,2016,Biotechnology,Healthcare,159,Dipal Doshi,"One Design Center Place, Suite 17- 500
Boston, Massachusetts 02210
United States",857 520 9158,entradatx.com,TRDA,NASDAQ,January - December,USD,0001689375,29384C108,US29384C1080,2834,"Oct 29, 2021",Common Stock,81-3983399,$20.00,
Mind Medicine (MindMed) Inc.,"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.
The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Mind Medicine (MindMed) Inc. is headquartered in New York, New York.",Data/company_logos_stock_analysis\Mind_Medicine_(MindMed)_Inc._logo.svg,https://stockanalysis.com/stocks/mnmd/,United States,2019,Biotechnology,Healthcare,57,Robert Barrow,"One World Trade Center, Suite 8500
New York, New York 10007
United States",212-220-6633,mindmed.co,MNMD,NASDAQ,January - December,USD,0001813814,60255C109,CA60255C8850,2833,,,,,
"Xeris Biopharma Holdings, Inc.","Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois.
The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome.
It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies.
The company was incorporated in 2005 and is headquartered in Chicago, Illinois.","Data/company_logos_stock_analysis\Xeris_Biopharma_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/xers/,United States,2005,Biotechnology,Healthcare,377,John Shannon,"180 North LaSalle Street, Suite 1600
Chicago, Illinois 60601
United States",844 445 5704,xerispharma.com,XERS,NASDAQ,January - December,USD,0001346302,98422E103,US98422E1038,2834,"Jun 21, 2018",Common Stock,20-3352427,,
"Tourmaline Bio, Inc.","Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases.
It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
The company’s development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED).
The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022.
Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.","Data/company_logos_stock_analysis\Tourmaline_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/trml/,United States,2021,Biotechnology,Healthcare,44,Sandeep Kulkarni,"27 West 24th Street, Suite 702
New York, New York 10010
United States",646 481 9832,tourmalinebio.com,TRML,NASDAQ,January - December,USD,0001827506,,US89157D1054,2836,,Common Stock,,,
"Altimmune, Inc.","Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015.
Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.","Data/company_logos_stock_analysis\Altimmune,_Inc._logo.svg",https://stockanalysis.com/stocks/alt/,United States,1997,Biotechnology,Healthcare,59,Vipin Garg,"910 Clopper Road, Suite 201S
Gaithersburg, Maryland 20878
United States",240 654 1450,altimmune.com,ALT,NASDAQ,January - December,USD,0001326190,02155H200,US02155H2004,2834,,,20-2726770,,
"Mineralys Therapeutics, Inc.","Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases.
It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.
The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.","Data/company_logos_stock_analysis\Mineralys_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/mlys/,United States,2019,Biotechnology,Healthcare,28,Jon Congleton,"150 N. Radnor Chester Rd., Suite F200
Radnor, Pennsylvania 19087
United States",888 378 6240,mineralystx.com,MLYS,NASDAQ,January - December,USD,0001933414,603170101,US6031701013,2834,"Feb 10, 2023",Common Stock,,$16.00,
Arcturus Therapeutics Holdings Inc.,"Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases.
Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis.
Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial.
Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.",Data/company_logos_stock_analysis\Arcturus_Therapeutics_Holdings_Inc._logo.svg,https://stockanalysis.com/stocks/arct/,United States,2013,Biotechnology,Healthcare,180,Joseph Payne,"10628 Science Center Drive, Suite 250
San Diego, California 92121
United States",858 900 2660,arcturusrx.com,ARCT,NASDAQ,January - December,USD,0001566049,03969T109,US03969T1097,2834,,,,,
MeiraGTx Holdings plc,"MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases.
The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.
Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson’s program that has completed a Phase II trial.
It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease.
The company was incorporated in 2015 and is based in New York, New York.",Data/company_logos_stock_analysis\MeiraGTx_Holdings_plc_logo.svg,https://stockanalysis.com/stocks/mgtx/,United States,2015,Biotechnology,Healthcare,425,Alexandria Forbes,"450 East 29th Street, 14th Floor
New York, New York 10016
United States",646 860 7985,meiragtx.com,MGTX,NASDAQ,January - December,USD,0001735438,G59665102,KYG596651029,2836,,,98-1448305,,
"Stoke Therapeutics, Inc.","Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States.
The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy.
The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye.
The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system.
The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.
Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.","Data/company_logos_stock_analysis\Stoke_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/stok/,United States,2014,Biotechnology,Healthcare,110,Edward Kaye,"45 Wiggins Avenue
Bedford, Massachusetts 01730
United States",781 430 8200,stoketherapeutics.com,STOK,NASDAQ,January - December,USD,0001623526,86150R107,US86150R1077,2834,"Jun 19, 2019",,47-1144582,$18.00,
"Phathom Pharmaceuticals, Inc.","Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection.
The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.","Data/company_logos_stock_analysis\Phathom_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/phat/,United States,2018,Biotechnology,Healthcare,452,Terrie Curran,"100 Campus Drive, Suite 102
Florham Park, New Jersey 07932
United States",877 742 8466,phathompharma.com,PHAT,NASDAQ,January - December,USD,0001783183,71722W107,US71722W1071,2834,"Oct 25, 2019",Common Stock,82-4151574,$19.00,
ProKidney Corp.,"ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States.
The company’s lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.",Data/company_logos_stock_analysis\ProKidney_Corp._logo.svg,https://stockanalysis.com/stocks/prok/,United States,2015,Biotechnology,Healthcare,163,Bruce Culleton,"2000 Frontis Plaza Blvd., Suite 250
Winston-Salem, North Carolina 27103
United States",336 999 7028,prokidney.com,PROK,NASDAQ,January - December,USD,0001850270,,KYG7S53R1049,2836,,,98-1586514,,Class A Shares
"Verve Therapeutics, Inc.","Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States.
The company’s lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.
It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College.
The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019.
Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Verve_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/verv/,United States,2018,Biotechnology,Healthcare,255,Sekar Kathiresan,"201 Brookline Avenue, Suite 601
Cambridge, Massachusetts 02215
United States",617 603 0070,vervetx.com,VERV,NASDAQ,January - December,USD,0001840574,92539P101,US92539P1012,2834,"Jun 17, 2021",Common Stock,82-4800132,$19.00,
"Esperion Therapeutics, Inc.","Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).
Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.
The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH.
Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.","Data/company_logos_stock_analysis\Esperion_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/espr/,United States,2008,Drug Manufacturers - Specialty & Generic,Healthcare,240,Sheldon Koenig,"3891 Ranchero Drive, Suite 150
Ann Arbor, Michigan 48108
United States",734 887 3903,esperion.com,ESPR,NASDAQ,January - December,USD,0001434868,29664W105,US29664W1053,2834,"Jun 26, 2013",Common Stock,,,
GH Research PLC,"GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders.
It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
The company’s lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression.
It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders.
The company was founded in 2018 and is based in Dublin, Ireland.",Data/company_logos_stock_analysis\GH_Research_PLC_logo.svg,https://stockanalysis.com/stocks/ghrs/,Ireland,2018,Biotechnology,Healthcare,49,Velichka Valcheva,"Joshua Dawson House, Dawson Street
Dublin, D02 RY95
Ireland",353 1 437 8334,ghres.com,GHRS,NASDAQ,January - December,USD,0001855129,G3855L106,IE000GID8VI0,2834,"Jun 25, 2021",,,$16.00,
"SIGA Technologies, Inc.","SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States.
Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
The company was incorporated in 1995 and is headquartered in New York, New York.","Data/company_logos_stock_analysis\SIGA_Technologies,_Inc._logo.svg",https://stockanalysis.com/stocks/siga/,United States,1995,Drug Manufacturers - Specialty & Generic,Healthcare,45,Diem Nguyen,"31 East 62nd Street
New York, New York 10065
United States",212 672 9100,siga.com,SIGA,NASDAQ,January - December,USD,0001010086,826917106,US8269171067,2834,"Sep 9, 1997",Common Stock,13-3864870,,
Celcuity Inc.,"Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
The company’s CELsignia diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the related targeted therapy for the treatment.
Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer.
It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib.
The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.",Data/company_logos_stock_analysis\Celcuity_Inc._logo.svg,https://stockanalysis.com/stocks/celc/,United States,2011,Biotechnology,Healthcare,55,Brian Sullivan,"16305–36th Avenue North, Suite 100
Minneapolis, Minnesota 55446
United States",763 392 0767,celcuity.com,CELC,NASDAQ,January - December,USD,0001603454,15102K100,US15102K1007,8071,"Sep 20, 2017",,,,
Kodiak Sciences Inc.,"Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
The company’s preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions.
The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015.
Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.",Data/company_logos_stock_analysis\Kodiak_Sciences_Inc._logo.svg,https://stockanalysis.com/stocks/kod/,United States,2009,Biotechnology,Healthcare,111,Victor Perlroth,"1200 Page Mill Road
Palo Alto, California 94304
United States",650 281 0850,kodiak.com,KOD,NASDAQ,January - December,USD,0001468748,50015M109,US50015M1099,2836,"Oct 4, 2018",Common Stock,27-0476525,,
"Cartesian Therapeutics, Inc.","Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases.
It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases.
Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.","Data/company_logos_stock_analysis\Cartesian_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/rnac/,United States,2007,Biotechnology,Healthcare,38,Carsten Brunn,"704 Quince Orchard Road
Gaithersburg, Maryland 20878
United States",617 923 1400,cartesiantherapeutics.com,RNAC,NASDAQ,January - December,USD,0001453687,816212104,US8162123025,2834,"Jun 22, 2016",Common Stock,,,
"Zevra Therapeutics, Inc.","Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.
The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.
In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder.
The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA.
The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023.
Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.","Data/company_logos_stock_analysis\Zevra_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/zvra/,United States,2006,Biotechnology,Healthcare,69,Neil McFarlane,"1180 Celebration Boulevard, Suite 103
Celebration, Florida 34747
United States",321 939 3416,zevra.com,ZVRA,NASDAQ,January - December,USD,0001434647,,US4884452065,2834,"Apr 16, 2015",Common Stock,20-5894398,,
UroGen Pharma Ltd.,"UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).
It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H.
to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma.
UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.",Data/company_logos_stock_analysis\UroGen_Pharma_Ltd._logo.svg,https://stockanalysis.com/stocks/urgn/,United States,2004,Biotechnology,Healthcare,201,Elizabeth Barrett,"400 Alexander Park Drive, 4th Floor
Princeton, New Jersey 08540
United States",646 768 9780,urogen.com,URGN,NASDAQ,January - December,USD,0001668243,M96088105,IL0011407140,2834,"May 4, 2017",,,,
"Theravance Biopharma, Inc.","Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe.
It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD).
The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.
It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.","Data/company_logos_stock_analysis\Theravance_Biopharma,_Inc._logo.svg",https://stockanalysis.com/stocks/tbph/,United States,2013,Biotechnology,Healthcare,99,Rick Winningham,"901 Gateway Boulevard
South San Francisco, California 94080
United States",650 808 6000,theravance.com,TBPH,NASDAQ,January - December,USD,0001583107,G8807B106,KYG8807B1068,2834,,,,,
"Allogene Therapeutics, Inc.","Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.
It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia.
In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer.
The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3.
The company was incorporated in 2017 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Allogene_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/allo/,United States,2017,Biotechnology,Healthcare,233,David Chang,"210 East Grand Avenue
South San Francisco, California 94080
United States",650 457 2700,allogene.com,ALLO,NASDAQ,January - December,USD,0001737287,019770106,US0197701065,2836,"Oct 11, 2018",Common Stock,82-3562771,,
"AnaptysBio, Inc.","AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics.
Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006.
AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.","Data/company_logos_stock_analysis\AnaptysBio,_Inc._logo.svg",https://stockanalysis.com/stocks/anab/,United States,2005,Biotechnology,Healthcare,117,Daniel Faga,"10770 Wateridge Circle, Suite 210
San Diego, California 92121-5801
United States",858 362 6295,anaptysbio.com,ANAB,NASDAQ,January - December,USD,0001370053,032724106,US0327241065,2834,"Jan 26, 2017",Common Stock,20-3828755,,
Kamada Ltd.,"Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B.
In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers.
The company was incorporated in 1990 and is headquartered in Rehovot, Israel.",Data/company_logos_stock_analysis\Kamada_Ltd._logo.svg,https://stockanalysis.com/stocks/kmda/,Israel,1990,Drug Manufacturers - Specialty & Generic,Healthcare,378,Amir London,"2 Holzman Street, Science Park
Rehovot, 7670402
Israel",972 8 940 6472,kamada.com,KMDA,NASDAQ,January - December,USD,0001567529,M6240T109,IL0010941198,2834,,,,,
"Alpha Teknova, Inc.","Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.
The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions.
Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.","Data/company_logos_stock_analysis\Alpha_Teknova,_Inc._logo.svg",https://stockanalysis.com/stocks/tkno/,United States,1996,Drug Manufacturers - Specialty & Generic,Healthcare,211,Stephen Gunstream,"2451 Bert Dr.
Hollister, California 95023
United States",831 637 1100,teknova.com,TKNO,NASDAQ,January - December,USD,0001850902,02080L102,US02080L1026,2835,"Jun 25, 2021",Common Stock,94-3368109,$16.00,
"Astria Therapeutics, Inc.","Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching.
The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021.
Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Astria_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/atxs/,United States,2008,Biotechnology,Healthcare,59,Jill Milne,"75 State Street, Suite 1400
Boston, Massachusetts 02109
United States",617 349 1971,astriatx.com,ATXS,NASDAQ,January - December,USD,0001454789,04635X102,US04635X1028,2834,"Jun 25, 2015",,,,
ABIVAX Société Anonyme,"ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases.
The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.",Data/company_logos_stock_analysis\ABIVAX_Société_Anonyme_logo.svg,https://stockanalysis.com/stocks/abvx/,France,2013,Biotechnology,Healthcare,61,Marc M. de Garidel,"7-11 boulevard Haussmann
Paris, 75009
France",33 1 53 83 09 63,abivax.com,ABVX,NASDAQ,January - December,EUR,0001956827,,US00370M1036,2834,,,,$11.60,
"Terns Pharmaceuticals, Inc.","Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity.
The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity.
The company was incorporated in 2016 and is headquartered in Foster City, California.","Data/company_logos_stock_analysis\Terns_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/tern/,United States,2017,Biotechnology,Healthcare,66,Amy Burroughs,"1065 East Hillsdale Boulevard, Suite 100
Foster City, California 94404
United States",650 525 5535,ternspharma.com,TERN,NASDAQ,January - December,USD,0001831363,880881107,US8808811074,2834,"Feb 5, 2021",Common Stock,,$17.00,
"OmniAb, Inc.","OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States.
The company’s technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners’ drug development efforts.
Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
The company’s OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities.
OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.","Data/company_logos_stock_analysis\OmniAb,_Inc._logo.svg",https://stockanalysis.com/stocks/oabi/,United States,2012,Biotechnology,Healthcare,106,Matthew Foehr,"5980 Horton Street, Suite 600
EmeryVille, California 94608
United States",510 250 7800,omniab.com,OABI,NASDAQ,January - December,USD,0001846253,68218J103,US68218J1034,8731,,Common Stock,,,
PureTech Health plc,"PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders.
In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development.
The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.",Data/company_logos_stock_analysis\PureTech_Health_plc_logo.svg,https://stockanalysis.com/stocks/prtc/,United States,2015,Biotechnology,Healthcare,90,Bharatt Chowrira,"6 Tide Street, Suite 400
Boston, Massachusetts 02210
United States",617 482 2333,puretechhealth.com,PRTC,NASDAQ,January - December,USD,0001782999,746237106,US7462371060,2834,,,,,
Organogenesis Holdings Inc.,"Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States.
The company’s advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold.
The company’s pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns.
It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies.
Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.",Data/company_logos_stock_analysis\Organogenesis_Holdings_Inc._logo.svg,https://stockanalysis.com/stocks/orgo/,United States,1985,Drug Manufacturers - Specialty & Generic,Healthcare,862,Gary Gillheeney,"85 Dan Road
Canton, Massachusetts 02021
United States",781 575 0775,organogenesis.com,ORGO,NASDAQ,January - December,USD,0001661181,68621F102,US68621F1021,2834,,Common Stock,,,Class A Shares
enGene Holdings Inc.,"enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer.
Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG).
enGene Holdings Inc. is based in Montreal, Canada.",Data/company_logos_stock_analysis\enGene_Holdings_Inc._logo.svg,https://stockanalysis.com/stocks/engn/,Canada,1999,Biotechnology,Healthcare,57,Ronald H. Cooper,"4868 Rue Levy, Suite 220
Montreal, QC H4R 2P1
Canada",514 332 4888,engene.com,ENGN,NASDAQ,November - October,USD,0001980845,46429B226,CA29286M1059,2836,,,,,Class A Shares
"KalVista Pharmaceuticals, Inc.","KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.
The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks.
The company is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\KalVista_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/kalv/,United States,,Biotechnology,Healthcare,150,Benjamin Palleiko,"55 Cambridge Parkway, Suite 901 East
Cambridge, Massachusetts 02142
United States",857 999 0075,kalvista.com,KALV,NASDAQ,May - April,USD,0001348911,483497103,US4834971032,2834,,,20-0915291,,
Alumis Inc.,"Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases.
The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022.
The company was incorporated in 2021 and is headquartered in South San Francisco, California.",Data/company_logos_stock_analysis\Alumis_Inc._logo.svg,https://stockanalysis.com/stocks/alms/,United States,2021,Biotechnology,Healthcare,109,Martin Babler,"280 East Grand Avenue
South San Francisco, California 94080
United States",650 231 6625,alumis.com,ALMS,NASDAQ,January - December,USD,0001847367,,US0223071020,2834,"Jun 28, 2024",Common Stock,,$16.00,
"Akebia Therapeutics, Inc.","Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.
The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth.
It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide.
Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Akebia_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/akba/,United States,2007,Drug Manufacturers - Specialty & Generic,Healthcare,167,John Butler,"245 First Street, Suite 1400
Cambridge, Massachusetts 02142
United States",617 871 2098,akebia.com,AKBA,NASDAQ,January - December,USD,0001517022,00972D105,US00972D1054,2834,"Mar 20, 2014",Common Stock,20-8756903,,
"Third Harmonic Bio, Inc.","Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases.
The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions.
The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019.
Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.","Data/company_logos_stock_analysis\Third_Harmonic_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/thrd/,United States,2019,Biotechnology,Healthcare,30,Natalie Holles,"1700 Montgomery Street, Suite 210
San Francisco, California 94111
United States",209 727 2457,thirdharmonicbio.com,THRD,NASDAQ,January - December,USD,0001923840,88427A107,US88427A1079,2834,"Sep 15, 2022",Common Stock,83-4553503,$17.00,
"Prime Medicine, Inc.","Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology.
The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.
The company has a strategic research collaboration and license agreement with bristol myers squibb to develop and commercialize multiple prime edited ex vivo t-cell therapies.
Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Prime_Medicine,_Inc._logo.svg",https://stockanalysis.com/stocks/prme/,United States,2019,Biotechnology,Healthcare,234,Keith Gottesdiener,"21 Erie Street
Cambridge, Massachusetts 02139
United States",617 564 0013,primemedicine.com,PRME,NASDAQ,January - December,USD,0001894562,74168J101,US74168J1016,2836,"Oct 20, 2022",Common Stock,,$17.00,
"Aura Biosciences, Inc.","Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors.
The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer.
The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette–guérin therapy.
Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Aura_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/aura/,United States,2007,Biotechnology,Healthcare,89,Elisabet de los Pinos,"80 Guest Street, 5th Floor
Boston, Massachusetts 02135
United States",617 500 8864,aurabiosciences.com,AURA,NASDAQ,January - December,USD,0001501796,05153U107,US05153U1079,2836,"Oct 29, 2021",Common Stock,32-0271970,$14.00,
"Olema Pharmaceuticals, Inc.","Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.
Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009.
Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.","Data/company_logos_stock_analysis\Olema_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/olma/,United States,2006,Biotechnology,Healthcare,74,Sean Bohen,"780 Brannan Street
San Francisco, California 94103
United States",415 651 3316,olema.com,OLMA,NASDAQ,January - December,USD,0001750284,68062P106,US68062P1066,2834,"Nov 19, 2020",Common Stock,30-0409740,$19.00,
REGENXBIO Inc.,"REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease.
In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies.
Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States.
REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.",Data/company_logos_stock_analysis\REGENXBIO_Inc._logo.svg,https://stockanalysis.com/stocks/rgnx/,United States,2008,Biotechnology,Healthcare,344,Curran Simpson,"9804 Medical Center Drive
Rockville, Maryland 20850
United States",240 552 8181,regenxbio.com,RGNX,NASDAQ,January - December,USD,0001590877,75901B107,US75901B1070,2836,"Sep 17, 2015",,47-1851754,,
Valneva SE,"Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally.
Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine.
The company was founded in 1998 and is based in Saint-Herblain, France.",Data/company_logos_stock_analysis\Valneva_SE_logo.svg,https://stockanalysis.com/stocks/valn/,France,2012,Biotechnology,Healthcare,676,Thomas Lingelbach,"6 rue Alain Bombard
Saint-Herblain, 44800
France",33 2 28 07 37 10,valneva.com,VALN,NASDAQ,January - December,EUR,0001836564,92025Y103,US92025Y1038,2836,"May 6, 2021",,,$26.41,
"Taysha Gene Therapies, Inc.","Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center.
Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.","Data/company_logos_stock_analysis\Taysha_Gene_Therapies,_Inc._logo.svg",https://stockanalysis.com/stocks/tsha/,United States,2019,Biotechnology,Healthcare,52,Sean Nolan,"3000 Pegasus Park Drive, Suite 1430
Dallas, Texas 75247
United States",214 612 0000,tayshagtx.com,TSHA,NASDAQ,January - December,USD,0001806310,877619106,US8776191061,2836,"Sep 24, 2020",Common Stock,84-3199512,$20.00,
"Codexis, Inc.","Codexis, Inc. discovers, develops, and sells enzymes and other proteins.
The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services.
The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.
The company’s platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency.
The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe.
The company was incorporated in 2002 and is headquartered in Redwood City, California.","Data/company_logos_stock_analysis\Codexis,_Inc._logo.svg",https://stockanalysis.com/stocks/cdxs/,United States,2002,Biotechnology,Healthcare,174,Stephen Dilly,"200 Penobscot Drive
Redwood City, California 94063
United States",650 421 8100,codexis.com,CDXS,NASDAQ,January - December,USD,0001200375,192005106,US1920051067,2860,"Apr 22, 2010",Common Stock,71-0872999,,
"Neumora Therapeutics, Inc.","Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.
The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders.
In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease.
The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.
Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.","Data/company_logos_stock_analysis\Neumora_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/nmra/,United States,2019,Biotechnology,Healthcare,124,Henry Gosebruch,"490 Arsenal Way, Suite 200
Watertown, Massachusetts 02472
United States",857 760 0900,neumoratx.com,NMRA,NASDAQ,January - December,USD,0001885522,640979100,US6409791000,2836,"Sep 15, 2023",Common Stock,84-4367680,$17.00,
"Monte Rosa Therapeutics, Inc.","Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins.
The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1ᵦ/NLRP3 driven inflammatory diseases.
It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Monte_Rosa_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/glue/,United States,2019,Biotechnology,Healthcare,133,Markus Warmuth,"321 Harrison Avenue, Suite 900
Boston, Massachusetts 02118
United States",617 949 2643,monterosatx.com,GLUE,NASDAQ,January - December,USD,0001826457,61225M102,US61225M1027,2836,"Jun 24, 2021",Common Stock,,$19.00,
"Precigen, Inc.","Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification.
It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors.
In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus.
Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications.
The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020.
Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.","Data/company_logos_stock_analysis\Precigen,_Inc._logo.svg",https://stockanalysis.com/stocks/pgen/,United States,1998,Biotechnology,Healthcare,202,Helen Sabzevari,"20358 Seneca Meadows Parkway
Germantown, Maryland 20876
United States",301 556 9900,precigen.com,PGEN,NASDAQ,January - December,USD,0001356090,74017N105,US74017N1054,2834,,Common Stock,,,
"Eton Pharmaceuticals, Inc.","Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases.
The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.","Data/company_logos_stock_analysis\Eton_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/eton/,United States,2017,Drug Manufacturers - Specialty & Generic,Healthcare,30,Sean Brynjelsen,"21925 W. Field Parkway, Suite 235
Deer Park, Illinois 60010-7278
United States",847 787 7361,etonpharma.com,ETON,NASDAQ,January - December,USD,0001710340,29772L108,US29772L1089,2834,"Nov 13, 2018",Common Stock,37-1858472,,
"Contineum Therapeutics, Inc.","Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.
Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.
Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023.
The company was incorporated in 2009 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Contineum_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ctnm/,United States,2009,Biotechnology,Healthcare,31,Carmine Stengone,"10578 Science Center Drive, Suite 200
San Diego, California 92121
United States",858 333 5280,contineum-tx.com,CTNM,NASDAQ,January - December,USD,0001855175,,US21217B1008,2834,"Apr 5, 2024",Common Stock,27-1467257,$16.00,Class A Shares
"Revance Therapeutics, Inc.","Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.
The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids.
It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA.
The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005.
Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.","Data/company_logos_stock_analysis\Revance_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/rvnc/,United States,1999,Biotechnology,Healthcare,597,Mark Foley,"1222 Demonbreun Street, Suite 2000
Nashville, Tennessee 37203
United States",615 724 7755,revance.com,RVNC,NASDAQ,January - December,USD,0001479290,761330109,US7613301099,2834,"Feb 6, 2014",Common Stock,77-0551645,,
"Sage Therapeutics, Inc.","Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines.
Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington’s disease, Parkinson’s diseases, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain.
The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products.
The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011.
Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Sage_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/sage/,United States,2010,Biotechnology,Healthcare,487,Barry Greene,"215 First Street
Cambridge, Massachusetts 02142
United States",617 299 8380,sagerx.com,SAGE,NASDAQ,January - December,USD,0001597553,78667J108,US78667J1088,2834,"Jul 18, 2014",Common Stock,,,
"Zenas BioPharma, Inc.","Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.
Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia.
The company also develops ZB002, an anti-TNFα monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody.
Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023.
The company was incorporated in 2019 and is based in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Zenas_BioPharma,_Inc._logo.svg",https://stockanalysis.com/stocks/zbio/,United States,2019,Biotechnology,Healthcare,114,Leon Moulder,"North Building, Suite 1200
Waltham, Massachusetts 02451
United States",857 271 2954,zenasbio.com,ZBIO,NASDAQ,January - December,USD,0001953926,,US98937L1052,2834,"Sep 13, 2024",Common Stock,,$17.00,
"Corvus Pharmaceuticals, Inc.","Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases.
Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer.
In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis.
Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab.
Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.","Data/company_logos_stock_analysis\Corvus_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/crvs/,United States,2014,Biotechnology,Healthcare,28,Richard Miller,"863 Mitten Road, Suite 102
Burlingame, California 94010
United States",650 900 4520,corvuspharma.com,CRVS,NASDAQ,January - December,USD,0001626971,221015100,US2210151005,2834,"Mar 23, 2016",Common Stock,46-4670809,,
"Korro Bio, Inc.","Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States.
Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain.
Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases.
Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Korro_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/krro/,United States,2014,Biotechnology,Healthcare,102,Ram Aiyar,"One Kendall Square, Building 600-700
Cambridge, Massachusetts 02139
United States",617 468 1999,korrobio.com,KRRO,NASDAQ,January - December,USD,0001703647,500946108,US5009461089,2834,"Oct 3, 2019",,47-2324450,$14.00,
Absci Corporation,"Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.
The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI.
The company was founded in 2011 and is headquartered in Vancouver, Washington.",Data/company_logos_stock_analysis\Absci_Corporation_logo.svg,https://stockanalysis.com/stocks/absi/,United States,2011,Biotechnology,Healthcare,155,Sean McClain,"18105 SE Mill Plain Boulevard
Vancouver, Washington 98683
United States",360 949 1041,absci.com,ABSI,NASDAQ,January - December,USD,0001672688,00091E109,US00091E1091,8731,"Jul 22, 2021",Common Stock,85-3383487,$16.00,
"Y-mAbs Therapeutics, Inc.","Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally.
It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform.
In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products.
Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.","Data/company_logos_stock_analysis\Y-mAbs_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ymab/,United States,2015,Biotechnology,Healthcare,100,Michael Rossi,"230 Park Avenue, Suite 3350
New York, New York 10169
United States",646 885 8505,ymabs.com,YMAB,NASDAQ,January - December,USD,0001722964,984241109,US9842411095,2834,"Sep 21, 2018",Common Stock,47-4619612,,
"Tango Therapeutics, Inc.","Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer.
Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers.
It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer.
Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Tango_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/tngx/,United States,2014,Biotechnology,Healthcare,140,Barbara Weber,"201 Brookline Avenue, Suite 901
Boston, Massachusetts 02215
United States",857 320 4900,tangotx.com,TNGX,NASDAQ,January - December,USD,0001819133,87583X109,US87583X1090,2834,,Common Stock,,,
"Voyager Therapeutics, Inc.","Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases.
The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer’s disease.
Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer’s disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer’s disease and is in preclinical trial.
In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich’s ataxia; and GBA1 gene replacement to treat parkinson’s disease and is in preclinical trial.
Further, it provides research program for the treatment of Huntington’s disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.","Data/company_logos_stock_analysis\Voyager_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/vygr/,United States,2013,Biotechnology,Healthcare,162,Alfred Sandrock,"75 Hayden Avenue
Lexington, Massachusetts 02421
United States",857 259 5340,voyagertherapeutics.com,VYGR,NASDAQ,January - December,USD,0001640266,92915B106,US92915B1061,2836,"Nov 11, 2015",Common Stock,,,
"aTyr Pharma, Inc.","aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States.
Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.
It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan.
aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\aTyr_Pharma,_Inc._logo.svg",https://stockanalysis.com/stocks/atyr/,United States,2005,Biotechnology,Healthcare,59,Sanjay Shukla,"10240 Sorrento Valley Road, Suite 300
San Diego, California 92121
United States",858 731 8389,atyrpharma.com,ATYR,NASDAQ,January - December,USD,0001339970,,US0021202025,2836,"May 7, 2015",,20-3435077,,
XOMA Royalty Corporation,"XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific.
It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates.
The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024.
XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.",Data/company_logos_stock_analysis\XOMA_Royalty_Corporation_logo.svg,https://stockanalysis.com/stocks/xoma/,United States,1981,Biotechnology,Healthcare,13,Owen Hughes,"2200 Powell Street, Suite 310
EmeryVille, California 94608
United States",510 204 7200,xoma.com,XOMA,NASDAQ,January - December,USD,0000791908,98419J206,US98419J2069,2834,,Common Stock,52-2154066,,
"Aldeyra Therapeutics, Inc.","Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases.
Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases.
The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss.
In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy.
The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.
Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.","Data/company_logos_stock_analysis\Aldeyra_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/aldx/,United States,2004,Biotechnology,Healthcare,10,Todd Brady,"131 Hartwell Avenue, Suite 320
Lexington, Massachusetts 02421
United States",781 761 4904,aldeyra.com,ALDX,NASDAQ,January - December,USD,0001341235,01438T106,US01438T1060,2834,"May 2, 2014",Common Stock,,,
"Trevi Therapeutics, Inc.","Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis.
It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation.
The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.","Data/company_logos_stock_analysis\Trevi_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/trvi/,United States,2011,Biotechnology,Healthcare,25,Jennifer Good,"195 Church Street, 16th Floor
New Haven, Connecticut 06510
United States",203 304 2499,trevitherapeutics.com,TRVI,NASDAQ,January - December,USD,0001563880,89532M101,US89532M1018,2834,"May 7, 2019",,45-0834299,$10.00,
"Chimerix, Inc.","Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases.
Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox.
Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.","Data/company_logos_stock_analysis\Chimerix,_Inc._logo.svg",https://stockanalysis.com/stocks/cmrx/,United States,2000,Biotechnology,Healthcare,72,Michael Andriole,"2505 Meridian Parkway, Suite 100
Durham, North Carolina 27713
United States",919 806 1074,chimerix.com,CMRX,NASDAQ,January - December,USD,0001117480,16934W106,US16934W1062,2834,"Apr 11, 2013",Common Stock,33-0903395,,
Neurogene Inc.,"Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases.
The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC.
The company is headquartered in New York, New York.",Data/company_logos_stock_analysis\Neurogene_Inc._logo.svg,https://stockanalysis.com/stocks/ngne/,United States,2003,Biotechnology,Healthcare,91,Rachel McMinn,"535 W 24th Street, 5th Floor
New York, New York 10011
United States",855 508 3568,neurogene.com,NGNE,NASDAQ,January - December,USD,0001404644,64135M105,US64135M1053,2834,,Common Stock,98-0542593,,
Immutep Limited,"Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.
Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers.
The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.
In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development.
Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer.
Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings.
The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017.
The company was incorporated in 1987 and is based in Sydney, Australia.",Data/company_logos_stock_analysis\Immutep_Limited_logo.svg,https://stockanalysis.com/stocks/immp/,Australia,1987,Biotechnology,Healthcare,31,Marc Voigt,"Australia Square, Level 32
Sydney, NSW 2000
Australia",61 2 8315 7003,immutep.com,IMMP,NASDAQ,July - June,AUD,0001692528,45257L108,US45257L1089,,,,,,
"Rigel Pharmaceuticals, Inc.","Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.
The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company.
In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo.
The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers.
The company was incorporated in 1996 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Rigel_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/rigl/,United States,1996,Biotechnology,Healthcare,147,Raul Rodriguez,"611 Gateway Blvd, Suite 900
South San Francisco, California 94080
United States",650 624 1100,rigel.com,RIGL,NASDAQ,January - December,USD,0001034842,766559603,US7665596034,2834,"Nov 29, 2000",Common Stock,94-3248524,,
"Rezolute, Inc.","Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
The company’s lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema.
The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.
Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.","Data/company_logos_stock_analysis\Rezolute,_Inc._logo.svg",https://stockanalysis.com/stocks/rzlt/,United States,2010,Biotechnology,Healthcare,59,Nevan Elam,"275 Shoreline Drive, Suite 500
Redwood City, California 94065
United States",650 206 4507,rezolutebio.com,RZLT,NASDAQ,July - June,USD,0001509261,76200L309,US76200L3096,2834,,Common Stock,27-3440894,,
Silence Therapeutics plc,"Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
The company’s mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera.
It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2.
It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders.
The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007.
Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.",Data/company_logos_stock_analysis\Silence_Therapeutics_plc_logo.svg,https://stockanalysis.com/stocks/sln/,United Kingdom,1994,Biotechnology,Healthcare,109,Craig Tooman,"72 Hammersmith Road
London, W14 8TH
United Kingdom",44 20 3457 6900,silence-therapeutics.com,SLN,NASDAQ,January - December,GBP,0001479615,82686Q101,US82686Q1013,2834,,,,,
"iTeos Therapeutics, Inc.","Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer.
The company’s lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or FcγR to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials.
Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.","Data/company_logos_stock_analysis\iTeos_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/itos/,United States,2011,Biotechnology,Healthcare,157,Michel Detheux,"321 Arsenal Street, Suite 301
Watertown, Massachusetts 02472
United States",339 217 0161,iteostherapeutics.com,ITOS,NASDAQ,January - December,USD,0001808865,46565G104,US46565G1040,2836,"Jul 24, 2020",Common Stock,,$19.00,
"Aquestive Therapeutics, Inc.","Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis.
The company’s proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis.
In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.","Data/company_logos_stock_analysis\Aquestive_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/aqst/,United States,2004,Drug Manufacturers - Specialty & Generic,Healthcare,135,Daniel Barber,"30 Technology Drive
Warren, New Jersey 07059
United States",908 941 1900,aquestive.com,AQST,NASDAQ,January - December,USD,0001398733,03843E104,US03843E1047,2834,"Jul 25, 2018",Common Stock,20-8623253,,
"Lexicon Pharmaceuticals, Inc.","Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.
Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.","Data/company_logos_stock_analysis\Lexicon_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/lxrx/,United States,1995,Biotechnology,Healthcare,285,Michael Exton,"2445 Technology Forest Boulevard, 11th Floor
The Woodlands, Texas 77381
United States",281 863 3000,lexpharma.com,LXRX,NASDAQ,January - December,USD,0001062822,528872302,US5288723027,2834,"Apr 7, 2000",,76-0474169,,
"Atea Pharmaceuticals, Inc.","Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections.
Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.
The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19.
It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV.
Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Atea_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/avir/,United States,2012,Biotechnology,Healthcare,75,Jean-Pierre Sommadossi,"225 Franklin Street, Suite 2100
Boston, Massachusetts 02110
United States",857 284 8891,ateapharma.com,AVIR,NASDAQ,January - December,USD,0001593899,04683R106,US04683R1068,2834,"Oct 30, 2020",Common Stock,46-0574869,$24.00,
Bright Minds Biosciences Inc.,"Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.
Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.
The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications.
Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin.
The company was founded in 2017 and is headquartered in New York, New York.",Data/company_logos_stock_analysis\Bright_Minds_Biosciences_Inc._logo.svg,https://stockanalysis.com/stocks/drug/,United States,2019,Biotechnology,Healthcare,,Ian McDonald,"19 Vestry Street
New York, New York 10013
United States",647 865 8622,brightmindsbio.com,DRUG,NASDAQ,October - September,CAD,0001827401,10919W108,CA10919W4056,2834,,,,,
AC Immune SA,"AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer’s disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD.
The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson’s disease; and ACI-35.030, designs to stimulate a patient’s immune system to produce antibodies against pathological phosphorylated Tau.
In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease.
Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies.
Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3.
The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company.
AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.",Data/company_logos_stock_analysis\AC_Immune_SA_logo.svg,https://stockanalysis.com/stocks/aciu/,Switzerland,2003,Biotechnology,Healthcare,161,Andrea Pfeifer,"Building B, EPFL Innovation Park
Lausanne, 1015
Switzerland",41 21 345 91 21,acimmune.com,ACIU,NASDAQ,January - December,CHF,0001651625,H00263105,CH0329023102,2834,"Sep 23, 2016",,,,
Vanda Pharmaceuticals Inc.,"Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia.
The company’s pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules.
In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera.
Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.",Data/company_logos_stock_analysis\Vanda_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/vnda/,United States,2002,Biotechnology,Healthcare,203,Mihael Polymeropoulos,"2200 Pennsylvania Avenue NW, Suite 300E
Washington, District of Columbia 20037
United States",202 734 3400,vandapharma.com,VNDA,NASDAQ,January - December,USD,0001347178,921659108,US9216591084,2834,"Apr 12, 2006",Common Stock,03-0491827,,
"Candel Therapeutics, Inc.","Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.
It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma.
It also develops the enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020.
Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.","Data/company_logos_stock_analysis\Candel_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/cadl/,United States,1999,Biotechnology,Healthcare,42,Paul-Peter Tak,"117 Kendrick Street, Suite 450
Needham, Massachusetts 02494
United States",617 916 5445,candeltx.com,CADL,NASDAQ,January - December,USD,0001841387,137404109,US1374041093,2836,"Jul 27, 2021",Common Stock,52-2214851,$8.00,
"Cidara Therapeutics, Inc.","Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases.
The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials.
The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014.
The company was incorporated in 2012 and is based in San Diego, California.","Data/company_logos_stock_analysis\Cidara_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/cdtx/,United States,2012,Biotechnology,Healthcare,69,Jeffrey Stein,"6310 Nancy Ridge Drive, Suite 101
San Diego, California 92121
United States",858 752 6170,cidara.com,CDTX,NASDAQ,January - December,USD,0001610618,171757107,US1717571079,2836,"Apr 15, 2015",,46-1537286,,
Canopy Growth Corporation,"Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally.
It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices.
It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands.
The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015.
Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.",Data/company_logos_stock_analysis\Canopy_Growth_Corporation_logo.svg,https://stockanalysis.com/stocks/cgc/,Canada,2009,Drug Manufacturers - Specialty & Generic,Healthcare,"1,029",Luc Mongeau,"1 Hershey Drive
Smiths Falls, ON K7A 0A8
Canada",855 558 9333,canopygrowth.com,CGC,NASDAQ,April - March,CAD,0001737927,138035100,CA1380357048,2833,,,,,
"Design Therapeutics, Inc.","Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.
Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.","Data/company_logos_stock_analysis\Design_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/dsgn/,United States,2017,Biotechnology,Healthcare,58,Pratik Shah,"6005 Hidden Valley Road, Suite 110
Carlsbad, California 92011
United States",858 293 4900,designtx.com,DSGN,NASDAQ,January - December,USD,0001807120,25056L103,US25056L1035,2834,"Mar 26, 2021",Common Stock,82-3929248,$20.00,
Benitec Biopharma Inc.,"Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions.
It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.",Data/company_logos_stock_analysis\Benitec_Biopharma_Inc._logo.svg,https://stockanalysis.com/stocks/bntc/,United States,1995,Biotechnology,Healthcare,16,Jerel Banks,"3940 Trust Way
Hayward, California 94545
United States",510 780 0819,benitec.com,BNTC,NASDAQ,July - June,USD,0001552795,08205P100,US08205P2092,2834,,,,,
"C4 Therapeutics, Inc.","C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.
Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC.
It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.","Data/company_logos_stock_analysis\C4_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/cccc/,United States,2015,Biotechnology,Healthcare,145,Andrew Hirsch,"490 Arsenal Way, Suite120
Watertown, Massachusetts 02472
United States",617 231 0700,c4therapeutics.com,CCCC,NASDAQ,January - December,USD,0001662579,12529R107,US12529R1077,2836,"Oct 2, 2020",Common Stock,47-5617627,$19.00,
"4D Molecular Therapeutics, Inc.","4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States.
The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema.
The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial.
In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development.
The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation.
4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.","Data/company_logos_stock_analysis\4D_Molecular_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/fdmt/,United States,2013,Biotechnology,Healthcare,147,David Kirn,"5858 Horton Street, Suite 455
EmeryVille, California 94608
United States",510 505 2680,4dmoleculartherapeutics.com,FDMT,NASDAQ,January - December,USD,0001650648,35104E100,US35104E1001,2836,"Dec 11, 2020",Common Stock,47-3506994,$23.00,
Atai Life Sciences N.V.,"Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression.
The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology.
In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder.
Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression.
ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.",Data/company_logos_stock_analysis\Atai_Life_Sciences_N.V._logo.svg,https://stockanalysis.com/stocks/atai/,Germany,2018,Biotechnology,Healthcare,83,Srinivas Rao,"Wallstrasse 16
Berlin, 10179
Germany",49 89 2153 9035,atai.life,ATAI,NASDAQ,January - December,USD,0001840904,N0731H103,NL0015000DX5,2834,"Jun 18, 2021",,,$15.00,
Tevogen Bio Holdings Inc.,"Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer.
The company was founded in 2020 and is headquartered in Warren, New Jersey.",Data/company_logos_stock_analysis\Tevogen_Bio_Holdings_Inc._logo.svg,https://stockanalysis.com/stocks/tvgn/,United States,2020,Biotechnology,Healthcare,17,Ryan Saadi,"15 Independence Boulevard, Suite #410
Warren, New Jersey 07059
United States",877 838 6436,tevogen.com,TVGN,NASDAQ,January - December,USD,0001860871,,US88165K1016,2836,,Common Stock,98-1597194,,
"Compass Therapeutics, Inc.","Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States.
The company’s lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies.
The company was founded in 2014 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Compass_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/cmpx/,United States,2014,Biotechnology,Healthcare,32,Thomas Schuetz,"80 Guest Street, Suite 601
Boston, Massachusetts 02135
United States",617 500 8099,compasstherapeutics.com,CMPX,NASDAQ,January - December,USD,0001738021,20454B104,US20454B1044,2836,,Common Stock,,,
ProQR Therapeutics N.V.,"ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).
It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets.
In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.
The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.",Data/company_logos_stock_analysis\ProQR_Therapeutics_N.V._logo.svg,https://stockanalysis.com/stocks/prqr/,Netherlands,2012,Biotechnology,Healthcare,157,Daniel de Boer,"Zernikedreef 9
Leiden, 2333 CK
Netherlands",31 88 166 7000,proqr.com,PRQR,NASDAQ,January - December,EUR,0001612940,N71542109,NL0010872495,2834,"Sep 18, 2014",,,,
"Eledon Pharmaceuticals, Inc.","Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential.
It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation.
The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021.
Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.","Data/company_logos_stock_analysis\Eledon_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/eldn/,United States,2004,Biotechnology,Healthcare,20,David-Alexandre Gros,"19900 MacArthur Boulevard, Suite 550
Irvine, California 92612
United States",949 238 8090,eledon.com,ELDN,NASDAQ,January - December,USD,0001404281,28617K101,US28617K1016,2834,,Common Stock,,,
"Sangamo Therapeutics, Inc.","Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases.
Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine.
The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017.
Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.","Data/company_logos_stock_analysis\Sangamo_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/sgmo/,United States,1995,Biotechnology,Healthcare,405,Alexander Macrae,"501 Canal Blvd
Richmond, California 94804
United States",510 970 6000,sangamo.com,SGMO,NASDAQ,January - December,USD,0001001233,800677106,US8006771062,2836,"Apr 6, 2000",Common Stock,68-0359556,,
Abeona Therapeutics Inc.,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa.
The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.
In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015.
Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.",Data/company_logos_stock_analysis\Abeona_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/abeo/,United States,,Biotechnology,Healthcare,84,Vishwas Seshadri,"6555 Carnegie Avenue, 4th Floor
Cleveland, Ohio 44103
United States",646 813 4701,abeonatherapeutics.com,ABEO,NASDAQ,January - December,USD,0000318306,00289Y107,US00289Y2063,2834,"Sep 19, 1980",Common Stock,83-0221517,,
"Verastem, Inc.","Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205.
It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer’s inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans.
In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen’s KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers.
Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.","Data/company_logos_stock_analysis\Verastem,_Inc._logo.svg",https://stockanalysis.com/stocks/vstm/,United States,2010,Biotechnology,Healthcare,73,Daniel Paterson,"117 Kendrick Street, Suite 500
Needham, Massachusetts 02494
United States",781 292 4200,verastem.com,VSTM,NASDAQ,January - December,USD,0001526119,92337C104,US92337C2035,2834,"Jan 27, 2012",Common Stock,27-3269467,,
Foghorn Therapeutics Inc.,"Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome.
The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma.
It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM.
Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Foghorn_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/fhtx/,United States,2015,Biotechnology,Healthcare,116,Adrian H. Gottschalk,"500 Technology Square, Suite 700
Cambridge, Massachusetts 02139
United States",617 586 3100,foghorntx.com,FHTX,NASDAQ,January - December,USD,0001822462,344174107,US3441741077,2834,"Oct 23, 2020",Common Stock,,$16.00,
"Amylyx Pharmaceuticals, Inc.","Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases.
The company’s products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Amylyx_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/amlx/,United States,2014,Biotechnology,Healthcare,384,Joshua B. Cohen,"43 Thorndike Street
Cambridge, Massachusetts 02141
United States",617 682 0917,amylyx.com,AMLX,NASDAQ,January - December,USD,0001658551,03237H101,US03237H1014,2834,"Jan 7, 2022",Common Stock,46-4600503,$19.00,
"Heron Therapeutics, Inc.","Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care.
The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults.
The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014.
Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.","Data/company_logos_stock_analysis\Heron_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/hrtx/,United States,1983,Biotechnology,Healthcare,126,Craig Collard,"100 Regency Forest Drive, Suite 300
Cary, North Carolina 27518
United States",844 437 6611,herontx.com,HRTX,NASDAQ,January - December,USD,0000818033,427746102,US4277461020,2834,"Aug 26, 1987",Common Stock,94-2875566,,
"Fulcrum Therapeutics, Inc.","Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.
The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases.
It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy.
Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Fulcrum_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/fulc/,United States,2015,Biotechnology,Healthcare,76,Alexander Sapir,"26 Landsdowne Street
Cambridge, Massachusetts 02139
United States",617 651 8851,fulcrumtx.com,FULC,NASDAQ,January - December,USD,0001680581,359616109,US3596161097,2834,"Jul 18, 2019",Common Stock,47-4839948,$16.00,
"Larimar Therapeutics, Inc.","Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease.
Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.","Data/company_logos_stock_analysis\Larimar_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/lrmr/,United States,,Biotechnology,Healthcare,42,Carole Ben-Maimon,"Three Bala Plaza East, Suite 506
Bala Cynwyd, Pennsylvania 19004
United States",844 511 9056,larimartx.com,LRMR,NASDAQ,January - December,USD,0001374690,517125100,US5171251003,2834,,Common Stock,20-3857670,,
"Lifecore Biomedical, Inc.","Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States.
The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.
It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products.
The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022.
Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.","Data/company_logos_stock_analysis\Lifecore_Biomedical,_Inc._logo.svg",https://stockanalysis.com/stocks/lfcr/,United States,1986,Drug Manufacturers - Specialty & Generic,Healthcare,524,Paul Josephs,"3515 Lyman Boulevard
Chaska, Minnesota 55318
United States",(952) 368-4300,lifecore.com,LFCR,NASDAQ,June - May,USD,0001005286,,US5147661046,2834,,Common Stock,94-3025618,,
"Ocugen, Inc.","Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health.
The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult.
In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates.
The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.","Data/company_logos_stock_analysis\Ocugen,_Inc._logo.svg",https://stockanalysis.com/stocks/ocgn/,United States,2013,Biotechnology,Healthcare,65,Shankar Musunuri,"11 Great Valley Parkway
Malvern, Pennsylvania 19355
United States",484 328 4701,ocugen.com,OCGN,NASDAQ,January - December,USD,0001372299,67577C105,US67577C1053,2836,,Common Stock,,,
"Anika Therapeutics, Inc.","Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform.
Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief.
The company’s joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions.
In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products.
The company was founded in 1983 and is headquartered in Bedford, Massachusetts.","Data/company_logos_stock_analysis\Anika_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/anik/,United States,1983,Drug Manufacturers - Specialty & Generic,Healthcare,357,Cheryl Blanchard,"32 Wiggins Avenue
Bedford, Massachusetts 01730
United States",781 457 9000,anika.com,ANIK,NASDAQ,January - December,USD,0000898437,035255108,US0352551081,3841,"Apr 29, 1993",Common Stock,04-3145961,,
"Artiva Biotherapeutics, Inc.","Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate.
The company was incorporated in 2019 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Artiva_Biotherapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/artv/,United States,2019,Biotechnology,Healthcare,43,Fred Aslan,"5505 Morehouse Drive, Suite 100
San Diego, California 92121
United States",858 267 4467,artivabio.com,ARTV,NASDAQ,January - December,USD,0001817241,,,2836,"Jul 19, 2024",Common Stock,86-3614316,$12.00,
Alpha Tau Medical Ltd.,"Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States.
The company’s Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.",Data/company_logos_stock_analysis\Alpha_Tau_Medical_Ltd._logo.svg,https://stockanalysis.com/stocks/drts/,Israel,2015,Biotechnology,Healthcare,121,Uzi Sofer,"Kiryat Hamada Street 5
Jerusalem, 9777605
Israel",972 3 577 4115,alphatau.com,DRTS,NASDAQ,January - December,USD,0001871321,M0740A108,IL0011839383,3841,,,,,
Aurora Cannabis Inc.,"Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally.
It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers medical and consumer cannabis products; supplies propagated vegetables and ornamental plants; and distributes and sells hemp-derived cannabidiol (CBD) products.
The company also cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, dried flowers, vapes, dried milled strains, edibles, concentrates, and strain specific cannabis oils and extracts; and provides patient counseling and outreach services.
Its adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant.
The company was founded in 2013 and is headquartered in Edmonton, Canada.",Data/company_logos_stock_analysis\Aurora_Cannabis_Inc._logo.svg,https://stockanalysis.com/stocks/acb/,Canada,2013,Drug Manufacturers - Specialty & Generic,Healthcare,"1,073",Miguel Martin,"90B Street SW, Suite 2207
Edmonton, AB T6X 1V8
Canada",855 279 4652,auroramj.com,ACB,NASDAQ,April - March,CAD,0001683541,05156X884,CA05156X8504,2833,,,,,
DiaMedica Therapeutics Inc.,"DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke.
Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases.
In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016.
DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.",Data/company_logos_stock_analysis\DiaMedica_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/dmac/,United States,2000,Biotechnology,Healthcare,19,Dietrich Pauls,"301 Carlson Parkway, Suite 210
Minneapolis, Minnesota 55305
United States",(763) 496-5454,diamedica.com,DMAC,NASDAQ,January - December,USD,0001401040,25253X207,CA25253X2077,2834,,,,,
"Nautilus Biotechnology, Inc.","Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.
The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system.
In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs.
Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.","Data/company_logos_stock_analysis\Nautilus_Biotechnology,_Inc._logo.svg",https://stockanalysis.com/stocks/naut/,United States,2016,Biotechnology,Healthcare,167,Sujal Patel,"2701 Eastlake Avenue East
Seattle, Washington 98102
United States",206 333 2001,nautilus.bio,NAUT,NASDAQ,January - December,USD,0001808805,63909J108,US63909J1088,3826,,Common Stock,98-1541723,,
"Gossamer Bio, Inc.","Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.
The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.
The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017.
Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Gossamer_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/goss/,United States,2015,Biotechnology,Healthcare,135,Faheem Hasnain,"3013 Science Park Road, Suite 200
San Diego, California 92121
United States",858 684 1300,gossamerbio.com,GOSS,NASDAQ,January - December,USD,0001728117,38341P102,US38341P1021,2834,"Feb 8, 2019",Common Stock,47-5461709,$16.00,
"Orchestra BioMed Holdings, Inc.","Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company.
The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease.
Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.","Data/company_logos_stock_analysis\Orchestra_BioMed_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/obio/,United States,2017,Biotechnology,Healthcare,56,David Hochman,"150 Union Square Drive
New Hope, Pennsylvania 18938
United States",212 862 5797,orchestrabiomed.com,OBIO,NASDAQ,January - December,USD,0001814114,68572M106,US68572M1062,3841,,Common Stock,,,
"Lexeo Therapeutics, Inc.","Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases.
The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease.
The company was incorporated in 2017 and is based in New York, New York.","Data/company_logos_stock_analysis\Lexeo_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/lxeo/,United States,2017,Biotechnology,Healthcare,58,R. Townsend,"345 Park Avenue South, 6th Floor
New York, New York 10010
United States",212 547 9879,lexeotx.com,LXEO,NASDAQ,January - December,USD,0001907108,52886X107,US52886X1072,2836,"Nov 3, 2023",Common Stock,85-4012572,$11.00,
"Acelyrin, Inc.","Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
The company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease.
In addition, the company’s develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria.
Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.","Data/company_logos_stock_analysis\Acelyrin,_Inc._logo.svg",https://stockanalysis.com/stocks/slrn/,United States,2020,Biotechnology,Healthcare,135,Mina Kim,"4149 Liberty Canyon Road
Agoura Hills, California 91301
United States",805-730-0360,acelyrin.com,SLRN,NASDAQ,January - December,USD,0001962918,00445A100,US00445A1007,2834,"May 5, 2023",Common Stock,85-2406735,$18.00,
"Inhibrx Biosciences, Inc.","Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma.
The company was incorporated in 2024 and is based in La Jolla, California.","Data/company_logos_stock_analysis\Inhibrx_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/inbx/,United States,2010,Biotechnology,Healthcare,172,Mark Lappe,"11025 North Torrey Pines Road, Suite 140
La Jolla, California 92037
United States",858 795 4220,inhibrx.com,INBX,NASDAQ,January - December,USD,0001739614,45720L107,US45720L1070,2836,"Aug 19, 2020",Common Stock,82-4257312,$17.00,
"TuHURA Biosciences, Inc.","TuHURA Biosciences, Inc. operates as a biotechnology company that develops novel cell and gene therapies based on distinct and synergistic technology platforms.
The company owns and develops a product portfolio of cellular and gene therapies that can detect, monitor, and control cancer.
It offers ImmuneFx, a cancer vaccine; Morphogenesis Allograft Tissue with Compatible HLA (MATCH) stem cell banks; Polymer Antibody Cell Separation System (PACS), a device that captures and releases viable targeted cells from large volumes; and BlueBio, a program for mining microbial compounds from the ocean floor.
The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December, 2023.
TuHURA Biosciences, Inc. was incorporated in 1993 and is based in Tampa, Florida.TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc. .","Data/company_logos_stock_analysis\TuHURA_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/hura/,United States,2009,Biotechnology,Healthcare,1,James Bianco,"10500 University Center Drive, Suite 110
Tampa, Florida 33612
United States",813 875 6600,tuhurabio.com,HURA,NASDAQ,January - December,USD,0001498382,,US8989201038,2834,,,99-0360497,,
"MacroGenics, Inc.","MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.
Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.
The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies.
In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types.
Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications.
It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.","Data/company_logos_stock_analysis\MacroGenics,_Inc._logo.svg",https://stockanalysis.com/stocks/mgnx/,United States,2000,Biotechnology,Healthcare,339,Scott Koenig,"9704 Medical Center Drive
Rockville, Maryland 20850
United States",301 251 5172,macrogenics.com,MGNX,NASDAQ,January - December,USD,0001125345,556099109,US5560991094,2834,"Oct 10, 2013",Common Stock,,,
Organigram Holdings Inc.,"Organigram Holdings Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands.
The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers.
It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online.
The company is headquartered in Toronto, Canada.",Data/company_logos_stock_analysis\Organigram_Holdings_Inc._logo.svg,https://stockanalysis.com/stocks/ogi/,Canada,2013,Drug Manufacturers - Specialty & Generic,Healthcare,898,Beena Goldenberg,"145 King Street West, Suite #1400
Toronto, ON M5H 1J8
Canada",844-644-4726,organigram.ca,OGI,NASDAQ,October - September,CAD,0001620737,68620P101,CA68620P7056,2834,,,,,
"Inhibikase Therapeutics, Inc.","Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders.
Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.
The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia.
Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.","Data/company_logos_stock_analysis\Inhibikase_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ikt/,United States,2008,Biotechnology,Healthcare,9,Milton Werner,"3350 Riverwood Parkway SE, Suite 1900
Atlanta, Georgia 30339
United States",678 392 3419,inhibikase.com,IKT,NASDAQ,January - December,USD,0001750149,45719W106,US45719W2052,2836,"Dec 23, 2020",Common Stock,26-3407249,$10.00,
"Zentalis Pharmaceuticals, Inc.","Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers.
Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
The company’s products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies.
Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc.
The company was incorporated in 2014 and is headquartered in New York, New York.","Data/company_logos_stock_analysis\Zentalis_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/zntl/,United States,2014,Biotechnology,Healthcare,124,Julie Eastland,"1359 Broadway, Suite 1710
New York, New York 10018
United States",212 433 3791,zentalis.com,ZNTL,NASDAQ,January - December,USD,0001725160,98943L107,US98943L1070,2834,"Apr 3, 2020",,82-3607803,$18.00,
Vor Biopharma Inc.,"Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company.
Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.
The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Vor_Biopharma_Inc._logo.svg,https://stockanalysis.com/stocks/vor/,United States,2015,Biotechnology,Healthcare,168,Robert Ang,"100 Cambridgepark Drive, Suite 101
Cambridge, Massachusetts 02140
United States",617 655 6580,vorbio.com,VOR,NASDAQ,January - December,USD,0001817229,929033108,US9290331084,2836,"Feb 5, 2021",Common Stock,,$18.00,
Inventiva S.A.,"Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.
Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.",Data/company_logos_stock_analysis\Inventiva_S.A._logo.svg,https://stockanalysis.com/stocks/iva/,France,2011,Biotechnology,Healthcare,123,Frederic Cren,"50 rue de Dijon
Daix, 21121
France",33 3 80 44 75 00,inventivapharma.com,IVA,NASDAQ,January - December,EUR,0001756594,46124U107,US46124U1079,2834,"Jul 10, 2020",,,$14.40,
Nektar Therapeutics,"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders.
It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer.
The company serves its clients in the United States and internationally. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F.
Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.",Data/company_logos_stock_analysis\Nektar_Therapeutics_logo.svg,https://stockanalysis.com/stocks/nktr/,United States,1990,Biotechnology,Healthcare,137,Howard Robin,"455 Mission Bay Boulevard South
San Francisco, California 94158
United States",415 482 5300,nektar.com,NKTR,NASDAQ,January - December,USD,0000906709,640268108,US6402681083,2834,"May 3, 1994",Common Stock,94-3134940,,
"Cardiff Oncology, Inc.","Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California.
Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012.
Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Cardiff_Oncology,_Inc._logo.svg",https://stockanalysis.com/stocks/crdf/,United States,1999,Biotechnology,Healthcare,32,Mark Erlander,"11055 Flintkote Avenue
San Diego, California 92121
United States",858 952 7570,cardiffoncology.com,CRDF,NASDAQ,January - December,USD,0001213037,14147L108,US14147L1089,2836,,Common Stock,27-2004382,,
Molecular Partners AG,"Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland.
The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.
It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics.
Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.",Data/company_logos_stock_analysis\Molecular_Partners_AG_logo.svg,https://stockanalysis.com/stocks/moln/,Switzerland,2004,Biotechnology,Healthcare,168,Patrick Amstutz,"Wagistrasse 14
Schlieren, 8952
Switzerland",41 44 755 77 00,molecularpartners.com,MOLN,NASDAQ,January - December,CHF,0001745114,60853G106,US60853G1067,2836,"Jun 16, 2021",,,$21.25,
Cellectis S.A.,"Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates.
The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer.
It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited.
Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.",Data/company_logos_stock_analysis\Cellectis_S.A._logo.svg,https://stockanalysis.com/stocks/clls/,France,1999,Biotechnology,Healthcare,221,Andre Choulika,"8, rue de la Croix Jarry
Paris, 75013
France",33 1 81 69 16 00,cellectis.com,CLLS,NASDAQ,January - December,USD,0001627281,15117K103,US15117K1034,2836,"Feb 7, 2007",,,,
ADC Therapeutics SA,"ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs).
In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia.
Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets.
The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.",Data/company_logos_stock_analysis\ADC_Therapeutics_SA_logo.svg,https://stockanalysis.com/stocks/adct/,Switzerland,2011,Biotechnology,Healthcare,274,Ameet Mallik,"BiopOle, Route de la Corniche 3B
Epalinges, 1066
Switzerland",41 21 653 02 00,adctherapeutics.com,ADCT,NYSE,January - December,USD,0000061478,H0036K147,CH0499880968,3661,"May 15, 2020",,41-0743912,$19.00,Class A Shares
MediWound Ltd.,"MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally.
It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.
MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.",Data/company_logos_stock_analysis\MediWound_Ltd._logo.svg,https://stockanalysis.com/stocks/mdwd/,Israel,2000,Biotechnology,Healthcare,100,Ofer Gonen,"42 Hayarkon Street
Yavne, 8122745
Israel",972 7 797 14100,mediwound.com,MDWD,NASDAQ,January - December,USD,0001593984,M68830104,IL0011316309,2833,"Mar 20, 2014",,,,
Procaps Group S.A.,"Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide.
The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory.
It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products.
In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals.
Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies.
The company was founded in 1977 and is based in Luxembourg, Luxembourg.",Data/company_logos_stock_analysis\Procaps_Group_S.A._logo.svg,https://stockanalysis.com/stocks/proc/,Luxembourg,1976,Drug Manufacturers - Specialty & Generic,Healthcare,"5,500",Jose Antonio Vieira,"9 Rue de Bitbourg
Luxembourg, 1273
Luxembourg",356 7995 6138,procapsgroup.com,PROC,NASDAQ,January - December,USD,0001863362,L7756P102,LU2376511205,2834,,,,,
"Vaxart, Inc.","Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform.
The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.
It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.
Vaxart, Inc. is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Vaxart,_Inc._logo.svg",https://stockanalysis.com/stocks/vxrt/,United States,,Biotechnology,Healthcare,109,Steven Lo,"170 Harbor Way, Suite 300
South San Francisco, California 94080
United States",650 550 3500,vaxart.com,VXRT,NASDAQ,January - December,USD,0000072444,92243A200,US92243A2006,2836,,Common Stock,59-1212264,,
"RAPT Therapeutics, Inc.","RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States.
The company’s lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer.
The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019.
RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\RAPT_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/rapt/,United States,2015,Biotechnology,Healthcare,131,Brian Wong,"561 Eccles Avenue
South San Francisco, California 94080
United States",650 489 9000,rapt.com,RAPT,NASDAQ,January - December,USD,0001673772,75382E109,US75382E1091,2834,"Oct 31, 2019",,47-3313701,$12.00,
Cybin Inc.,"Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.
The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers.
The company is headquartered in Toronto, Canada.",Data/company_logos_stock_analysis\Cybin_Inc._logo.svg,https://stockanalysis.com/stocks/cybn/,Canada,2019,Biotechnology,Healthcare,50,Douglas Drysdale,"100 King Street West, Suite 5600
Toronto, ON M5X 1C9
Canada",,cybin.com,CYBN,NYSEAMERICAN,April - March,CAD,0001833141,23256X100,CA23256X1006,2834,,,,,
"Lyell Immunopharma, Inc.","Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors.
The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications.
In addition, the company’s preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product.
Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Lyell_Immunopharma,_Inc._logo.svg",https://stockanalysis.com/stocks/lyel/,United States,2018,Biotechnology,Healthcare,224,Lynn Seely,"201 Haskins Way
South San Francisco, California 94080
United States",650 695 0677,lyell.com,LYEL,NASDAQ,January - December,USD,0001806952,55083R104,US55083R1041,2834,"Jun 17, 2021",,83-3006753,$17.00,
"Alector, Inc.","Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.
Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases.
The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer’s disease.
Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases.
The company was founded in 2013 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Alector,_Inc._logo.svg",https://stockanalysis.com/stocks/alec/,United States,2013,Biotechnology,Healthcare,244,Arnon Rosenthal,"131 Oyster Point Boulevard, Suite 600
South San Francisco, California 94080
United States",415 231 5660,alector.com,ALEC,NASDAQ,January - December,USD,0001653087,014442107,US0144421072,2836,"Feb 7, 2019",Common Stock,82-2933343,$19.00,
Genfit S.A.,"Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.
The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis.
It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA.
The company was incorporated in 1999 and is headquartered in Loos, France.",Data/company_logos_stock_analysis\Genfit_S.A._logo.svg,https://stockanalysis.com/stocks/gnft/,France,1999,Biotechnology,Healthcare,159,M. Prigent,"Parc EurasantE, 885, avenue EugEne AvinEe
Loos, 59120
France",33 3 20 16 40 00,genfit.com,GNFT,NASDAQ,January - December,EUR,0001757064,372279109,US3722791098,2836,"Mar 27, 2019",,,$22.00,
scPharmaceuticals Inc.,"scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products.
Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
The company’s product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector.
It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.",Data/company_logos_stock_analysis\scPharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/scph/,United States,2013,Biotechnology,Healthcare,136,John Tucker,"25 Mall Road, Suite 203
Burlington, Massachusetts 01803
United States",617 517 0730,scpharmaceuticals.com,SCPH,NASDAQ,January - December,USD,0001604950,810648105,US8106481059,2834,"Nov 17, 2017",Common Stock,46-5184075,,
"Acrivon Therapeutics, Inc.","Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform.
The company’s Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer.
The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor.
Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.","Data/company_logos_stock_analysis\Acrivon_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/acrv/,United States,2018,Biotechnology,Healthcare,61,Peter Blume-Jensen,"480 Arsenal Way, Suite 100
Watertown, Massachusetts 02472
United States",617 207 8979,acrivon.com,ACRV,NASDAQ,January - December,USD,0001781174,004890109,US0048901096,2834,"Nov 15, 2022",Common Stock,82-5125532,$12.50,
"Coherus BioSciences, Inc.","Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States.
The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.
It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME.
In addition, the company’s licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors.
Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis.
It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No.
4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012.
Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.","Data/company_logos_stock_analysis\Coherus_BioSciences,_Inc._logo.svg",https://stockanalysis.com/stocks/chrs/,United States,2010,Biotechnology,Healthcare,306,Dennis Lanfear,"333 Twin Dolphin Drive, Suite 600
Redwood City, California 94065
United States",650 649 3530,coherus.com,CHRS,NASDAQ,January - December,USD,0001512762,19249H103,US19249H1032,2836,"Nov 6, 2014",Common Stock,27-3615821,,
"Protalix BioTherapeutics, Inc.","Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases.
The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel.","Data/company_logos_stock_analysis\Protalix_BioTherapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/plx/,Israel,1993,Biotechnology,Healthcare,208,Dror Bashan,"Science Park, 2 Snunit St.
Karmiel, 2161401
Israel",972 4 902 8100,protalix.com,PLX,NYSEAMERICAN,January - December,USD,0001006281,74365A309,US74365A3095,2836,"May 15, 1998",,65-0643773,,
"Fate Therapeutics, Inc.","Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors.
The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer.
Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Fate_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/fate/,United States,2007,Biotechnology,Healthcare,181,Bahram Valamehr,"12278 Scripps Summit Drive
San Diego, California 92131
United States",858 875 1800,fatetherapeutics.com,FATE,NASDAQ,January - December,USD,0001434316,31189P102,US31189P1021,2836,"Oct 1, 2013",Common Stock,65-1311552,,
Sagimet Biosciences Inc.,"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.
The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.
It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019.
Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.",Data/company_logos_stock_analysis\Sagimet_Biosciences_Inc._logo.svg,https://stockanalysis.com/stocks/sgmt/,United States,2006,Biotechnology,Healthcare,10,David Happel,"155 Bovet Road, Suite 303
San Mateo, California 94402
United States",650 561 8600,sagimet.com,SGMT,NASDAQ,January - December,USD,0001400118,786700104,US7867001049,2834,"Jul 14, 2023",Common Stock,20-5991472,$16.00,Class A Shares
"Greenwich LifeSciences, Inc.","Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.
Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018.
Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.","Data/company_logos_stock_analysis\Greenwich_LifeSciences,_Inc._logo.svg",https://stockanalysis.com/stocks/glsi/,United States,2006,Biotechnology,Healthcare,7,Snehal Patel,"Building 14, 3992 Bluebonnet Drive
Stafford, Texas 77477
United States",832 819 3232,greenwichlifesciences.com,GLSI,NASDAQ,January - December,USD,0001799788,396879108,US3968791083,2834,"Sep 25, 2020",Common Stock,20-5473709,$5.75,
"Nkarta, Inc.","Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors.
In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease.
It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.","Data/company_logos_stock_analysis\Nkarta,_Inc._logo.svg",https://stockanalysis.com/stocks/nktx/,United States,2015,Biotechnology,Healthcare,150,Paul Hastings,"1150 Veterans Boulevard
South San Francisco, California 94080
United States",925 407 1049,nkartatx.com,NKTX,NASDAQ,January - December,USD,0001787400,65487U108,US65487U1088,2834,"Jul 10, 2020",Common Stock,47-4515206,$18.00,
"Puma Biotechnology, Inc.","Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer.
The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.","Data/company_logos_stock_analysis\Puma_Biotechnology,_Inc._logo.svg",https://stockanalysis.com/stocks/pbyi/,United States,2010,Biotechnology,Healthcare,185,Alan Auerbach,"10880 Wilshire Boulevard, Suite 2150
Los Angeles, California 90024
United States",424 248 6500,pumabiotechnology.com,PBYI,NASDAQ,January - December,USD,0001401667,74587V107,US74587V1070,2834,,Common Stock,77-0683487,,
Fennec Pharmaceuticals Inc.,"Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States.
The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients.
It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.
Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.",Data/company_logos_stock_analysis\Fennec_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/fenc/,United States,1996,Biotechnology,Healthcare,29,Rostislav Raykov,"68 TW Alexander Drive, PO Box 13628
Research Triangle Park, North Carolina 27709
United States",919 636 4530,fennecpharma.com,FENC,NASDAQ,January - December,USD,0001211583,31447P100,CA31447P1009,2836,"Jun 5, 2001",,,,
"Actuate Therapeutics, Inc.","Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers.
The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma.
It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015.
The company was incorporated in 2015 and is based in Fort Worth, Texas.","Data/company_logos_stock_analysis\Actuate_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/actu/,United States,2015,Biotechnology,Healthcare,5,Daniel Schmitt,"1751 River Run, Suite 400
Fort Worth, Texas 76107
United States",817 887 8455,actuatetherapeutics.com,ACTU,NASDAQ,January - December,USD,0001652935,,,2834,"Aug 13, 2024",Common Stock,47-3044785,$8.00,
"TScan Therapeutics, Inc.","TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
The company’s lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors.
In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease using TargetScan, a proprietary target discovery platform.
TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.","Data/company_logos_stock_analysis\TScan_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/tcrx/,United States,2018,Biotechnology,Healthcare,154,Gavin MacBeath,"830 Winter Street
Waltham, Massachusetts 02451
United States",857 399 9500,tscan.com,TCRX,NASDAQ,January - December,USD,0001783328,89854M101,US89854M1018,2836,"Jul 16, 2021",Common Stock,82-5282075,$15.00,
Adaptimmune Therapeutics plc,"Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.
It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center.
Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.",Data/company_logos_stock_analysis\Adaptimmune_Therapeutics_plc_logo.svg,https://stockanalysis.com/stocks/adap/,United Kingdom,2008,Biotechnology,Healthcare,449,Adrian G. Rawcliffe,"60 Jubilee Avenue, Milton Park
Abingdon, OX14 4RX
United Kingdom",44 12 3543 0000,adaptimmune.com,ADAP,NASDAQ,January - December,USD,0001621227,00653A107,US00653A1079,2836,"May 6, 2015",,,,
"Checkpoint Therapeutics, Inc.","Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally.
The company’s lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell.
The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.","Data/company_logos_stock_analysis\Checkpoint_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ckpt/,United States,2014,Biotechnology,Healthcare,23,James Oliviero,"95 Sawyer Road, Suite 110
Waltham, Massachusetts 02453
United States",781 652 4500,checkpointtx.com,CKPT,NASDAQ,January - December,USD,0001651407,162828107,US1628282063,2834,"Jun 26, 2017",,47-2568632,,
"Sutro Biopharma, Inc.","Sutro Biopharma, Inc. operates as a clinical-stage oncology company.
The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+.
Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
The company’s pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer.
Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC.
The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Sutro_Biopharma,_Inc._logo.svg",https://stockanalysis.com/stocks/stro/,United States,2003,Biotechnology,Healthcare,302,William Newell,"111 Oyster Point Boulevard
South San Francisco, California 94080
United States",650 881 6500,sutrobio.com,STRO,NASDAQ,January - December,USD,0001382101,869367102,US8693671021,2836,"Sep 27, 2018",Common Stock,45-2441988,,
Innate Pharma S.A.,"Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally.
The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.
The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited.
Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.",Data/company_logos_stock_analysis\Innate_Pharma_S.A._logo.svg,https://stockanalysis.com/stocks/ipha/,France,1999,Biotechnology,Healthcare,179,Jonathan Dickinson,"117, Avenue de Luminy, BP 30191
Marseille, 13009
France",33 4 30 30 30 30,innate-pharma.com,IPHA,NASDAQ,January - December,EUR,0001598599,45781K204,US45781K2042,2836,"Oct 17, 2019",,,$5.50,
"Kyverna Therapeutics, Inc.","Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases.
Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases.
In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn’s disease and ulcerative colitis.
Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases.
The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019.
Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.","Data/company_logos_stock_analysis\Kyverna_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/kytx/,United States,2018,Biotechnology,Healthcare,96,Warner Biddle,"5980 Horton Street, Suite 550
Emeryville, California 94608
United States",(510) 925-2492,kyvernatx.com,KYTX,NASDAQ,January - December,USD,0001994702,,US5019761049,2836,"Feb 8, 2024",Common Stock,83-1365441,$22.00,
"Caribou Biosciences, Inc.","Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally.
Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia.
Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.","Data/company_logos_stock_analysis\Caribou_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/crbu/,United States,2011,Biotechnology,Healthcare,158,Rachel Haurwitz,"2929 7th Street, Suite 105
Berkeley, California 94710
United States",510 982 6030,cariboubio.com,CRBU,NASDAQ,January - December,USD,0001619856,142038108,US1420381089,2836,"Jul 23, 2021",Common Stock,45-3728228,$16.00,
"Ventyx Biosciences, Inc.","Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases.
The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.
It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.
In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.","Data/company_logos_stock_analysis\Ventyx_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/vtyx/,United States,2018,Biotechnology,Healthcare,80,Raju Mohan,"12790 El Camino Real, Suite 200
San Diego, California 92130
United States",760 593 4832,ventyxbio.com,VTYX,NASDAQ,January - December,USD,0001851194,92332V107,US92332V1070,2834,"Oct 21, 2021",Common Stock,83-2996852,$16.00,
Solid Biosciences Inc.,"Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States.
The company’s lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich’s ataxia, as well as other drugs for the treatment of cardiac and other diseases.
In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid.
The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida.
Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.",Data/company_logos_stock_analysis\Solid_Biosciences_Inc._logo.svg,https://stockanalysis.com/stocks/sldb/,United States,2013,Biotechnology,Healthcare,88,Alexander Cumbo,"500 Rutherford Avenue, Third Floor
Charlestown, Massachusetts 02129
United States",617 337 4680,solidbio.com,SLDB,NASDAQ,January - December,USD,0001707502,83422E105,US83422E2046,2836,"Jan 26, 2018",Common Stock,90-0943402,,
Compugen Ltd.,"Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe.
The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.
The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets.
It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid.
Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.",Data/company_logos_stock_analysis\Compugen_Ltd._logo.svg,https://stockanalysis.com/stocks/cgen/,Israel,1993,Biotechnology,Healthcare,68,Anat Cohen-Dayag,"Azrieli Center, Building D
Holon, 5885849
Israel",972 3 765 8585,cgen.com,CGEN,NASDAQ,January - December,USD,0001119774,M25722105,IL0010852080,2836,"Aug 11, 2000",,,,
"Biomea Fusion, Inc.","Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.
Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.
The company was incorporated in 2017 and is headquartered in Redwood City, California.","Data/company_logos_stock_analysis\Biomea_Fusion,_Inc._logo.svg",https://stockanalysis.com/stocks/bmea/,United States,2017,Biotechnology,Healthcare,103,Thomas Butler,"900 Middlefield Road, 4th Floor
Redwood City, California 94063
United States",650 980 9099,biomeafusion.com,BMEA,NASDAQ,January - December,USD,0001840439,09077A106,US09077A1060,2834,"Apr 16, 2021",Common Stock,,$17.00,
Nanobiotix S.A.,"Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.",Data/company_logos_stock_analysis\Nanobiotix_S.A._logo.svg,https://stockanalysis.com/stocks/nbtx/,France,2003,Biotechnology,Healthcare,102,Laurent Levy,"60 rue de Wattignies
Paris, 75012
France",33 1 40 26 04 70,nanobiotix.com,NBTX,NASDAQ,January - December,EUR,0001760854,63009J107,US63009J1079,2834,"Dec 11, 2020",,,$13.50,
"Seres Therapeutics, Inc.","Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome.
It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection.
Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation.
In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis.
Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease.
The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015.
Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Seres_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/mcrb/,United States,2010,Biotechnology,Healthcare,233,Eric Shaff,"101 Cambridgepark Drive
Cambridge, Massachusetts 02140
United States",617 945 9626,serestherapeutics.com,MCRB,NASDAQ,January - December,USD,0001609809,81750R102,US81750R1023,2834,"Jun 26, 2015",,27-4326290,,
"Corbus Pharmaceuticals Holdings, Inc.","Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness.
It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
The company was incorporated in 2009 and is based in Norwood, Massachusetts.","Data/company_logos_stock_analysis\Corbus_Pharmaceuticals_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/crbp/,United States,2009,Biotechnology,Healthcare,19,Yuval Cohen,"500 River Ridge Drive
Norwood, Massachusetts 02062
United States",617 963 0100,corbuspharma.com,CRBP,NASDAQ,January - December,USD,0001595097,21833P103,US21833P3010,2834,,,46-4348039,,
"Seer, Inc.","Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome.
It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes.
It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018.
Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.","Data/company_logos_stock_analysis\Seer,_Inc._logo.svg",https://stockanalysis.com/stocks/seer/,United States,2017,Biotechnology,Healthcare,147,Omid Farokhzad,"3800 Bridge Parkway, Suite 102
Redwood City, California 94065
United States",650 453 0000,seer.bio,SEER,NASDAQ,January - December,USD,0001726445,81578P106,US81578P1066,3826,"Dec 4, 2020",Common Stock,82-1153150,$19.00,Class A Shares
Milestone Pharmaceuticals Inc.,"Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.
The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers.
The company was incorporated in 2003 and is headquartered in Montréal, Canada.",Data/company_logos_stock_analysis\Milestone_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/mist/,Canada,2003,Biotechnology,Healthcare,47,Joseph Oliveto,"1111 Dr. Frederik-Philips Boulevard, Suite 420
Montreal, QC H4M 2X6
Canada",514 336 0444,milestonepharma.com,MIST,NASDAQ,January - December,USD,0001408443,59935V107,CA59935V1076,2834,,,,,
Zura Bio Limited,"Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.
It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
The company is based in Henderson, Nevada.",Data/company_logos_stock_analysis\Zura_Bio_Limited_logo.svg,https://stockanalysis.com/stocks/zura/,United States,2022,Biotechnology,Healthcare,15,Robert Lisicki,"1489 W. Warm Springs Road, Suite 110
Henderson, Nevada 89014
United States",702 757 6133,zurabio.com,ZURA,NASDAQ,January - December,USD,0001855644,,KYG9TY5A1016,2836,,,,,Class A Shares
"Climb Bio, Inc.","Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases.
It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy.
The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024.
Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.","Data/company_logos_stock_analysis\Climb_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/clym/,United States,2018,Biotechnology,Healthcare,11,Aoife Brennan,"PMB #117, 2801 Centerville Road, 1st Floor
Wilmington, Delaware 19808-1609
United States",866 857 2596,eliemtx.com,CLYM,NASDAQ,January - December,USD,0001768446,,US28658R1068,2834,"Aug 10, 2021",Common Stock,83-2273741,,
"Cassava Sciences, Inc.","Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.","Data/company_logos_stock_analysis\Cassava_Sciences,_Inc._logo.svg",https://stockanalysis.com/stocks/sava/,United States,1998,Biotechnology,Healthcare,29,Richard Barry,"6801 N. Capital of Texas Highway, Suite 300
Austin, Texas 78731
United States",512 501 2444,cassavasciences.com,SAVA,NASDAQ,January - December,USD,0001069530,14817C107,US14817C1071,2834,,Common Stock,91-1911336,,
Monopar Therapeutics Inc.,"Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers.
It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers.
Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer.
The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.",Data/company_logos_stock_analysis\Monopar_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/mnpr/,United States,2014,Biotechnology,Healthcare,10,Chandler Robinson,"1000 Skokie Boulevard, Suite 350
Wilmette, Illinois 60091
United States",847 388 0349,monopartx.com,MNPR,NASDAQ,January - December,USD,0001645469,61023L108,US61023L1089,2834,"Dec 19, 2019",Common Stock,32-0463781,$8.00,
InflaRx N.V.,"InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases.
Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS.
It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V.
and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.",Data/company_logos_stock_analysis\InflaRx_N.V._logo.svg,https://stockanalysis.com/stocks/ifrx/,Germany,2007,Biotechnology,Healthcare,62,Niels Riedemann,"Winzerlaer Str. 2
Jena, 07745
Germany",49 3641 508 180,inflarx.de,IFRX,NASDAQ,January - December,EUR,0001708688,N44821101,NL0012661870,2834,"Nov 8, 2017",Common Stock,,,
"Champions Oncology, Inc.","Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States.
The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.
It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process.
In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies.
The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies.
Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011.
The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.","Data/company_logos_stock_analysis\Champions_Oncology,_Inc._logo.svg",https://stockanalysis.com/stocks/csbr/,United States,1985,Biotechnology,Healthcare,210,Ronnie Morris,"One University Plaza, Suite 307
Hackensack, New Jersey 07601
United States",201 808 8400,championsoncology.com,CSBR,NASDAQ,May - April,USD,0000771856,15870P307,US15870P3073,2836,"Mar 25, 1986",Common Stock,52-1401755,,
"Instil Bio, Inc.","Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.
The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer.
It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.","Data/company_logos_stock_analysis\Instil_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/til/,United States,2018,Biotechnology,Healthcare,49,Bronson Crouch,"3963 Maple Avenue, Suite 350
Dallas, Texas 75219
United States",972 499 3350,instilbio.com,TIL,NASDAQ,January - December,USD,0001789769,45783C101,US45783C2008,2836,"Mar 19, 2021",Common Stock,83-2072195,$20.00,
"2seventy bio, Inc.","2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States.
The company’s products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\2seventy_bio,_Inc._logo.svg",https://stockanalysis.com/stocks/tsvt/,United States,2021,Biotechnology,Healthcare,274,William Baird,"60 Binney Street
Cambridge, Massachusetts 02142
United States",617 675 7270,2seventybio.com,TSVT,NASDAQ,January - December,USD,0001860782,901384107,US9013841070,2834,,,86-3658454,,
"Inozyme Pharma, Inc.","Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases.
The company’s lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Inozyme_Pharma,_Inc._logo.svg",https://stockanalysis.com/stocks/inzy/,United States,2015,Biotechnology,Healthcare,59,Douglas Treco,"321 Summer Street, Suite 400
Boston, Massachusetts 02210
United States",857 330 4340,inozyme.com,INZY,NASDAQ,January - December,USD,0001693011,45790W108,US45790W1080,2834,"Jul 24, 2020",Common Stock,47-5129768,$16.00,
Renovaro Inc.,"Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands.
It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.
It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024.
Renovaro Inc. is headquartered in Los Angeles, California.",Data/company_logos_stock_analysis\Renovaro_Inc._logo.svg,https://stockanalysis.com/stocks/renb/,United States,2011,Biotechnology,Healthcare,25,David Weinstein,"2080 Century Park East, Suite 906
Los Angeles, California 90067
United States",305 918 1980,renovarobio.com,RENB,NASDAQ,July - June,USD,0001527728,236078101,US29350E1047,2834,,Common Stock,45-2259340,,
"Lineage Cell Therapeutics, Inc.","Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally.
The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology.
Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme.
The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019.
Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.","Data/company_logos_stock_analysis\Lineage_Cell_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/lctx/,United States,1990,Biotechnology,Healthcare,75,Brian Culley,"2173 Salk Avenue, Suite 200
Carlsbad, California 92008
United States",442 287 8990,lineagecell.com,LCTX,NYSEAMERICAN,January - December,USD,0000876343,53566P109,US53566P1093,2836,,,94-3127919,,
"IGM Biosciences, Inc.","IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases.
It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.
IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.
The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010.
IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.","Data/company_logos_stock_analysis\IGM_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/igms/,United States,1993,Biotechnology,Healthcare,224,Mary Harler,"325 East Middlefield Road
Mountain View, California 94043
United States",650 965 7873,igmbio.com,IGMS,NASDAQ,January - December,USD,0001496323,449585108,US4495851085,2834,"Sep 18, 2019",Common Stock,77-0349194,$16.00,
"INmune Bio, Inc.","INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers.
It also provides XPro1595 for the treatment of Alzheimer’s disease and treatment resistant depression.
It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.","Data/company_logos_stock_analysis\INmune_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/inmb/,United States,2015,Biotechnology,Healthcare,17,Raymond Tesi,"225 NE Mizner Blvd., Suite 640
Boca Raton, Florida 33432
United States",858 964 3720,inmunebio.com,INMB,NASDAQ,January - December,USD,0001711754,45782T105,US45782T1051,2836,"Feb 4, 2019",Common Stock,47-5205835,$8.00,
"Alto Neuroscience, Inc.","Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD.
In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient.
The company was incorporated in 2019 and is headquartered in Los Altos, California.","Data/company_logos_stock_analysis\Alto_Neuroscience,_Inc._logo.svg",https://stockanalysis.com/stocks/anro/,United States,2019,Biotechnology,Healthcare,67,Amit Etkin,"369 South San Antonio Road
Los Altos, California 94022
United States",650 200 0412,altoneuroscience.com,ANRO,NYSE,January - December,USD,0001999480,,US02157Q1094,2834,"Feb 2, 2024",Common Stock,83-4210124,$16.00,
"Telomir Pharmaceuticals, Inc.","Telomir Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, is engaged in the advancement of age reversal science.
The company is developing Telomir 1, a small molecule intended to lengthen and protect telomeres, the DNA end caps of chromosomes that are associated with cellular aging.
Telomir 1 is designed for oral administration and is aimed at extending longevity, improving quality of life, and potentially influencing biological aging.
Telomir Pharmaceuticals is also involved in ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer’s disease, osteoarthritis, and other age related conditions to assess the potential effects of Telomir 1.
The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022.
Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.","Data/company_logos_stock_analysis\Telomir_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/telo/,United States,2021,Biotechnology,Healthcare,9,Erez Aminov,"100 SE 2nd St., Suite 2000 #1009
Miami, Florida 33131
United States",813 864 2558,telomirpharma.com,TELO,NASDAQ,January - December,USD,0001971532,,US87975F1049,2834,"Feb 9, 2024",Common Stock,87-2606031,$7.00,
XBiotech Inc.,"XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases.
The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases.
It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
The company was incorporated in 2005 and is headquartered in Austin, Texas.",Data/company_logos_stock_analysis\XBiotech_Inc._logo.svg,https://stockanalysis.com/stocks/xbit/,United States,2005,Biotechnology,Healthcare,82,John Simard,"5217 Winnebago Lane
Austin, Texas 78744
United States",512 386 2900,xbiotech.com,XBIT,NASDAQ,January - December,USD,0001626878,98400H102,CA98400H1029,2834,"Apr 15, 2015",Common Stock,,,
"Aligos Therapeutics, Inc.","Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.
Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.
In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus.
The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors.
It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Aligos_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/algs/,United States,2018,Biotechnology,Healthcare,66,Lawrence Blatt,"One Corporate Drive, 2nd Floor
South San Francisco, California 94080
United States",800 466 6059,aligos.com,ALGS,NASDAQ,January - December,USD,0001799448,01626L105,US01626L1052,2836,"Oct 16, 2020",Common Stock,,$15.00,
"Leap Therapeutics, Inc.","Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer.
Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.
Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015.
Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Leap_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/lptx/,United States,2011,Biotechnology,Healthcare,54,Douglas Onsi,"47 Thorndike Street, Suite B1-1
Cambridge, Massachusetts 02141
United States",617 714 0360,leaptx.com,LPTX,NASDAQ,January - December,USD,0001509745,52187K101,US52187K2006,2834,,Common Stock,27-4412575,,
"Metagenomi, Inc.","Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
The company’s genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies.
The company was incorporated in 2016 and is based in Emeryville, California.","Data/company_logos_stock_analysis\Metagenomi,_Inc._logo.svg",https://stockanalysis.com/stocks/mgx/,United States,2018,Biotechnology,Healthcare,236,Brian Thomas,"5959 Horton Street, 7th Floor
EmeryVille, California 94608
United States",510 871 4880,metagenomi.co,MGX,NASDAQ,January - December,USD,0001785279,,US59102M1045,2836,"Feb 9, 2024",Common Stock,81-3909017,$15.00,
"Achieve Life Sciences, Inc.","Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction.
The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.","Data/company_logos_stock_analysis\Achieve_Life_Sciences,_Inc._logo.svg",https://stockanalysis.com/stocks/achv/,Canada,,Biotechnology,Healthcare,22,Richard A. Stewart,"1040 West Georgia Street, Suite 1030
Vancouver, BC V6E 4H1
Canada",604-210-2217,achievelifesciences.com,ACHV,NASDAQ,January - December,USD,0000949858,004468203,US0044685008,2835,,Common Stock,95-4343413,,
"Tenaya Therapeutics, Inc.","Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.
It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction.
Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Tenaya_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/tnya/,United States,2016,Biotechnology,Healthcare,140,Faraz Ali,"171 Oyster Point Boulevard, Suite 500
South San Francisco, California 94080
United States",650 825 6990,tenayatherapeutics.com,TNYA,NASDAQ,January - December,USD,0001858848,87990A106,US87990A1060,2836,"Jul 30, 2021",Common Stock,81-3789973,$15.00,
"Protara Therapeutics, Inc.","Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition.
The company is headquartered in New York, New York.","Data/company_logos_stock_analysis\Protara_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/tara/,United States,,Biotechnology,Healthcare,27,Jesse Shefferman,"345 Park Avenue South, 3rd Floor
New York, New York 10010
United States",646 844 0337,protaratx.com,TARA,NASDAQ,January - December,USD,0001359931,74365U107,US74365U1079,2836,,Common Stock,20-4580525,,
Veru Inc.,"Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS).
Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death.
The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017.
Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.",Data/company_logos_stock_analysis\Veru_Inc._logo.svg,https://stockanalysis.com/stocks/veru/,United States,1971,Biotechnology,Healthcare,210,Mitchell Steiner,"2916 North Miami Avenue, Suite 1000
Miami, Florida 33127
United States",305-509-6897,verupharma.com,VERU,NASDAQ,October - September,USD,0000863894,92536C103,US92536C1036,2834,"Jul 19, 1990",Common Stock,39-1144397,,
"Atossa Therapeutics, Inc.","Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.
The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.
Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.","Data/company_logos_stock_analysis\Atossa_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/atos/,United States,2009,Biotechnology,Healthcare,12,Steven Quay,"107 Spring Street
Seattle, Washington 98104
United States",206 588 0256,atossatherapeutics.com,ATOS,NASDAQ,January - December,USD,0001488039,04962H506,US04962H5063,2834,"Nov 8, 2012",Common Stock,26-4753208,,
"Nuvectis Pharma, Inc.","Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology.
The company’s lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases.
It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives.
The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021.
Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.","Data/company_logos_stock_analysis\Nuvectis_Pharma,_Inc._logo.svg",https://stockanalysis.com/stocks/nvct/,United States,2020,Biotechnology,Healthcare,13,Ron Bentsur,"1 Bridge Plaza, Suite 275
Fort Lee, New Jersey 07024
United States",201 614 3150,nuvectis.com,NVCT,NASDAQ,January - December,USD,0001875558,67080T108,US67080T1088,2834,"Feb 4, 2022",Common Stock,86-2405608,$5.00,
"Enanta Pharmaceuticals, Inc.","Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.
The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.
Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.
The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.","Data/company_logos_stock_analysis\Enanta_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/enta/,United States,1995,Biotechnology,Healthcare,131,Jay Luly,"4 Kingsbury Avenue
Watertown, Massachusetts 02472
United States",617 607 0800,enanta.com,ENTA,NASDAQ,October - September,USD,0001177648,29251M106,US29251M1062,2834,"Mar 21, 2013",Common Stock,04-3205099,,
"Black Diamond Therapeutics, Inc.","Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
The company’s lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial.
In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage.
The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018.
Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Black_Diamond_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/bdtx/,United States,2014,Biotechnology,Healthcare,54,Mark Velleca,"One Main Street, 14th Floor
Cambridge, Massachusetts 02142
United States",617 252 0848,blackdiamondtherapeutics.com,BDTX,NASDAQ,January - December,USD,0001701541,09203E105,US09203E1055,2836,"Jan 30, 2020",Common Stock,,$19.00,
Cardiol Therapeutics Inc.,"Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.
Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.
It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.",Data/company_logos_stock_analysis\Cardiol_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/crdl/,Canada,2017,Drug Manufacturers - Specialty & Generic,Healthcare,6,David Elsley,"2265 Upper Middle Road East, Suite 602
Oakville, ON L6H 0G5
Canada",289-910-0850,cardiolrx.com,CRDL,NASDAQ,January - December,CAD,0001702123,14161Y200,CA14161Y2006,2836,,,,,Class A Shares
OS Therapies Incorporated,"OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.",Data/company_logos_stock_analysis\OS_Therapies_Incorporated_logo.svg,https://stockanalysis.com/stocks/ostx/,United States,2018,Biotechnology,Healthcare,4,Paul Romness,"15825 Shady Grove Road, Suite 135
Rockville, Maryland 20850
United States",410-297-7793,ostherapies.com,OSTX,NYSEAMERICAN,January - December,USD,0001795091,,,2834,"Aug 1, 2024",Common Stock,82-5118368,$4.00,
Eupraxia Pharmaceuticals Inc.,"Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector.
The company’s lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery.
It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.
Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.",Data/company_logos_stock_analysis\Eupraxia_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/eprx/,Canada,2011,Biotechnology,Healthcare,29,James Helliwell,"2067 Cadboro Bay Road, Suite 201
Victoria, BC V8R 5G4
Canada",250 590 3968,eupraxiapharma.com,EPRX,NASDAQ,January - December,USD,0001581178,,CA29842P1053,2834,,,,,
"Jasper Therapeutics, Inc.","Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.
The company’s lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation.
In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency.
Jasper Therapeutics, Inc. is headquartered in Redwood City, California.","Data/company_logos_stock_analysis\Jasper_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/jspr/,United States,2018,Biotechnology,Healthcare,45,Ronald Martell,"2200 Bridge Pkwy, Suite 102
Redwood City, California 94065
United States",650 549 1400,jaspertherapeutics.com,JSPR,NASDAQ,January - December,USD,0001788028,471871103,US4718712023,2836,,Common Stock,84-2984849,,
"Editas Medicine, Inc.","Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer.
It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases.
The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.
Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Editas_Medicine,_Inc._logo.svg",https://stockanalysis.com/stocks/edit/,United States,2013,Biotechnology,Healthcare,265,Gilmore O’Neill,"11 Hurley Street
Cambridge, Massachusetts 02141
United States",617 401 9000,editasmedicine.com,EDIT,NASDAQ,January - December,USD,0001650664,28106W103,US28106W1036,2836,"Feb 3, 2016",Common Stock,46-4097528,,
"Cabaletta Bio, Inc.","Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
The company’s lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.
It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis.
It has a collaboration with the University of Pennsylvania and the Children’s Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018.
Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.","Data/company_logos_stock_analysis\Cabaletta_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/caba/,United States,2017,Biotechnology,Healthcare,103,Steven Nichtberger,"2929 Arch Street, Suite 600
Philadelphia, Pennsylvania 19104
United States",267 759 3100,cabalettabio.com,CABA,NASDAQ,January - December,USD,0001759138,12674W109,US12674W1099,2836,"Oct 25, 2019",Common Stock,,$11.00,
"Assembly Biosciences, Inc.","Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases.
It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV).
In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-α receptor agonist targeting HBV and HDV.
The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014.
Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Assembly_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/asmb/,United States,2005,Biotechnology,Healthcare,65,Jason Okazaki,"Two Tower Place, 7th Floor
South San Francisco, California 94080
United States",833 509 4583,assemblybio.com,ASMB,NASDAQ,January - December,USD,0001426800,045396108,US0453962070,2834,"Dec 17, 2010",Common Stock,,,
"Acumen Pharmaceuticals, Inc.","Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.
The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.
The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug.
Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.","Data/company_logos_stock_analysis\Acumen_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/abos/,United States,1996,Biotechnology,Healthcare,52,Daniel O'Connell,"427 Park Street
Charlottesville, Virginia 22902
United States",434 297 1000,acumenpharm.com,ABOS,NASDAQ,January - December,USD,0001576885,00509G209,US00509G2093,2836,"Jul 1, 2021",Common Stock,36-4108129,$16.00,
"OnKure Therapeutics, Inc.","OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers.
Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation for the treatment of solid tumors, including breast cancer.
The company is headquartered in Boulder, Colorado.","Data/company_logos_stock_analysis\OnKure_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/okur/,United States,2011,Biotechnology,Healthcare,,Nicholas Saccomano,"6707 Winchester Circle, Suite 400
Boulder, Colorado 80301
United States",720 307 2892,onkuretherapeutics.com,OKUR,NASDAQ,January - December,USD,0001637715,,US68277Q1058,2834,,Common Stock,47-2309515,,Class A Shares
"HilleVax, Inc.","HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.
It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021.
HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\HilleVax,_Inc._logo.svg",https://stockanalysis.com/stocks/hlvx/,United States,2020,Biotechnology,Healthcare,90,Robert Hershberg,"321 Harrison Avenue, 5th floor
Boston, Massachusetts 02118
United States",617 213 5054,hillevax.com,HLVX,NASDAQ,January - December,USD,0001888012,43157M102,US43157M1027,2836,"Apr 29, 2022",Common Stock,,$17.00,
"X4 Pharmaceuticals, Inc.","X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.
The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases.
It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications.
The company is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\X4_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/xfor/,United States,2014,Biotechnology,Healthcare,93,Paula Ragan,"61 North Beacon Street, 4th Floor
Boston, Massachusetts 02134
United States",857 529 8300,x4pharma.com,XFOR,NASDAQ,January - December,USD,0001501697,98420X103,US98420X1037,2836,,,27-3181608,,
"Coya Therapeutics, Inc.","Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs).
The company’s product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis.
The company’s product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases.
It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage.
The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis.
The company was incorporated in 2020 and is headquartered in Houston, Texas.","Data/company_logos_stock_analysis\Coya_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/coya/,United States,2020,Biotechnology,Healthcare,8,Arun Swaminathan,"5850 San Felipe Street, Suite 500
Houston, Texas 77057
United States",800 587 8170,coyatherapeutics.com,COYA,NASDAQ,January - December,USD,0001835022,,US22407B1089,2834,"Dec 29, 2022",Common Stock,,$5.00,
PepGen Inc.,"PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD.
PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.",Data/company_logos_stock_analysis\PepGen_Inc._logo.svg,https://stockanalysis.com/stocks/pepg/,United States,2018,Biotechnology,Healthcare,64,James McArthur,"321 Harrison Avenue, 8th Floor
Boston, Massachusetts 02118
United States",781 797 0979,pepgen.com,PEPG,NASDAQ,January - December,USD,0001835597,713317105,US7133171055,2834,"May 6, 2022",Common Stock,,$12.00,
Oramed Pharmaceuticals Inc.,"Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides.
The company’s product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.
Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.",Data/company_logos_stock_analysis\Oramed_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/ormp/,United States,2002,Biotechnology,Healthcare,13,Nadav Kidron,"1185 Avenue of the Americas, 3rd Floor
New York, New York 10036
United States",844 967 2633,oramed.com,ORMP,NASDAQ,January - December,USD,0001176309,68403P203,US68403P2039,2834,,Common Stock,98-0376008,,
"MediciNova, Inc.","MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
The company’s product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers.
It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.","Data/company_logos_stock_analysis\MediciNova,_Inc._logo.svg",https://stockanalysis.com/stocks/mnov/,United States,2000,Biotechnology,Healthcare,13,Yuichi Iwaki,"4275 Executive Square, Suite 300
La Jolla, California 92037
United States",858 373 1500,medicinova.com,MNOV,NASDAQ,January - December,USD,0001226616,58468P206,US58468P2065,2834,"Feb 8, 2005",Common Stock,33-0927979,,
"Cue Biopharma, Inc.","Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body.
Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.
The company is also developing CUE-102 targets Wilms’ Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series.
It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine.
The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016.
Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Cue_Biopharma,_Inc._logo.svg",https://stockanalysis.com/stocks/cue/,United States,2014,Biotechnology,Healthcare,53,Daniel Passeri,"40 Guest Street
Boston, Massachusetts 02135
United States",617 949 2680,cuebiopharma.com,CUE,NASDAQ,January - December,USD,0001645460,22978P106,US22978P1066,2834,"Jan 2, 2018",Common Stock,47-3324577,,
"Immunic, Inc.","Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.
Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.
Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.","Data/company_logos_stock_analysis\Immunic,_Inc._logo.svg",https://stockanalysis.com/stocks/imux/,United States,2016,Biotechnology,Healthcare,77,Daniel Vitt,"1200 Avenue of the Americas, Suite 200
New York, New York 10036
United States",332 255 9818,imux.com,IMUX,NASDAQ,January - December,USD,0001280776,4525EP101,US4525EP1011,2834,,Common Stock,56-2358443,,
ALX Oncology Holdings Inc.,"ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.
It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer.
In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses.
It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.",Data/company_logos_stock_analysis\ALX_Oncology_Holdings_Inc._logo.svg,https://stockanalysis.com/stocks/alxo/,United States,2015,Biotechnology,Healthcare,72,Jason Lettmann,"323 Allerton Avenue
South San Francisco, California 94080
United States",650 466 7125,alxoncology.com,ALXO,NASDAQ,January - December,USD,0001810182,00166B105,US00166B1052,2834,"Jul 17, 2020",,85-0642577,$19.00,
Regulus Therapeutics Inc.,"Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.
Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.",Data/company_logos_stock_analysis\Regulus_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/rgls/,United States,2007,Biotechnology,Healthcare,30,Joseph Hagan,"4224 Campus Point Court, Suite 210
San Diego, California 92121
United States",858 202 6300,regulusrx.com,RGLS,NASDAQ,January - December,USD,0001505512,75915K309,US75915K3095,2834,"Oct 4, 2012",Common Stock,26-4738379,,
"Pyxis Oncology, Inc.","Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers.
Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy.
It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate.
Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Pyxis_Oncology,_Inc._logo.svg",https://stockanalysis.com/stocks/pyxs/,United States,2018,Biotechnology,Healthcare,50,Lara Sullivan,"321 Harrison Avenue, 11th Floor, Suite 1
Boston, Massachusetts 02118
United States",617 221 9059,pyxisoncology.com,PYXS,NASDAQ,January - December,USD,0001782223,747324101,US7473241013,2834,"Oct 1, 2021",Common Stock,83-1160910,$16.00,
DBV Technologies S.A.,"DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.
Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.
The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.
DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.",Data/company_logos_stock_analysis\DBV_Technologies_S.A._logo.svg,https://stockanalysis.com/stocks/dbvt/,France,2002,Biotechnology,Healthcare,105,Daniel Tassé,"177-181 Avenue Pierre Brossolette
Montrouge, 92120
France",33 1 55 42 78 78,dbv-technologies.com,DBVT,NASDAQ,January - December,USD,0001613780,23306J101,US23306J1016,2836,,,,,
Tiziana Life Sciences Ltd,"Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States.
The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications.
Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.",Data/company_logos_stock_analysis\Tiziana_Life_Sciences_Ltd_logo.svg,https://stockanalysis.com/stocks/tlsa/,United Kingdom,2013,Biotechnology,Healthcare,9,Ivor Elrifi,"14/15 Conduit Street
London, W1S 2XJ
United Kingdom",,tizianalifesciences.com,TLSA,NASDAQ,January - December,USD,0001723069,88875G101,BMG889121031,2834,"Mar 24, 2000",,,,
Karyopharm Therapeutics Inc.,"Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds.
The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma.
Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.",Data/company_logos_stock_analysis\Karyopharm_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/kpti/,United States,2008,Biotechnology,Healthcare,325,Richard Paulson,"85 Wells Avenue, Suite 210
Newton, Massachusetts 02459-3298
United States",617 658 0600,karyopharm.com,KPTI,NASDAQ,January - December,USD,0001503802,48576U106,US48576U1060,2834,"Nov 6, 2013",Common Stock,26-3931704,,
Entera Bio Ltd.,"Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care.
The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream.
Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis.
The company is also developing EB612 as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism.
In addition, it is developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome.
The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.",Data/company_logos_stock_analysis\Entera_Bio_Ltd._logo.svg,https://stockanalysis.com/stocks/entx/,Israel,2010,Biotechnology,Healthcare,18,Miranda Toledano,"Kiryat Hadassah Minrav Building, Fifth Floor
Jerusalem, 9112002
Israel",972 2 532 7151,enterabio.com,ENTX,NASDAQ,January - December,USD,0001638097,M40527109,IL0011429839,2836,"Jun 28, 2018",,,,
"Fractyl Health, Inc.","Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.
Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021.
The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.","Data/company_logos_stock_analysis\Fractyl_Health,_Inc._logo.svg",https://stockanalysis.com/stocks/guts/,United States,2010,Biotechnology,Healthcare,102,Harith Rajagopalan,"3 Van de Graaff Drive, Suite 200
Burlington, Massachusetts 01803
United States",781 902 8800,fractyl.com,GUTS,NASDAQ,January - December,USD,0001572616,,US35168W1036,3841,"Feb 2, 2024",Common Stock,27-3553477,$15.00,
"Atara Biotherapeutics, Inc.","Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom.
Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.
Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis.
The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.
Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.","Data/company_logos_stock_analysis\Atara_Biotherapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/atra/,United States,2012,Biotechnology,Healthcare,225,Anhco Nguyen,"2380 Conejo Spectrum Street, Suite 200
Thousand Oaks, California 91320
United States",805 623 4211,atarabio.com,ATRA,NASDAQ,January - December,USD,0001604464,046513107,US0465131078,2836,"Oct 16, 2014",Common Stock,46-0920988,,
"Mersana Therapeutics, Inc.","Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs.
The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC.
It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005.
Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Mersana_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/mrsn/,United States,2001,Biotechnology,Healthcare,123,Martin Huber,"840 Memorial Drive
Cambridge, Massachusetts 02139
United States",617 498 0020,mersana.com,MRSN,NASDAQ,January - December,USD,0001442836,59045L106,US59045L1061,2834,"Jun 28, 2017",Common Stock,,,
"Adverum Biotechnologies, Inc.","Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases.
Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.
The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection.
Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016.
Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.","Data/company_logos_stock_analysis\Adverum_Biotechnologies,_Inc._logo.svg",https://stockanalysis.com/stocks/advm/,United States,2006,Biotechnology,Healthcare,121,Laurent Fischer,"100 Cardinal Way
Redwood City, California 94063
United States",650 656 9323,adverum.com,ADVM,NASDAQ,January - December,USD,0001501756,00773U108,US00773U1088,2836,"Jul 31, 2014",Common Stock,20-5258327,,
"Aadi Bioscience, Inc.","Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.
Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway.
Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.","Data/company_logos_stock_analysis\Aadi_Bioscience,_Inc._logo.svg",https://stockanalysis.com/stocks/aadi/,United States,2011,Biotechnology,Healthcare,89,David Lennon,"17383 Sunset Boulevard, Suite A250
Pacific Palisades, California 90272
United States",424 744 8055,aadibio.com,AADI,NASDAQ,January - December,USD,0001422142,00032Q104,US00032Q1040,2834,,Common Stock,61-1547850,,
Genenta Science S.p.A.,"Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.
Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma.
In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages.
Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.",Data/company_logos_stock_analysis\Genenta_Science_S.p.A._logo.svg,https://stockanalysis.com/stocks/gnta/,Italy,2014,Biotechnology,Healthcare,14,Pierluigi Paracchi,"Via Olgettina No. 58
Milan, Michigan 20132
Italy",,genenta.com,GNTA,NASDAQ,January - December,EUR,0001838716,36870W100,US36870W1009,2836,"Dec 15, 2021",,,$11.50,
Allakos Inc.,"Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States.
The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.
The company was incorporated in 2012 and is headquartered in San Carlos, California.",Data/company_logos_stock_analysis\Allakos_Inc._logo.svg,https://stockanalysis.com/stocks/allk/,United States,2012,Biotechnology,Healthcare,131,Robert Alexander,"825 Industrial Road, Suite 500
San Carlos, California 94070
United States",650 597 5002,allakos.com,ALLK,NASDAQ,January - December,USD,0001564824,01671P100,US01671P1003,2834,"Jul 19, 2018",Common Stock,45-4798831,,
"Century Therapeutics, Inc.","Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.
Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.
The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors.
In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma.
The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.","Data/company_logos_stock_analysis\Century_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ipsc/,United States,2019,Biotechnology,Healthcare,165,Brent Pfeiffenberger,"25 North 38th Street, 11th Floor
Philadelphia, Pennsylvania 19104
United States",267 817 5790,centurytx.com,IPSC,NASDAQ,January - December,USD,0001850119,15673T100,US15673T1007,2836,"Jun 18, 2021",Common Stock,84-2040295,$20.00,
I-Mab,"I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States.
It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy.
It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor.
The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer.
I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.",Data/company_logos_stock_analysis\I-Mab_logo.svg,https://stockanalysis.com/stocks/imab/,United States,2014,Biotechnology,Healthcare,220,Xi-Yong Fu,"2440 Research Boulevard, Suite 400
Rockville, Maryland 20850
United States",240 745 6330,ir.i-mabbiopharma.com,IMAB,NASDAQ,January - December,USD,0001778016,44975P103,US44975P1030,2834,"Jan 17, 2020",,,$14.00,
Theratechnologies Inc.,"Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe.
The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers.
The company was incorporated in 1993 and is headquartered in Montreal, Canada.",Data/company_logos_stock_analysis\Theratechnologies_Inc._logo.svg,https://stockanalysis.com/stocks/thtx/,Canada,1993,Biotechnology,Healthcare,103,Paul Lévesque,"2015 Peel Street, 11th Floor
Montreal, QC H3A 1T8
Canada",514 336 7800,theratech.com,THTX,NASDAQ,December - November,USD,0001512717,88338H100,CA88338H7040,2834,,,,,
Genelux Corporation,"Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate.
The company was incorporated in 2001 and is headquartered in Westlake Village, California.",Data/company_logos_stock_analysis\Genelux_Corporation_logo.svg,https://stockanalysis.com/stocks/gnlx/,United States,2001,Biotechnology,Healthcare,23,Thomas Zindrick,"2625 Townsgate Road, Suite 230
Westlake Village, California 91361
United States",805 267 9889,genelux.com,GNLX,NASDAQ,January - December,USD,0001231457,,US36870H1032,2834,"Jan 26, 2023",Common Stock,,$6.00,
Adagene Inc.,"Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers.
The company’s product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.
It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs.
The company was incorporated in 2011 and is headquartered in Suzhou, China.",Data/company_logos_stock_analysis\Adagene_Inc._logo.svg,https://stockanalysis.com/stocks/adag/,China,2011,Biotechnology,Healthcare,174,Peter P. Luo,"Building C14, 4th Floor
Suzhou, 215123
China",86 512 8777 3632,adagene.com,ADAG,NASDAQ,January - December,USD,0001818838,005329107,US0053291078,2834,"Feb 9, 2021",,,$19.00,
"Citius Oncology, Inc.","Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies.
It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma.
The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.","Data/company_logos_stock_analysis\Citius_Oncology,_Inc._logo.svg",https://stockanalysis.com/stocks/ctor/,United States,2021,Drug Manufacturers - Specialty & Generic,Healthcare,,Leonard Mazur,"420 Lexington Avenue, Suite 2446
New York, New York 10170
United States",347-627-0058,,CTOR,NASDAQ,October - September,USD,0001851484,,US17331Y1091,2834,,Common Stock,,,
"Vistagen Therapeutics, Inc.","Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders.
The company’s product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder.
It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women’s health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders.
In addition, the company’s clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines.
It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders.
Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Vistagen_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/vtgn/,United States,1998,Biotechnology,Healthcare,40,Shawn Singh,"343 Allerton Avenue
South San Francisco, California 94080
United States",650 577 3600,vistagen.com,VTGN,NASDAQ,April - March,USD,0001411685,92840H202,US92840H4002,2834,,Common Stock,20-5093315,,
"bluebird bio, Inc.","bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States.
The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with β-thalassemia.
The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010.
bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.","Data/company_logos_stock_analysis\bluebird_bio,_Inc._logo.svg",https://stockanalysis.com/stocks/blue/,United States,1992,Biotechnology,Healthcare,375,Andrew Obenshain,"455 Grand Union Boulevard
Somerville, Massachusetts 02145
United States",339 499 9300,bluebirdbio.com,BLUE,NASDAQ,January - December,USD,0001293971,09609G100,US09609G1004,2836,"Jun 19, 2013",,,,
Camp4 Therapeutics Corporation,"Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases.
Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders.
Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Camp4_Therapeutics_Corporation_logo.svg,https://stockanalysis.com/stocks/camp/,United States,2016,Biotechnology,Healthcare,64,Joshua Mandel-Brehm,"One Kendall Square, Building 1400 West
Cambridge, Massachusetts 02139
United States",(617) 651-8867,camp4tx.com,CAMP,NASDAQ,January - December,USD,0001736730,13463J101,US13463J1016,2834,"Oct 11, 2024",Common Stock,,$11.00,
"Assertio Holdings, Inc.","Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States.
Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.
It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia.
The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020.
Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.","Data/company_logos_stock_analysis\Assertio_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/asrt/,United States,1995,Drug Manufacturers - Specialty & Generic,Healthcare,53,Brendan O’Grady,"100 South Saunders Road, Suite 300
Lake Forest, Illinois 60045
United States",224 419 7106,assertiotx.com,ASRT,NASDAQ,January - December,USD,0001005201,04546C205,US04546C2052,2834,"Nov 5, 1997",Common Stock,94-3229046,,
Context Therapeutics Inc.,"Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors.
Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.",Data/company_logos_stock_analysis\Context_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/cntx/,United States,2015,Biotechnology,Healthcare,5,Martin Lehr,"2001 Market Street, Suite 3915
Philadelphia, Pennsylvania 19103
United States",267 225 7416,contexttherapeutics.com,CNTX,NASDAQ,January - December,USD,0001842952,21077P108,US21077P1084,2834,"Oct 20, 2021",Common Stock,86-3738787,$5.00,
Journey Medical Corporation,"Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis.
In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne.
The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation.
Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.",Data/company_logos_stock_analysis\Journey_Medical_Corporation_logo.svg,https://stockanalysis.com/stocks/derm/,United States,2014,Drug Manufacturers - Specialty & Generic,Healthcare,41,Claude Maraoui,"9237 East Via de Ventura Boulevard, Suite 105
Scottsdale, Arizona 85258
United States",480 434 6670,journeymedicalcorp.com,DERM,NASDAQ,January - December,USD,0001867066,48115J109,US48115J1097,2834,"Nov 12, 2021",Common Stock,47-1879539,$10.00,
"Quince Therapeutics, Inc.","Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
The company’s lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.
The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022.
Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Quince_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/qncx/,United States,2012,Biotechnology,Healthcare,32,Dirk Thye,"611 Gateway Boulevard, Suite 273
South San Francisco, California 94080
United States",415-910-5717,quincetx.com,QNCX,NASDAQ,January - December,USD,0001145404,22053A107,US22053A1079,2834,"May 9, 2019",Common Stock,04-3523569,$17.00,
"Applied Therapeutics, Inc.","Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States.
The company’s lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.
It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy.
The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007.
Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.","Data/company_logos_stock_analysis\Applied_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/aplt/,United States,2016,Biotechnology,Healthcare,25,Les Funtleyder,"545 Fifth Avenue, Suite 1400
New York, New York 10017
United States",212 220 9226,appliedtherapeutics.com,APLT,NASDAQ,January - December,USD,0001697532,03828A101,US03828A1016,2834,"May 14, 2019",Common Stock,,$10.00,
ESSA Pharma Inc.,"ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\ESSA_Pharma_Inc._logo.svg,https://stockanalysis.com/stocks/epix/,Canada,2009,Biotechnology,Healthcare,35,David Parkinson,"999 West Broadway, Suite 720
Vancouver, BC V5Z 1K5
Canada",(778) 331-0962,essapharma.com,EPIX,NASDAQ,October - September,USD,0001633932,29668H708,CA29668H7085,2834,,,,,
InterCure Ltd.,"InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally.
The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector.
The company was incorporated in 1994 and is headquartered in Herzliya, Israel.",Data/company_logos_stock_analysis\InterCure_Ltd._logo.svg,https://stockanalysis.com/stocks/incr/,Israel,1994,Drug Manufacturers - Specialty & Generic,Healthcare,270,Alexander Rabinovich,"85 Medinat ha-Yehudim Street
Herzliya, 4676670
Israel",972 7 746 05012,intercure.co,INCR,NASDAQ,January - December,ILS,0001857030,M549GJ111,IL0011063760,2834,,,,,
"Armata Pharmaceuticals, Inc.","Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents.
The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.","Data/company_logos_stock_analysis\Armata_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/armp/,United States,,Biotechnology,Healthcare,66,Deborah Birx,"5005 McConnell Avenue
Los Angeles, California 90066
United States",310 665 2928,armatapharma.com,ARMP,NYSEAMERICAN,January - December,USD,0000921114,04216R102,US04216R1023,2836,,,91-1549568,,
"Adicet Bio, Inc.","Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients.
Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications.
The company was founded in 2014 and is based in Boston, Massachusetts.","Data/company_logos_stock_analysis\Adicet_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/acet/,United States,1947,Biotechnology,Healthcare,143,Chen Schor,"131 Dartmouth Street, 3rd Floor
Boston, Massachusetts 02116
United States",650 503 9095,adicetbio.com,ACET,NASDAQ,January - December,USD,0000002034,007002108,US0070021086,5122,,Common Stock,11-1720520,,
"PMV Pharmaceuticals, Inc.","PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.
It’s lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.
The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013.
PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.","Data/company_logos_stock_analysis\PMV_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/pmvp/,United States,2013,Biotechnology,Healthcare,63,David Mack,"1 Research Way
Princeton, New Jersey 08540
United States",609 642 6670,pmvpharma.com,PMVP,NASDAQ,January - December,USD,0001699382,69353Y103,US69353Y1038,2834,"Sep 25, 2020",Common Stock,46-3218129,$18.00,
"Ikena Oncology, Inc.","Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States.
Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex.
Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Ikena_Oncology,_Inc._logo.svg",https://stockanalysis.com/stocks/ikna/,United States,2016,Biotechnology,Healthcare,43,Mark Manfredi,"645 Summer Street, Suite 101
Boston, Massachusetts 02210
United States",857 273 8343,ikenaoncology.com,IKNA,NASDAQ,January - December,USD,0001835579,45175G108,US45175G1085,2836,"Mar 26, 2021",Common Stock,,$16.00,
"Clearside Biomedical, Inc.","Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.
It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences.
Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.","Data/company_logos_stock_analysis\Clearside_Biomedical,_Inc._logo.svg",https://stockanalysis.com/stocks/clsd/,United States,2011,Biotechnology,Healthcare,30,George Lasezkay,"900 North Point Parkway, Suite 200
Alpharetta, Georgia 30005
United States",678 270 3631,clearsidebio.com,CLSD,NASDAQ,January - December,USD,0001539029,185063104,US1850631045,2834,"Jun 2, 2016",Common Stock,45-2437375,,
"Aerovate Therapeutics, Inc.","Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States.
It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Aerovate_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/avte/,United States,2018,Biotechnology,Healthcare,51,Timothy Noyes,"930 Winter Street, Suite M-500
Waltham, Massachusetts 02451
United States",617 443 2400,aerovatetx.com,AVTE,NASDAQ,January - December,USD,0001798749,008064107,US0080641071,2834,"Jun 30, 2021",Common Stock,83-1377888,$14.00,
"Avalo Therapeutics, Inc.","Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.
The company’s drug candidates include AVTX-009, an Anti-IL-1β monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases.
The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021.
Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.","Data/company_logos_stock_analysis\Avalo_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/avtx/,United States,2011,Biotechnology,Healthcare,19,Garry Neil,"540 Gaither Road, Suite 400
Rockville, Maryland 20850
United States",410-522-8707,avalotx.com,AVTX,NASDAQ,January - December,USD,0001534120,05338F108,US05338F3064,2834,"Oct 15, 2015",Common Stock,45-0705648,,
Adlai Nortye Ltd.,"Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China.
Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1.
Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor.
The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.",Data/company_logos_stock_analysis\Adlai_Nortye_Ltd._logo.svg,https://stockanalysis.com/stocks/anl/,Cayman Islands,2004,Biotechnology,Healthcare,127,Yang Lu,"Ugland House, PO Box 309
Grand Cayman, KY1-1104
Cayman Islands",848 230 7430,adlainortye.com,ANL,NASDAQ,January - December,USD,0001944552,,US00704R1095,2834,"Sep 29, 2023",,,$23.00,
"Vigil Neuroscience, Inc.","Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain.
Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial.
It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2.
The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.","Data/company_logos_stock_analysis\Vigil_Neuroscience,_Inc._logo.svg",https://stockanalysis.com/stocks/vigl/,United States,2020,Biotechnology,Healthcare,69,Ivana Magovcevic-Liebisch,"100 Forge Road, Suite 700
Watertown, Massachusetts 02472
United States",857 254 4445,vigilneuro.com,VIGL,NASDAQ,January - December,USD,0001827087,92673K108,US92673K1088,2836,"Jan 7, 2022",Common Stock,,$14.00,
Agenus Inc.,"Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally.
The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFβ TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies.
In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody.
The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011.
Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.",Data/company_logos_stock_analysis\Agenus_Inc._logo.svg,https://stockanalysis.com/stocks/agen/,United States,1994,Biotechnology,Healthcare,389,Garo Armen,"3 Forbes Road
Lexington, Massachusetts 02421-7305
United States",781 674 4400,agenusbio.com,AGEN,NASDAQ,January - December,USD,0001098972,00847G705,US00847G7051,2836,"Feb 4, 2000",Common Stock,06-1562417,,
"Anixa Biosciences, Inc.","Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.
Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
The company’s vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate.
Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer.
The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018.
Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.","Data/company_logos_stock_analysis\Anixa_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/anix/,United States,1982,Biotechnology,Healthcare,5,Amit Kumar,"3150 Almaden Expressway, Suite 250
San Jose, California 95118
United States",408 708 9808,anixa.com,ANIX,NASDAQ,November - October,USD,0000715446,03528H109,US03528H1095,2834,"Jan 1, 1987",Common Stock,11-2622630,,
"Rani Therapeutics Holdings, Inc.","Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States.
The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions.
The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity.
Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.","Data/company_logos_stock_analysis\Rani_Therapeutics_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/rani/,United States,2012,Biotechnology,Healthcare,140,Talat Imran,"2051 Ringwood Avenue
San Jose, California 95131
United States",408 457 3700,ranitherapeutics.com,RANI,NASDAQ,January - December,USD,0001856725,753018100,US7530181004,2834,"Jul 30, 2021",Common Stock,,$11.00,Class A Shares
"Vivani Medical, Inc.","Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases.
The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence.
Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes.
The company is headquartered in Alameda, California.","Data/company_logos_stock_analysis\Vivani_Medical,_Inc._logo.svg",https://stockanalysis.com/stocks/vani/,United States,1998,Biotechnology,Healthcare,44,Adam Mendelsohn,"1350 South Loop Road
Alameda, California 94502
United States",415 506 8462,vivani.com,VANI,NASDAQ,January - December,USD,0001266806,92854B109,US92854B1098,3845,"Nov 19, 2014",Common Stock,,,
"Abpro Holdings, Inc.","Abpro Holdings, Inc., a biotechnology company, provides antibody therapeutics for cancer related issues.
Its platform DiversImmune addresses the antibody therapeutics. The company’s product candidates include ABP-102 for the treatment of breast and gastric cancer; and ABP-110 for the treatment of liver cancer.
It also offers ABP-105 for the treatment of gastric cancer and ABP 201 for vascular diseases of the eye and diabetic macular edema.
Abpro Holdings, Inc. was incorporated in 2004 and is based in Woburn, Massachusetts.","Data/company_logos_stock_analysis\Abpro_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/abp/,United States,2004,Biotechnology,Healthcare,16,Ian Chan,"68 Cummings Park Drive
Woburn, Massachusetts 01801
United States",800 396 5890,abpro.com,ABP,NASDAQ,January - December,USD,"0001893219,CIK_0001670356",,,,,Common Stock,20-1546491,,
Galectin Therapeutics Inc.,"Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.
Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration.
The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011.
Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.",Data/company_logos_stock_analysis\Galectin_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/galt/,United States,2000,Biotechnology,Healthcare,14,Joel Lewis,"4960 Peachtree Industrial Boulevard, Suite 240
Norcross, Georgia 30071
United States",(678) 620-3186,galectintherapeutics.com,GALT,NASDAQ,January - December,USD,0001133416,363225202,US3632252025,2834,,Common Stock,04-3562325,,
"Cibus, Inc.","Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties.
The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.
Cibus, Inc. is based in San Diego, California.","Data/company_logos_stock_analysis\Cibus,_Inc._logo.svg",https://stockanalysis.com/stocks/cbus/,United States,2010,Biotechnology,Healthcare,183,Rory Riggs,"6455 Nancy Ridge Drive
San Diego, California 92121
United States",858 450 0008,cibus.com,CBUS,NASDAQ,January - December,USD,0001705843,17166A101,US17166A1016,2870,"Jul 20, 2017",Common Stock,27-1967997,,Class A Shares
"Unicycive Therapeutics, Inc.","Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States.
Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee’s Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.","Data/company_logos_stock_analysis\Unicycive_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/uncy/,United States,2016,Biotechnology,Healthcare,14,Shalabh Gupta,"4300 El Camino Real, Suite 210
Los Altos, California 94022
United States",650 351 4495,unicycive.com,UNCY,NASDAQ,January - December,USD,0001766140,90466Y103,US90466Y1038,2834,"Jul 13, 2021",Common Stock,81-3638692,$5.00,
"CytomX Therapeutics, Inc.","CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.
In addition, the company’s development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab.
It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\CytomX_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ctmx/,United States,2008,Biotechnology,Healthcare,122,Sean McCarthy,"151 Oyster Point Boulevard, Suite 400
South San Francisco, California 94080
United States",650 515 3185,cytomx.com,CTMX,NASDAQ,January - December,USD,0001501989,23284F105,US23284F1057,2834,"Oct 8, 2015",Common Stock,27-3521219,,
"Rockwell Medical, Inc.","Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide.
Also, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers.
The company’s hemodialysis concentrate products are used to sustain patient’s life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream.
The company serves to hemodialysis clinics. Rockwell Medical, Inc. was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012.
Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.","Data/company_logos_stock_analysis\Rockwell_Medical,_Inc._logo.svg",https://stockanalysis.com/stocks/rmti/,United States,1994,Drug Manufacturers - Specialty & Generic,Healthcare,237,Mark Strobeck,"30142 South Wixom road
Wixom, Michigan 48393
United States",248 960 9009,rockwellmed.com,RMTI,NASDAQ,January - December,USD,0001041024,774374300,US7743743004,2834,"Jan 27, 1998",,38-3317208,,
"Annovis Bio, Inc.","Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.
The company’s lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer’s disease (AD), Parkinson’s disease, and other chronic neurodegenerative diseases.
It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia.
The company was incorporated in 2008 and is based in Malvern, Pennsylvania.","Data/company_logos_stock_analysis\Annovis_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/anvs/,United States,2008,Biotechnology,Healthcare,16,Maria Maccecchini,"101 Lindenwood Drive, Suite 225
Malvern, Pennsylvania 19355
United States",(484) 875-3192,annovisbio.com,ANVS,NYSE,January - December,USD,0001477845,03615A108,US03615A1088,2834,"Jan 29, 2020",Common Stock,26-2540421,$6.00,
"SELLAS Life Sciences Group, Inc.","SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States.
The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials.
SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.","Data/company_logos_stock_analysis\SELLAS_Life_Sciences_Group,_Inc._logo.svg",https://stockanalysis.com/stocks/sls/,United States,2012,Biotechnology,Healthcare,16,Angelos Stergiou,"Times Square Tower, Suite 2503
New York, New York 10036
United States",646 200 5278,sellaslifesciences.com,SLS,NASDAQ,January - December,USD,0001390478,81642T209,US81642T2096,2834,,,,,
BeyondSpring Inc.,"BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.
The company’s lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.
It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type.
In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer.
Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration.
The company was founded in 2010 and is headquartered in Florham Park, New Jersey.",Data/company_logos_stock_analysis\BeyondSpring_Inc._logo.svg,https://stockanalysis.com/stocks/bysi/,United States,2010,Biotechnology,Healthcare,36,Lan Huang,"100 Campus Drive, 4th Floor, Suite 410
Florham Park, New Jersey 07932
United States",646 305 6387,beyondspringpharma.com,BYSI,NASDAQ,January - December,USD,0001677940,G10830100,KYG108301006,2834,"Mar 9, 2017",,,,
Oncolytics Biotech Inc.,"Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer.
The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG.
The company was incorporated in 1998 and is headquartered in Calgary, Canada.",Data/company_logos_stock_analysis\Oncolytics_Biotech_Inc._logo.svg,https://stockanalysis.com/stocks/oncy/,Canada,1998,Biotechnology,Healthcare,29,Wayne Pisano,"322 11th Avenue SW, Suite 804
Calgary, AB T2R 0C5
Canada",403 670 7377,oncolyticsbiotech.com,ONCY,NASDAQ,January - December,CAD,0001129928,682310875,CA6823108759,2834,"Nov 8, 1999",,,,
Mural Oncology plc,"Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer.
The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs.
Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.",Data/company_logos_stock_analysis\Mural_Oncology_plc_logo.svg,https://stockanalysis.com/stocks/mura/,Ireland,2013,Biotechnology,Healthcare,117,Caroline Loew,"10 Earlsfort Terrace
Dublin, D02 T380
Ireland",353 1 905 8020,muraloncology.com,MURA,NASDAQ,January - December,USD,0001971543,,IE000LK2BOB4,2834,,Common Stock,,,
"Elicio Therapeutics, Inc.","Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer.
Its lead product candidate is ELI-002, a multivalent lymph node–targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
The company is also developing ELI-007, a multivalent lymph node–targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine to target p53 hotspot mutations.
The company is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Elicio_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/eltx/,United States,2011,Biotechnology,Healthcare,32,Robert Connelly,"451 D Street, 5th Floor
Boston, Massachusetts 02210
United States",857 209 0050,elicio.com,ELTX,NASDAQ,January - December,USD,0001555192,28657F103,US28657F1030,2834,"Feb 5, 2021",Common Stock,45-2966790,,
"FibroBiologics, Inc.","FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company.
It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials.
It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.","Data/company_logos_stock_analysis\FibroBiologics,_Inc._logo.svg",https://stockanalysis.com/stocks/fblg/,United States,2021,Biotechnology,Healthcare,10,Peter O’Heeron,"455 East Medical Center Boulevard, Suite 300
Houston, Texas 77598
United States",281 651 5150,fibrobiologics.com,FBLG,NASDAQ,January - December,USD,0001958777,,US31573L1052,2834,"Jan 31, 2024",Common Stock,86-3329066,$30.00,
Immuneering Corporation,"Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients.
Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Immuneering_Corporation_logo.svg,https://stockanalysis.com/stocks/imrx/,United States,2008,Biotechnology,Healthcare,68,Benjamin Zeskind,"245 Main Street, Second Floor
Cambridge, Massachusetts 02142
United States",617 500 8080,immuneering.com,IMRX,NASDAQ,January - December,USD,0001790340,45254E107,US45254E1073,2834,"Jul 30, 2021",Common Stock,,$15.00,Class A Shares
"Reviva Pharmaceuticals Holdings, Inc.","Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.
The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.
It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.","Data/company_logos_stock_analysis\Reviva_Pharmaceuticals_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/rvph/,United States,2006,Biotechnology,Healthcare,15,Laxminarayan Bhat,"10080 N. Wolfe Road, Suite SW3-200
Cupertino, California 95014
United States",408 501 8881,revivapharma.com,RVPH,NASDAQ,January - December,USD,0001742927,76152G100,US76152G1004,2834,,Common Stock,,,
Regencell Bioscience Holdings Limited,"Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong.
The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.
Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.",Data/company_logos_stock_analysis\Regencell_Bioscience_Holdings_Limited_logo.svg,https://stockanalysis.com/stocks/rgc/,Hong Kong,2014,Drug Manufacturers - Specialty & Generic,Healthcare,12,Yat-Gai Au,"Chinachem Leighton Plaza, 9th Floor
Causeway Bay
Hong Kong",852 2155 0823,regencellbioscience.com,RGC,NASDAQ,July - June,USD,0001829667,G7487R100,KYG7487R1002,2833,"Jul 16, 2021",,,$9.50,
"FibroGen, Inc.","FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.","Data/company_logos_stock_analysis\FibroGen,_Inc._logo.svg",https://stockanalysis.com/stocks/fgen/,United States,1993,Biotechnology,Healthcare,486,Thane Wettig,"409 Illinois Street
San Francisco, California 94158
United States",415 978 1200,fibrogen.com,FGEN,NASDAQ,January - December,USD,0000921299,31572Q808,US31572Q8087,2834,"Nov 14, 2014",Common Stock,,,
Generation Bio Co.,"Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases.
The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.
It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system.
The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017.
Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Generation_Bio_Co._logo.svg,https://stockanalysis.com/stocks/gbio/,United States,2016,Biotechnology,Healthcare,174,Cameron McDonough,"301 Binney Street
Cambridge, Massachusetts 02142
United States",617 655 7500,generationbio.com,GBIO,NASDAQ,January - December,USD,0001733294,37148K100,US37148K1007,2834,"Jun 12, 2020",Common Stock,81-4301281,$19.00,
"Werewolf Therapeutics, Inc.","Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.
The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma.
The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer.
Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.","Data/company_logos_stock_analysis\Werewolf_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/howl/,United States,2017,Biotechnology,Healthcare,47,Daniel Hicklin,"200 Talcott Ave, 2nd Floor
Watertown, Massachusetts 02472
United States",617 952 0555,werewolftx.com,HOWL,NASDAQ,January - December,USD,0001785530,95075A107,US95075A1079,2834,"Apr 30, 2021",Common Stock,82-3523180,$16.00,
"Gain Therapeutics, Inc.","Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas.
Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
The company’s lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials.
It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer’s Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors.
The company was founded in 2017 and is headquartered in Bethesda, Maryland.","Data/company_logos_stock_analysis\Gain_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ganx/,United States,2017,Biotechnology,Healthcare,32,Gene Mack,"4800 Montgomery Lane, Suite 220
Bethesda, Maryland 20814
United States",301 500 1556,gaintherapeutics.com,GANX,NASDAQ,January - December,USD,0001819411,36269B105,US36269B1052,2834,"Mar 18, 2021",Common Stock,85-1726310,$11.00,
Connect Biopharma Holdings Limited,"Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases.
The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn’s disease.
The company was founded in 2012 and is based in San Diego, California.",Data/company_logos_stock_analysis\Connect_Biopharma_Holdings_Limited_logo.svg,https://stockanalysis.com/stocks/cntb/,United States,2012,Biotechnology,Healthcare,81,Barry Quart,"12265 El Camino Real, Suite 350
San Diego, California 92130
United States",858 727 1040,connectbiopharm.com,CNTB,NASDAQ,January - December,USD,0001835268,207523101,US2075231017,2834,"Mar 19, 2021",,,$17.00,
Verrica Pharmaceuticals Inc.,"Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States.
Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial.
In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma.
Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.",Data/company_logos_stock_analysis\Verrica_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/vrca/,United States,2013,Biotechnology,Healthcare,100,Jayson Rieger,"44 West Gay Street, Suite 400
West Chester, Pennsylvania 19380
United States",484 453 3300,verrica.com,VRCA,NASDAQ,January - December,USD,0001660334,92511W108,US92511W1080,2834,"Jun 15, 2018",Common Stock,46-3137900,,
"Outlook Therapeutics, Inc.","Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.
Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018.
Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.","Data/company_logos_stock_analysis\Outlook_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/otlk/,United States,2010,Biotechnology,Healthcare,23,Lawrence Kenyon,"111 S. Wood Avenue, Unit #100
Iselin, New Jersey 08830
United States",609 619 3990,outlooktherapeutics.com,OTLK,NASDAQ,October - September,USD,0001649989,69012T206,US69012T3059,2836,"May 13, 2016",Common Stock,38-3982704,,
"LakeShore Biopharma Co., Ltd","LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer.
The company’s product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials.
It operates in China, Singapore, the United States, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024.
The company was founded in 2002 and is based in Beijing, China.","Data/company_logos_stock_analysis\LakeShore_Biopharma_Co.,_Ltd_logo.svg",https://stockanalysis.com/stocks/lsb/,China,2002,Biotechnology,Healthcare,758,Wang Xu,"Building No. 2, 38 Yongda Road
Beijing, 102629
China",86 10 8920 2086,ysbiopharm.com,LSB,NASDAQ,April - March,CNY,0001946399,,KYG9845F1090,2834,,,,,
Repare Therapeutics Inc.,"Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States.
It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
The company’s lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase I/Ib clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations.
The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; Foundation Medicine, Inc. for the provision of prospective genomic profiling of lunresertib alone or in combinations in genomically-defined patient populations; cooperative research and development agreement with US National Cancer Institute to advance the development of Camonsertib; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer.
Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.",Data/company_logos_stock_analysis\Repare_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/rptx/,Canada,2016,Biotechnology,Healthcare,179,Lloyd Segal,"7171 Frederick-Banting, Building 2, Suite 270
Montreal, QC H4S 1Z9
Canada",857 412 7018,reparerx.com,RPTX,NASDAQ,January - December,USD,0001808158,760273102,US7602731025,2834,"Jun 19, 2020",,,$20.00,
Prelude Therapeutics Incorporated,"Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.
The company’s CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB.
Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.",Data/company_logos_stock_analysis\Prelude_Therapeutics_Incorporated_logo.svg,https://stockanalysis.com/stocks/prld/,United States,2016,Biotechnology,Healthcare,128,Krishna Vaddi,"175 Innovation Boulevard
Wilmington, Delaware 19805
United States",302 467 1280,preludetx.com,PRLD,NASDAQ,January - December,USD,0001678660,74065P101,US74065P1012,2834,"Sep 25, 2020",Common Stock,81-1384762,$19.00,
"NRx Pharmaceuticals, Inc.","NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain.
Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.
The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital.
The company was founded in 2015 and is based in Wilmington, Delaware.","Data/company_logos_stock_analysis\NRx_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/nrxp/,United States,2015,Biotechnology,Healthcare,2,Jonathan Javitt,"1201 Orange Street, Suite 600
Wilmington, Delaware 19801
United States",(484) 254-6134,nrxpharma.com,NRXP,NASDAQ,January - December,USD,0001719406,089482103,US6294441000,2834,,Common Stock,82-2844431,,
Ovid Therapeutics Inc.,"Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.
It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome.
The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.",Data/company_logos_stock_analysis\Ovid_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/ovid/,United States,2014,Biotechnology,Healthcare,40,Jeremy Levin,"41 Ninth Avenue, 14th Floor
New York, New York 10001
United States",646 661 7661,ovidrx.com,OVID,NASDAQ,January - December,USD,0001636651,690469101,US6904691010,2834,"May 5, 2017",Common Stock,46-5270895,,
"Immix Biopharma, Inc.","Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia.
The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma.
It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab.
Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.","Data/company_logos_stock_analysis\Immix_Biopharma,_Inc._logo.svg",https://stockanalysis.com/stocks/immx/,United States,2014,Biotechnology,Healthcare,17,Ilya Rachman,"11400 West Olympic Boulevard, Suite 200
Los Angeles, California 90064
United States",310 651 8041,immixbio.com,IMMX,NASDAQ,January - December,USD,0001873835,45258H106,US45258H1068,2834,"Dec 16, 2021",Common Stock,45-4869378,$5.00,
"Kronos Bio, Inc.","Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States.
Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
The company was incorporated in 2017 and is headquartered in San Mateo, California.","Data/company_logos_stock_analysis\Kronos_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/kron/,United States,2017,Biotechnology,Healthcare,63,Deborah Knobelman,"1300 South El Camino Real, Suite 400
San Mateo, California 94402
United States",650 781 5200,kronosbio.com,KRON,NASDAQ,January - December,USD,0001741830,50107A104,US50107A1043,2834,"Oct 9, 2020",Common Stock,,$19.00,
"IO Biotech, Inc.","IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.
The company’s lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers.
The company was incorporated in 2014 and is based in Copenhagen, Denmark.","Data/company_logos_stock_analysis\IO_Biotech,_Inc._logo.svg",https://stockanalysis.com/stocks/iobt/,Denmark,2014,Biotechnology,Healthcare,68,Mai-Britt Zocca,"Ole MaalOees Vej 3, Copenhagen N
Copenhagen, 2200
Denmark",45 70 70 29 80,iobiotech.com,IOBT,NASDAQ,January - December,USD,0001865494,449778109,US4497781090,2834,"Nov 5, 2021",,87-0909276,$14.00,
"Shattuck Labs, Inc.","Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States.
The company’s lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.","Data/company_logos_stock_analysis\Shattuck_Labs,_Inc._logo.svg",https://stockanalysis.com/stocks/sttk/,United States,2016,Biotechnology,Healthcare,75,Taylor Schreiber,"500 West 5th Street, Suite 1200
Austin, Texas 78701
United States",512 900 4690,shattucklabs.com,STTK,NASDAQ,January - December,USD,0001680367,82024L103,US82024L1035,2834,"Oct 9, 2020",Common Stock,81-2575858,$17.00,
"Fortress Biotech, Inc.","Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States.
The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.
It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea.
The company’s early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency.
Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform.
The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015.
Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.","Data/company_logos_stock_analysis\Fortress_Biotech,_Inc._logo.svg",https://stockanalysis.com/stocks/fbio/,United States,2006,Biotechnology,Healthcare,186,Lindsay Rosenwald,"1111 Kane Concourse, Suite 301
Bay Harbor Islands, Florida 33154
United States",781 652 4500,fortressbiotech.com,FBIO,NASDAQ,January - December,USD,0001429260,34960Q109,US34960Q3074,2834,,Common Stock,20-5157386,,
"Invivyd, Inc.","Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.
The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19.
It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses.
The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022.
Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Invivyd,_Inc._logo.svg",https://stockanalysis.com/stocks/ivvd/,United States,2020,Biotechnology,Healthcare,95,William Duke,"1601 Trapelo Road, Suite 178
Waltham, Massachusetts 02451
United States",781 819 0080,invivyd.com,IVVD,NASDAQ,January - December,USD,0001832038,00534A102,US00534A1025,2836,"Aug 6, 2021",Common Stock,85-1403134,$17.00,
"MAIA Biotechnology, Inc.","MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.
Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.
The company was incorporated in 2018 and is headquartered in Chicago, Illinois.","Data/company_logos_stock_analysis\MAIA_Biotechnology,_Inc._logo.svg",https://stockanalysis.com/stocks/maia/,United States,2018,Biotechnology,Healthcare,13,Vlad Vitoc,"444 West Lake Street, Suite 1700
Chicago, Illinois 60606
United States",312 416 8592,maiabiotech.com,MAIA,NYSEAMERICAN,January - December,USD,0001878313,552641102,US5526411021,2834,"Jul 28, 2022",Common Stock,,$5.00,
"Boundless Bio, Inc.","Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA.
Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers.
The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA.
Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019.
The company was incorporated in 2018 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Boundless_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/bold/,United States,2018,Biotechnology,Healthcare,72,Zachary Hornby,"9880 Campus Point Drive, Suite 120
San Diego, California 92121
United States",858 766 9912,boundlessbio.com,BOLD,NASDAQ,January - December,USD,0001782303,,US10170A1007,2834,"Mar 28, 2024",Common Stock,83-0751369,$16.00,
"Spero Therapeutics, Inc.","Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite.
Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Spero_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/spro/,United States,2013,Biotechnology,Healthcare,46,Esther Rajavelu,"675 Massachusetts Avenue, 14th Floor
Cambridge, Massachusetts 02139
United States",857 242 1600,sperotherapeutics.com,SPRO,NASDAQ,January - December,USD,0001701108,84833T103,US84833T1034,2834,"Nov 2, 2017",Common Stock,,,
PDS Biotechnology Corporation,"PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States.
The company’s lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers.
In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma.
Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu.
It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH.
The company was founded in 2005 and is based in Princeton, New Jersey.",Data/company_logos_stock_analysis\PDS_Biotechnology_Corporation_logo.svg,https://stockanalysis.com/stocks/pdsb/,United States,2005,Biotechnology,Healthcare,25,Frank Bedu-Addo,"303A College Road East
Princeton, New Jersey 08540
United States",800 208 3343,pdsbiotech.com,PDSB,NASDAQ,January - December,USD,0001472091,70465T107,US70465T1079,2834,,Common Stock,26-4231384,,
"OptiNose, Inc.","OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States.
The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail.
The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.","Data/company_logos_stock_analysis\OptiNose,_Inc._logo.svg",https://stockanalysis.com/stocks/optn/,United States,2010,Drug Manufacturers - Specialty & Generic,Healthcare,132,Ramy Mahmoud,"1020 Stony Hill Road, Suite 300
Yardley, Pennsylvania 19067
United States",267 364 3500,optinose.com,OPTN,NASDAQ,January - December,USD,0001494650,68404V100,US68404V1008,2834,"Oct 13, 2017",Common Stock,42-1771610,,
Tonix Pharmaceuticals Holding Corp.,"Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering.
It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates.
The company’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia.
TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition.
Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA.
The company’s rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS).
Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases.
The company’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox.
TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19.
Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development.
Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals.
The company was founded in 2007 and is headquartered in Chatham, New Jersey.",Data/company_logos_stock_analysis\Tonix_Pharmaceuticals_Holding_Corp._logo.svg,https://stockanalysis.com/stocks/tnxp/,United States,2007,Biotechnology,Healthcare,103,Seth Lederman,"26 Main Street, Suite 101
Chatham, New Jersey 07928
United States",862 799 8599,tonixpharma.com,TNXP,NASDAQ,January - December,USD,0001430306,890260862,US8902608541,2834,,Common Stock,26-1434750,,
VYNE Therapeutics Inc.,"VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions.
The company’s lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.
It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications.
The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020.
VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.",Data/company_logos_stock_analysis\VYNE_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/vyne/,United States,2003,Biotechnology,Healthcare,10,David Domzalski,"685 Route 202/206 N, Suite 301
Bridgewater, New Jersey 08807
United States",800 775 7936,vynetherapeutics.com,VYNE,NASDAQ,January - December,USD,0001566044,92941V209,US92941V3087,2834,"Jan 25, 2018",Common Stock,45-3757789,,
"AlloVir, Inc.","Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases.
The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.
The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019.
The company was incorporated in 2013 and is based in Waltham, Massachusetts.","Data/company_logos_stock_analysis\AlloVir,_Inc._logo.svg",https://stockanalysis.com/stocks/alvr/,United States,2013,Biotechnology,Healthcare,112,Vikas Sinha,"1100 Winter Street
Waltham, Massachusetts 02451
United States",617 433 2605,allovir.com,ALVR,NASDAQ,January - December,USD,0001754068,019818103,US0198181036,2836,"Jul 30, 2020",Common Stock,83-1971007,$17.00,
"Dyadic International, Inc.","Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally.
It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.
The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform.
It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness.
The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa’s Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.","Data/company_logos_stock_analysis\Dyadic_International,_Inc._logo.svg",https://stockanalysis.com/stocks/dyai/,United States,1979,Biotechnology,Healthcare,7,Mark Emalfarb,"1044 North U.S. Highway One, Suite 201
Jupiter, Florida 33477-5094
United States",561 743 8333,dyadic.com,DYAI,NASDAQ,January - December,USD,0001213809,26745T101,US26745T1016,2836,"Nov 5, 2004",Common Stock,45-0486747,,
Celularity Inc.,"Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases.
The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn’s disease.
In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis.
Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand.
The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates.
Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.",Data/company_logos_stock_analysis\Celularity_Inc._logo.svg,https://stockanalysis.com/stocks/celu/,United States,2016,Biotechnology,Healthcare,120,Robert Hariri,"170 Park Avenue
Florham Park, New Jersey 07932
United States",908 768 2170,celularity.com,CELU,NASDAQ,January - December,USD,0001752828,151190105,US1511902041,2834,,,83-1702591,,Class A Shares
"Xilio Therapeutics, Inc.","Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies.
The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.
It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies.
The company was founded in 2016 and is headquartered in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Xilio_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/xlo/,United States,2016,Biotechnology,Healthcare,73,Rene Russo,"828 Winter Street, Suite 300
Waltham, Massachusetts 02451
United States",857 524 2466,xiliotx.com,XLO,NASDAQ,January - December,USD,0001840233,98422T100,US98422T1007,2834,"Oct 22, 2021",Common Stock,85-1623397,$16.00,
Achilles Therapeutics plc,"Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors.
Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.
It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.
The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021.
Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.",Data/company_logos_stock_analysis\Achilles_Therapeutics_plc_logo.svg,https://stockanalysis.com/stocks/achl/,United Kingdom,2016,Biotechnology,Healthcare,215,Iraj Ali,"245 Hammersmith Road
London, W6 8PW
United Kingdom",44 20 8154 4600,achillestx.com,ACHL,NASDAQ,January - December,USD,0001830749,00449L102,US00449L1026,2836,"Mar 31, 2021",,,$18.00,
"Inovio Pharmaceuticals, Inc.","Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial.
Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.
The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.","Data/company_logos_stock_analysis\Inovio_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/ino/,United States,1979,Biotechnology,Healthcare,122,Jacqueline Shea,"660 West Germantown Pike, Suite 110
Plymouth Meeting, Pennsylvania 19462
United States",267 440 4200,inovio.com,INO,NASDAQ,January - December,USD,0001055726,45773H201,US45773H4092,2834,"Feb 12, 1998",Common Stock,33-0969592,,
CollPlant Biotechnologies Ltd.,"CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.
The company’s products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures.
It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies.
The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019.
The company was incorporated in 1981 and is headquartered in Rehovot, Israel.",Data/company_logos_stock_analysis\CollPlant_Biotechnologies_Ltd._logo.svg,https://stockanalysis.com/stocks/clgn/,Israel,2004,Biotechnology,Healthcare,75,Yehiel Tal,"Weizmann Science Park, 4 Oppenheimer
Rehovot, 7670104
Israel",972 73 232 5600,collplant.com,CLGN,NASDAQ,January - December,USD,0001631487,19516R107,IL0004960188,3842,,,,,
"Kezar Life Sciences, Inc.","Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.
The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.
Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.
Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Kezar_Life_Sciences,_Inc._logo.svg",https://stockanalysis.com/stocks/kzr/,United States,2015,Biotechnology,Healthcare,58,Christopher Kirk,"4000 Shoreline Court, Suite 300
South San Francisco, California 94080
United States",650 822 5600,kezarlifesciences.com,KZR,NASDAQ,January - December,USD,0001645666,49372L100,US49372L1008,2834,"Jun 21, 2018",Common Stock,47-3366145,,
ImmuCell Corporation,"ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.
The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E.
coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation.
In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.
It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.",Data/company_logos_stock_analysis\ImmuCell_Corporation_logo.svg,https://stockanalysis.com/stocks/iccc/,United States,1982,Biotechnology,Healthcare,79,Michael Brigham,"56 Evergreen Drive
Portland, Maine 04103
United States",207 878 2770,immucell.com,ICCC,NASDAQ,January - December,USD,0000811641,452525306,US4525253062,2835,"Apr 30, 1987",Common Stock,01-0382980,,
"SCYNEXIS, Inc.","SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States.
It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC.
The company’s lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No.
3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp.
SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002.
The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.","Data/company_logos_stock_analysis\SCYNEXIS,_Inc._logo.svg",https://stockanalysis.com/stocks/scyx/,United States,1999,Drug Manufacturers - Specialty & Generic,Healthcare,29,David Angulo,"1 Evertrust Plaza, 13th Floor
Jersey City, New Jersey 07302-6548
United States",201 884 5485,scynexis.com,SCYX,NASDAQ,January - December,USD,0001178253,811292200,US8112922005,2834,"May 2, 2014",Common Stock,56-2181648,,
Nutriband Inc.,"Nutriband Inc. develops a portfolio of transdermal pharmaceutical products.
The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products.
The company was incorporated in 2016 and is headquartered in Orlando, Florida.",Data/company_logos_stock_analysis\Nutriband_Inc._logo.svg,https://stockanalysis.com/stocks/ntrb/,United States,2016,Biotechnology,Healthcare,13,Gareth Sheridan,"121 South Orange Avenue, Suite 1500
Orlando, Florida 32801
United States",407 377 6695,nutriband.com,NTRB,NASDAQ,February - January,USD,0001676047,67092M208,US67092M2089,3842,,Common Stock,81-1118176,,
Iterum Therapeutics plc,"Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States.
It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
The company was incorporated in 2015 and is headquartered in Dublin, Ireland.",Data/company_logos_stock_analysis\Iterum_Therapeutics_plc_logo.svg,https://stockanalysis.com/stocks/itrm/,Ireland,2015,Biotechnology,Healthcare,14,Corey Fishman,"Fitzwilliam Court, 1st Floor
Dublin, D02 YW24
Ireland",353 1 669 4820,iterumtx.com,ITRM,NASDAQ,January - December,USD,0001659323,G6333L101,IE000TTOOBX0,2834,"May 25, 2018",,,,
"Opus Genetics, Inc.","Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.
The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances.
Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy.
The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications.
The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.","Data/company_logos_stock_analysis\Opus_Genetics,_Inc._logo.svg",https://stockanalysis.com/stocks/ird/,United States,2018,Biotechnology,Healthcare,14,George Magrath,"37000 Grand River Avenue, Suite 120
Farmington Hills, Michigan 48335
United States",248 957 9024,opusgtx.com,IRD,NASDAQ,January - December,USD,0001228627,,US67577R1023,2834,,,11-3516358,,
"Serina Therapeutics, Inc.","Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.
Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy.
In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases.
Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.","Data/company_logos_stock_analysis\Serina_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ser/,United States,2017,Biotechnology,Healthcare,11,Steven Ledger,"601 Genome Way, Suite 2001
Huntsville, Alabama 35806
United States",256 327 9630,serinatherapeutics.com,SER,NYSEAMERICAN,January - December,USD,0001708599,,US81751A1088,2834,"Nov 29, 2018",Common Stock,82-1436829,,
vTv Therapeutics Inc.,"vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases.
The company’s lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention.
In addition, the company’s other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions.
vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S.
The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.",Data/company_logos_stock_analysis\vTv_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/vtvt/,United States,2015,Biotechnology,Healthcare,16,Paul Sekhri,"3980 Premier Drive, Suite 310
High Point, North Carolina 27265
United States",336 841 0300,vtvtherapeutics.com,VTVT,NASDAQ,January - December,USD,0001641489,918385105,US9183852048,2834,"Jul 30, 2015",Common Stock,47-3916571,,Class A Shares
"Estrella Immunopharma, Inc.","Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
The company’s lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103.
Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.","Data/company_logos_stock_analysis\Estrella_Immunopharma,_Inc._logo.svg",https://stockanalysis.com/stocks/esla/,United States,2021,Biotechnology,Healthcare,,Cheng Liu,"5858 Horton Street, Suite 370
EmeryVille, California 94608
United States",510 318 9098,estrellabio.com,ESLA,NASDAQ,July - June,USD,0001844417,,US2975841048,2836,,,86-1314502,,
"Precision BioSciences, Inc.","Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States.
The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency.
The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products.
Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.","Data/company_logos_stock_analysis\Precision_BioSciences,_Inc._logo.svg",https://stockanalysis.com/stocks/dtil/,United States,2006,Biotechnology,Healthcare,109,Michael Amoroso,"302 East Pettigrew Street, Suite A-100
Durham, North Carolina 27701
United States",919 314 5512,precisionbiosciences.com,DTIL,NASDAQ,January - December,USD,0001357874,74019P108,US74019P2074,2836,"Mar 28, 2019",Common Stock,,$16.00,
"Grace Therapeutics, Inc.","Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.
It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024.
The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.","Data/company_logos_stock_analysis\Grace_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/grce/,United States,2002,Biotechnology,Healthcare,,Prashant Kohli,"103 Carnegie Center, Suite 300
Princeton, New Jersey 08540
United States",818 839 4378,gracetx.com,GRCE,NASDAQ,April - March,USD,0001444192,,US00439U1043,2834,,,,,Class A Shares
Barinthus Biotherapeutics plc,"Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
The company’s development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older.
In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection.
Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus.
The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023.
Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.",Data/company_logos_stock_analysis\Barinthus_Biotherapeutics_plc_logo.svg,https://stockanalysis.com/stocks/brns/,United Kingdom,2016,Biotechnology,Healthcare,130,William Enright,"Zeus Building, Unit 6-10
Didcot, OX11 0DF
United Kingdom",44 1865 818 808,barinthusbio.com,BRNS,NASDAQ,January - December,USD,0001828185,,US91864C1071,2834,"Apr 30, 2021",,,$17.00,
Lantern Pharma Inc.,"Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process.
Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin’s lymphomas, including mantle cell lymphoma and double hit lymphoma.
The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation.
In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment.
Further, the company’s artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data.
Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications.
The company was incorporated in 2013 and is headquartered in Dallas, Texas.",Data/company_logos_stock_analysis\Lantern_Pharma_Inc._logo.svg,https://stockanalysis.com/stocks/ltrn/,United States,2013,Biotechnology,Healthcare,21,Panna Sharma,"1920 McKinney Avenue, 7th Floor
Dallas, Texas 75201
United States",972 277 1136,lanternpharma.com,LTRN,NASDAQ,January - December,USD,0001763950,51654W101,US51654W1018,2834,"Jun 11, 2020",Common Stock,46-3973463,$15.00,
"Tempest Therapeutics, Inc.","Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors.
The company’s two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.
It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition.
The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab.
Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.","Data/company_logos_stock_analysis\Tempest_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/tpst/,United States,2011,Biotechnology,Healthcare,17,Stephen Brady,"2000 Sierra Point Parkway, Suite 400
Brisbane, California 94005
United States",415 798 8589,tempesttx.com,TPST,NASDAQ,January - December,USD,0001544227,87978U108,US87978U1088,2834,,,45-1472564,,
"Rain Enhancement Technologies Holdco, Inc.","Rain Enhancement Technologies Holdco, Inc. develops, manufactures, and commercializes ionization rainfall generation technology.
The company is based in Naples, Florida. Rain Enhancement Technologies Holdco, Inc. operates as a subsidiary of Rainwater, LLC.","Data/company_logos_stock_analysis\Rain_Enhancement_Technologies_Holdco,_Inc._logo.svg",https://stockanalysis.com/stocks/rain/,United States,2022,Biotechnology,Healthcare,63,Avanish Vellanki M.B.A.,"1659 Chinaberry Ct.
Naples, Florida 34105
United States",(508) 361-6699,rainwatertech.com,RAIN,NASDAQ,January - December,USD,0002028293,75082Q105,US75082Q1058,3590,,,99-3527155,,Class A Shares
"Passage Bio, Inc.","Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases.
It develops PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.
The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington’s disease.
It has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.","Data/company_logos_stock_analysis\Passage_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/pasg/,United States,2017,Biotechnology,Healthcare,58,William Chou,"One Commerce Square, 39th Floor
Philadelphia, Pennsylvania 19103
United States",267 866 0311,passagebio.com,PASG,NASDAQ,January - December,USD,0001787297,702712100,US7027121000,2836,"Feb 28, 2020",Common Stock,82-2729751,$18.00,
Q32 Bio Inc.,"Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States.
Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.
The company is also developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata.
Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020.
The company was founded in 2017 and is based in Waltham, Massachusetts.",Data/company_logos_stock_analysis\Q32_Bio_Inc._logo.svg,https://stockanalysis.com/stocks/qttb/,United States,2015,Biotechnology,Healthcare,37,Jodie Morrison,"830 Winter Street
Waltham, Massachusetts 02451
United States",781 999 0232,q32bio.com,QTTB,NASDAQ,January - December,USD,0001661998,,US7469641051,2834,,Common Stock,47-3468154,,
"CASI Pharmaceuticals, Inc.","CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally.
It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
The company’s other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-FcγRIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants.
The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C.
to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH.
CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People’s Republic of China.","Data/company_logos_stock_analysis\CASI_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/casi/,China,1991,Biotechnology,Healthcare,176,Wei-Wu He,"1701-1702, China Central Office Tower 1, No. 81 Jianguo Road
Beijing, 100025
China",86 10 6508 6063,casipharmaceuticals.com,CASI,NASDAQ,January - December,USD,0000895051,14757U208,US14757U2087,2836,"Jun 11, 1996",Common Stock,58-1959440,,
"Actinium Pharmaceuticals, Inc.","Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).
The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients.
In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies.
Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies.
Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications.
The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron.
The company is based in New York, New York.","Data/company_logos_stock_analysis\Actinium_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/atnm/,United States,2000,Biotechnology,Healthcare,49,Sandesh Seth,"100 Park Avenue, 23rd Floor
New York, New York 10017
United States",646 677 3870,actiniumpharma.com,ATNM,NYSEAMERICAN,January - December,USD,0001388320,00507W107,US00507W2061,2834,,Common Stock,88-0378336,,
Chemomab Therapeutics Ltd.,"Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States.
Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.",Data/company_logos_stock_analysis\Chemomab_Therapeutics_Ltd._logo.svg,https://stockanalysis.com/stocks/cmmb/,Israel,2004,Biotechnology,Healthcare,20,Adi George,"Building 7, Kiryat Atidim
Tel Aviv, 6158002
Israel",972 77 331 0156,chemomab.com,CMMB,NASDAQ,January - December,USD,0001534248,03280X102,US16385C1045,2834,,,81-3676773,,
BioVie Inc.,"BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease.
The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program.
The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016.
BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.",Data/company_logos_stock_analysis\BioVie_Inc._logo.svg,https://stockanalysis.com/stocks/bivi/,United States,2013,Biotechnology,Healthcare,14,Cuong Viet Do,"680 West Nye Lane, Suite 204
Carson City, Nevada 89703
United States",775 888 3162,bioviepharma.com,BIVI,NASDAQ,July - June,USD,0001580149,09074F207,US09074F2074,2834,,Common Stock,46-2510769,,
"Omega Therapeutics, Inc.","Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company.
The company’s OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences.
It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.
In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body.
Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Omega_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/omga/,United States,2017,Biotechnology,Healthcare,94,Kaan Certel,"20 Acorn Park Drive
Cambridge, Massachusetts 02140
United States",617 949 4360,omegatherapeutics.com,OMGA,NASDAQ,January - December,USD,0001850838,68217N105,US68217N1054,2836,"Jul 30, 2021",Common Stock,,$17.00,
Rallybio Corporation,"Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.
The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.
Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia.
The company was founded in 2018 and is headquartered in New Haven, Connecticut.",Data/company_logos_stock_analysis\Rallybio_Corporation_logo.svg,https://stockanalysis.com/stocks/rlyb/,United States,2018,Biotechnology,Healthcare,43,Stephen Uden,"234 Church Street, Suite 1020
New Haven, Connecticut 06510
United States",203 859 3820,rallybio.com,RLYB,NASDAQ,January - December,USD,0001739410,75120L100,US75120L1008,2834,"Jul 29, 2021",Common Stock,85-1083789,$13.00,
"Elevation Oncology, Inc.","Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.
The company’s lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2.
Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021.
The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020.
The company was incorporated in 2019 and is based in Boston, Massachusetts.","Data/company_logos_stock_analysis\Elevation_Oncology,_Inc._logo.svg",https://stockanalysis.com/stocks/elev/,United States,2019,Biotechnology,Healthcare,29,Joseph Ferra,"101 Federal Street, Suite 1900
Boston, Massachusetts 02110
United States",716 371 1125,elevationoncology.com,ELEV,NASDAQ,January - December,USD,0001783032,28623U101,US28623U1016,2836,"Jun 25, 2021",Common Stock,84-1771427,$16.00,
"Anebulo Pharmaceuticals, Inc.","Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States.
Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity.
The company was incorporated in 2020 and is based in Lakeway, Texas.","Data/company_logos_stock_analysis\Anebulo_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/aneb/,United States,2020,Biotechnology,Healthcare,3,Richard Cunningham,"1017 Ranch Road 620 South, Suite 107
Lakeway, Texas 78734
United States",512 598 0931,anebulo.com,ANEB,NASDAQ,July - June,USD,0001815974,034569103,US0345691036,2834,"May 7, 2021",Common Stock,85-1170950,$7.00,
OKYO Pharma Limited,"OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis.
The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain.
OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.",Data/company_logos_stock_analysis\OKYO_Pharma_Limited_logo.svg,https://stockanalysis.com/stocks/okyo/,United Kingdom,2007,Biotechnology,Healthcare,3,Gary Jacob,"14/15 Conduit St, Floor 4
London, W1S 2XJ
United Kingdom",44 20 7495 2379,okyopharma.com,OKYO,NASDAQ,April - March,USD,0001849296,679345108,US6793451088,2836,"May 17, 2022",,,$4.00,
Lexaria Bioscience Corp.,"Lexaria Bioscience Corp. operates as a biotechnology company.
It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.
The company’s DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids.
Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods.
The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016.
Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.",Data/company_logos_stock_analysis\Lexaria_Bioscience_Corp._logo.svg,https://stockanalysis.com/stocks/lexx/,Canada,2004,Biotechnology,Healthcare,7,Richard Christopher,"740 McCurdy Road, Suite 100
Kelowna, BC V1X 2P7
Canada",250 765 6424,lexariabioscience.com,LEXX,NASDAQ,September - August,USD,0001348362,52886N406,US52886N4060,2834,,,20-2000871,,
"AN2 Therapeutics, Inc.","AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.
It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease.
The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials.
It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases.
The company was incorporated in 2017 and is headquartered in Menlo Park, California.","Data/company_logos_stock_analysis\AN2_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/antx/,United States,2017,Biotechnology,Healthcare,41,Eric Easom,"1800 El Camino Real, Suite D
Menlo Park, California 94027
United States",650 331 9090,an2therapeutics.com,ANTX,NASDAQ,January - December,USD,0001880438,037326105,US0373261058,2834,"Mar 25, 2022",Common Stock,82-0606654,$15.00,
"Surrozen, Inc.","Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair.
The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis.
The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases.
Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies.
Surrozen, Inc. is based in South San Francisco, California.","Data/company_logos_stock_analysis\Surrozen,_Inc._logo.svg",https://stockanalysis.com/stocks/srzn/,United States,2015,Biotechnology,Healthcare,42,Craig Parker,"171 Oyster Point Boulevard, Suite 400
South San Francisco, California 94080
United States",650 489 9000,surrozen.com,SRZN,NASDAQ,January - December,USD,0001824893,86889P109,US86889P2083,2836,,Common Stock,30-1374889,,
"SAB Biotherapeutics, Inc.","SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases.
It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.
The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma.
In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes.
Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza.
SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.","Data/company_logos_stock_analysis\SAB_Biotherapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/sabs/,United States,2014,Biotechnology,Healthcare,57,Samuel Reich,"777 W 41st St., Suite 401
Miami Beach, Florida 33140
United States",605 679 6980,sabbiotherapeutics.com,SABS,NASDAQ,January - December,USD,0001833214,78397T103,US78397T2024,2836,,Common Stock,85-3899721,,
Moolec Science SA,"Moolec Science SA, a science-based food ingredient company, focuses on developing ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology.
It develops textured soy proteins, safflower oil, meat replacement products, food ingredients, and nutritional supplements.
It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.",Data/company_logos_stock_analysis\Moolec_Science_SA_logo.svg,https://stockanalysis.com/stocks/mlec/,Luxembourg,2008,Biotechnology,Healthcare,52,Gaston Paladini,"17, Boulevard F.W. Raiffeisen
Luxembourg City, 2411
Luxembourg",352 26 49 65 65,moolecscience.com,MLEC,NASDAQ,July - June,USD,0001937737,,LU2559000059,6770,,,,,
"ProMIS Neurosciences, Inc.","ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada.
The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils.
The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015.
ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","Data/company_logos_stock_analysis\ProMIS_Neurosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/pmn/,Canada,2004,Biotechnology,Healthcare,7,Neil K. Warma,"1920 Yonge Street, Suite 200
Toronto, ON M4S 3E2
Canada",416 847 6898,promisneurosciences.com,PMN,NASDAQ,January - December,USD,0001374339,74346M406,CA74346M4065,2834,,,,,
Cumberland Pharmaceuticals Inc.,"Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally.
The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis.
In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension.
Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases.
The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.",Data/company_logos_stock_analysis\Cumberland_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/cpix/,United States,1999,Drug Manufacturers - Specialty & Generic,Healthcare,91,A. Kazimi,"1600 West End Avenue, Suite 1300
Nashville, Tennessee 37203
United States",615 255 0068,cumberlandpharma.com,CPIX,NASDAQ,January - December,USD,0001087294,230770109,US2307701092,2834,"Aug 11, 2009",Common Stock,,,
Incannex Healthcare Inc.,"Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia.
The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn’s disease.
Incannex Healthcare Inc. is headquartered in Sydney, Australia.",Data/company_logos_stock_analysis\Incannex_Healthcare_Inc._logo.svg,https://stockanalysis.com/stocks/ixhl/,Australia,2001,Drug Manufacturers - Specialty & Generic,Healthcare,9,Joel Latham,"8 Century Circuit, Suite 105
Sydney, NSW 2153
Australia",61 4 0984 0786,incannex.com,IXHL,NASDAQ,July - June,USD,0001873875,45333L106,US45333F1093,2834,,,,$9.38,
"RenovoRx, Inc.","RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors.
RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.","Data/company_logos_stock_analysis\RenovoRx,_Inc._logo.svg",https://stockanalysis.com/stocks/rnxt/,United States,2012,Biotechnology,Healthcare,8,Shaun Bagai,"4546 El Camino Real, Suite B1
Los Altos, California 94022
United States",650 284 4433,renovorx.com,RNXT,NASDAQ,January - December,USD,0001574094,75989R107,US75989R1077,2834,"Aug 26, 2021",Common Stock,27-1448452,$9.00,
"Intensity Therapeutics, Inc.","Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States.
Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.","Data/company_logos_stock_analysis\Intensity_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ints/,United States,2012,Biotechnology,Healthcare,7,Lewis Bender,"1 Enterprise Drive, Suite 430
Shelton, Connecticut 06484-4779
United States",203 221 7381,intensitytherapeutics.com,INTS,NASDAQ,January - December,USD,0001567264,45812M104,US45828J1034,2836,"Jun 30, 2023",Common Stock,46-1488089,$5.00,
CytoMed Therapeutics Limited,"CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.
Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.
It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore.
The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers.
CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.",Data/company_logos_stock_analysis\CytoMed_Therapeutics_Limited_logo.svg,https://stockanalysis.com/stocks/gdtc/,Singapore,2018,Biotechnology,Healthcare,28,Wee Kiat Tan,"1 Commonwealth Lane, No. 08-22
Singapore, 149544
Singapore",65 6250 7738,w2.cytomed.sg,GDTC,NASDAQ,January - December,SGD,0001873093,,SGXZ17669631,2834,"Apr 14, 2023",,,$4.00,
"Cognition Therapeutics, Inc.","Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.
The company was incorporated in 2007 and is headquartered in Purchase, New York.","Data/company_logos_stock_analysis\Cognition_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/cgtx/,United States,2007,Biotechnology,Healthcare,28,Lisa Ricciardi,"2500 Westchester Ave.
Purchase, New York 10577
United States",412 481 2210,cogrx.com,CGTX,NASDAQ,January - December,USD,0001455365,19243B102,US19243B1026,2836,"Oct 8, 2021",Common Stock,,$12.00,
"Aileron Therapeutics, Inc.","Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.
The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.
The company’s pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications.
The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007.
Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.","Data/company_logos_stock_analysis\Aileron_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/alrn/,United States,2001,Biotechnology,Healthcare,15,Dr. James Brian Windsor Ph.D.,"12407 N. Mopac Expy., Suite 250 #390
Austin, Texas 78758
United States",(737) 802-1989,aileronrx.com,ALRN,NASDAQ,January - December,USD,0001420565,00887A105,US00887A2042,2834,"Jun 29, 2017",,13-4196017,,
"KALA BIO, Inc.","KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States.
The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.
Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.
The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.
KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.","Data/company_logos_stock_analysis\KALA_BIO,_Inc._logo.svg",https://stockanalysis.com/stocks/kala/,United States,2009,Biotechnology,Healthcare,43,Mark Iwicki,"1167 Massachusetts Avenue
Arlington, Massachusetts 02476
United States",781 996 5252,kalarx.com,KALA,NASDAQ,January - December,USD,0001479419,483119103,US4831192020,2834,"Jul 20, 2017",Common Stock,27-0604595,,
"Lisata Therapeutics, Inc.","Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases.
Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.
Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.","Data/company_logos_stock_analysis\Lisata_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/lsta/,United States,1980,Biotechnology,Healthcare,25,David Mazzo,"110 Allen Road, 2nd Floor
Basking Ridge, New Jersey 07920
United States",908 842 0100,lisata.com,LSTA,NASDAQ,January - December,USD,0000320017,128058302,US1280583022,2834,,Common Stock,22-2343568,,
"Unity Biotechnology, Inc.","Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.
The company’s lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a α-Klotho hormone drug candidate for multiple neurology indications.
The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015.
Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Unity_Biotechnology,_Inc._logo.svg",https://stockanalysis.com/stocks/ubx/,United States,2009,Biotechnology,Healthcare,19,Anirvan Ghosh,"285 East Grand Avenue
South San Francisco, California 94080
United States",650 416 1192,unitybiotechnology.com,UBX,NASDAQ,January - December,USD,0001463361,91381U101,US91381U2006,2834,"May 3, 2018",Common Stock,26-4726035,,
"Marinus Pharmaceuticals, Inc.","Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders.
It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.
It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex.
Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.","Data/company_logos_stock_analysis\Marinus_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/mrns/,United States,2003,Biotechnology,Healthcare,166,Scott Braunstein,"5 Radnor Corporate Center, Suite 500
Radnor, Pennsylvania 19087
United States",484 801 4670,marinuspharma.com,MRNS,NASDAQ,January - December,USD,0001267813,56854Q200,US56854Q2003,2834,"Jul 31, 2014",Common Stock,,,
"Akari Therapeutics, Plc","Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.
Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities.
The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA.
The company is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Akari_Therapeutics,_Plc_logo.svg",https://stockanalysis.com/stocks/aktx/,United States,,Biotechnology,Healthcare,12,Samir Patel,"22 Boston Wharf Road, Floor 7
Boston, Massachusetts 02210
United States",929 274 7510,akaritx.com,AKTX,NASDAQ,January - December,USD,0001541157,00972G108,US00972G2075,2834,,,98-1034922,,
Sol-Gel Technologies Ltd.,"Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel.
The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products.
It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.",Data/company_logos_stock_analysis\Sol-Gel_Technologies_Ltd._logo.svg,https://stockanalysis.com/stocks/slgl/,Israel,1997,Biotechnology,Healthcare,36,Moshe Arkin,"7 Golda Meir Street, Weizmann Science Park
Ness Ziona, 7403650
Israel",972 8 931 3433,sol-gel.com,SLGL,NASDAQ,January - December,USD,0001684693,M8694L103,IL0011417206,2834,"Jan 23, 2018",,,,
"Cadrenal Therapeutics, Inc.","Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company.
The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.","Data/company_logos_stock_analysis\Cadrenal_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/cvkd/,United States,2022,Biotechnology,Healthcare,4,Quang Pham,"822 A1A North, Suite 306
Ponte Vedra, Florida 32082
United States",904 300 0701,cadrenal.com,CVKD,NASDAQ,January - December,USD,0001937993,,US1276361086,2834,"Jan 20, 2023",,88-0860746,$5.00,
Alterity Therapeutics Limited,"Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease.
It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease.
The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.
Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.",Data/company_logos_stock_analysis\Alterity_Therapeutics_Limited_logo.svg,https://stockanalysis.com/stocks/athe/,Australia,1997,Biotechnology,Healthcare,10,David Stamler,"350 Collins Street, Suite 4
Melbourne, VIC 3000
Australia",61 3 9349 4906,alteritytherapeutics.com,ATHE,NASDAQ,July - June,AUD,0001131343,02155X106,US02155X2053,2834,,,,,
"Curis, Inc.","Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3.
It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib.
Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.","Data/company_logos_stock_analysis\Curis,_Inc._logo.svg",https://stockanalysis.com/stocks/cris/,United States,2000,Biotechnology,Healthcare,49,James Dentzer,"Building C, Suite 500
Lexington, Massachusetts 02421
United States",617 503 6500,curis.com,CRIS,NASDAQ,January - December,USD,0001108205,231269200,US2312693094,2836,"Aug 1, 2000",Common Stock,04-3505116,,
"MiNK Therapeutics, Inc.","MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors.
The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York.
MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.","Data/company_logos_stock_analysis\MiNK_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/inkt/,United States,2017,Biotechnology,Healthcare,31,Jennifer Buell,"149 Fifth Avenue, Suite 500
New York, New York 10010
United States",212 994 8250,minktherapeutics.com,INKT,NASDAQ,January - December,USD,0001840229,603693102,US6036931029,2836,"Oct 15, 2021",Common Stock,,$12.00,
"Exicure, Inc.","Exicure, Inc. does not have significant operations.
previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets.
Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.","Data/company_logos_stock_analysis\Exicure,_Inc._logo.svg",https://stockanalysis.com/stocks/xcur/,United States,2011,Biotechnology,Healthcare,6,Andy Yoo,"2430 North Halsted Street
Chicago, Illinois 60614
United States",847 673 1700,exicuretx.com,XCUR,NASDAQ,January - December,USD,0001698530,30205M101,US30205M2008,2834,,Common Stock,81-5333008,,
"Daré Bioscience, Inc.","Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women’s health in the United States.
It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.
The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies.
The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth.
In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein.
Daré Bioscience, Inc. is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Daré_Bioscience,_Inc._logo.svg",https://stockanalysis.com/stocks/dare/,United States,,Biotechnology,Healthcare,26,Sabrina Johnson,"3655 Nobel Drive, Suite 260
San Diego, California 92122
United States",858 926 7655,darebioscience.com,DARE,NASDAQ,January - December,USD,0001401914,23666P101,US23666P1012,2834,,Common Stock,20-4139823,,
"Citius Pharmaceuticals, Inc.","Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products.
Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.","Data/company_logos_stock_analysis\Citius_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/ctxr/,United States,2007,Biotechnology,Healthcare,23,Leonard Mazur,"11 Commerce Drive, First Floor
Cranford, New Jersey 07016
United States",908 967 6677,citiuspharma.com,CTXR,NASDAQ,October - September,USD,0001506251,17322U207,US17322U2078,2834,,Common Stock,27-3425913,,
Longeveron Inc.,"Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan.
The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.
It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome.
Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.",Data/company_logos_stock_analysis\Longeveron_Inc._logo.svg,https://stockanalysis.com/stocks/lgvn/,United States,2014,Biotechnology,Healthcare,24,Mohamed Wa'el Hashad,"Life Science & Technology Park, Suite 520
Miami, Florida 33136
United States",844 470 2550,longeveron.com,LGVN,NASDAQ,January - December,USD,0001721484,54303L104,US54303L1044,2834,"Feb 12, 2021",Common Stock,47-2174146,$10.00,Class A Shares
"Cardio Diagnostics Holdings, Inc.","Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.
Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.","Data/company_logos_stock_analysis\Cardio_Diagnostics_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/cdio/,United States,2017,Biotechnology,Healthcare,9,Meeshanthini Dogan,"311 West Superior Street, Suite 444
Chicago, Illinois 60654
United States",302 281 2147,cardiodiagnosticsinc.com,CDIO,NASDAQ,January - December,USD,0001870144,14159C103,US14159C1036,2835,,Common Stock,87-0925574,,
CEL-SCI Corporation,"CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States.
The company’s lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.
It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer.
In addition, the company’s product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease.
CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.",Data/company_logos_stock_analysis\CEL-SCI_Corporation_logo.svg,https://stockanalysis.com/stocks/cvm/,United States,1983,Biotechnology,Healthcare,43,Geert Kersten,"8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
United States",703 506 9460,cel-sci.com,CVM,NYSEAMERICAN,October - September,USD,0000725363,150837607,US1508376076,2836,"Jan 1, 1987",Common Stock,84-0916344,,
Lipocine Inc.,"Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders.
Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
The company’s pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor.
It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth.
The company was founded in 1997 and is headquartered in Salt Lake City, Utah.",Data/company_logos_stock_analysis\Lipocine_Inc._logo.svg,https://stockanalysis.com/stocks/lpcn/,United States,1997,Biotechnology,Healthcare,17,Mahesh Patel,"675 Arapeen Drive, Suite 202
Salt Lake City, Utah 84108
United States",801 994 7383,lipocine.com,LPCN,NASDAQ,January - December,USD,0001535955,53630X104,US53630X2036,2834,,Common Stock,99-0370688,,
"IGC Pharma, Inc.","IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease.
The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development.
The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023.
The company was incorporated in 2005 and is headquartered in Potomac, Maryland.","Data/company_logos_stock_analysis\IGC_Pharma,_Inc._logo.svg",https://stockanalysis.com/stocks/igc/,United States,2005,Biotechnology,Healthcare,67,Ram Mukunda,"10224 Falls Road
Potomac, Maryland 20854
United States",301 983 0998,igcpharma.com,IGC,NYSEAMERICAN,April - March,USD,0001326205,45408X308,US45408X3089,2834,,Common Stock,20-2760393,,
"Forte Biosciences, Inc.","Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States.
The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata.
Forte Biosciences, Inc. is headquartered in Dallas, Texas.","Data/company_logos_stock_analysis\Forte_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/fbrx/,United States,,Biotechnology,Healthcare,9,Paul A. Wagner,"3060 Pegasus Park Drive, Building 6
Dallas, Texas 75247
United States",310 618 6994,fortebiorx.com,FBRX,NASDAQ,January - December,USD,0001419041,34962G109,US34962G1094,2834,,Common Stock,26-1243872,,
HOOKIPA Pharma Inc.,"HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.
The company’s lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers.
Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial.
The company’s preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus.
HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.",Data/company_logos_stock_analysis\HOOKIPA_Pharma_Inc._logo.svg,https://stockanalysis.com/stocks/hook/,United States,2011,Biotechnology,Healthcare,179,Malte Peters,"350 Fifth Avenue, 72nd Floor
New York, New York 10118
United States",431 890 6360,hookipapharma.com,HOOK,NASDAQ,January - December,USD,0001760542,43906K100,US43906K1007,2834,"Apr 18, 2019",Common Stock,81-5395687,$14.00,
LAVA Therapeutics N.V.,"LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments.
The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.
The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies.
LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207.
LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.",Data/company_logos_stock_analysis\LAVA_Therapeutics_N.V._logo.svg,https://stockanalysis.com/stocks/lvtx/,Netherlands,2016,Biotechnology,Healthcare,37,Stephen Hurly,"Yalelaan 62
Utrecht, 3584 CM
Netherlands",31 85 016 3100,lavatherapeutics.com,LVTX,NASDAQ,January - December,USD,0001840748,N51517105,NL0015000AG6,2834,"Mar 25, 2021",,,$15.00,
"Marker Therapeutics, Inc.","Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.
The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer.
Marker Therapeutics, Inc. is headquartered in Houston, Texas.","Data/company_logos_stock_analysis\Marker_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/mrkr/,United States,,Biotechnology,Healthcare,8,Juan Vera,"9350 Kirby Drive, Suite 300
Houston, Texas 77054
United States",713 400 6400,markertherapeutics.com,MRKR,NASDAQ,January - December,USD,0001094038,57055L107,US57055L2060,2834,,Common Stock,88-0277072,,
"BioAtla, Inc.","BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types.
The company was founded in 2007 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\BioAtla,_Inc._logo.svg",https://stockanalysis.com/stocks/bcab/,United States,2007,Biotechnology,Healthcare,65,Jay Short,"11085 Torreyana Road
San Diego, California 92121
United States",858 558 0708,bioatla.com,BCAB,NASDAQ,January - December,USD,0001826892,09077B104,US09077B1044,2836,"Dec 16, 2020",Common Stock,85-1922320,$18.00,
Enlivex Therapeutics Ltd.,"Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.
Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis.
The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.
Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.",Data/company_logos_stock_analysis\Enlivex_Therapeutics_Ltd._logo.svg,https://stockanalysis.com/stocks/enlv/,Israel,2005,Biotechnology,Healthcare,71,Oren Hershkovitz,"14 Einstein Street
Ness Ziona, 7403618
Israel",972 2 670 8072,enlivex.com,ENLV,NASDAQ,January - December,USD,0000919794,M4130Y106,IL0011319527,7372,"Dec 12, 1995",,95-4102687,,
DURECT Corporation,"DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program.
The company’s lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals.
In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder.
It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries.
The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited.
DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.",Data/company_logos_stock_analysis\DURECT_Corporation_logo.svg,https://stockanalysis.com/stocks/drrx/,United States,1998,Drug Manufacturers - Specialty & Generic,Healthcare,58,James Brown,"10240 Bubb Road
Cupertino, California 95014-4166
United States",408 777 1417,durect.com,DRRX,NASDAQ,January - December,USD,0001082038,266605104,US2666055007,2834,"Sep 28, 2000",Common Stock,94-3297098,,
"Equillium, Inc.","Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need.
The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.
It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications.
In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area.
Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy.
The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017.
Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.","Data/company_logos_stock_analysis\Equillium,_Inc._logo.svg",https://stockanalysis.com/stocks/eq/,United States,2017,Biotechnology,Healthcare,44,Bruce Steel,"2223 Avenida De La Playa, Suite 105
La Jolla, California 92037
United States",858 240 1200,equilliumbio.com,EQ,NASDAQ,January - December,USD,0001746466,29446K106,US29446K1060,2834,"Oct 11, 2018",Common Stock,82-1554746,,
"Traws Pharma, Inc.","Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer.
The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.
It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers.
The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024.
Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.","Data/company_logos_stock_analysis\Traws_Pharma,_Inc._logo.svg",https://stockanalysis.com/stocks/traw/,United States,1998,Biotechnology,Healthcare,18,Werner Cautreels,"12 Penns Trail
Newtown, Pennsylvania 18940
United States",267 759 3680,trawspharma.com,TRAW,NASDAQ,January - December,USD,0001130598,,US68232V8019,2834,"Jul 25, 2013",Common Stock,,,
NeuroSense Therapeutics Ltd.,"NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally.
The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.
Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease.
The company was incorporated in 2017 and is headquartered in Herzliya, Israel.",Data/company_logos_stock_analysis\NeuroSense_Therapeutics_Ltd._logo.svg,https://stockanalysis.com/stocks/nrsn/,Israel,2017,Biotechnology,Healthcare,18,Alon Ben-Noon,"Building B, 11 HaMenofim Street
Herzliya, 4672562
Israel",972 9 799 6183,neurosense-tx.com,NRSN,NASDAQ,January - December,USD,0001875091,M74240108,IL0011809592,2834,"Dec 9, 2021",,,$6.00,
Pluri Inc.,"Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries.
It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform.
The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, is composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and phase I trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform.
It also offers cell manufacturing services; cell-based coffee; and develops and commercializes cultivated meat products.
The company operates in the field of regenerative medicine, food-tech, CDMO, and agtech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors.
The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022.
Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.",Data/company_logos_stock_analysis\Pluri_Inc._logo.svg,https://stockanalysis.com/stocks/plur/,Israel,2001,Biotechnology,Healthcare,118,Yaacov Yanay,"Building No. 5, MATAM Advanced Technology Park
Haifa, 3508409
Israel",972 74 710 8600,pluri-biotech.com,PLUR,NASDAQ,July - June,USD,0001158780,72942G104,US72942G1040,2836,,Common Stock,98-0351734,,
"NeurAxis, Inc.","NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.
It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome.
The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022.
The company was founded in 2011 and is headquartered in Carmel, Indiana.","Data/company_logos_stock_analysis\NeurAxis,_Inc._logo.svg",https://stockanalysis.com/stocks/nrxs/,United States,2011,Biotechnology,Healthcare,19,Brian Carrico,"11611 North Meridian Street, Suite 330
Carmel, Indiana 46032
United States",812 689 0791,neuraxis.com,NRXS,NYSEAMERICAN,January - December,USD,0001933567,64134X201,US64134X2018,3845,"Aug 9, 2023",Common Stock,45-5079684,$6.00,
"iBio, Inc.","iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases.
The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies.
In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells.
It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases.
iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\iBio,_Inc._logo.svg",https://stockanalysis.com/stocks/ibio/,United States,2008,Biotechnology,Healthcare,16,Martin Brenner,"11750 Sorrento Valley Road, Suite 200
San Diego, California 92121
United States",979 446 0027,ibioinc.com,IBIO,NYSEAMERICAN,July - June,USD,0001420720,451033203,US4510337086,2834,,Common Stock,26-2797813,,
"Cocrystal Pharma, Inc.","Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases.
It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection.
It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections.
Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections.
The company is headquartered in Bothell, Washington.","Data/company_logos_stock_analysis\Cocrystal_Pharma,_Inc._logo.svg",https://stockanalysis.com/stocks/cocp/,United States,,Biotechnology,Healthcare,12,Dr. Sam Lee Ph.D.,"19805 North Creek Parkway
Bothell, Washington 98011
United States",877 262 7123,cocrystalpharma.com,COCP,NASDAQ,January - December,USD,0001412486,19188J300,US19188J4094,2834,,Common Stock,35-2528215,,
"Ocean Biomedical, Inc.","Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States.
The company develops an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of idiopathic pulmonary fibrosis and Hermansky-Pudlak syndrome.
It is also developing three product candidates based on the whole proteome differential screening target discovery platform, including a malaria vaccine candidate against plasmodium falciparum Schizont Egress Antigen-1 (PfSEA-1) and/or against plasmodium falciparum Glutamic Acid Rich Protein (PfGARP); a humanized mAb malaria therapeutic candidate targeting PfGARP; and a small molecule malaria product candidate targeting PfGARP.
The company was founded in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. is a subsidiary of Poseidon Bio, LLC.","Data/company_logos_stock_analysis\Ocean_Biomedical,_Inc._logo.svg",https://stockanalysis.com/stocks/ocea/,United States,2019,Biotechnology,Healthcare,9,M. Berrey,"55 Claverick Street, Room 325
Providence, Rhode Island 02903
United States",401 444 7375,oceanbiomedical.com,OCEA,NASDAQ,January - December,USD,0001869974,67644P105,US67644C1045,2834,,Common Stock,87-1309280,,
"Pulmatrix, Inc.","Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States.
The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine.
It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates.
The company was founded in 2003 and is headquartered in Bedford, Massachusetts.","Data/company_logos_stock_analysis\Pulmatrix,_Inc._logo.svg",https://stockanalysis.com/stocks/pulm/,United States,2003,Biotechnology,Healthcare,22,Peter Ludlum,"36 Crosby Drive, Suite 100
Bedford, Massachusetts 01730
United States",781 357 2333,pulmatrix.com,PULM,NASDAQ,January - December,USD,0001574235,74584P301,US74584P3010,2834,,Common Stock,46-1821392,,
Gelteq Limited,"Gelteq Limited focuses on developing, testing, and commercializing white label gel-based delivery solutions for humans and animals.
It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products.
Gelteq Limited was incorporated in 2017 and is headquartered in Caulfield, Australia.",Data/company_logos_stock_analysis\Gelteq_Limited_logo.svg,https://stockanalysis.com/stocks/gels/,Australia,2018,Drug Manufacturers - Specialty & Generic,Healthcare,8,Nathan Givoni,"639-641 Glenhuntly Road
Caulfield, VIC 3162
Australia",61 3 9087 3990,gelteq.com,GELS,NASDAQ,July - June,AUD,0001920092,,,2834,"Oct 29, 2024",,,$4.00,
"NextCure, Inc.","NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.
The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.
Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules.
It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.","Data/company_logos_stock_analysis\NextCure,_Inc._logo.svg",https://stockanalysis.com/stocks/nxtc/,United States,2015,Biotechnology,Healthcare,82,Michael Richman,"9000 Virginia Manor Road, Suite 200
Beltsville, Maryland 20705
United States",240 399 4900,nextcure.com,NXTC,NASDAQ,January - December,USD,0001661059,65343E108,US65343E1082,2834,"May 9, 2019",Common Stock,47-5231247,$15.00,
"Palatin Technologies, Inc.","Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.
The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases.
In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy.
Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials.
Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.","Data/company_logos_stock_analysis\Palatin_Technologies,_Inc._logo.svg",https://stockanalysis.com/stocks/ptn/,United States,1986,Biotechnology,Healthcare,30,Carl Spana,"Cedar Brook Corporate Center, 4-B Cedar Brook Drive
Cranbury, New Jersey 08512
United States",609 495 2200,palatin.com,PTN,NYSEAMERICAN,July - June,USD,0000911216,696077403,US6960775020,2834,"Oct 28, 1993",Common Stock,95-4078884,,
"IN8bio, Inc.","IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors.
Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types.
The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020.
IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.","Data/company_logos_stock_analysis\IN8bio,_Inc._logo.svg",https://stockanalysis.com/stocks/inab/,United States,2016,Biotechnology,Healthcare,31,Tai-Wei Ho,"350 5th Avenue, Suite 5330
New York, New York 10118
United States",646 600 6438,in8bio.com,INAB,NASDAQ,January - December,USD,0001740279,45674E109,US45674E1091,2836,"Jul 30, 2021",,82-5462585,$10.00,
"Athira Pharma, Inc.","Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.
Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer’s disease, as well as is in Phase 2 clinical trials to treat Parkinson’s disease dementia and Dementia with Lewy bodies.
The company’s product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis.
In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton.
The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019.
Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.","Data/company_logos_stock_analysis\Athira_Pharma,_Inc._logo.svg",https://stockanalysis.com/stocks/atha/,United States,2011,Biotechnology,Healthcare,67,Mark Litton,"18706 North Creek Parkway, Suite 104
Bothell, Washington 98011
United States",425 620 8501,athira.com,ATHA,NASDAQ,January - December,USD,0001620463,04746L104,US04746L1044,2836,"Sep 18, 2020",Common Stock,45-3368487,$17.00,
"Cara Therapeutics, Inc.","Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States.
The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica.
The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea.
Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.","Data/company_logos_stock_analysis\Cara_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/cara/,United States,2004,Biotechnology,Healthcare,55,Christopher Posner,"400 Atlantic Street, Suite 500
Stamford, Connecticut 06901
United States",203 406 3700,caratherapeutics.com,CARA,NASDAQ,January - December,USD,0001346830,140755109,US1407551092,2834,"Jan 31, 2014",Common Stock,,,
"Tenax Therapeutics, Inc.","Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States.
The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.
Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.","Data/company_logos_stock_analysis\Tenax_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/tenx/,United States,1967,Biotechnology,Healthcare,6,Christopher Giordano,"101 Glen Lennox Drive, Suite 300
Chapel Hill, North Carolina 27517
United States",(919) 855-2100,tenaxthera.com,TENX,NASDAQ,January - December,USD,0000034956,88032L209,US88032L6056,2834,,Common Stock,26-2593535,,
"GeoVax Labs, Inc.","GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform.
It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever.
It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute.
GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.","Data/company_logos_stock_analysis\GeoVax_Labs,_Inc._logo.svg",https://stockanalysis.com/stocks/govx/,United States,2001,Biotechnology,Healthcare,17,David Dodd,"1900 Lake Park Drive, Suite 380
Smyrna, Georgia 30080
United States",678 384 7220,geovax.com,GOVX,NASDAQ,January - December,USD,0000832489,373678507,US3736786068,2834,,Common Stock,87-0455038,,
"Carisma Therapeutics, Inc.","Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States.
The company’s ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.
It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases.
The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017.
The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.","Data/company_logos_stock_analysis\Carisma_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/carm/,United States,2016,Biotechnology,Healthcare,107,Steven Kelly,"3675 Market Street, Suite 200
Philadelphia, Pennsylvania 19104
United States",267 491 6422,carismatx.com,CARM,NASDAQ,January - December,USD,0001485003,14216R101,US14216R1014,2834,,Common Stock,26-2025616,,
"Bolt Biotherapeutics, Inc.","Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.
The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer.
The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F.
Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.
Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.","Data/company_logos_stock_analysis\Bolt_Biotherapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/bolt/,United States,2015,Biotechnology,Healthcare,100,William Quinn,"900 Chesapeake Drive
Redwood City, California 94063
United States",650 665 9295,boltbio.com,BOLT,NASDAQ,January - December,USD,0001641281,097702104,US0977021049,2834,"Feb 5, 2021",Common Stock,47-2804636,$20.00,
"Aprea Therapeutics, Inc.","Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors.
The company is headquartered in Doylestown, Pennsylvania.","Data/company_logos_stock_analysis\Aprea_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/apre/,United States,2006,Biotechnology,Healthcare,7,Oren Gilad,"3805 Old Easton Road
Doylestown, Pennsylvania 18902
United States",617 463 9385,aprea.com,APRE,NASDAQ,January - December,USD,0001781983,03836J102,US03836J2015,2834,"Oct 3, 2019",Common Stock,,$15.00,
"NanoViricides, Inc.","NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections.
The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia.
In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses.
NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.","Data/company_logos_stock_analysis\NanoViricides,_Inc._logo.svg",https://stockanalysis.com/stocks/nnvc/,United States,2005,Biotechnology,Healthcare,7,Anil Diwan,"1 Controls Drive
Shelton, Connecticut 06484
United States",203 937 6137,nanoviricides.com,NNVC,NYSEAMERICAN,July - June,USD,0001379006,630087302,US6300873022,2834,,Common Stock,76-0674577,,
Affimed N.V.,"Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany.
The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.
It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors.
It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers.
The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014.
Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.",Data/company_logos_stock_analysis\Affimed_N.V._logo.svg,https://stockanalysis.com/stocks/afmd/,Germany,2000,Biotechnology,Healthcare,76,Shawn Leland,"Gottlieb-Daimler-Straße 2
Mannheim, 68165
Germany",49 621 560030,affimed.com,AFMD,NASDAQ,January - December,EUR,0001608390,N01045108,NL0015001ZQ0,2834,"Sep 12, 2014",,,,
PolyPid Ltd.,"PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. The company has research and development collaboration with ImmunoGenesis, Inc. to enhance cancer immunotherapy using PLEX technology.
PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.",Data/company_logos_stock_analysis\PolyPid_Ltd._logo.svg,https://stockanalysis.com/stocks/pypd/,Israel,2008,Biotechnology,Healthcare,62,Dikla Czaczkes Akselbrad,"18 Hasivim Street
Petah Tikva, 4959376
Israel",972 7 4719 5700,polypid.com,PYPD,NASDAQ,January - December,USD,0001611842,M8001Q118,IL0011326795,3841,"Jun 26, 2020",,,$16.00,
"BioXcel Therapeutics, Inc.","BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer’s disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia.
In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia.
BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.","Data/company_logos_stock_analysis\BioXcel_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/btai/,United States,2017,Biotechnology,Healthcare,74,Vimal Mehta,"555 Long Wharf Drive, 12th Floor
New Haven, Connecticut 06511
United States",475 238 6837,bioxceltherapeutics.com,BTAI,NASDAQ,January - December,USD,0001720893,09075P105,US09075P1057,2834,"Mar 8, 2018",Common Stock,82-1386754,,
BriaCell Therapeutics Corp.,"BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care.
Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.
It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer.
BriaCell Therapeutics Corp. is based in West Vancouver, Canada.",Data/company_logos_stock_analysis\BriaCell_Therapeutics_Corp._logo.svg,https://stockanalysis.com/stocks/bctx/,Canada,2014,Biotechnology,Healthcare,16,William Williams,"Bellevue Centre, Suite 300
West Vancouver, BC V7T 2X1
Canada",604-921-1810,briacell.com,BCTX,NASDAQ,August - July,USD,0001610820,10778Y302,CA1079301091,2834,,,,,
"MEI Pharma, Inc.","MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.
It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors.
The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012.
MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\MEI_Pharma,_Inc._logo.svg",https://stockanalysis.com/stocks/meip/,United States,2000,Biotechnology,Healthcare,28,Justin File,"9920 Pacific Heights Blvd., Suite 150
San Diego, California 92121
United States",858 369 7100,meipharma.com,MEIP,NASDAQ,July - June,USD,0001262104,55279B202,US55279B3015,2834,"Dec 19, 2003",Common Stock,51-0407811,,
"Senti Biosciences, Inc.","Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases.
Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells.
In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells.
The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors.
Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Senti_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/snti/,United States,2016,Biotechnology,Healthcare,48,Timothy Lu,"2 Corporate Drive, First Floor
South San Francisco, California 94080
United States",650 239 2030,sentibio.com,SNTI,NASDAQ,January - December,USD,0001854270,81726A100,US81726A1007,2836,,Common Stock,86-2437900,,
"Cyclo Therapeutics, Inc.","Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases.
The company’s lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer’s disease.
It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019.
Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.","Data/company_logos_stock_analysis\Cyclo_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/cyth/,United States,1990,Drug Manufacturers - Specialty & Generic,Healthcare,8,N. Fine,"6714 NW 16th Street, Suite B
Gainesville, Florida 32653
United States",386 418 8060,cyclotherapeutics.com,CYTH,NASDAQ,January - December,USD,0000922247,550241103,US23254X2018,2836,,Common Stock,59-3029743,,Class A Shares
MetaVia Inc.,"MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases.
It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.
The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia.
It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726.
The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024.
MetaVia Inc. is headquartered in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\MetaVia_Inc._logo.svg,https://stockanalysis.com/stocks/mtva/,United States,2014,Biotechnology,Healthcare,8,Hyung-Heon Kim,"545 Concord Avenue, Suite 210
Cambridge, Massachusetts 02138
United States",857 702 9600,metaviatx.com,MTVA,NASDAQ,January - December,USD,0001638287,,US64132R4048,2834,,Common Stock,47-2389984,,
Flora Growth Corp.,"Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide.
It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.
It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs.
In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants.
The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.",Data/company_logos_stock_analysis\Flora_Growth_Corp._logo.svg,https://stockanalysis.com/stocks/flgc/,United States,2019,Drug Manufacturers - Specialty & Generic,Healthcare,108,Clifford Starke,"3406 SW 26th Terrace, Suite C-1
Fort Lauderdale, Florida 33132
United States",954 842 4989,floragrowth.com,FLGC,NASDAQ,January - December,USD,0001790169,339764102,CA3397642016,2834,"May 11, 2021",,,$5.00,
ImmunoPrecise Antibodies Ltd.,"ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies.
The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving industry challenges.
It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection.
In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development.
Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes.
Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of antibody domain; Eurofins preclinical services; hybrid service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services.
The company was founded in 1983 and is headquartered in Victoria, Canada.",Data/company_logos_stock_analysis\ImmunoPrecise_Antibodies_Ltd._logo.svg,https://stockanalysis.com/stocks/ipa/,Canada,1983,Biotechnology,Healthcare,101,Jennifer Bath,"3204–4464 Markham Street
Victoria, BC V8Z 7X8
Canada",250 483 0308,ipatherapeutics.com,IPA,NASDAQ,May - April,CAD,0001715925,45257F200,CA45257F2008,2834,"Jan 3, 2017",,,,
"Calidi Biotherapeutics, Inc.","Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States.
Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.
The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Calidi_Biotherapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/cldi/,United States,2014,Biotechnology,Healthcare,41,Allan Camaisa,"4475 Executive Drive, Suite 200
San Diego, California 92121
United States",858 794 9600,calidibio.com,CLDI,NYSEAMERICAN,January - December,USD,0001855485,,US3207031010,2836,,Common Stock,86-2967193,,
"NKGen Biotech, Inc.","NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies.
Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors.
The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.","Data/company_logos_stock_analysis\NKGen_Biotech,_Inc._logo.svg",https://stockanalysis.com/stocks/nkgn/,United States,2017,Biotechnology,Healthcare,63,Paul Y. Song,"3001 Daimler Street
Santa Ana, California 92705
United States",949-396-6830,nkgenbiotech.com,NKGN,NASDAQ,January - December,USD,0001845459,,US65488A1016,2836,,Common Stock,,,
CervoMed Inc.,"CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer’s diseases, frontotemporal dementia, and ischemic stroke recovery.
The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.",Data/company_logos_stock_analysis\CervoMed_Inc._logo.svg,https://stockanalysis.com/stocks/crvo/,United States,2001,Biotechnology,Healthcare,8,John Alam,"20 Park Plaza, Suite 424
Boston, Massachusetts 02116
United States",617 744 4400,cervomed.com,CRVO,NASDAQ,January - December,USD,0001053691,,US15713L1098,2834,,,30-0645032,,
"Synlogic, Inc.","Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.
Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.
The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Synlogic,_Inc._logo.svg",https://stockanalysis.com/stocks/sybx/,United States,,Biotechnology,Healthcare,6,Mary Dooley,"301 Binney Street, Suite 402
Cambridge, Massachusetts 02142
United States",617 401 9975,synlogictx.com,SYBX,NASDAQ,January - December,USD,0001527599,87166L100,US87166L2097,2834,,,26-1824804,,
"GlycoMimetics, Inc.","GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States.
It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein.
In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma.
The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687.
GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.","Data/company_logos_stock_analysis\GlycoMimetics,_Inc._logo.svg",https://stockanalysis.com/stocks/glyc/,United States,2003,Biotechnology,Healthcare,35,Harout Semerjian,"9708 Medical Center Drive
Rockville, Maryland 20850
United States",240 243 1201,glycomimetics.com,GLYC,NASDAQ,January - December,USD,0001253689,38000Q102,US38000Q1022,2834,"Jan 10, 2014",Common Stock,,,
BioLineRx Ltd.,"BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.
The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.
BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.",Data/company_logos_stock_analysis\BioLineRx_Ltd._logo.svg,https://stockanalysis.com/stocks/blrx/,Israel,2003,Biotechnology,Healthcare,79,Philip Serlin,"Modi’in Technology Park, 2 HaMa’ayan Street
Hevel Modi'in, 7177871
Israel",972 8 642 9100,biolinerx.com,BLRX,NASDAQ,January - December,USD,0001498403,09071M205,US09071M2052,2834,"Jul 25, 2011",,,,
HCW Biologics Inc.,"HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States.
The company’s lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.
It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment.
The company was incorporated in 2018 and is headquartered in Miramar, Florida.",Data/company_logos_stock_analysis\HCW_Biologics_Inc._logo.svg,https://stockanalysis.com/stocks/hcwb/,United States,2018,Biotechnology,Healthcare,45,Hing Wong,"2929 North Commerce Parkway
Miramar, Florida 33025
United States",954 842 2024,hcwbiologics.com,HCWB,NASDAQ,January - December,USD,0001828673,40423R105,US40423R1059,2834,"Jul 20, 2021",Common Stock,82-5024477,$8.00,Class A Shares
Cingulate Inc.,"Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States.
The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.
It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.",Data/company_logos_stock_analysis\Cingulate_Inc._logo.svg,https://stockanalysis.com/stocks/cing/,United States,2012,Biotechnology,Healthcare,13,Shane Schaffer,"1901 West 47th Place
Kansas City, Kansas 66205
United States",913 942 2300,cingulate.com,CING,NASDAQ,January - December,USD,0001862150,17248W105,US17248W2044,2834,"Dec 8, 2021",Common Stock,86-3825535,$6.00,
"Spruce Biosciences, Inc.","Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders.
The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.
It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial.
Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan.
The company was incorporated in 2014 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Spruce_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/sprb/,United States,2014,Biotechnology,Healthcare,29,Javier Szwarcberg,"611 Gateway Boulevard, Suite 740
South San Francisco, California 94080
United States",415 655 4168,sprucebiosciences.com,SPRB,NASDAQ,January - December,USD,0001683553,85209E109,US85209E1091,2834,"Oct 9, 2020",Common Stock,81-2154263,$15.00,
Eterna Therapeutics Inc.,"Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies.
Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system.
The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Eterna_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/erna/,United States,2018,Biotechnology,Healthcare,8,Sanjeev Luther,"1035 Cambridge Street, Suite 18A
Cambridge, Massachusetts 02141
United States",212 582 1199,eternatx.com,ERNA,NASDAQ,January - December,USD,0000748592,114082209,US1140822099,2834,,Common Stock,31-1103425,,
"Minerva Neurosciences, Inc.","Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders.
The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia.
Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.","Data/company_logos_stock_analysis\Minerva_Neurosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/nerv/,United States,2007,Biotechnology,Healthcare,9,Remy Luthringer,"1500 District Avenue
Burlington, Massachusetts 01803
United States",617 600 7373,minervaneurosciences.com,NERV,NASDAQ,January - December,USD,0001598646,603380205,US6033802058,2834,"Jul 1, 2014",Common Stock,26-0784194,,
XTL Biopharmaceuticals Ltd.,"XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel.
Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome.
It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995.
XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.",Data/company_logos_stock_analysis\XTL_Biopharmaceuticals_Ltd._logo.svg,https://stockanalysis.com/stocks/xtlb/,Israel,1993,Biotechnology,Healthcare,7,Shlomo Shalev,"26 Ben-Gurion St.
Ramat Gan, 5112001
Israel",972 3 611 6600,xtlbio.com,XTLB,NASDAQ,January - December,USD,0001696804,98386D307,US98386D3070,,"Sep 1, 2005",,,,
BiomX Inc.,"BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease.
It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.
The company’s product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials.
BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.",Data/company_logos_stock_analysis\BiomX_Inc._logo.svg,https://stockanalysis.com/stocks/phge/,Israel,2015,Biotechnology,Healthcare,71,Jonathan Solomon,"22 Einstein Street, Floor 4
Ness Ziona, 7414003
Israel",972 7 2394 2377,biomx.com,PHGE,NYSEAMERICAN,January - December,USD,0001739174,09090D103,US09090D1037,2836,,Common Stock,82-3364020,,
Conduit Pharmaceuticals Inc.,"Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave’s disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.",Data/company_logos_stock_analysis\Conduit_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/cdt/,United States,2019,Biotechnology,Healthcare,7,David Tapolczay,"4995 Murphy Canyon Road, Suite 300
San Diego, California 92123
United States",760 471 8536,conduitpharma.com,CDT,NASDAQ,January - December,USD,0001896212,20678X106,US20678X1063,2834,,Common Stock,87-3272543,,
AIM ImmunoTech Inc.,"AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease.
AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell’Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation.
The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019.
AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.",Data/company_logos_stock_analysis\AIM_ImmunoTech_Inc._logo.svg,https://stockanalysis.com/stocks/aim/,United States,1966,Biotechnology,Healthcare,28,Thomas Equels,"2117 SW Highway 484
Ocala, Florida 34473
United States",352 448 7797,aimimmuno.com,AIM,NYSEAMERICAN,January - December,USD,0000109471,00901B105,US00901B1052,3812,,,74-1668471,,
"Hoth Therapeutics, Inc.","Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs.
It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer’s or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; and HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases.
The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus.
The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003.
Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.","Data/company_logos_stock_analysis\Hoth_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/hoth/,United States,2017,Biotechnology,Healthcare,3,Robb Knie,"590 Madison Avenue, 21st Floor
New York, New York 10022
United States",646 756 2997,hoththerapeutics.com,HOTH,NASDAQ,January - December,USD,0001711786,44148G105,US44148G2049,2834,"Feb 15, 2019",Common Stock,82-1553794,$5.60,
COSCIENS Biopharma Inc.,"COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally.
Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.
The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease.
In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism.
The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024.
COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.",Data/company_logos_stock_analysis\COSCIENS_Biopharma_Inc._logo.svg,https://stockanalysis.com/stocks/csci/,Canada,1990,Biotechnology,Healthcare,12,Gilles Gagnon,"222 Bay Street, Suite 3000
Toronto, ON M5K 1E7
Canada",,cosciensbio.com,CSCI,NASDAQ,January - December,USD,0001113423,22112H101,CA22112H1010,2834,"Jul 18, 1996",,,,
"Imunon, Inc.","Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases.
The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon’s DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines.
Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022.
The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.","Data/company_logos_stock_analysis\Imunon,_Inc._logo.svg",https://stockanalysis.com/stocks/imnn/,United States,1982,Biotechnology,Healthcare,33,Stacy Lindborg,"997 Lenox Drive, Suite 100
Lawrenceville, New Jersey 08648
United States",609 896 9100,imunon.com,IMNN,NASDAQ,January - December,USD,0000749647,,US15117N6022,2834,"Mar 5, 1985",Common Stock,52-1256615,,
"Acurx Pharmaceuticals, Inc.","Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.
The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia.
Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.","Data/company_logos_stock_analysis\Acurx_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/acxp/,United States,2017,Biotechnology,Healthcare,4,David Luci,"259 Liberty Avenue
Staten Island, New York 10305
United States",917 533 1469,acurxpharma.com,ACXP,NASDAQ,January - December,USD,0001736243,00510M104,US00510M1045,2834,"Jun 25, 2021",Common Stock,,$6.00,
"Lyra Therapeutics, Inc.","Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases.
It’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps.
It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand.
The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018.
Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.","Data/company_logos_stock_analysis\Lyra_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/lyra/,United States,2005,Biotechnology,Healthcare,88,Maria Palasis,"480 Arsenal Way
Watertown, Massachusetts 02472
United States",617 393 4600,lyratherapeutics.com,LYRA,NASDAQ,January - December,USD,0001327273,55234L105,US55234L1052,3841,"May 1, 2020",Common Stock,,$16.00,
Aptose Biosciences Inc.,"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.
The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin’s lymphomas, as well as relapsed or refractory acute myeloid leukemia.
It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib.
The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014.
Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.",Data/company_logos_stock_analysis\Aptose_Biosciences_Inc._logo.svg,https://stockanalysis.com/stocks/apto/,Canada,1986,Biotechnology,Healthcare,36,William Rice,"251 Consumers Road, Suite 1105
Toronto, ON M2J 4R3
Canada",647 479 9828,aptose.com,APTO,NASDAQ,January - December,USD,0000882361,03835T200,CA03835T3091,2836,,,,,
"TherapeuticsMD, Inc.","TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States.
It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names.
The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.","Data/company_logos_stock_analysis\TherapeuticsMD,_Inc._logo.svg",https://stockanalysis.com/stocks/txmd/,United States,2008,Drug Manufacturers - Specialty & Generic,Healthcare,1,Marlan Walker,"951 Yamato Road, Suite 220
Boca Raton, Florida 33431
United States",561 961 1900,therapeuticsmd.com,TXMD,NASDAQ,January - December,USD,0000025743,88338N206,US88338N2062,2834,,Common Stock,87-0233535,,
"Sensei Biotherapeutics, Inc.","Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients.
The company’s Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.
It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.
The company’s pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28.
It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program.
The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.","Data/company_logos_stock_analysis\Sensei_Biotherapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/snse/,United States,2005,Biotechnology,Healthcare,28,John Celebi,"1405 Research Boulevard, Suite 125
Rockville, Maryland 20850
United States",240 243 8000,senseibio.com,SNSE,NASDAQ,January - December,USD,0001829802,81728A108,US81728A1088,2834,"Feb 4, 2021",Common Stock,,$19.00,
"Jaguar Health, Inc.","Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea.
The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
The company’s products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs.
It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea.
In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea.
The company is headquartered in San Francisco, California.","Data/company_logos_stock_analysis\Jaguar_Health,_Inc._logo.svg",https://stockanalysis.com/stocks/jagx/,United States,2013,Biotechnology,Healthcare,49,Lisa Conte,"200 Pine Street, Suite 400
San Francisco, California 94104
United States",415 371 8300,jaguar.health,JAGX,NASDAQ,January - December,USD,0001585608,47010C607,US47010C7065,2834,,Common Stock,,,
"Eyenovia, Inc.","Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics.
It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery.
The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications.
It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi.
The company has agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014.
Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.","Data/company_logos_stock_analysis\Eyenovia,_Inc._logo.svg",https://stockanalysis.com/stocks/eyen/,United States,2014,Biotechnology,Healthcare,57,Michael Rowe,"295 Madison Avenue, Suite 2400
New York, New York 10017
United States",833 393 6684,eyenovia.com,EYEN,NASDAQ,January - December,USD,0001682639,30234E104,US30234E1047,2834,"Jan 25, 2018",Common Stock,47-1178401,,
"Mustang Bio, Inc.","Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.
Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment.
The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus.
It has license agreements with Nationwide Children’s Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH.
The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. Avenue Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.","Data/company_logos_stock_analysis\Mustang_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/mbio/,United States,2015,Biotechnology,Healthcare,80,Manuel Litchman,"377 Plantation Street, 1st Floor
Worcester, Massachusetts 01605
United States",781 652 4500,mustangbio.com,MBIO,NASDAQ,January - December,USD,0001680048,62818Q104,US62818Q2030,2834,,,47-3828760,,
"Relmada Therapeutics, Inc.","Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States.
Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
The company is headquartered in Coral Gables, Florida.","Data/company_logos_stock_analysis\Relmada_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/rlmd/,United States,2004,Biotechnology,Healthcare,20,Sergio Traversa,"2222 Ponce de Leon Boulevard, Floor 3
Coral Gables, Florida 33134
United States",786-629-1376,relmada.com,RLMD,NASDAQ,January - December,USD,0001553643,75955J402,US75955J4022,2834,,Common Stock,45-5401931,,
"Cellectar Biosciences, Inc.","Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors.
It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.","Data/company_logos_stock_analysis\Cellectar_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/clrb/,United States,2002,Biotechnology,Healthcare,20,James Caruso,"100 Campus Drive
Florham Park, New Jersey 07932
United States",608 441 8120,cellectar.com,CLRB,NASDAQ,January - December,USD,0001279704,15117F500,US15117F8077,2834,,Common Stock,04-3321804,,
"Apollomics, Inc.","Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer.
The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.
Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers.
The company’s pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810.
Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019.
The company was incorporated in 2015 and is based in Foster City, California.","Data/company_logos_stock_analysis\Apollomics,_Inc._logo.svg",https://stockanalysis.com/stocks/aplm/,United States,2016,Biotechnology,Healthcare,45,Guo-Liang Yu,"989 East Hillsdale Blvd, Suite 220
Foster City, California 94404
United States",650 209 4055,apollomicsinc.com,APLM,NASDAQ,January - December,USD,0001944885,,KYG0411D1079,2834,,,,,Class A Shares
Immuron Limited,"Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.
It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.
It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers’ diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection.
The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products.
The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008.
Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.",Data/company_logos_stock_analysis\Immuron_Limited_logo.svg,https://stockanalysis.com/stocks/imrn/,Australia,1994,Biotechnology,Healthcare,7,Steven Lydeamore,"62 Lygon Street, Level 3
Carlton, VIC 3053
Australia",61 3 9824 5254,immuron.com.au,IMRN,NASDAQ,July - June,AUD,0001660046,45254U101,US45254U1016,2834,,,,,
Brainstorm Cell Therapeutics Inc.,"Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.
The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases.
Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.",Data/company_logos_stock_analysis\Brainstorm_Cell_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/bcli/,United States,2000,Biotechnology,Healthcare,29,Chaim Lebovits,"1325 Avenue of Americas, 28th Floor
New York, New York 10019
United States",201 488 0460,brainstorm-cell.com,BCLI,NASDAQ,January - December,USD,0001137883,10501E201,US10501E2019,2836,,Common Stock,20-7273918,,
"BioRestorative Therapies, Inc.","BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue.
The company also provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body.
BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania.
The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011.
BioRestorative Therapies, Inc. is based in Melville, New York.","Data/company_logos_stock_analysis\BioRestorative_Therapies,_Inc._logo.svg",https://stockanalysis.com/stocks/brtx/,United States,1997,Biotechnology,Healthcare,11,Lance Alstodt,"40 Marcus Drive, Suite 1
Melville, New York 11747
United States",631 760 8100,biorestorative.com,BRTX,NASDAQ,January - December,USD,0001505497,090655606,US0906556065,8090,,Common Stock,30-1341024,,
Turnstone Biologics Corp.,"Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors.
The company’s lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.
It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors.
The company was founded in 2014 and is based in LA Jolla, California.",Data/company_logos_stock_analysis\Turnstone_Biologics_Corp._logo.svg,https://stockanalysis.com/stocks/tsbx/,United States,2015,Biotechnology,Healthcare,80,Sammy Farah,"9310 Athena Circle, Suite 300
La Jolla, California 92037
United States",347 897 5988,turnstonebio.com,TSBX,NASDAQ,January - December,USD,0001764974,90042W100,US90042W1009,2836,"Jul 21, 2023",Common Stock,83-2909368,$12.00,
Can-Fite BioPharma Ltd.,"Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.
The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.
It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.
In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001.
The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.",Data/company_logos_stock_analysis\Can-Fite_BioPharma_Ltd._logo.svg,https://stockanalysis.com/stocks/canf/,Israel,1994,Biotechnology,Healthcare,8,Motti Farbstein,"26 Ben Gurion Street
Ramat Gan, 5257346
Israel",972 3 924 1114,canfite.com,CANF,NYSEAMERICAN,January - December,USD,0001536196,13471N201,US13471N3008,2834,,,,,
Evogene Ltd.,"Evogene Ltd., together with its subsidiaries, operates as a computational biology company.
It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform.
The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance.
The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms.
The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses.
The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally.
Evogene Ltd. was incorporated in 1999 and is headquartered in Rehovot, Israel.",Data/company_logos_stock_analysis\Evogene_Ltd._logo.svg,https://stockanalysis.com/stocks/evgn/,Israel,1999,Biotechnology,Healthcare,142,Ofer Haviv,"13 Gad Feinstein Street, Park Rehovot
Rehovot, 7638517
Israel",972 8 931 1900,evogene.com,EVGN,NASDAQ,January - December,USD,0001574565,M4119S104,IL0011050551,2870,,,,,
"Aytu BioPharma, Inc.","Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally.
The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old.
It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency.
The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021.
Aytu BioPharma, Inc. is headquartered in Denver, Colorado.","Data/company_logos_stock_analysis\Aytu_BioPharma,_Inc._logo.svg",https://stockanalysis.com/stocks/aytu/,United States,,Drug Manufacturers - Specialty & Generic,Healthcare,102,Joshua Disbrow,"Denver Corporate Center III, Suite 920
Denver, Colorado 80237
United States",(720) 437-6580,aytubio.com,AYTU,NASDAQ,July - June,USD,0001385818,054754874,US0547548588,2834,,Common Stock,47-0883144,,
"PharmaCyte Biotech, Inc.","PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States.
Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment.
The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015.
PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.","Data/company_logos_stock_analysis\PharmaCyte_Biotech,_Inc._logo.svg",https://stockanalysis.com/stocks/pmcb/,United States,1996,Biotechnology,Healthcare,2,Joshua Silverman,"3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
United States",917-595-2850,pharmacyte.com,PMCB,NASDAQ,May - April,USD,0001157075,71715X203,US71715X2036,2836,,Common Stock,62-1772151,,
"Kiora Pharmaceuticals, Inc.","Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States.
Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair.
It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Théa Open Innovation for the development KIO-301.
The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021.
Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.","Data/company_logos_stock_analysis\Kiora_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/kprx/,United States,1998,Biotechnology,Healthcare,12,Brian Strem,"332 Encinitas Boulevard, Suite 102
Encinitas, California 92024
United States",858 224 9600,kiorapharma.com,KPRX,NASDAQ,January - December,USD,0001372514,49721T101,US49721T3095,2834,,,,,
"Talphera, Inc.","Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.
It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.
The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024.
The company was incorporated in 2005 and is headquartered in San Mateo, California.","Data/company_logos_stock_analysis\Talphera,_Inc._logo.svg",https://stockanalysis.com/stocks/tlph/,United States,2005,Drug Manufacturers - Specialty & Generic,Healthcare,15,Vincent Angotti,"1850 Gateway Drive, Suite 175
San Mateo, California 94404
United States",650 216 3500,talphera.com,TLPH,NASDAQ,January - December,USD,0001427925,,US00444T2096,2834,"Feb 14, 2011",Common Stock,,,
"Klotho Neurosciences, Inc.","Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics.
Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors.
The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.
The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024.
Klotho Neurosciences, Inc. is based in Omaha, Nebraska.","Data/company_logos_stock_analysis\Klotho_Neurosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/klto/,United States,2019,Biotechnology,Healthcare,,Joseph Sinkule,"13576 Walnut Street, Suite A
Omaha, Nebraska 68144
United States",833 931 6330,klothoneuro.com,KLTO,NASDAQ,January - December,USD,0001907223,,US49876K1034,2836,,,86-2727441,,
Virax Biolabs Group Limited,"Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology.
The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.
It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual’s immunological profiling data and provide advice on the users’ immune system.
It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions.
The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally.
The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021.
Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.",Data/company_logos_stock_analysis\Virax_Biolabs_Group_Limited_logo.svg,https://stockanalysis.com/stocks/vrax/,United Kingdom,2013,Biotechnology,Healthcare,17,James Foster,"BioCity Glasgow, Bo’Ness Road Newhouse
Lanarkshire, ML1 5UH
United Kingdom",44 20 7788 7414,viraxbiolabs.com,VRAX,NASDAQ,April - March,USD,0001885827,G9495L109,KYG9495L1251,2835,"Jul 21, 2022",,,$5.00,
Purple Biotech Ltd,"Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States.
Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.
The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy.
The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020.
The company was incorporated in 1968 and is headquartered in Rehovot, Israel.",Data/company_logos_stock_analysis\Purple_Biotech_Ltd_logo.svg,https://stockanalysis.com/stocks/ppbt/,Israel,2010,Biotechnology,Healthcare,20,Gil Efron,"4 Oppenheimer Street, Science Park
Rehovot, 7670104
Israel",972 3 933 3121,purple-biotech.com,PPBT,NASDAQ,January - December,USD,0001614744,74638P109,US74638P1093,2834,,,,,
"Ensysce Biosciences, Inc.","Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States.
It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis.
It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder.
The company was founded in 2003 and is based in La Jolla, California.","Data/company_logos_stock_analysis\Ensysce_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/ensc/,United States,2003,Biotechnology,Healthcare,7,D. Kirkpatrick,"7946 Ivanhoe Avenue, Suite 201
La Jolla, California 92037
United States",858 263 4196,ensysce.com,ENSC,NASDAQ,January - December,USD,0001716947,293602108,US2936024056,2834,,Common Stock,82-2755287,,
"BioCardia, Inc.","BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.
Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome.
In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths.
The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction.
BioCardia, Inc. is based in Sunnyvale, California.","Data/company_logos_stock_analysis\BioCardia,_Inc._logo.svg",https://stockanalysis.com/stocks/bcda/,United States,,Biotechnology,Healthcare,20,Peter Altman,"320 Soquel Way
Sunnyvale, California 94085
United States",650 226 0120,biocardia.com,BCDA,NASDAQ,January - December,USD,0000925741,09060U507,US09060U5074,2836,,Common Stock,23-2753988,,
"Indaptus Therapeutics, Inc.","Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.
Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.
Indaptus Therapeutics, Inc. is headquartered in New York, New York.","Data/company_logos_stock_analysis\Indaptus_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/indp/,United States,2000,Biotechnology,Healthcare,7,Jeffrey Meckler,"Three Columbus Circle, 15th Floor
New York, New York 10019
United States",646 427 2727,indaptusrx.com,INDP,NASDAQ,January - December,USD,0001857044,45339J105,US45339J1051,2834,,Common Stock,86-3158720,,
SeaStar Medical Holding Corporation,"SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.
The company offers inflammatory response to fend off infections and repair damaged tissue in the body.
It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.
The company is headquartered in Denver, Colorado.",Data/company_logos_stock_analysis\SeaStar_Medical_Holding_Corporation_logo.svg,https://stockanalysis.com/stocks/icu/,United States,2018,Biotechnology,Healthcare,12,Eric Schlorff,"3513 Brighton Boulevard, Suite 410
Denver, Colorado 80216
United States",844 427 8100,seastarmedical.com,ICU,NASDAQ,January - December,USD,0001831868,81256L104,US81256L1044,3841,,Common Stock,85-3681132,,
"Evoke Pharma, Inc.","Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.","Data/company_logos_stock_analysis\Evoke_Pharma,_Inc._logo.svg",https://stockanalysis.com/stocks/evok/,United States,2007,Drug Manufacturers - Specialty & Generic,Healthcare,4,Matthew D'Onofrio,"420 Stevens Avenue, Suite 230
Solana Beach, California 92075
United States",858 345 1494,evokepharma.com,EVOK,NASDAQ,January - December,USD,0001403708,30049G104,US30049G2030,2834,"Sep 25, 2013",Common Stock,20-8447886,,
Biofrontera Inc.,"Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo.
The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.",Data/company_logos_stock_analysis\Biofrontera_Inc._logo.svg,https://stockanalysis.com/stocks/bfri/,United States,1997,Drug Manufacturers - Specialty & Generic,Healthcare,85,Hermann Luebbert,"120 Presidential Way, Suite 330
Woburn, Massachusetts 01801
United States",781 245 1325,biofrontera-us.com,BFRI,NASDAQ,January - December,USD,0001858685,09077D100,US09077D2099,2834,"Oct 29, 2021",Common Stock,47-3765675,$5.00,
"Soligenix, Inc.","Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.
The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet’s Disease.
The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19.
The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009.
Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.","Data/company_logos_stock_analysis\Soligenix,_Inc._logo.svg",https://stockanalysis.com/stocks/sngx/,United States,1987,Biotechnology,Healthcare,15,Christopher Schaber,"29 Emmons Drive, Suite B-10
Princeton, New Jersey 08540
United States",609 538 8200,soligenix.com,SNGX,NASDAQ,January - December,USD,0000812796,834223307,US8342235053,2834,"Jun 15, 1987",Common Stock,41-1505029,,
"Silo Pharma, Inc.","Silo Pharma Inc. operates as a developmental stage biopharmaceutical company.
The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases.
It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems.
The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief.
In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).
The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore; and has joint development agreement with Kymanox for the design and development of a subcutaneous insertion device for SP-26.
The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020.
Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.","Data/company_logos_stock_analysis\Silo_Pharma,_Inc._logo.svg",https://stockanalysis.com/stocks/silo/,United States,2010,Biotechnology,Healthcare,3,Eric Weisblum,"677 N. Washington Boulevard
Sarasota, Florida 34236
United States",718 400 9031,silopharma.com,SILO,NASDAQ,January - December,USD,0001514183,82711P102,US82711P2011,2834,,Common Stock,46-2137136,,
Aptorum Group Limited,"Aptorum Group Limited, through its subsidiaries, operates as a clinical stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic products for the treatment of oncology and infectious diseases.
The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; ALS-1 to treat viral infections caused by influenza virus A; and ALS-2/3 for the treatment of gram+ve bacterial infections.
The company is also developing RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity.
Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases.
The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, and other disease areas.
In addition, it is involved in the operation of medical clinics. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017.
Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.",Data/company_logos_stock_analysis\Aptorum_Group_Limited_logo.svg,https://stockanalysis.com/stocks/apm/,United Kingdom,2010,Biotechnology,Healthcare,3,Chung Yuen Huen,"17 Hanover Square
London, W1S 1BN
United Kingdom",44 20 8092 9299,aptorumgroup.com,APM,NASDAQ,January - December,USD,0001734005,G6096M106,KYG6096M1226,2834,"Dec 18, 2018",,,,Class A Shares
"Cyclerion Therapeutics, Inc.","Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases.
It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease.
The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Cyclerion_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/cycn/,United States,2018,Biotechnology,Healthcare,1,Dr. Regina Graul Ph.D.,"245 First Street, Riverview II, 18th Floor
Cambridge, Massachusetts 02142
United States",857 327 8778,cyclerion.com,CYCN,NASDAQ,January - December,USD,0001755237,23255M105,US23255M2044,2834,,Common Stock,83-1895370,,
RedHill Biopharma Ltd.,"RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.
The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults.
Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.",Data/company_logos_stock_analysis\RedHill_Biopharma_Ltd._logo.svg,https://stockanalysis.com/stocks/rdhl/,Israel,2009,Drug Manufacturers - Specialty & Generic,Healthcare,53,Dror Ben-Asher,"21 Ha’arba’a Street
Tel Aviv, 6473921
Israel",972 3 541 3131,redhillbio.com,RDHL,NASDAQ,January - December,USD,0001553846,757468103,US7574682024,2834,,,,,
IM Cannabis Corp.,"IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany.
It offers medical cannabis dried flowers; and full-spectrum, strain-specific cannabis extracts under the IMC, BLKMT, WAGNERS, and LOT420 brands.
The company serves medical patients. IM Cannabis Corp. was founded in 2008 and is headquartered in Tel Aviv, Israel.",Data/company_logos_stock_analysis\IM_Cannabis_Corp._logo.svg,https://stockanalysis.com/stocks/imcc/,Israel,1980,Drug Manufacturers - Specialty & Generic,Healthcare,95,Oren Shuster,"Kibbutz Glil Yam, Central District
Tel Aviv, 4690500
Israel",,imcannabis.com,IMCC,NASDAQ,January - December,CAD,0001792030,44969Q208,CA44969Q3070,2833,,,,,
"AEON Biopharma, Inc.","AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.
The company is based in Irvine, California.","Data/company_logos_stock_analysis\AEON_Biopharma,_Inc._logo.svg",https://stockanalysis.com/stocks/aeon/,United States,,Biotechnology,Healthcare,10,Marc Forth,"5 Park Plaza, Suite 1750
Irvine, California 92614
United States",(949) 354-6499,aeonbiopharma.com,AEON,NYSEAMERICAN,January - December,USD,0001837607,00775E102,US00791X1000,2834,,Common Stock,85-3940478,,Class A Shares
"Viracta Therapeutics, Inc.","Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide.
Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.
The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate.
The company is headquartered in Cardiff, California.","Data/company_logos_stock_analysis\Viracta_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/virx/,United States,2007,Biotechnology,Healthcare,40,Mark Rothera,"2533 South Coast Highway 101, Suite 210
Cardiff, California 92007
United States",858 400 8470,viracta.com,VIRX,NASDAQ,January - December,USD,0001061027,92765F108,US92765F1084,2834,,Common Stock,94-3295878,,
Quantum BioPharma Ltd.,"Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development.
The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices.
In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property.
The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024.
Quantum BioPharma Ltd., is headquartered in Toronto, Canada.",Data/company_logos_stock_analysis\Quantum_BioPharma_Ltd._logo.svg,https://stockanalysis.com/stocks/qntm/,Canada,1998,Drug Manufacturers - Specialty & Generic,Healthcare,17,Zeeshan Saeed,"55 University Ave., Suite 1003
Toronto, ON M5J 2H7
Canada",,quantumbiopharma.com,QNTM,NASDAQ,January - December,USD,0001771885,,CA74764Y2050,2834,,,,,Class B Shares
Addex Therapeutics Ltd,"Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot–Marie–Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A.
The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.",Data/company_logos_stock_analysis\Addex_Therapeutics_Ltd_logo.svg,https://stockanalysis.com/stocks/adxn/,Switzerland,2002,Biotechnology,Healthcare,23,Timothy Dyer,"Chemin des Mines, 9
Geneva, 1202
Switzerland",41 22 884 1555,addextherapeutics.com,ADXN,NASDAQ,January - December,CHF,0001574232,00654J107,US00654J2069,2834,,,,,
Kazia Therapeutics Limited,"Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea.
Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer.
The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors.
It has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017.
Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.",Data/company_logos_stock_analysis\Kazia_Therapeutics_Limited_logo.svg,https://stockanalysis.com/stocks/kzia/,Australia,1994,Biotechnology,Healthcare,9,John Friend,"Three International Towers, Level 24
Sydney, NSW 2000
Australia",61 2 9472 4101,kaziatherapeutics.com,KZIA,NASDAQ,July - June,AUD,0001055886,48669G105,US48669G1058,8880,"Jan 6, 1999",,,,
Dominari Holdings Inc.,"Dominari Holdings Inc., through its subsidiaries, is engaged in wealth management, investment banking, sales and trading, and asset management.
It operates through two segments: Dominari Financial and Legacy AIkido. It offers full-service brokerage services, including exchange-traded and over-the-counter corporate equity and debt securities, money market instruments, exchange-traded options, municipal bonds, mutual funds, exchange-traded funds, and unit investment trusts; financial and wealth planning services, such as asset management, individual and corporate retirement solutions, insurance and annuity products, IRAs and 401(k) plans, U.S. stock plan services, education savings programs, and trust and fiduciary services; and margin lending services.
The company also provides financial advisory services to buyers and sellers on sales, divestitures, mergers, acquisitions, tender offers, privatizations, spin-offs, joint ventures, restructurings, and liability management; capital raising solutions through initial public offerings, follow-on offerings, confidentially marketed public offerings, registered directs, private investments in public equity, private placements, at-the-market offerings, and equity-linked offerings for corporate clients; institutional equity sales and trading; equity derivatives and index options; and trading in public and private debt securities, including investment and non-investment grade, distressed and convertible corporate securities.
In addition, it offers asset management solutions, such as separately managed accounts, discretionary advisory accounts, non-discretionary advisory accounts, alternative investments, and private market platform.
The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022.
Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.",Data/company_logos_stock_analysis\Dominari_Holdings_Inc._logo.svg,https://stockanalysis.com/stocks/domh/,United States,1967,Biotechnology,Healthcare,28,Anthony Hayes,"725 5th Avenue, 22nd Floor
New York, New York 10022
United States",212-393-4540,dominariholdings.com,DOMH,NASDAQ,January - December,USD,0000012239,008875304,US0088753043,6211,,Common Stock,52-0849320,,
"Plus Therapeutics, Inc.","Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.
Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection.
It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio.
The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019.
Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.","Data/company_logos_stock_analysis\Plus_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/pstv/,United States,1996,Biotechnology,Healthcare,20,Marc Hedrick,"4200 Marathon Boulevard, Suite 200
Austin, Texas 78756
United States",737 255 7194,plustherapeutics.com,PSTV,NASDAQ,January - December,USD,0001095981,72941H400,US72941H5090,3841,,Common Stock,33-0827593,,
"ABVC BioPharma, Inc.","ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.
It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer.
ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.
The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.","Data/company_logos_stock_analysis\ABVC_BioPharma,_Inc._logo.svg",https://stockanalysis.com/stocks/abvc/,United States,2015,Biotechnology,Healthcare,19,Uttam Patil,"44370 Old Warm Springs Boulevard
Fremont, California 94538
United States",510 668 0881,abvcpharma.com,ABVC,NASDAQ,January - December,USD,0001173313,00091F106,US00091F3047,2834,,Common Stock,26-0014658,,
"Galecto, Inc.","Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases.
The company’s lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis.
It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.","Data/company_logos_stock_analysis\Galecto,_Inc._logo.svg",https://stockanalysis.com/stocks/glto/,Denmark,2011,Biotechnology,Healthcare,13,Hans Schambye,"Ole Maaloes Vej 3, Copenhagen N
Copenhagen, 2200
Denmark",45 70 70 52 10,galecto.com,GLTO,NASDAQ,January - December,USD,0001800315,36322Q107,US36322Q1076,2834,"Oct 29, 2020",,37-1957007,$15.00,
"CNS Pharmaceuticals, Inc.","CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors.
The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.
CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D.
Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.","Data/company_logos_stock_analysis\CNS_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/cnsp/,United States,2017,Biotechnology,Healthcare,5,John Climaco,"2100 West Loop South, Suite 900
Houston, Texas 77027
United States",800 946 9185,cnspharma.com,CNSP,NASDAQ,January - December,USD,0001729427,18978H102,US18978H2013,2834,"Nov 8, 2019",Common Stock,82-2318545,$4.00,
"Genprex, Inc.","Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.
The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.
Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.
The company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation.
The company’s diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.
In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body’s immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive.
Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.","Data/company_logos_stock_analysis\Genprex,_Inc._logo.svg",https://stockanalysis.com/stocks/gnpx/,United States,2009,Biotechnology,Healthcare,26,Ryan Confer,"3300 Bee Cave Road, Suite 650-227
Austin, Texas 78746
United States",877-774-4679,genprex.com,GNPX,NASDAQ,January - December,USD,0001595248,372446104,US3724462037,2834,"Mar 29, 2018",Common Stock,90-0772347,,
"Adial Pharmaceuticals, Inc.","Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.
It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders.
The company was founded in 2010 and is based in Glen Allen, Virginia.","Data/company_logos_stock_analysis\Adial_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/adil/,United States,2010,Biotechnology,Healthcare,7,Cary Claiborne,"4870 Sadler Road, Suite 300
Glen Allen, Virginia 23060
United States",804 487 8196,adial.com,ADIL,NASDAQ,January - December,USD,0001513525,00688A106,US00688A2050,2834,"Jul 30, 2018",Common Stock,80-0667150,,
"Vincerx Pharma, Inc.","Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.
The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors.
Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies.
Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.","Data/company_logos_stock_analysis\Vincerx_Pharma,_Inc._logo.svg",https://stockanalysis.com/stocks/vinc/,United States,2019,Biotechnology,Healthcare,42,Ahmed Hamdy,"260 Sheridan Avenue, Suite 400
Palo Alto, California 94306
United States",650 800 6676,vincerx.com,VINC,NASDAQ,January - December,USD,0001796129,92731L106,US92731L1061,2834,,Common Stock,83-3197402,,
PMGC Holdings Inc.,"PMGC Holdings Inc., a skincare development company, designs, manufactures, and markets skincare products in the United States.
The company offers Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions.
It serves dermatologists, plastic surgeons, medical spa owners, and physicians focused on aesthetic and therapeutic skincare.
The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024.
PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.",Data/company_logos_stock_analysis\PMGC_Holdings_Inc._logo.svg,https://stockanalysis.com/stocks/elab/,United States,2020,Biotechnology,Healthcare,18,Graydon Bensler,"120 Newport Center Drive, Suite 250
Newport Beach, California 92660
United States",866-794-4940,pmgcholdings.com,ELAB,NASDAQ,January - December,USD,0001840563,,US28622K1043,2834,"Nov 21, 2023",Common Stock,85-1399981,$4.00,
"Edesa Biotech, Inc.","Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.
Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
The company develops EB07, a monoclonal antibody, which is in Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo.
It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions.
The company was founded in 2015 and is headquartered in Markham, Canada.","Data/company_logos_stock_analysis\Edesa_Biotech,_Inc._logo.svg",https://stockanalysis.com/stocks/edsa/,Canada,2015,Biotechnology,Healthcare,16,Pardeep Nijhawan,"100 Spy Court
Markham, ON L3R 5H6
Canada",289 800 9600,edesabiotech.com,EDSA,NASDAQ,October - September,USD,0001540159,27966L108,CA27966L3065,2834,,,,,
"Organovo Holdings, Inc.","Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease.
Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
The company’s lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis.
Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters.
The company was incorporated in 2007 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Organovo_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/onvo/,United States,2007,Biotechnology,Healthcare,20,Keith E. Murphy,"11555 Sorrento Valley Road, Suite 100
San Diego, California 92121
United States",858 224 1000,organovo.com,ONVO,NASDAQ,April - March,USD,0001497253,68620A203,US68620A2033,2836,,Common Stock,27-1488943,,
"Alzamend Neuro, Inc.","Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease.
The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001.
Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.","Data/company_logos_stock_analysis\Alzamend_Neuro,_Inc._logo.svg",https://stockanalysis.com/stocks/alzn/,United States,2016,Biotechnology,Healthcare,7,Stephan Jackman,"3480 Peachtree Road NE, Second Floor, Suite 103
Atlanta, Georgia 30326
United States",844 722 6333,alzamend.com,ALZN,NASDAQ,May - April,USD,0001677077,02262M308,US02262M4078,2834,"Jun 15, 2021",Common Stock,81-1822909,$5.00,
"Syros Pharmaceuticals, Inc.","Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies.
The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.
Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Syros_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/syrs/,United States,2011,Biotechnology,Healthcare,68,Gerald Quirk,"35 CambridgePark Drive, 4th Floor
Cambridge, Massachusetts 02140
United States",617 744 1340,syros.com,SYRS,NASDAQ,January - December,USD,0001556263,87184Q107,US87184Q2066,2834,"Jun 30, 2016",Common Stock,45-3772460,,
"Xenetic Biosciences, Inc.","Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers.
The company’s proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer.
Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors.
The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery.
It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies.
Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.","Data/company_logos_stock_analysis\Xenetic_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/xbio/,United States,,Biotechnology,Healthcare,4,James Parslow,"945 Concord Street
Framingham, Massachusetts 01701
United States",781 778 7720,xeneticbio.com,XBIO,NASDAQ,January - December,USD,0001534525,984015503,US9840156023,2834,,Common Stock,45-2952962,,
"GT Biopharma, Inc.","GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.
It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.
The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors.
GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology.
The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017.
GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.","Data/company_logos_stock_analysis\GT_Biopharma,_Inc._logo.svg",https://stockanalysis.com/stocks/gtbp/,United States,1965,Biotechnology,Healthcare,2,Michael Breen,"8000 Marina Boulevard, Suite 100
Brisbane, California 94005
United States",415 919 4040,gtbiopharma.com,GTBP,NASDAQ,January - December,USD,0000109657,36254L209,US36254L3087,2834,,Common Stock,94-1620407,,
"Sunshine Biopharma, Inc.","Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.
It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.
The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer.
It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products.
In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications.
Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.","Data/company_logos_stock_analysis\Sunshine_Biopharma,_Inc._logo.svg",https://stockanalysis.com/stocks/sbfm/,United States,2006,Drug Manufacturers - Specialty & Generic,Healthcare,44,Steve Slilaty,"333 Las Olas Way, CU4 Suite 433
Fort Lauderdale, Florida 33301
United States",954-515-0810,sunshinebiopharma.com,SBFM,NASDAQ,January - December,USD,0001402328,867781304,US8677814035,2834,,Common Stock,20-5566275,,
Clearmind Medicine Inc.,"Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally.
It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.
The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction.
In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders; and Dr.
Glitter Pty Ltd to develop and commercialize the MEAI-based alcohol substitute and ActivCrystal technology.
The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021.
Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.",Data/company_logos_stock_analysis\Clearmind_Medicine_Inc._logo.svg,https://stockanalysis.com/stocks/cmnd/,Canada,2017,Biotechnology,Healthcare,4,Adi Zuloff-Shani,"1220 West 6th Avenue, Suite 101
Vancouver, BC V6H 1A5
Canada",604 260 1566,clearmindmedicine.com,CMND,NASDAQ,November - October,USD,0001892500,,CA1850534027,2834,,,,,
"CERo Therapeutics Holdings, Inc.","CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies.
The company was incorporated in 2021 and is based in South San Francisco, California.","Data/company_logos_stock_analysis\CERo_Therapeutics_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/cero/,United States,2017,Biotechnology,Healthcare,9,Christopher Ehrlich,"201 Haskins Way, Suite 230
South San Francisco, California 94080
United States",215 731 9450,cero.bio,CERO,NASDAQ,January - December,USD,0001870404,,US71902K1051,2836,,Common Stock,87-1088814,,Class A Shares
"Lixte Biotechnology Holdings, Inc.","LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.
Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.
The company’s Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma.
The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute.
Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.","Data/company_logos_stock_analysis\Lixte_Biotechnology_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/lixt/,United States,2005,Biotechnology,Healthcare,4,Bastiaan van der Baan,"680 East Colorado Boulevard, Suite 180
Pasadena, California 91101
United States",631 830 7092,lixte.com,LIXT,NASDAQ,January - December,USD,0001335105,539319202,US5393193017,2834,,Common Stock,20-2903526,,
Channel Therapeutics Corporation,"Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain.
The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family.
Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.
The company was Chromocell Therapeutics Corporation and changed its name to Channel Therapeutics Corporation in November 2024.
Channel Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.",Data/company_logos_stock_analysis\Channel_Therapeutics_Corporation_logo.svg,https://stockanalysis.com/stocks/chro/,United States,2002,Biotechnology,Healthcare,8,Francis Knuettel,"4400 Route 9 South, Suite 1000
Freehold, New Jersey 07728
United States",877 265 8266,chromocell.com,CHRO,NYSEAMERICAN,January - December,USD,0001919246,,US1711261057,2836,"Feb 16, 2024",,86-3335449,$6.00,
Evaxion Biotech A/S,"Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies.
The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.
Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S.
aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N.
gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus.
Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.",,https://stockanalysis.com/stocks/evax/,Denmark,2008,Biotechnology,Healthcare,49,Christian Kanstrup,"Dr. Neergaards Vej, 5th Floor
Horsholm, 2970
Denmark",45 31 31 97 53,evaxion-biotech.com,EVAX,NASDAQ,January - December,USD,0001828253,29970R105,US29970R2040,2836,"Feb 5, 2021",,,$10.00,
Psyence Biomedical Ltd.,"Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines.
It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context.
The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.
It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer.
The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.",Data/company_logos_stock_analysis\Psyence_Biomedical_Ltd._logo.svg,https://stockanalysis.com/stocks/pbm/,Canada,1994,Biotechnology,Healthcare,,Neil Maresky,"121 Richmond Street West, Penthouse Suite, 1300
Toronto, ON M5H2K1
Canada",416-346-7764,psyencebiomed.com,PBM,NASDAQ,April - March,USD,0001985062,,CA74449F1009,2834,,,,,
Portage Biotech Inc.,"Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products.
Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors.
The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials.
Portage Biotech Inc. is based in Tortola, British Virgin Islands.",Data/company_logos_stock_analysis\Portage_Biotech_Inc._logo.svg,https://stockanalysis.com/stocks/prtg/,British Virgin Islands,1973,Biotechnology,Healthcare,7,Alexander Pickett,"Clarence Thomas Building, P.O. Box 4649
Tortola, VG1110
British Virgin Islands",203 221 7378,portagebiotech.com,PRTG,NASDAQ,April - March,USD,0001095435,G7185A128,VGG7185A1286,2834,,,,,
"Moleculin Biotech, Inc.","Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses.
Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers.
In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers.
The company was incorporated in 2015 and is headquartered in Houston, Texas.","Data/company_logos_stock_analysis\Moleculin_Biotech,_Inc._logo.svg",https://stockanalysis.com/stocks/mbrx/,United States,2015,Biotechnology,Healthcare,18,Walter Klemp,"5300 Memorial Drive, Suite 950
Houston, Texas 77007
United States",(713) 300-5160,moleculin.com,MBRX,NASDAQ,January - December,USD,0001659617,60855D200,US60855D2009,2834,"Jun 2, 2016",Common Stock,47-4671997,,
Polyrizon Ltd.,"Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.
The company uses its proprietary technology to develop its products comprising Capture and Contain, a containment barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.
It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.",Data/company_logos_stock_analysis\Polyrizon_Ltd._logo.svg,https://stockanalysis.com/stocks/plrz/,Israel,2005,Biotechnology,Healthcare,3,Tomer Izraeli,"5 Ha-Tidhar Street
Ra'anana, 4366507
Israel",972 5 5433 5665,polyrizon-biotech.com,PLRZ,NASDAQ,January - December,USD,0001893645,,IL0011814113,2834,"Oct 29, 2024",,,$4.38,
"Sonnet BioTherapeutics Holdings, Inc.","Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action.
The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer.
The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB.
It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210.
The company is headquartered in Princeton, New Jersey.","Data/company_logos_stock_analysis\Sonnet_BioTherapeutics_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/sonn/,United States,,Biotechnology,Healthcare,13,Pankaj Mohan,"100 Overlook Center, Suite 102
Princeton, New Jersey 08540
United States",609 375 2227,sonnetbio.com,SONN,NASDAQ,October - September,USD,0001106838,83548R105,US83548R3030,2834,,Common Stock,52-2102141,,
"Allarity Therapeutics, Inc.","Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.
Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.
Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors.
The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Allarity_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/allr/,United States,2004,Biotechnology,Healthcare,6,Thomas Jensen,"24 School Street, 2nd Floor
Boston, Massachusetts 02108
United States",401 426 4664,allarity.com,ALLR,NASDAQ,January - December,USD,0001860657,016744104,US0167443029,2834,,Common Stock,,,
NuCana plc,"NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer.
It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.
The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.
Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer.
It is also developing NUC-7738, a ProTide transformation of 3’-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors.
The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates.
The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017.
NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.",Data/company_logos_stock_analysis\NuCana_plc_logo.svg,https://stockanalysis.com/stocks/ncna/,United Kingdom,1997,Biotechnology,Healthcare,28,Hugh Griffith,"3 Lochside Way
Edinburgh, EH12 9DT
United Kingdom",44 13 1357 1111,nucana.com,NCNA,NASDAQ,January - December,GBP,0001709626,67022C106,US67022C1062,2834,"Sep 28, 2017",,,,
XORTX Therapeutics Inc.,"XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection.
It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy.
It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.",Data/company_logos_stock_analysis\XORTX_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/xrtx/,Canada,2011,Biotechnology,Healthcare,3,Allen Davidoff,"3710 – 33rd Street NW
Alberta Beach, AB T2L 2M1
Canada",403 455 7727,xortx.com,XRTX,NASDAQ,January - December,USD,0001729214,98420Q207,CA98420Q3061,2834,,,,,Class A Shares
Galmed Pharmaceuticals Ltd.,"Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.
It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.
Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma.
Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform.
Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.",Data/company_logos_stock_analysis\Galmed_Pharmaceuticals_Ltd._logo.svg,https://stockanalysis.com/stocks/glmd/,Israel,2000,Biotechnology,Healthcare,8,Allen Baharaff,"16 Abba Hillel Road
Ramat Gan, 5250608
Israel",972 3 693 8448,galmedpharma.com,GLMD,NASDAQ,January - December,USD,0001595353,M47238106,IL0011313900,2834,"Mar 13, 2014",,98-1147233,,
"Synaptogenix, Inc.","Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company.
It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease.
Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury.
The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.
The company was incorporated in 2012 and is headquartered in New York, New York.","Data/company_logos_stock_analysis\Synaptogenix,_Inc._logo.svg",https://stockanalysis.com/stocks/snpx/,United States,2012,Biotechnology,Healthcare,5,Alan Tuchman,"1185 Avenue of the Americas, 3rd Floor
New York, New York 10036
United States",973 242 0005,synaptogen.com,SNPX,NASDAQ,January - December,USD,0001571934,87167T201,US87167T2015,2834,,Common Stock,46-1585656,,
"China Pharma Holdings, Inc.","China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China.
The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.
In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets.
Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases.
Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks.
It offers its products through distributors, its network of sales offices, and sales representatives.
The company is based in Haikou, the People’s Republic of China.","Data/company_logos_stock_analysis\China_Pharma_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/cphi/,China,,Drug Manufacturers - Specialty & Generic,Healthcare,231,Zhilin Li,"No. 17, Jinpan Road, Second Floor
Haikou, 570216
China",86 89 8668 11730,chinapharmaholdings.com,CPHI,NYSEAMERICAN,January - December,USD,0001106644,16941T104,US16941T2033,2834,,Common Stock,73-1564807,,
"Onconetix, Inc.","Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology.
It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.","Data/company_logos_stock_analysis\Onconetix,_Inc._logo.svg",https://stockanalysis.com/stocks/onco/,United States,2018,Biotechnology,Healthcare,12,Ralph Schiess,"201 East Fifth Street, Suite 1900
Cincinnati, Ohio 45202
United States",513 620 4101,onconetix.gcs-web.com,ONCO,NASDAQ,January - December,USD,0001782107,682160106,US09610B1089,2834,"Feb 18, 2022",Common Stock,,$9.00,
"Oragenics, Inc.","Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States.
Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification.
The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics.
It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.","Data/company_logos_stock_analysis\Oragenics,_Inc._logo.svg",https://stockanalysis.com/stocks/ogen/,United States,1996,Biotechnology,Healthcare,5,Janet Huffman,"4902 Eisenhower Boulevard, Suite 125
Tampa, Florida 33634
United States",813 286 7900,oragenics.com,OGEN,NYSEAMERICAN,January - December,USD,0001174940,684023500,US6840235005,2834,,Common Stock,59-3410522,,
"Bio-Path Holdings, Inc.","Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.
The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome.
It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML.
The company was founded in 2007 and is based in Bellaire, Texas.","Data/company_logos_stock_analysis\Bio-Path_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/bpth/,United States,2007,Biotechnology,Healthcare,10,Peter Nielsen,"4710 Bellaire Boulevard, Suite 210
Bellaire, Texas 77401
United States",832 742 1357,biopathholdings.com,BPTH,NASDAQ,January - December,USD,0001133818,09057N300,US09057N3008,2834,,Common Stock,87-0652870,,
"Petros Pharmaceuticals, Inc.","Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men’s health therapeutics in the United States and internationally.
It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie’s disease.
The company offers men’s health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction.
Petros Pharmaceuticals, Inc. is based in New York, New York.","Data/company_logos_stock_analysis\Petros_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/ptpi/,United States,2020,Drug Manufacturers - Specialty & Generic,Healthcare,21,Fady Boctor,"1185 Avenue of the Americas, Suite 249
New York, New York 10036
United States",973 242 0005,petrospharma.com,PTPI,NASDAQ,January - December,USD,0001513856,71678J100,US71678J2096,2834,,Common Stock,46-3522381,,
"Creative Medical Technology Holdings, Inc.","Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.
It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure.
In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson’s disease.
Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.","Data/company_logos_stock_analysis\Creative_Medical_Technology_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/celz/,United States,1998,Biotechnology,Healthcare,4,Timothy Warbington,"211 East Osborn Road
Phoenix, Arizona 85012
United States",(480) 399-2822,creativemedicaltechnology.com,CELZ,NASDAQ,January - December,USD,0001187953,22529Y200,US22529Y4089,2836,,Common Stock,87-0622284,,
"Theriva Biologics, Inc.","Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.
The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.
It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.
In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral β-lactam antibiotics.
It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d’Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004.
Theriva Biologics, Inc. is headquartered in Rockville, Maryland.","Data/company_logos_stock_analysis\Theriva_Biologics,_Inc._logo.svg",https://stockanalysis.com/stocks/tovx/,United States,2001,Biotechnology,Healthcare,22,Steven Shallcross,"9605 Medical Center Drive, Suite 270
Rockville, Maryland 20850
United States",301 417 4364,therivabio.com,TOVX,NYSEAMERICAN,January - December,USD,0000894158,,US87164U4094,2834,"Jun 26, 2006",Common Stock,13-3808303,,
"Enveric Biosciences, Inc.","Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.
Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.
The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer.
Enveric Biosciences, Inc. is headquartered in Naples, Florida.","Data/company_logos_stock_analysis\Enveric_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/envb/,United States,1994,Biotechnology,Healthcare,7,Joseph Tucker,"4851 Tamiami Trail N, Suite 200
Naples, Florida 34103
United States",239 302 1707,enveric.com,ENVB,NASDAQ,January - December,USD,0000890821,29405E208,US29405E2081,2834,,,95-4484725,,
NLS Pharmaceutics AG,"NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders.
The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).
Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD.
The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist.
It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S.A. for commercialization and distribution of Nolazol in Latin America.
NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.",Data/company_logos_stock_analysis\NLS_Pharmaceutics_AG_logo.svg,https://stockanalysis.com/stocks/nlsp/,Switzerland,2015,Biotechnology,Healthcare,7,Alexander Zwyer,"The Circle 6
Zurich, 8058
Switzerland",41 44 512 21 50,nlspharma.com,NLSP,NASDAQ,January - December,USD,0001783036,H57830103,CH0523961370,2834,"Jan 29, 2021",,,$4.15,
"Artelo Biosciences, Inc.","Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States.
It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.
The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017.
Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.","Data/company_logos_stock_analysis\Artelo_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/artl/,United States,2011,Biotechnology,Healthcare,6,Gregory Gorgas,"505 Lomas Santa Fe, Suite 160
Solana Beach, California 92075
United States",858 925 7049,artelobio.com,ARTL,NASDAQ,January - December,USD,0001621221,04301G201,US04301G5080,2834,,Common Stock,33-1220924,,
"Hepion Pharmaceuticals, Inc.","Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.
It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.
The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.
Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.","Data/company_logos_stock_analysis\Hepion_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/hepa/,United States,2013,Biotechnology,Healthcare,22,John Brancaccio,"399 Thornall Street, First Floor
Edison, New Jersey 08837
United States",732 902 4000,hepionpharma.com,HEPA,NASDAQ,January - December,USD,0001583771,426897104,US4268973025,2834,,Common Stock,46-2783806,,
Lipella Pharmaceuticals Inc.,"Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.
The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).
Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.",Data/company_logos_stock_analysis\Lipella_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/lipo/,United States,2005,Biotechnology,Healthcare,7,Jonathan Kaufman,"7800 Susquehanna St., Suite 505
Pittsburgh, Pennsylvania 15208
United States",412-901-0315,lipella.com,LIPO,NASDAQ,January - December,USD,0001347242,53630L100,US53630L1008,2834,"Dec 20, 2022",Common Stock,,$5.75,
"TNF Pharmaceuticals, Inc.","TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms.
Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.
The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation.
The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy.
The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs.
TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024.
The company was founded in 2014 and is headquartered in Baltimore, Maryland.","Data/company_logos_stock_analysis\TNF_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/tnfa/,United States,2014,Biotechnology,Healthcare,6,Ian Rhodes CPA,"855 N. Wolfe Street, Suite 623
Baltimore, Maryland 21205
United States",856 848 8698,tnfpharma.com,TNFA,NASDAQ,January - December,USD,0001321834,,US62856X2018,2835,,Common Stock,,,
"Sonoma Pharmaceuticals, Inc.","Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.
The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel.
It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product.
In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions.
The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016.
Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.","Data/company_logos_stock_analysis\Sonoma_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/snoa/,United States,1999,Drug Manufacturers - Specialty & Generic,Healthcare,10,Amy Trombly,"5445 Conestoga Court, Suite 150
Boulder, Colorado 80301
United States",800 759 9305,sonomapharma.com,SNOA,NASDAQ,April - March,USD,0001367083,83558L204,US83558L2043,3841,"Jan 25, 2007",Common Stock,68-0423298,,
"NovaBay Pharmaceuticals, Inc.","NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally.
It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.
The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
It sells its products through the company’s web stores, third-party online retailers and distribution partners.
The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.
NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.","Data/company_logos_stock_analysis\NovaBay_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/nby/,United States,2000,Biotechnology,Healthcare,26,Justin Hall,"2000 Powell Street, Suite 1150, eleventh floor
EmeryVille, California 94608
United States",510 899 8800,novabay.com,NBY,NYSEAMERICAN,January - December,USD,0001389545,66987P201,US66987P3001,2834,"Oct 26, 2007",Common Stock,68-0454536,,
"Avenue Therapeutics, Inc.","Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases.
Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.
The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.","Data/company_logos_stock_analysis\Avenue_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/atxi/,United States,2015,Biotechnology,Healthcare,3,Alexandra MacLean,"1111 Kane Concourse, Suite 301
Bay Harbor Islands, Florida 33154
United States",781 652 4500,avenuetx.com,ATXI,NASDAQ,January - December,USD,0001644963,05360L205,US05360L3042,2834,"Jun 27, 2017",,47-4113275,,
"ZyVersa Therapeutics, Inc.","ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases.
The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson’s and Huntington’s disease, atherosclerosis, Alzheimer’s disease, and obesity.
ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.","Data/company_logos_stock_analysis\ZyVersa_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/zvsa/,United States,2014,Biotechnology,Healthcare,7,Stephen Glover,"2200 N. Commerce Parkway, Suite 208
Weston, Florida 33326
United States",754 231 1688,zyversa.com,ZVSA,NASDAQ,January - December,USD,0001859007,,US98987D2018,2834,,Common Stock,86-2685744,,
TC Biopharm (Holdings) Plc,"TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform.
Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.
The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.",Data/company_logos_stock_analysis\TC_Biopharm_(Holdings)_Plc_logo.svg,https://stockanalysis.com/stocks/tcbp/,United Kingdom,2013,Biotechnology,Healthcare,41,Bryan Kobel,"Maxim 1, 2 Parklands Way
Motherwell, ML1 4WR
United Kingdom",44 14 1433 7557,tcbiopharm.com,TCBP,NASDAQ,January - December,GBP,0001872812,87807D103,US87807D4007,2836,"Feb 11, 2022",,,$4.25,
"Protagenic Therapeutics, Inc.","Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.
Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Protagenic Therapeutics, Inc. is headquartered in New York, New York.","Data/company_logos_stock_analysis\Protagenic_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ptix/,United States,1994,Biotechnology,Healthcare,3,Dr. Garo H. Armen Ph.D.,"149 Fifth Avenue, Suite 500
New York, New York 10010
United States",212 994 8200,protagenic.com,PTIX,NASDAQ,January - December,USD,0001022899,74365N103,US74365N2027,2834,"Jan 5, 2016",Common Stock,06-1390025,,
Pasithea Therapeutics Corp.,"Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases.
Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.
The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia.
Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.",Data/company_logos_stock_analysis\Pasithea_Therapeutics_Corp._logo.svg,https://stockanalysis.com/stocks/ktta/,United States,2020,Biotechnology,Healthcare,8,Tiago Marques,"1111 Lincoln Road, Suite 500
Miami Beach, Florida 33139
United States",702 514 4174,pasithea.com,KTTA,NASDAQ,January - December,USD,0001841330,70261F103,US70261F2020,2834,"Sep 15, 2021",Common Stock,85-1591963,$5.00,
"Shuttle Pharmaceuticals Holdings, Inc.","Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers.
It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .
The company is based in Gaithersburg, Maryland.","Data/company_logos_stock_analysis\Shuttle_Pharmaceuticals_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/shph/,United States,2012,Drug Manufacturers - Specialty & Generic,Healthcare,8,Anatoly Dritschilo,"401 Professional Drive, Suite 260
Gaithersburg, Maryland 20879
United States",240 403 4212,shuttlepharma.com,SHPH,NASDAQ,January - December,USD,0001757499,825693203,US8256932034,2834,"Aug 31, 2022",,,$8.13,
"Matinas BioPharma Holdings, Inc.","Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.
The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy.
It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium.
The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead’s remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations.
Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.","Data/company_logos_stock_analysis\Matinas_BioPharma_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/mtnb/,United States,2013,Biotechnology,Healthcare,32,Jerome Jabbour,"1545 Route 206 South, Suite 302
Bedminster, New Jersey 07921
United States",908 484 8805,matinasbiopharma.com,MTNB,NYSEAMERICAN,January - December,USD,0001582554,576810105,US5768101058,2834,,Common Stock,46-3011414,,
Silexion Therapeutics Corp,"Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.
The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.
Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment.
The company was founded in 2008 and is headquartered in Jerusalem, Israel.",Data/company_logos_stock_analysis\Silexion_Therapeutics_Corp_logo.svg,https://stockanalysis.com/stocks/slxn/,Israel,2008,Biotechnology,Healthcare,,Ilan Hadar,"The Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Medical Center
Jerusalem, 9112001
Israel",972 2 674 3430,silexion.com,SLXN,NASDAQ,January - December,USD,0002022416,,KYG1281K1067,2836,,,,,
"Dogwood Therapeutics, Inc.","Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.
The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID.
The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024.
The company was founded in 2012 and is headquartered in Alpharetta, Georgia.","Data/company_logos_stock_analysis\Dogwood_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/dwtx/,United States,2012,Biotechnology,Healthcare,4,Gregory Duncan,"44 Milton Avenue
Alpharetta, Georgia 30009
United States",866 620 8655,dwtx.com,DWTX,NASDAQ,January - December,USD,0001818844,,US92829J2033,2834,,Common Stock,85-4314201,,
"Qualigen Therapeutics, Inc.","Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States.
The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors.
It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors.
Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.","Data/company_logos_stock_analysis\Qualigen_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/qlgn/,United States,1996,Biotechnology,Healthcare,4,Kevin Richardson,"5857 Owens Avenue, Suite 300
Carlsbad, California 92008
United States",760 452 8111,qlgntx.com,QLGN,NASDAQ,January - December,USD,0001460702,74754R103,US74754R2022,2834,,Common Stock,26-3474527,,
"Quoin Pharmaceuticals, Ltd.","Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases.
Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.
It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.
Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.","Data/company_logos_stock_analysis\Quoin_Pharmaceuticals,_Ltd._logo.svg",https://stockanalysis.com/stocks/qnrx/,United States,2018,Biotechnology,Healthcare,4,Michael Myers,"42127 Pleasant Forest Court
Ashburn, Virginia 20148-7349
United States",703 980 4182,quoinpharma.com,QNRX,NASDAQ,January - December,USD,0001671502,74907L102,US74907L3006,2834,,,,,
"cbdMD, Inc.","cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States.
The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, hempMD, and cbdMD Botanicals.
Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, drink mixes, ready to drink cans, and sleep, focus, and calming aids.
It also provides veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name; nootropic mushroom line under the ATRx brand; and hemp derived solutions under the hempMD brand.
It distributes its products through its e-commerce website, third-party e-commerce sites, select distributors and marketing partners, wholesalers, and various brick and mortar retailers.
The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019.
cbdMD, Inc. is headquartered in Charlotte, North Carolina.","Data/company_logos_stock_analysis\cbdMD,_Inc._logo.svg",https://stockanalysis.com/stocks/ycbd/,United States,2015,Drug Manufacturers - Specialty & Generic,Healthcare,42,T. Kennedy,"2101 Westinghouse Blvd, Suite A
Charlotte, North Carolina 28273
United States",704 445 3060,cbdmd.com,YCBD,NYSEAMERICAN,October - September,USD,0001644903,12482W101,US12482W3097,2844,,Common Stock,47-3414576,,
InMed Pharmaceuticals Inc.,"InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States.
It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products.
The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.
Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs.
The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa.
It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases.
In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin.
The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014.
InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\InMed_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/inm/,Canada,1981,Biotechnology,Healthcare,13,Eric Adams,"885 West Georgia Street, Suite 1445
Vancouver, BC V6C 3E8
Canada",604 669 7207,inmedpharma.com,INM,NASDAQ,July - June,USD,0001728328,457637601,CA4576376012,2834,,,,,
"Titan Pharmaceuticals, Inc.","Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally.
It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
The company was founded in 1991 and is based in South San Francisco, California.","Data/company_logos_stock_analysis\Titan_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/ttnp/,United States,1991,Biotechnology,Healthcare,4,Weei Chay,"400 Oyster Point Boulevard, Suite 505
South San Francisco, California 94080
United States",650 244 4990,titanpharm.com,TTNP,NASDAQ,January - December,USD,0000910267,888314606,US8883147055,2836,"Jan 18, 1996",Common Stock,94-3171940,,
"Tharimmune, Inc.","Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases.
The company’s pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2.
The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023.
Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.","Data/company_logos_stock_analysis\Tharimmune,_Inc._logo.svg",https://stockanalysis.com/stocks/thar/,United States,2017,Biotechnology,Healthcare,3,Randy Milby,"1200 Route 22 East, Suite 2000
Bridgewater, New Jersey 08807
United States",908 955 3140,tharimmune.com,THAR,NASDAQ,January - December,USD,0001861657,,US4327052001,2834,"Jan 12, 2022",Common Stock,84-2642541,$4.00,
Scinai Immunotherapeutics Ltd.,"Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel.
It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023.
Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.",Data/company_logos_stock_analysis\Scinai_Immunotherapeutics_Ltd._logo.svg,https://stockanalysis.com/stocks/scni/,Israel,2003,Biotechnology,Healthcare,31,Amir Reichman,"Jerusalem BioPark, 2nd floor
Jerusalem
Israel",972 8 930 2529,scinai.com,SCNI,NASDAQ,January - December,USD,0001611747,,US09073Q2049,2836,,,,,
180 Life Sciences Corp.,"180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases.
The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and α7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor.
The company is headquartered in Palo Alto, California.",Data/company_logos_stock_analysis\180_Life_Sciences_Corp._logo.svg,https://stockanalysis.com/stocks/atnf/,United States,2016,Biotechnology,Healthcare,4,Lloyd Jordan,"Building 4, Suite 200
Palo Alto, California 94306
United States",650 507 0669,180lifesciences.com,ATNF,NASDAQ,January - December,USD,0001690080,68236V104,US68236V3024,2834,,Common Stock,81-3832378,,
SciSparc Ltd.,"SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies.
Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form.
It also has an agreement with The Israeli Medical Center for Alzheimer’s to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer’s disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021.
SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.",Data/company_logos_stock_analysis\SciSparc_Ltd._logo.svg,https://stockanalysis.com/stocks/sprc/,Israel,2004,Biotechnology,Healthcare,3,Oz Adler,"Tower A, 2nd Floor
Tel Aviv, 6971916
Israel",972 7 334 47180,scisparc.com,SPRC,NASDAQ,January - December,USD,0001611746,M82618105,IL0010951403,5500,,,,,
"Alaunos Therapeutics, Inc.","Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types.
It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.
The company was founded in 2003 and is headquartered in Houston, Texas.","Data/company_logos_stock_analysis\Alaunos_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/tcrt/,United States,1998,Biotechnology,Healthcare,1,Dale Hogue,"2617 Bissonnet Street, Suite 225
Houston, Texas 77005
United States",346 355 4099,alaunos.com,TCRT,NASDAQ,January - December,USD,0001107421,98973P101,US98973P2002,2834,,Common Stock,84-1475642,,
"Cyclacel Pharmaceuticals, Inc.","Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally.
The company’s lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias.
The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.","Data/company_logos_stock_analysis\Cyclacel_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/cycc/,United States,1992,Biotechnology,Healthcare,12,David Lazar,"200 Connell Drive, Suite 1500
Berkeley Heights, New Jersey 07922
United States",908 517 7330,cyclacel.com,CYCC,NASDAQ,January - December,USD,0001130166,23254L603,US23254L8019,2834,,Common Stock,91-1766850,,
Biodexa Pharmaceuticals Plc,"Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain.
Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.
In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.
It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023.
Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.",Data/company_logos_stock_analysis\Biodexa_Pharmaceuticals_Plc_logo.svg,https://stockanalysis.com/stocks/bdrx/,United Kingdom,2000,Biotechnology,Healthcare,21,Stephen Stamp,"1 Caspian Point, Caspian Way
Cardiff, CF10 4DQ
United Kingdom",44 29 2048 0180,biodexapharma.com,BDRX,NASDAQ,January - December,GBP,0001643918,,US59564R7089,2834,,,,,
"Entero Therapeutics, Inc.","Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases.
The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.
It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.
The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024.
Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.","Data/company_logos_stock_analysis\Entero_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ento/,United States,2014,Biotechnology,Healthcare,9,James Sapirstein,"777 Yamato Road, Suite 502
Boca Raton, Florida 33431
United States",561 589 7020,enterothera.com,ENTO,NASDAQ,January - December,USD,0001604191,,US33749P4081,2834,"Oct 11, 2016",Common Stock,46-4993860,,
"Processa Pharmaceuticals, Inc.","Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment.
Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.
The company’s pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.
It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica.
The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.","Data/company_logos_stock_analysis\Processa_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/pcsa/,United States,2011,Biotechnology,Healthcare,13,George Ng,"7380 Coca Cola Drive, Suite 106
Hanover, Maryland 21076
United States",443 776 3133,processapharmaceuticals.com,PCSA,NASDAQ,January - December,USD,0001533743,74275C205,US74275C3043,2834,,Common Stock,45-1539785,,
"Azitra, Inc.","Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases.
It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.
The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease.
It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.","Data/company_logos_stock_analysis\Azitra,_Inc._logo.svg",https://stockanalysis.com/stocks/aztr/,United States,2014,Biotechnology,Healthcare,10,Francisco Salva,"21 Business Park Drive
Branford, Connecticut 06405
United States",203 646 6446,azitrainc.com,AZTR,NYSEAMERICAN,January - December,USD,0001701478,05479L104,US05479L1044,2834,"Jun 16, 2023",Common Stock,46-4478536,$5.00,
"Palisade Bio, Inc.","Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States.
The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.
It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy.
The company is based in Carlsbad, California.","Data/company_logos_stock_analysis\Palisade_Bio,_Inc._logo.svg",https://stockanalysis.com/stocks/pali/,United States,1996,Biotechnology,Healthcare,9,J. Finley,"7750 El Camino Real, Suite 2A
Carlsbad, California 92009
United States",858 704 4900,palisadebio.com,PALI,NASDAQ,January - December,USD,0001357459,696389105,US6963892046,2836,,,52-2007292,,
"Dermata Therapeutics, Inc.","Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases.
The company’s lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions.
Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Dermata_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/drma/,United States,2014,Biotechnology,Healthcare,8,Gerald Proehl,"3525 Del Mar Heights Road, Suite 332
San Diego, California 92130
United States",858 800 2543,dermatarx.com,DRMA,NASDAQ,January - December,USD,0001853816,249845108,US2498453065,2834,"Aug 13, 2021",Common Stock,,$7.00,
"Aditxt, Inc.","Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems.
The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.
It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University.
The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021.
Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.","Data/company_logos_stock_analysis\Aditxt,_Inc._logo.svg",https://stockanalysis.com/stocks/adtx/,United States,2017,Biotechnology,Healthcare,47,Amro Albanna,"737 North Fifth Street, Suite 200
Richmond, Virginia 23219
United States",650 870 1200,aditxt.com,ADTX,NASDAQ,January - December,USD,0001726711,007025109,US0070256047,2834,"Jun 30, 2020",Common Stock,82-3204328,$9.00,
"60 Degrees Pharmaceuticals, Inc.","60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States.
The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.
It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis.
The company was founded in 2010 and is headquartered in Washington, District Of Columbia.","Data/company_logos_stock_analysis\60_Degrees_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/sxtp/,United States,2010,Biotechnology,Healthcare,3,Geoffrey Dow,"1025 Connecticut Avenue NW, Suite 1000
Washington, District of Columbia 20036
United States",202 327 5422,60degreespharma.com,SXTP,NASDAQ,January - December,USD,0001946563,83006G104,US83006G1040,2834,"Jul 12, 2023",Common Stock,45-2406880,$5.30,Class A Shares
"Windtree Therapeutics, Inc.","Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases.
The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.
It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.
In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials.
Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr.
Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee’s Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program.
The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016.
The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.","Data/company_logos_stock_analysis\Windtree_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/wint/,United States,1992,Biotechnology,Healthcare,20,Jed Latkin,"2600 Kelly Road, Suite 100
Warrington, Pennsylvania 18976-3622
United States",215 488 9300,windtreetx.com,WINT,NASDAQ,January - December,USD,0000946486,97382D303,US97382D4025,2836,"Aug 8, 1995",,94-3171943,,
Aptevo Therapeutics Inc.,"Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
The company’s lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia.
It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer.
The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.
Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.",Data/company_logos_stock_analysis\Aptevo_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/apvo/,United States,2016,Biotechnology,Healthcare,40,Marvin White,"2401 4th Avenue, Suite 1050
Seattle, Washington 98121
United States",206 838 0500,aptevotherapeutics.com,APVO,NASDAQ,January - December,USD,0001671584,03835L207,US03835L2079,2834,,,81-1567056,,
"Revelation Biosciences, Inc.","Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics.
It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.
The company was founded in 2020 and is based in San Diego, California.","Data/company_logos_stock_analysis\Revelation_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/revb/,United States,2020,Biotechnology,Healthcare,9,James Rolke,"4660 La Jolla Village Drive, Suite 100
San Diego, California 92122
United States",650 800 3717,revbiosciences.com,REVB,NASDAQ,January - December,USD,0001810560,76135L101,US76135L5075,2834,,Common Stock,84-3898466,,
"Salarius Pharmaceuticals, Inc.","Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need.
Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors.
It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities.
The company is headquartered in Houston, Texas.","Data/company_logos_stock_analysis\Salarius_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/slrx/,United States,,Biotechnology,Healthcare,2,David Arthur,"2450 Holcombe Boulevard, Suite X
Houston, Texas 77021
United States",832 834 9144,salariuspharma.com,SLRX,NASDAQ,January - December,USD,0001615219,79400X107,US79400X3052,2834,,Common Stock,46-5087339,,
"Virpax Pharmaceuticals, Inc.","Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders.
Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
The company’s preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain.
Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.","Data/company_logos_stock_analysis\Virpax_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/vrpx/,United States,2016,Biotechnology,Healthcare,7,Jatinder Dhaliwal,"1055 Westlakes Drive, Suite 300
Berwyn, Pennsylvania 19312
United States",610 727 4597,virpaxpharma.com,VRPX,NASDAQ,January - December,USD,0001708331,928251206,US9282512063,2834,"Feb 17, 2021",Common Stock,82-1510982,$10.00,
Phio Pharmaceuticals Corp.,"Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States.
The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor.
The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.
Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.",Data/company_logos_stock_analysis\Phio_Pharmaceuticals_Corp._logo.svg,https://stockanalysis.com/stocks/phio/,United States,2011,Biotechnology,Healthcare,9,Robert Bitterman,"11 Apex Drive, Suite 300A
Marlborough, Massachusetts 01752
United States",508 767 3861,phiopharma.com,PHIO,NASDAQ,January - December,USD,0001533040,71880W303,US71880W4024,2834,,Common Stock,,,
Akanda Corp.,"Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis-based products for medicinal use worldwide.
It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.",Data/company_logos_stock_analysis\Akanda_Corp._logo.svg,https://stockanalysis.com/stocks/akan/,United Kingdom,2021,Drug Manufacturers - Specialty & Generic,Healthcare,46,Katharyn Field,"1a, 1b Learoyd Road
New Romney, TN28 8XU
United Kingdom",44 20 2498 7917,akandacorp.com,AKAN,NASDAQ,January - December,USD,0001888014,00971M106,CA00971M2058,2833,"Mar 15, 2022",Common Stock,,$4.00,
PainReform Ltd.,"PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel.
It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.
The company was incorporated in 2007 and is based in Tel Aviv, Israel.",Data/company_logos_stock_analysis\PainReform_Ltd._logo.svg,https://stockanalysis.com/stocks/prfx/,Israel,2007,Drug Manufacturers - Specialty & Generic,Healthcare,7,Ehud Geller,"65 Yigal Alon St.
Tel Aviv, 6744316
Israel",972 3 7177050,painreform.com,PRFX,NASDAQ,January - December,USD,0001801834,M77798102,IL0011651580,2834,"Sep 1, 2020",,,$8.00,
"TransCode Therapeutics, Inc.","TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer.
The company’s lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells.
TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D.
Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.","Data/company_logos_stock_analysis\TransCode_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/rnaz/,United States,2016,Biotechnology,Healthcare,10,Thomas Fitzgerald,"6 Liberty Square, Suite 2382
Boston, Massachusetts 02109
United States",857 837 3099,transcodetherapeutics.com,RNAZ,NASDAQ,January - December,USD,0001829635,89357L105,US89357L3033,2834,"Jul 9, 2021",Common Stock,81-1065054,$4.00,
"Scorpius Holdings, Inc.","Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization.
The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities.
It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services.
The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024.
Scorpius Holdings, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.","Data/company_logos_stock_analysis\Scorpius_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/scpx/,United States,2008,Biotechnology,Healthcare,84,Jeffrey Wolf,"627 Davis Drive, Suite 300
Morrisville, North Carolina 27560
United States",919 240 7133,scorpiusbiologics.com,SCPX,NYSEAMERICAN,January - December,USD,0001476963,,US42237K4094,2834,"Jul 24, 2013",Common Stock,26-2844103,,
"China SXT Pharmaceuticals, Inc.","China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China.
The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang.
It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors.
China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.","Data/company_logos_stock_analysis\China_SXT_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/sxtc/,China,2005,Drug Manufacturers - Specialty & Generic,Healthcare,75,Feng Zhou,"178 North Taidong Road
Taizhou, 225300
China",86 523 8629 8290,sxtchina.com,SXTC,NASDAQ,April - March,USD,0001723980,G2161P108,VGG2161P1403,2834,"Jan 4, 2019",Common Stock,,$4.00,
CSL Limited,"CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology.
The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.",Data/company_logos_stock_analysis\CSL_Limited_logo.png,https://stockanalysis.com/quote/otc/CMXHF/,Australia,1916,Biotechnology,Healthcare,"32,698",Paul McKenzie,"655 Elizabeth Street
Melbourne, 3000
Australia",61 3 9389 1911,csl.com.au,CMXHF,OTCMKTS,July - June,USD,,,AU000000CSL8,2836,,,,,
CSL Limited,"CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology.
The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.",Data/company_logos_stock_analysis\CSL_Limited_logo.png,https://stockanalysis.com/quote/otc/CSLLY/,Australia,1916,Biotechnology,Healthcare,"32,698",Paul McKenzie,"655 Elizabeth Street
Melbourne, 3000
Australia",61 3 9389 1911,csl.com.au,CSLLY,OTCMKTS,July - June,USD,,,US12637N2045,2836,,,,,
Merck KGaA,"Merck KGaA operates as a science and technology company in Germany.
It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies.
Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software.
The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions.
In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins.
The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E.
Merck KGaA.",Data/company_logos_stock_analysis\Merck_KGaA_logo.png,https://stockanalysis.com/quote/otc/MKGAF/,Germany,1668,Drug Manufacturers - Specialty & Generic,Healthcare,"62,908",Belen Garijo Lopez,"Frankfurter Strasse 250
Darmstadt, 64293
Germany",49 6151 72 0,merckgroup.com,MKGAF,OTCMKTS,January - December,EUR,,,DE0006599905,2834,,,,,
Takeda Pharmaceutical Company Limited,"Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.
It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr.
Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr.
Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences.
The company was founded in 1781 and is headquartered in Tokyo, Japan.",Data/company_logos_stock_analysis\Takeda_Pharmaceutical_Company_Limited_logo.png,https://stockanalysis.com/quote/otc/TKPHF/,Japan,1781,Drug Manufacturers - Specialty & Generic,Healthcare,"49,281",Christophe Weber,"1-1, Nihonbashi-Honcho 2-chome
Tokyo, 103-8668
Japan",81 3 3278-2111,takeda.com,TKPHF,OTCMKTS,April - March,JPY,,,JP3463000004,2834,,Common Stock,,,
argenx SE,"argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.
It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH.
It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services.
argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.",Data/company_logos_stock_analysis\argenx_SE_logo.png,https://stockanalysis.com/quote/otc/ARGNF/,Netherlands,2008,Biotechnology,Healthcare,"1,148",Timothy Van Hauwermeiren,"Laarderhoogtweg 25
Amsterdam, 1101EB
Netherlands",31 10 703 8441,argenx.com,ARGNF,OTCMKTS,January - December,USD,,,NL0010832176,2836,,,,,
UCB SA,"UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome.
In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; minzasolmin and UCB0222 for Parkinson’s disease; and UCB1381 and UCB9741 for atropic dermatitis.
Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka.
The company was incorporated in 1925 and is headquartered in Brussels, Belgium.",Data/company_logos_stock_analysis\UCB_SA_logo.png,https://stockanalysis.com/quote/otc/UCBJY/,Belgium,1925,Biotechnology,Healthcare,"9,083",Jean-Christophe Tellier,"AllEe de la Recherche, 60
Brussels, 1070
Belgium",32 2 559 99 99,ucb.com,UCBJY,OTCMKTS,January - December,EUR,,,US9034801012,2836,,,,,
UCB SA,"UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome.
In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; minzasolmin and UCB0222 for Parkinson’s disease; and UCB1381 and UCB9741 for atropic dermatitis.
Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka.
The company was incorporated in 1925 and is headquartered in Brussels, Belgium.",Data/company_logos_stock_analysis\UCB_SA_logo.png,https://stockanalysis.com/quote/otc/UCBJF/,Belgium,1925,Biotechnology,Healthcare,"9,083",Jean-Christophe Tellier,"AllEe de la Recherche, 60
Brussels, 1070
Belgium",32 2 559 99 99,ucb.com,UCBJF,OTCMKTS,January - December,EUR,,,BE0003739530,2836,,,,,
Teva Pharmaceutical Industries Limited,"Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.
The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM.
In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder.
The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names.
It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH.
The company was founded in 1901 and is based in Tel Aviv, Israel.",Data/company_logos_stock_analysis\Teva_Pharmaceutical_Industries_Limited_logo.png,https://stockanalysis.com/quote/otc/TEVJF/,Israel,1901,Drug Manufacturers - Specialty & Generic,Healthcare,"36,472",Richard Francis,"124 Dvora HaNevi’a Street
Tel Aviv, 6944020
Israel",972 3 914 8213,tevapharm.com,TEVJF,OTCMKTS,January - December,USD,,,IL0006290147,2834,,,,,
Genmab A/S,"Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.
In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease.
It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.
It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S.
Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.",,https://stockanalysis.com/quote/otc/GNMSF/,Denmark,1999,Biotechnology,Healthcare,"2,204",Jan G.J. de Winkel,"Carl Jacobsens Vej 30
Copenhagen, 2500
Denmark",45 70 20 27 28,genmab.com,GNMSF,OTCMKTS,January - December,DKK,,,DK0010272202,2836,,,,,
"Shionogi & Co., Ltd.","Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.
It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.
It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.
In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes.
The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943.
Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.","Data/company_logos_stock_analysis\Shionogi_&_Co.,_Ltd._logo.png",https://stockanalysis.com/quote/otc/SGIOF/,Japan,1878,Drug Manufacturers - Specialty & Generic,Healthcare,"4,959",Isao Teshirogi,"1-8, Doshomachi 3-chome
Osaka, 541-0045
Japan",81 6 6202 2161,shionogi.com,SGIOF,OTCMKTS,April - March,JPY,,,JP3347200002,2834,,Common Stock,,,
"Shionogi & Co., Ltd.","Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.
It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.
It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.
In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes.
The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943.
Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.","Data/company_logos_stock_analysis\Shionogi_&_Co.,_Ltd._logo.png",https://stockanalysis.com/quote/otc/SGIOY/,Japan,1878,Drug Manufacturers - Specialty & Generic,Healthcare,"4,959",Isao Teshirogi,"1-8, Doshomachi 3-chome
Osaka, 541-0045
Japan",81 6 6202 2161,shionogi.com,SGIOY,OTCMKTS,April - March,JPY,,,US8246671098,2834,,,,,
Ipsen S.A.,"Ipsen S.A. operates as a biopharmaceutical company worldwide.
The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases.
The company was founded in 1929 and is based in Boulogne-Billancourt, France.",Data/company_logos_stock_analysis\Ipsen_S.A._logo.png,https://stockanalysis.com/quote/otc/IPSEY/,France,1929,Drug Manufacturers - Specialty & Generic,Healthcare,"5,325",David Loew,"65, quai Georges Gorse
Boulogne-Billancourt, 92100
France",33 1 58 33 50 00,ipsen.com,IPSEY,OTCMKTS,January - December,EUR,,,US4626292050,2834,,,,,
Ipsen S.A.,"Ipsen S.A. operates as a biopharmaceutical company worldwide.
The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases.
The company was founded in 1929 and is based in Boulogne-Billancourt, France.",Data/company_logos_stock_analysis\Ipsen_S.A._logo.png,https://stockanalysis.com/quote/otc/IPSEF/,France,1929,Drug Manufacturers - Specialty & Generic,Healthcare,"5,325",David Loew,"65, quai Georges Gorse
Boulogne-Billancourt, 92100
France",33 1 58 33 50 00,ipsen.com,IPSEF,OTCMKTS,January - December,EUR,,,FR0010259150,2834,,,,,
WuXi Biologics (Cayman) Inc.,"WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia.
It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh.
It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities.
The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates.
The company was incorporated in 2014 and is headquartered in Wuxi, China.",Data/company_logos_stock_analysis\WuXi_Biologics_(Cayman)_Inc._logo.png,https://stockanalysis.com/quote/otc/WXIBF/,Cayman Islands,2014,Biotechnology,Healthcare,"12,740",Zhisheng Chen,"No. 108, Meiliang Road
Wuxi, 214092
China",,wuxibiologics.com,WXIBF,OTCMKTS,January - December,CNY,,,KYG970081173,8731,,,,,
WuXi Biologics (Cayman) Inc.,"WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia.
It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh.
It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities.
The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates.
The company was incorporated in 2014 and is headquartered in Wuxi, China.",Data/company_logos_stock_analysis\WuXi_Biologics_(Cayman)_Inc._logo.png,https://stockanalysis.com/quote/otc/WXXWY/,Cayman Islands,2014,Biotechnology,Healthcare,"12,740",Zhisheng Chen,"No. 108, Meiliang Road
Wuxi, 214092
China",,wuxibiologics.com,WXXWY,OTCMKTS,January - December,CNY,,,US98260N1081,8731,,,,,
"Shanghai Fosun Pharmaceutical (Group) Co., Ltd.","Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally.
The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III.
It engages in the import and export of medical equipment; provision of related and other consulting services; medical devices and diagnosis products, and healthcare service; and investment management, as well as involves in the retail and wholesale distribution of medicines.
The company was founded in 1994 and is based in Shanghai, China.","Data/company_logos_stock_analysis\Shanghai_Fosun_Pharmaceutical_(Group)_Co.,_Ltd._logo.png",https://stockanalysis.com/quote/otc/SFOSF/,China,1994,Drug Manufacturers - Specialty & Generic,Healthcare,"40,370",Deyong Wen,"Building A
Shanghai, 200233
China",86 21 3398 7000,fosunpharma.com,SFOSF,OTCMKTS,January - December,CNY,,,CNE100001M79,2834,,,,,
"Eisai Co., Ltd.","Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.
It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer.
The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.
It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate; and a clinical trial collaboration and supply agreement with Medivir for the evaluation of fostrox, a liver-targeted treatment.
Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955.
Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.","Data/company_logos_stock_analysis\Eisai_Co.,_Ltd._logo.png",https://stockanalysis.com/quote/otc/ESALF/,Japan,1941,Drug Manufacturers - Specialty & Generic,Healthcare,"11,067",Haruo Naito,"4-6-10, Koishikawa
Tokyo, 112-8088
Japan",81 3 3817 3700,eisai.co.jp,ESALF,OTCMKTS,April - March,JPY,,,JP3160400002,2834,,Common Stock,,,
Zealand Pharma A/S,"Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.
It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs.
The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism.
The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome.
The company was incorporated in 1997 and is based in Søborg, Denmark.",,https://stockanalysis.com/quote/otc/ZLDPF/,Denmark,1997,Biotechnology,Healthcare,253,Adam Steensberg,"Sydmarken 11
Søborg, 2860
Denmark",45 88 77 36 00,zealandpharma.com,ZLDPF,OTCMKTS,January - December,DKK,,,DK0060257814,2836,,,,,
Hikma Pharmaceuticals PLC,"Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.
It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets.
The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management.
It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally.
Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.",Data/company_logos_stock_analysis\Hikma_Pharmaceuticals_PLC_logo.png,https://stockanalysis.com/quote/otc/HKMPF/,United Kingdom,1978,Drug Manufacturers - Specialty & Generic,Healthcare,"9,100",Riad Mishlawi,"1 New Burlington Place
London, W1S 2HR
United Kingdom",44 20 7399 2760,hikma.com,HKMPF,OTCMKTS,January - December,USD,,,GB00B0LCW083,2834,,,,,
Hikma Pharmaceuticals PLC,"Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.
It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets.
The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management.
It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally.
Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.",Data/company_logos_stock_analysis\Hikma_Pharmaceuticals_PLC_logo.png,https://stockanalysis.com/quote/otc/HKMPY/,United Kingdom,1978,Drug Manufacturers - Specialty & Generic,Healthcare,"9,100",Riad Mishlawi,"1 New Burlington Place
London, W1S 2HR
United Kingdom",44 20 7399 2760,hikma.com,HKMPY,OTCMKTS,January - December,USD,,,US4312881091,2834,,,,,
ALK-Abelló A/S,"ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally.
Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma.
The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.
It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment.
In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis.
The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy.
ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.",,https://stockanalysis.com/quote/otc/AKBLF/,Denmark,1923,Biotechnology,Healthcare,"2,824",Peter Halling,"BOege AllE 6-8
Horsholm, 2970
Denmark",45 45 74 75 76,alk.net,AKBLF,OTCMKTS,January - December,DKK,,,DK0061802139,2836,,,,,
Telix Pharmaceuticals Limited,"Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.
The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis.
Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma.
The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy.
Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.",Data/company_logos_stock_analysis\Telix_Pharmaceuticals_Limited_logo.png,https://stockanalysis.com/quote/otc/TLPPF/,Australia,2015,Biotechnology,Healthcare,234,Christian Behrenbruch,"55 Flemington Road
North Melbourne, VIC 3051
Australia",61 3 9093 3855,telixpharma.com,TLPPF,OTCMKTS,January - December,AUD,,,AU000000TLX2,2836,,,,,
Aspen Pharmacare Holdings Limited,"Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide.
It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general, local, and regional anesthetic; low molecular weight heparin; regional and spinal anesthetic; and opioid analegesic under the Diprivan, Emla, Fraxiparine, Marcaine, Ultiva, and Xylocaine brand names.
It also offers such as sleeping aid, thyroid hormone, immunosuppressant, iron supplement, analgesic anti-inflammatory, and hormone replacement therapy under the Circadin, Eltroxin, Foxair, Imuran, Maltofer, Mybulen, and Ovestin brand names.
In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products.
Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.",Data/company_logos_stock_analysis\Aspen_Pharmacare_Holdings_Limited_logo.png,https://stockanalysis.com/quote/otc/APNHY/,South Africa,1850,Drug Manufacturers - Specialty & Generic,Healthcare,"9,350",Stephen Saad,"Aspen Place
Durban
South Africa",27 31 580 8600,aspenpharma.com,APNHY,OTCMKTS,July - June,ZAR,,,US04530Y1064,2834,,,,,
Genscript Biotech Corporation,"Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People’s Republic of China, Japan, the other Asia Pacific regions, and internationally.
The company operates through four segments: Life Science Services and Products; Biologics Development Services; Industrial Synthetic Biology Products; and Cell Therapy.
The Life Science Services and Products segment provides products and services in various categories, including DNA synthesis, plasmid DNA preparation, molecular cloning, oligonucleotide synthesis, protein and antibody expression and purification, peptide synthesis, antibody development, IVT RNA production, assay cell line development and vector packing, molecular diagnostics tools, and genome editing tools and reagents, as well as instrument for protein analysis and purification, cell isolation and activation.
The Biologics Development Services segment offers end-to-end service offerings to biologics development and manufacturing for biopharma and biotech partners, as well as therapeutic antibodies, and gene/cell therapy products with an integrated platform.
The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes.
The Cell Therapy segment discovers and develops chimeric antigen receptor CAR-T cell therapies for the treatment of liquid and solid tumors.
It has a strategic partnership with Multiply Labs for automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process.
Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People’s Republic of China.",Data/company_logos_stock_analysis\Genscript_Biotech_Corporation_logo.png,https://stockanalysis.com/quote/otc/GNNSF/,Cayman Islands,2002,Biotechnology,Healthcare,"6,937",Weihui Shao,"Jiangning Science Park
Nanjing, 211100
China",86 25 5889 7288,genscript.com,GNNSF,OTCMKTS,January - December,USD,,,KYG3825B1059,8731,,,,,
Mesoblast Limited,"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.
It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy.
It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain.
The company was incorporated in 2004 and is headquartered in Melbourne, Australia.",Data/company_logos_stock_analysis\Mesoblast_Limited_logo.png,https://stockanalysis.com/quote/otc/MEOBF/,Australia,2004,Biotechnology,Healthcare,73,Silviu Itescu,"55 Collins Street
Melbourne, 3000
Australia",61 3 9639 6036,mesoblast.com,MEOBF,OTCMKTS,July - June,USD,,,AU000000MSB8,2836,,,,,
Bavarian Nordic A/S,"Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.
The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.
It is also developing MVA-BN for the treatment of smallpox. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally.
Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.",,https://stockanalysis.com/quote/otc/BVNKF/,Denmark,1992,Biotechnology,Healthcare,"1,379",Paul Chaplin,"Philip Heymans Alle 3
Hellerup, 2900
Denmark",45 33 26 83 83,bavarian-nordic.com,BVNKF,OTCMKTS,January - December,DKK,,,DK0015998017,2836,,,,,
Bavarian Nordic A/S,"Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.
The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.
It is also developing MVA-BN for the treatment of smallpox. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally.
Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.",,https://stockanalysis.com/quote/otc/BVNRY/,Denmark,1992,Biotechnology,Healthcare,"1,379",Paul Chaplin,"Philip Heymans Alle 3
Hellerup, 2900
Denmark",45 33 26 83 83,bavarian-nordic.com,BVNRY,OTCMKTS,January - December,DKK,,,US0717711099,2836,,,,,
Hypera S.A.,"Hypera S.A. operates as a pharmaceutical company in Brazil.
It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands.
The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand.
In addition, it offers nutritional and vitamin supplement products under the Tamarine, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brands.
The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018.
Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.",Data/company_logos_stock_analysis\Hypera_S.A._logo.png,https://stockanalysis.com/quote/otc/HYPMY/,Brazil,1999,Drug Manufacturers - Specialty & Generic,Healthcare,"10,301",Breno Pires de Oliveira,"Av. Magalhães de Castro, 4800
São Paulo, 05676-120
Brazil",,hypera.com.br,HYPMY,OTCMKTS,January - December,BRL,,,US44914U1060,2834,,,,,
Green Thumb Industries Inc.,"Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States.
It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, capsules, tinctures, edibles, topicals, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon’s, Good Green, incredibles, and RHYTHM brands.
It distributes its products primarily to third-party retail customers and sells finished products directly to consumers in its own retail stores, as well as direct-to consumer delivery channel.
Green Thumb Industries Inc. was founded in 2014 and is headquartered in Chicago, Illinois.",Data/company_logos_stock_analysis\Green_Thumb_Industries_Inc._logo.png,https://stockanalysis.com/quote/otc/GTBIF/,Canada,2014,Drug Manufacturers - Specialty & Generic,Healthcare,"4,561",Benjamin Kovler,"325 West Huron Street
Chicago, British Columbia 60654
United States",312 471 6720,gtigrows.com,GTBIF,OTCMKTS,January - December,USD,,,CA39342L1085,2834,,,,,
Evotec SE,"Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.
It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases.
The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.",Data/company_logos_stock_analysis\Evotec_SE_logo.png,https://stockanalysis.com/quote/otc/EVOTF/,Germany,1993,Drug Manufacturers - Specialty & Generic,Healthcare,"5,061",Christian Wojczewski,"Essener Bogen 7
Hamburg, 22419
Germany",49 40 560 81 0,evotec.com,EVOTF,OTCMKTS,January - December,EUR,,,DE0005664809,2836,,Common Stock,,,
"Pharma Mar, S.A.","Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally.
The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer.
The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa.
In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression.
Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.","Data/company_logos_stock_analysis\Pharma_Mar,_S.A._logo.png",https://stockanalysis.com/quote/otc/PHMMF/,Spain,1986,Biotechnology,Healthcare,509,Jose Fernandez Sousa-Faro,"Avenida de los Reyes, 1
Madrid, 28770
Spain",34 91 846 60 00,pharmamar.com,PHMMF,OTCMKTS,January - December,EUR,,,ES0169501022,2836,,,,,
Genus plc,"Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia.
The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development.
It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.
Further, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.",Data/company_logos_stock_analysis\Genus_plc_logo.png,https://stockanalysis.com/quote/otc/GENSF/,United Kingdom,1994,Biotechnology,Healthcare,"3,500",Jorgen Kokke,"Matrix House
Basingstoke, RG21 4DZ
United Kingdom",44 1256 347 100,genusplc.com,GENSF,OTCMKTS,July - June,GBP,,,GB0002074580,2836,,,,,
"Curaleaf Holdings, Inc.","Curaleaf Holdings, Inc. operates a cannabis operator in the United States.
It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels.
The company is headquartered in New York, New York.","Data/company_logos_stock_analysis\Curaleaf_Holdings,_Inc._logo.png",https://stockanalysis.com/quote/otc/CURLF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,"5,650",Boris Jordan,"420 Lexington Avenue
New York, British Columbia 10170
United States",,curaleaf.com,CURLF,OTCMKTS,January - December,USD,,,CA23126M1023,2834,,,,,
"Genomma Lab Internacional, S.A.B. de C.V.","Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America.
It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and sexual improvement, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, and infant nutrition.
The company was incorporated in 1996 and is based in Mexico City, Mexico.","Data/company_logos_stock_analysis\Genomma_Lab_Internacional,_S.A.B._de_C.V._logo.png",https://stockanalysis.com/quote/otc/GNMLF/,Mexico,1996,Drug Manufacturers - Specialty & Generic,Healthcare,"1,633",Juan Marco Sparvieri,"Av. Antonio Dovalí Jaime, number 70
Mexico City, 01210
Mexico",52 55 5081 0000,genommalab.com,GNMLF,OTCMKTS,January - December,MXN,,,MX01LA010006,2834,,,,,
Trulieve Cannabis Corp.,"Trulieve Cannabis Corp., together with its subsidiaries, operates as a cannabis retailer.
The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery.
It sells flowers, edibles, vapes, creams, balms, salves, lotions, vaporizers, batteries, cartridge, concentrates, topicals, capsules, synringes, tinctures, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, Trekkers, and Roll One brands.
The company operates dispensaries in Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania.
It also operates cultivation and processing facilities in Arizona, Colorado, Florida, Georgia, Maryland, Pennsylvania, and West Virginia.
The company was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018.
Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Quincy, Florida.",Data/company_logos_stock_analysis\Trulieve_Cannabis_Corp._logo.png,https://stockanalysis.com/quote/otc/TCNNF/,Canada,1940,Drug Manufacturers - Specialty & Generic,Healthcare,"5,400",Kimberly Rivers,"6749 Ben Bostic Road
Quincy, British Columbia 32351
United States",850 480 7955,trulieve.com,TCNNF,OTCMKTS,January - December,USD,,,CA89788C1041,2834,,,,,
Pharming Group N.V.,"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE.
The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105.
Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.",Data/company_logos_stock_analysis\Pharming_Group_N.V._logo.png,https://stockanalysis.com/quote/otc/PHGUF/,Netherlands,1988,Biotechnology,Healthcare,382,Sijmen de Vries,"Darwinweg 24
Leiden, 2333 CR
Netherlands",31 71 524 7400,pharming.com,PHGUF,OTCMKTS,January - December,USD,,,NL0010391025,2836,,,,,
Basilea Pharmaceutica AG,"Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives.
The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia.
Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials.
Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.",Data/company_logos_stock_analysis\Basilea_Pharmaceutica_AG_logo.png,https://stockanalysis.com/quote/otc/BPMUF/,Switzerland,2000,Biotechnology,Healthcare,147,David Veitch,"Hegenheimermattweg 167b
Allschwil, 4123
Switzerland",41 61 606 11 11,basilea.com,BPMUF,OTCMKTS,January - December,CHF,,,CH0011432447,2836,,,,,
Botanix Pharmaceuticals Limited,"Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States.
Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis.
Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.",Data/company_logos_stock_analysis\Botanix_Pharmaceuticals_Limited_logo.png,https://stockanalysis.com/quote/otc/BXPHF/,Australia,1984,Biotechnology,Healthcare,11,Howie McKibbon,"41 – 47 Colin Street
West Perth, 6005
Australia",61 8 6555 2945,botanixpharma.com,BXPHF,OTCMKTS,July - June,AUD,,,AU000000BOT2,2836,,,,,
Oxford Biomedica plc,"Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.
The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties.
The Product segment is involved in the research and development of new gene therapeutic product candidates.
The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types.
The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996.
Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.",Data/company_logos_stock_analysis\Oxford_Biomedica_plc_logo.png,https://stockanalysis.com/quote/otc/OXBDF/,United Kingdom,1996,Biotechnology,Healthcare,703,Frank Mathias,"Windrush Court
Oxford, OX4 6LT
United Kingdom",44 1865 783 000,oxb.com,OXBDF,OTCMKTS,January - December,GBP,,,,2836,,,,,
Boiron SA,"Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally.
The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy.
It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain.
In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia.
The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail.
Boiron SA was founded in 1932 and is headquartered in Messimy, France.",Data/company_logos_stock_analysis\Boiron_SA_logo.png,https://stockanalysis.com/quote/otc/BOIRF/,France,1932,Drug Manufacturers - Specialty & Generic,Healthcare,"2,810",Thierry Boiron,"2, avenue de l’Ouest Lyonnais
Messimy, 69510
France",33 4 78 45 61 00,boiron.fr,BOIRF,OTCMKTS,January - December,EUR,,,FR0000061129,2834,,,,,
PureTech Health plc,"PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders.
In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development.
The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.",Data/company_logos_stock_analysis\PureTech_Health_plc_logo.png,https://stockanalysis.com/quote/otc/PTCHF/,United Kingdom,2015,Biotechnology,Healthcare,90,Bharatt Chowrira,"6 Tide Street
Boston, 02210
United States",617 482 2333,puretechhealth.com,PTCHF,OTCMKTS,January - December,USD,,,GB00BY2Z0H74,2836,,,,,
Frontage Holdings Corporation,"Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies.
It offers laboratory testing services, such as method development and validation, and sample analysis and central laboratory services; chemistry, manufacturing, and control services, including assistance in drug product development and analysis, and delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services.
The company also provides early stage clinical/bioequivalence services; absolute bioavailability and human radiolabel studies; and chemistry services, including performing custom synthesis.
It operates in the United States, the People’s Republic of China, Europe, India, Japan, South Korea, and Australia.
The company was incorporated in 2018 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation operates as a subsidiary of Hongkong Tigermed Co., Limited.",Data/company_logos_stock_analysis\Frontage_Holdings_Corporation_logo.png,https://stockanalysis.com/quote/otc/FGHQF/,Cayman Islands,2018,Biotechnology,Healthcare,"1,759",Abdul Mutlib,"700 Pennsylvania Drive
Exton, 19341
United States",610 232 0100,frontagelab.com,FGHQF,OTCMKTS,January - December,USD,,,KYG3679P1019,8731,,,,,
Valneva SE,"Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally.
Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine.
The company was founded in 1998 and is based in Saint-Herblain, France.",Data/company_logos_stock_analysis\Valneva_SE_logo.png,https://stockanalysis.com/quote/otc/INRLF/,France,1998,Biotechnology,Healthcare,676,Thomas Lingelbach,"6 rue Alain Bombard
Saint-Herblain, 44800
France",33 2 28 07 37 10,valneva.com,INRLF,OTCMKTS,January - December,EUR,,,FR0004056851,2836,,,,,
"Northwest Biotherapeutics, Inc.","Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally.
The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.
Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer.
The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors.
The company was founded in 1996 and is headquartered in Bethesda, Maryland.","Data/company_logos_stock_analysis\Northwest_Biotherapeutics,_Inc._logo.png",https://stockanalysis.com/quote/otc/NWBO/,United States,1996,Biotechnology,Healthcare,25,Linda Powers,"4800 Montgomery Lane
Bethesda, Delaware 20814
United States",240 497 9024,nwbio.com,NWBO,OTCMKTS,January - December,USD,,,US66737P6007,2836,,Common Stock,,,
Cresco Labs Inc.,"Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.
It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy’s Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts.
In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.",Data/company_logos_stock_analysis\Cresco_Labs_Inc._logo.png,https://stockanalysis.com/quote/otc/CRLBF/,Canada,1990,Drug Manufacturers - Specialty & Generic,Healthcare,"2,760",Charles Bachtell,"400 West Erie Street
Chicago, British Columbia 60654
United States",312 410 8226,crescolabs.com,CRLBF,OTCMKTS,January - December,USD,,,CA22587M1068,2834,,,,,
Immutep Limited,"Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.
Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers.
The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.
In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development.
Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer.
Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings.
The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017.
The company was incorporated in 1987 and is based in Sydney, Australia.",Data/company_logos_stock_analysis\Immutep_Limited_logo.png,https://stockanalysis.com/quote/otc/PRRUF/,Australia,1987,Biotechnology,Healthcare,31,Marc Voigt,"Australia Square
Sydney, 2000
Australia",61 2 8315 7003,immutep.com,PRRUF,OTCMKTS,July - June,AUD,,,AU000000IMM6,2836,,,,,
Silence Therapeutics plc,"Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
The company’s mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera.
It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2.
It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders.
The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007.
Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.",Data/company_logos_stock_analysis\Silence_Therapeutics_plc_logo.png,https://stockanalysis.com/quote/otc/SLNCF/,United Kingdom,1994,Biotechnology,Healthcare,109,Craig Tooman,"72 Hammersmith Road
London, W14 8TH
United Kingdom",44 20 3457 6900,silence-therapeutics.com,SLNCF,OTCMKTS,January - December,GBP,,,GB00B9GTXM62,2836,,,,,
"BioStem Technologies, Inc.","BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.
Dave’s Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally.
The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.","Data/company_logos_stock_analysis\BioStem_Technologies,_Inc._logo.png",https://stockanalysis.com/quote/otc/BSEM/,United States,2006,Biotechnology,Healthcare,33,Jason Matuszewski,"2836 Center Port Circle
Pompano Beach, Florida 33064
United States",954 380 8342,biostemtechnologies.com,BSEM,OTCMKTS,January - December,USD,,,US0906842002,8731,,Common Stock,,,
Avacta Group Plc,"Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally.
The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets.
The company develops AVA6000, a peptide drug conjugate form of doxorubicin that is in Phase I clinical trial to treat locally advanced or metastatic solid tumour; AVA3996, a tumor-activated proteasome inhibitor based on Velcade; and AVA032, a bispecific molecule which is in pre-clinical trials that regulates the activation and proliferation of immune cells.
It develops AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPα.
The company has a collaboration agreement with LG Chem for developing and commercializing Affimer based therapeutics.
Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.",Data/company_logos_stock_analysis\Avacta_Group_Plc_logo.png,https://stockanalysis.com/quote/otc/AVCTF/,United Kingdom,2003,Biotechnology,Healthcare,154,Christina Coughlin,"Thorp Arch Estate
Wetherby, LS23 7FA
United Kingdom",44 1904 217 070,avacta.com,AVCTF,OTCMKTS,January - December,GBP,,,GB00BYYW9G87,8731,,,,,
Imugene Limited,"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.
Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study.
The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer.
The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.",Data/company_logos_stock_analysis\Imugene_Limited_logo.png,https://stockanalysis.com/quote/otc/IUGNF/,Australia,,Biotechnology,Healthcare,5,Leslie Chong,"4-6 Bligh Street
Sydney, 2000
Australia",61 2 9423 0881,imugene.com,IUGNF,OTCMKTS,July - June,AUD,,,AU000000IMU9,2836,,,,,
Molecular Partners AG,"Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland.
The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.
It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics.
Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.",Data/company_logos_stock_analysis\Molecular_Partners_AG_logo.png,https://stockanalysis.com/quote/otc/MLLCF/,Switzerland,2004,Biotechnology,Healthcare,168,Patrick Amstutz,"Wagistrasse 14
Schlieren, 8952
Switzerland",41 44 755 77 00,molecularpartners.com,MLLCF,OTCMKTS,January - December,CHF,,,CH0256379097,2836,,,,,
Genfit S.A.,"Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.
The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis.
It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA.
The company was incorporated in 1999 and is headquartered in Loos, France.",Data/company_logos_stock_analysis\Genfit_S.A._logo.png,https://stockanalysis.com/quote/otc/GNFTF/,France,1999,Biotechnology,Healthcare,159,M. Prigent,"Parc EurasantE
Loos, 59120
France",33 3 20 16 40 00,genfit.com,GNFTF,OTCMKTS,January - December,EUR,,,FR0004163111,2836,,,,,
CytoDyn Inc.,"CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications.
The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure.
The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.",Data/company_logos_stock_analysis\CytoDyn_Inc._logo.png,https://stockanalysis.com/quote/otc/CYDY/,United States,2002,Biotechnology,Healthcare,9,Jacob Lalezari,"1111 Main Street
Vancouver, Delaware 98660
United States",360 980 8524,cytodyn.com,CYDY,OTCMKTS,June - May,USD,,,US23283M1018,2836,,Common Stock,,,
Innate Pharma S.A.,"Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally.
The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.
The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited.
Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.",Data/company_logos_stock_analysis\Innate_Pharma_S.A._logo.png,https://stockanalysis.com/quote/otc/IPHYF/,France,1999,Biotechnology,Healthcare,179,Jonathan Dickinson,"117, Avenue de Luminy
Marseille, 13009
France",33 4 30 30 30 30,innate-pharma.com,IPHYF,OTCMKTS,January - December,EUR,,,FR0010331421,2836,,,,,
NervGen Pharma Corp.,"NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage.
The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer’s disease.
It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.
The company was incorporated in 2017 and is based in Vancouver, Canada.",Data/company_logos_stock_analysis\NervGen_Pharma_Corp._logo.png,https://stockanalysis.com/quote/otc/NGENF/,Canada,2017,Biotechnology,Healthcare,,Michael Kelly,"112-970 Burrard Street
Vancouver, British Columbia V6Z 2R4
Canada",778 731 1711,nervgen.com,NGENF,OTCMKTS,January - December,CAD,,,CA64082X2032,2834,,,,,
Grown Rogue International Inc.,"Grown Rogue International Inc., a craft cannabis company, focuses on premium flower and flower-derived products.
It produces a range of cultivars for consumers, which are classified as indicas, sativas, and hybrids.
The company sells its products through dispensaries. Grown Rogue International Inc. was incorporated in 1978 and is headquartered in Medford, Oregon.",Data/company_logos_stock_analysis\Grown_Rogue_International_Inc._logo.png,https://stockanalysis.com/quote/otc/GRUSF/,Canada,1978,Drug Manufacturers - Specialty & Generic,Healthcare,,J. Strickler,"550 Airport Road
Medford, Ontario 97504
United States",458 226 2100,grownrogue.com,GRUSF,OTCMKTS,January - December,USD,,,CA39986R1064,0100,,,,,
Photocure ASA,"Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States.
It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer.
It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions.
The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira, as well as strategic agreement with Richard Wolf GmbH to develop and commercialize a next-generation 4K LED high-definition (HD) reusable flexible blue light cystoscope based on Richard Wolf's System blue technology.
It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners.
Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.",Data/company_logos_stock_analysis\Photocure_ASA_logo.png,https://stockanalysis.com/quote/otc/PHCUF/,Norway,1993,Drug Manufacturers - Specialty & Generic,Healthcare,102,Daniel Schneider,"Hoffsveien 4
Oslo, 0275
Norway",47 22 06 22 10,photocure.com,PHCUF,OTCMKTS,January - December,NOK,,,NO0010000045,2834,,,,,
Healios K.K.,"Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States.
The company develops HLCM051, which is preparing for phase 3 clinical trial, as well as preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is in phase 2/3 and phase 3 clinical trial to treat ischemic stroke; and HLCM051, which is in phase 2 clinical trial to treat trauma.
It also develops HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration; and HLCN061, which is in discovery and preclinical trial for treating solid tumors.
The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013.
Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.",Data/company_logos_stock_analysis\Healios_K.K._logo.png,https://stockanalysis.com/quote/otc/HLOSF/,Japan,2011,Biotechnology,Healthcare,64,Tadahisa S. Kagimoto,"Hibiya Mitsui Tower, WORK STYLING
Tokyo, 100-0006
Japan",,healios.co.jp,HLOSF,OTCMKTS,January - December,JPY,,,JP3835100003,2836,,Common Stock,,,
Scancell Holdings plc,"Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease.
Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.
It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, melanoma, ovarian, lung, and pancreatic cancers; and Modi-2, which targets homocitrullinated cancer antigens.
In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus.
Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.",Data/company_logos_stock_analysis\Scancell_Holdings_plc_logo.png,https://stockanalysis.com/quote/otc/SCNLF/,United Kingdom,1997,Biotechnology,Healthcare,61,Phillip L'Huillier,"Bellhouse Building
Oxford, OX4 4GD
United Kingdom",44 18 6558 2066,scancell.co.uk,SCNLF,OTCMKTS,May - April,GBP,,,GB00B63D3314,2836,,,,,
AB Science S.A.,"AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France.
The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19.
It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe.
AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.",Data/company_logos_stock_analysis\AB_Science_S.A._logo.png,https://stockanalysis.com/quote/otc/ABSCF/,France,2001,Drug Manufacturers - Specialty & Generic,Healthcare,57,Alain Moussy,"3, avenue George V
Paris, Ile-de-France 75008
France",33 1 47 20 00 14,ab-science.com,ABSCF,OTCMKTS,January - December,EUR,,,FR0010557264,2834,,,,,
Futura Medical plc,"Futura Medical plc research, develops, and sells pharmaceutical and healthcare products for sexual health.
Its lead product is Eroxon, a topical gel for the treatment of erectile dysfunction. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.",Data/company_logos_stock_analysis\Futura_Medical_plc_logo.png,https://stockanalysis.com/quote/otc/FAMDF/,United Kingdom,2001,Biotechnology,Healthcare,12,James Barder,"Surrey Technology Centre
Guildford, GU2 7YG
United Kingdom",44 14 8368 5670,futuramedical.com,FAMDF,OTCMKTS,January - December,GBP,,,GB0033278473,2834,,,,,
Paradigm Biopharmaceuticals Limited,"Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia.
It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases.
The company was incorporated in 2014 and is headquartered in Melbourne, Australia.",Data/company_logos_stock_analysis\Paradigm_Biopharmaceuticals_Limited_logo.png,https://stockanalysis.com/quote/otc/PBIGF/,Australia,2014,Biotechnology,Healthcare,,Paul Rennie,"500 Collins Street
Melbourne, 3000
Australia",61 3 9629 5566,paradigmbiopharma.com,PBIGF,OTCMKTS,July - June,AUD,,,AU000000PAR5,2836,,,,,
Arch Biopartners Inc.,"Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada.
It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys.
The company also develops AB569 for treating antibiotic-resistant bacterial infections, and for the treatment of wounds; and Borg, a peptide-solid surface interface to reduce corrosion of metals.
Arch Biopartners Inc. is based in Toronto, Canada.",Data/company_logos_stock_analysis\Arch_Biopartners_Inc._logo.png,https://stockanalysis.com/quote/otc/ACHFF/,Canada,,Biotechnology,Healthcare,,Richard Muruve,"27 Street Clair Avenue East
Toronto, M4T 2M5
Canada",647 428 7031,archbiopartners.com,ACHFF,OTCMKTS,October - September,CAD,,,CA03938C1041,2836,,,,,
Medicenna Therapeutics Corp.,"Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases.
It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors.
In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.",Data/company_logos_stock_analysis\Medicenna_Therapeutics_Corp._logo.png,https://stockanalysis.com/quote/otc/MDNAF/,Canada,,Biotechnology,Healthcare,16,Fahar Merchant,"2 Bloor Street West
Toronto, Alberta M4W 3E2
Canada",416 648 5555,medicenna.com,MDNAF,OTCMKTS,April - March,CAD,,,,2836,,,,,
Medexus Pharmaceuticals Inc.,"Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States.
The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.
Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation.
In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products.
The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018.
Medexus Pharmaceuticals Inc. is based in Toronto, Canada.",Data/company_logos_stock_analysis\Medexus_Pharmaceuticals_Inc._logo.png,https://stockanalysis.com/quote/otc/MEDXF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,82,Kenneth d'Entremont,"10 King Street East
Toronto, ON M5C 1C3
Canada",877 422 5242,medexus.com,MEDXF,OTCMKTS,April - March,USD,,,CA58410Q2036,2834,,,,,
"ZIVO Bioscience, Inc.","ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers.
The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging.
The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014.
ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.","Data/company_logos_stock_analysis\ZIVO_Bioscience,_Inc._logo.png",https://stockanalysis.com/quote/otc/ZIVO/,United States,,Biotechnology,Healthcare,8,John Payne,"21 East Long Lake Road
Bloomfield Hills, Nevada 48304
United States",(248) 452 9866,zivobioscience.com,ZIVO,OTCMKTS,January - December,USD,,,US98978N2009,2834,,Common Stock,,,
MedMira Inc.,"MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, and internationally.
The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis.
It also provides the Miriad RVF toolkit, which facilitates the development and commercialization of rapid diagnostics; and REVEALCOVID-19 and Reveal G4 HIV tests.
The company distributes its products through a network of medical distributors and strategic business development partners, serving customers in various healthcare sectors, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies.
The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.",Data/company_logos_stock_analysis\MedMira_Inc._logo.png,https://stockanalysis.com/quote/otc/MMIRF/,Canada,1993,Biotechnology,Healthcare,52,Hermes Chan,"155 Chain Lake Drive
Halifax, Alberta B3S 1B3
Canada",902 450 1588,medmira.com,MMIRF,OTCMKTS,August - July,CAD,,,CA58501R1029,2835,,,,,
Covalon Technologies Ltd.,"Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally.
The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone.
It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device.
In addition, the company provides wound care dressings; surgical and peri-operative; and infection management products.
It offers its products under the ColActive PLUS, CovaClear, CovaView, CovaWound, IV Clear, SurgiClear, and VALGuard brand names.
The company serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians’ offices.
Covalon Technologies Ltd. was incorporated in 2004 and is headquartered in Mississauga, Canada.",Data/company_logos_stock_analysis\Covalon_Technologies_Ltd._logo.png,https://stockanalysis.com/quote/otc/CVALF/,Canada,2004,Biotechnology,Healthcare,37,Brent Ashton,"1660 Tech Avenue
Mississauga, Ontario L4W 5S7
Canada",905 568 8400,covalon.com,CVALF,OTCMKTS,October - September,CAD,,,CA22282D3022,2836,,,,,
Orexo AB (publ),"Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally.
Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia.
The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis.
In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder.
The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology.
Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.",Data/company_logos_stock_analysis\Orexo_AB_(publ)_logo.png,https://stockanalysis.com/quote/otc/ORXOY/,Sweden,1994,Drug Manufacturers - Specialty & Generic,Healthcare,116,Nikolaj Sorensen,"Rapsgatan 7E
Uppsala, Uppsala County Uppsala County
Sweden",46 1 87 80 88 00,orexo.com,ORXOY,OTCMKTS,January - December,SEK,,,US68616W1027,2834,,,,,
Jushi Holdings Inc.,"Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets.
The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands.
It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands.
It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.",Data/company_logos_stock_analysis\Jushi_Holdings_Inc._logo.png,https://stockanalysis.com/quote/otc/JUSHF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,"1,188",James Cacioppo,"301 Yamato Road
Boca Raton, British Columbia 33431
United States",561 617 9100,jushico.com,JUSHF,OTCMKTS,January - December,USD,,,CA48213Y1079,2834,,,,,
Cannara Biotech Inc.,"Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada.
The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations.
Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.",Data/company_logos_stock_analysis\Cannara_Biotech_Inc._logo.png,https://stockanalysis.com/quote/otc/LOVFF/,Canada,2017,Drug Manufacturers - Specialty & Generic,Healthcare,,Zohar Krivorot,"333 Decarie Blvd.
Saint-Laurent, British Columbia H4N 3M9
Canada",514 543 4200,cannara.ca,LOVFF,OTCMKTS,September - August,CAD,,,CA13765U2002,2834,,,,,
Sernova Corp.,"Sernova Corp. operates as a clinical-stage biotechnology company in Canada.
The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions.
Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability.
Sernova Corp. is headquartered in London, Canada.",Data/company_logos_stock_analysis\Sernova_Corp._logo.png,https://stockanalysis.com/quote/otc/SEOVF/,Canada,1998,Biotechnology,Healthcare,17,Jonathan M. Rigby,"700 Collip Circle
London, N6G 4X8
Canada",519 858 5184,sernova.com,SEOVF,OTCMKTS,November - October,CAD,,,CA81732W1041,2836,,,,,
Actinogen Medical Limited,"Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases.
The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.
Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.",Data/company_logos_stock_analysis\Actinogen_Medical_Limited_logo.png,https://stockanalysis.com/quote/otc/ATGGF/,Australia,1999,Biotechnology,Healthcare,6,Steven Gourlay,"109 Pitt Street
Sydney, 2000
Australia",61 2 8964 7401,actinogen.com.au,ATGGF,OTCMKTS,July - June,AUD,,,AU000000ACW3,2836,,,,,
"Provectus Biopharmaceuticals, Inc.","Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States.
The company’s lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.
It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds.
In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth.
It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013.
Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.","Data/company_logos_stock_analysis\Provectus_Biopharmaceuticals,_Inc._logo.png",https://stockanalysis.com/quote/otc/PVCT/,United States,2002,Biotechnology,Healthcare,4,Edward Pershing,"800 South Gay Street
Knoxville, Delaware 37929
United States",866 594 5999,provectusbio.com,PVCT,OTCMKTS,January - December,USD,,,US74373P1084,2834,,Common Stock,,,
"iAnthus Capital Holdings, Inc.","iAnthus Capital Holdings, Inc. owns and operates licensed cannabis cultivation, processing, and dispensary facilities in the United States.
It offers cannabis flower and trims, such as packaged flowers and pre-rolls; cannabis infused products, including topical creams and edibles; vape cartridges, concentrates, live resins, wax products, oils, and tinctures, as well as products for beauty and skincare that include lotions, creams, haircare products, lip balms, and bath bombs.
The company engages in the wholesale-distribution and retail of CBD products. iAnthus Capital Holdings, Inc. was founded in 2014 and is headquartered in Toronto, Canada.","Data/company_logos_stock_analysis\iAnthus_Capital_Holdings,_Inc._logo.png",https://stockanalysis.com/quote/otc/ITHUF/,Canada,2014,Drug Manufacturers - Specialty & Generic,Healthcare,802,Richard Proud,"214 King Street West
Toronto, British Columbia M5H 3S6
Canada",646 518 9418,ianthus.com,ITHUF,OTCMKTS,January - December,USD,,,CA45074T1021,2834,,,,,
MariMed Inc.,"MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally.
The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand.
It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand.
In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand.
The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.",Data/company_logos_stock_analysis\MariMed_Inc._logo.png,https://stockanalysis.com/quote/otc/MRMD/,United States,2011,Drug Manufacturers - Specialty & Generic,Healthcare,721,Jon Levine,"10 Oceana Way
Norwood, Delaware 02062
United States",781 277 0007,marimedinc.com,MRMD,OTCMKTS,January - December,USD,,,US56782V1070,2834,,Common Stock,,,
Auxly Cannabis Group Inc.,"Auxly Cannabis Group Inc. operates as a consumer packaged goods company in the cannabis products market in Canada.
It focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers.
The company offers cannabis products under various forms, including vape catridges, infused pre-rolls, pre-rolled, vape pens, milled and dried flower, concentrates, chocolates, soft chews, oil drops, capsules, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names.
It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers.
The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018.
The company was incorporated in 1987 and is headquartered in Toronto, Canada.",Data/company_logos_stock_analysis\Auxly_Cannabis_Group_Inc._logo.png,https://stockanalysis.com/quote/otc/CBWTF/,Canada,1987,Drug Manufacturers - Specialty & Generic,Healthcare,369,Hugo Alves,"777 Richmond Street West
Toronto, Ontario M6J 0C2
Canada",647 812 0121,auxly.com,CBWTF,OTCMKTS,January - December,CAD,,,CA05335P1099,6211,,,,,
Microbix Biosystems Inc.,"Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally.
The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products.
It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.",Data/company_logos_stock_analysis\Microbix_Biosystems_Inc._logo.png,https://stockanalysis.com/quote/otc/MBXBF/,Canada,1988,Biotechnology,Healthcare,100,Cameron Groome,"265 Watline Avenue
Mississauga, Ontario L4Z 1P3
Canada",905 361 8910,microbix.com,MBXBF,OTCMKTS,October - September,CAD,,,CA59501P1045,2836,,,,,
InnoCan Pharma Corporation,"InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally.
The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management.
The company is also involved in the development and sale of CBD-integrated pharmaceuticals and topical products.
In addition, it develops and markets a portfolio of self-care products for healthier lifestyle. The company offers its products under the Innocan Pharma, R&G Relief & Go, Shir, Synony, and Add On trade names.
InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.",Data/company_logos_stock_analysis\InnoCan_Pharma_Corporation_logo.png,https://stockanalysis.com/quote/otc/INNPF/,Canada,2018,Drug Manufacturers - Specialty & Generic,Healthcare,,Iris Bincovich,"1015, 926 – 5 Avenue SW
Calgary, T2P 0N7
Canada",403-777-1519,innocanpharma.com,INNPF,OTCMKTS,January - December,USD,,,CA45783P1027,2833,,,,,
GenSight Biologics S.A.,"GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system.
The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms.
Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration.
The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases.
It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies.
The company was incorporated in 2012 and is headquartered in Paris, France.",Data/company_logos_stock_analysis\GenSight_Biologics_S.A._logo.png,https://stockanalysis.com/quote/otc/GSGTF/,France,2012,Biotechnology,Healthcare,16,Laurence Rodriguez,"74, rue du Faubourg Saint-Antoine
Paris, 75012
France",33 1 76 21 72 20,gensight-biologics.com,GSGTF,OTCMKTS,January - December,EUR,,,FR0013183985,2836,,,,,
"Earth Science Tech, Inc.","Earth Science Tech, Inc. focuses on health and wellness industry.
It operates Peaks, a telemedicine referral site focused on health and wellness for men and women; and operates pharmacy under the RxCompound name.
The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014.
Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.","Data/company_logos_stock_analysis\Earth_Science_Tech,_Inc._logo.png",https://stockanalysis.com/quote/otc/ETST/,United States,2010,Drug Manufacturers - Specialty & Generic,Healthcare,32,Giorgio Saumat,"8950 Southwest 74th Court
Miami, Florida 33156
United States",305 724 5684,earthsciencetech.com,ETST,OTCMKTS,April - March,USD,,,US2703111037,2834,,Common Stock,,,
Medical Developments International Limited,"Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.
The company operates through Pain Management and Respiratory segments. It offers Penthrox, a trauma and emergency pain relief product for use in hospitals, emergency departments, ambulance services, sport medicines, and for analgesia during short procedures.
The company also distributes asthma and chronic obstructive pulmonary disease products, such space chambers, peak flow meters, portable nebulisers, and silicon face mask.
The company was founded in 1972 and is headquartered in Scoresby, Australia.",Data/company_logos_stock_analysis\Medical_Developments_International_Limited_logo.png,https://stockanalysis.com/quote/otc/MDDVF/,Australia,1972,Drug Manufacturers - Specialty & Generic,Healthcare,68,Brent MacGregor,"4 Caribbean Drive
Scoresby, 3179
Australia",61 3 9547 1888,medicaldev.com,MDDVF,OTCMKTS,July - June,AUD,,,AU000000MVP2,2834,,,,,
Helix BioPharma Corp.,"Helix BioPharma Corp. operates as an immune-oncology company in Canada.
Its product pipeline comprises L-DOS47, for the treatment of non-small cell lung cancer; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer.
It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor.
It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.
Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\Helix_BioPharma_Corp._logo.png,https://stockanalysis.com/quote/otc/HBPCF/,Canada,2008,Biotechnology,Healthcare,7,Jacek Antas,"1055 West Georgia Street
Vancouver, V6E 3P3
Canada",,helixbiopharma.com,HBPCF,OTCMKTS,August - July,CAD,,,US4229101096,2834,,,,,
Alterity Therapeutics Limited,"Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease.
It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease.
The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.
Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.",Data/company_logos_stock_analysis\Alterity_Therapeutics_Limited_logo.png,https://stockanalysis.com/quote/otc/PRNAF/,Australia,1997,Biotechnology,Healthcare,10,David Stamler,"350 Collins Street
Melbourne, 3000
Australia",61 3 9349 4906,alteritytherapeutics.com,PRNAF,OTCMKTS,July - June,AUD,,,AU0000043945,2836,,,,,
Decibel Cannabis Company Inc.,"Decibel Cannabis Company Inc., an integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada.
It is also involved in the extraction, processing, and manufacturing vape cartridges, cannabis infused products, cannabis extracts, and glass tube packaging for pre-rolls.
In addition, the company engages in the cannabis retail business through operating operational retail locations in Saskatchewan, as well as an e-commerce cannabis platform throughout the Province of Saskatchewan; and operational retail locations in Alberta.
It offers its products under the Qwest, Vox, Blendcraft, and General Admission brands. Further, the company exports its products to Israel and Australia.
Decibel Cannabis Company Inc. is headquartered in Calgary, Canada.",Data/company_logos_stock_analysis\Decibel_Cannabis_Company_Inc._logo.png,https://stockanalysis.com/quote/otc/DBCCF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,,Benjamin Sze,"140 - 4th Avenue SW
Calgary, Alberta T2P 3N3
Canada",844 993 4769,decibelcc.com,DBCCF,OTCMKTS,January - December,CAD,,,CA2434371001,2834,,,,,
IntelGenx Technologies Corp.,"IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market.
It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health.
It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression.
The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.",Data/company_logos_stock_analysis\IntelGenx_Technologies_Corp._logo.png,https://stockanalysis.com/quote/otc/IGXT/,United States,2003,Biotechnology,Healthcare,50,Dwight Gorham,"6420 Abrams
Montreal, Delaware H4S 1Y2
Canada",514 331 7440,intelgenx.com,IGXT,OTCMKTS,January - December,USD,,,US45822R1014,2834,,,,,
"Vext Science, Inc.","Vext Science, Inc., through its subsidiaries, operates as an integrated agricultural technology, services, and property management company in the cannabis industry in the United States.
It owns and manages cultivation facilities, manufacturing units, and dispensaries; and involves in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, and edibles.
The company also engages in the retail dispensary activities; and wholesale distribution of cannabis THC and hemp CBD products under the Vapen, Pure Touch, Appalachian Pharm, Herbal Wellness, and Revibe brands.
In addition, it provides management, advisory, cultivation, non-cannabis products, and dispensary services to entities in the cannabis field through operations agreements and direct sales.
The company was formerly known as Vapen MJ Ventures Corporation and changed its name to Vext Science, Inc. in November 2019.
Vext Science, Inc. was incorporated in 2015 and is headquartered in Phoenix, Arizona.","Data/company_logos_stock_analysis\Vext_Science,_Inc._logo.png",https://stockanalysis.com/quote/otc/VEXTF/,Canada,2015,Drug Manufacturers - Specialty & Generic,Healthcare,,Eric Offenberger,"4152 N. 39th Ave.
Phoenix, British Columbia 85019
United States",,vextscience.com,VEXTF,OTCMKTS,January - December,USD,,,CA9255401064,2834,,,,,
Starpharma Holdings Limited,"Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide.
The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating.
It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial.
In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; SPL7013 for vaginal gel; and DEP HER2 radiodiagnostic.
It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma’s dendrimer technology.
Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.",Data/company_logos_stock_analysis\Starpharma_Holdings_Limited_logo.png,https://stockanalysis.com/quote/otc/SPHRY/,Australia,1997,Biotechnology,Healthcare,40,Cheryl Maley,"4-6 Southampton Crescent
Abbotsford, 3067
Australia",61 3 8532 2700,starpharma.com,SPHRY,OTCMKTS,July - June,AUD,,,US8555631022,2836,,,,,
Starpharma Holdings Limited,"Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide.
The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating.
It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial.
In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; SPL7013 for vaginal gel; and DEP HER2 radiodiagnostic.
It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma’s dendrimer technology.
Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.",Data/company_logos_stock_analysis\Starpharma_Holdings_Limited_logo.png,https://stockanalysis.com/quote/otc/SPHRF/,Australia,1997,Biotechnology,Healthcare,40,Cheryl Maley,"4-6 Southampton Crescent
Abbotsford, 3067
Australia",61 3 8532 2700,starpharma.com,SPHRF,OTCMKTS,July - June,AUD,,,AU000000SPL0,2836,,,,,
Avicanna Inc.,"Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide.
It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome.
It also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand.
In addition, the company operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, and educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens, as well as collaborates with public and private payers for adjudication and reimbursement.
The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator’s various drug delivery and pharmaceutical formats.
Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.",Data/company_logos_stock_analysis\Avicanna_Inc._logo.png,https://stockanalysis.com/quote/otc/AVCNF/,Canada,2016,Drug Manufacturers - Specialty & Generic,Healthcare,87,Aras Azadian,"480 University Avenue
Toronto, Ontario M5G 1V2
Canada",,avicanna.com,AVCNF,OTCMKTS,January - December,CAD,,,CA05368K1003,2834,,,,,
Cansortium Inc.,"Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in Florida, Pennsylvania, and Texas.
The company’s medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flower, pre-rolls, cartridges, concentrates, and edibles under the Fluent brand name.
It also sells various third-party branded medical cannabis products. The company was incorporated in 2018 and is headquartered in Tampa, Florida.",Data/company_logos_stock_analysis\Cansortium_Inc._logo.png,https://stockanalysis.com/quote/otc/CNTMF/,Canada,2018,Drug Manufacturers - Specialty & Generic,Healthcare,,Robert Beasley,"5540 West Executive Drive
Tampa, Ontario 33609
United States",305 902 2720,getfluent.com,CNTMF,OTCMKTS,January - December,USD,,,CA13809L1094,2834,,,,,
Shield Therapeutics plc,"Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs.
Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia.
Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.",Data/company_logos_stock_analysis\Shield_Therapeutics_plc_logo.png,https://stockanalysis.com/quote/otc/SHIEF/,United Kingdom,2008,Drug Manufacturers - Specialty & Generic,Healthcare,73,Anders Lundstrom,"Northern Design Centre
Gateshead, NE8 3DF
United Kingdom",44 1915 118 500,shieldtherapeutics.com,SHIEF,OTCMKTS,January - December,USD,,,GB00BYV81293,2834,,,,,
International Isotopes Inc.,"International Isotopes Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally.
It operates through four segments: Nuclear Medicine Standards, Cobalt Products, Theranostics Products, and Fluorine Products.
The Nuclear Medicine Standards segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry.
This segment also offers flood sources, dose calibrators, rod sources, line sources, flexible and rigid rulers, spot markers, pen point markers, and various specialty design items.
The Cobalt Products segment produces bulk cobalt; fabricates cobalt capsules for radiation therapy and various industrial applications; and recycles expended cobalt sources.
The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotopically pure radiochemicals for medical, industrial, or research applications.
The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility.
The company sells its products directly to end users and distributors. International Isotopes Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.",Data/company_logos_stock_analysis\International_Isotopes_Inc._logo.png,https://stockanalysis.com/quote/otc/INIS/,United States,1995,Drug Manufacturers - Specialty & Generic,Healthcare,40,Shahe Bagerdjian,"4137 Commerce Circle
Idaho Falls, Texas 83401
United States",208 524 5300,intisoid.com,INIS,OTCMKTS,January - December,USD,,,US45972C1027,2835,,Common Stock,,,
Hemostemix Inc.,"Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada.
Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Hemostemix Inc. is headquartered in Calgary, Canada.",Data/company_logos_stock_analysis\Hemostemix_Inc._logo.png,https://stockanalysis.com/quote/otc/HMTXF/,Canada,,Biotechnology,Healthcare,,Thomas Smeenk,"707-7th Avenue SW
Calgary, Alberta T2P 3H6
Canada",,hemostemix.com,HMTXF,OTCMKTS,January - December,CAD,,,CA4236943060,2836,,,,,
Celyad Oncology SA,"Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer.
The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies.
It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets.
The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.",Data/company_logos_stock_analysis\Celyad_Oncology_SA_logo.png,https://stockanalysis.com/quote/otc/CLYYF/,Belgium,2004,Biotechnology,Healthcare,19,Matthew Kane,"Axis Business Park
Mont-Saint-Guibert, 1435
Belgium",32 1 039 41 00,celyad.com,CLYYF,OTCMKTS,January - December,EUR,,,BE0974260896,2836,,,,,
C21 Investments Inc.,"C21 Investments Inc., an integrated cannabis company, cultivates, processes, distributes, and sells cannabis and hemp-derived consumer products in the United States.
The company offers CO2, live resin, distillate, CBD cured resin, and CBD CO2 vaporizer pens; live, cured, and CBD cured resin extracts; bulk, wholesale, and packaged flowers; edibles; pre-rolls; tinctures; and topicals.
It also provides payroll and benefits services. The company was formerly known as Curlew Lake Resources Inc. and changed its name to C21 Investments Inc. in November 2017.
The company was incorporated in 1987 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\C21_Investments_Inc._logo.png,https://stockanalysis.com/quote/otc/CXXIF/,Canada,1987,Drug Manufacturers - Specialty & Generic,Healthcare,114,Sonny Newman,"#170 – 601 West Cordova
Vancouver, British Columbia V6B 1G1
Canada",833-289-2994,cxxi.ca,CXXIF,OTCMKTS,April - March,USD,,,CA12675Q1019,2834,,,,,
MediPharm Labs Corp.,"MediPharm Labs Corp., a pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally.
The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products.
It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products.
In addition, the company offers cannabis related medical information and services; and medical cannabis clinic services.
MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.",Data/company_logos_stock_analysis\MediPharm_Labs_Corp._logo.png,https://stockanalysis.com/quote/otc/MEDIF/,Canada,2015,Drug Manufacturers - Specialty & Generic,Healthcare,166,David Pidduck,"151 John Street
Barrie, Ontario L4N 2L1
Canada",705 719 7425,medipharmlabs.com,MEDIF,OTCMKTS,January - December,CAD,,,CA58504D1006,2834,,,,,
Rapid Dose Therapeutics Corp.,"Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance patient outcomes in Canada.
The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active molecule into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system, as well as dental products.
It also engages in the research, production, provision, and distribution of technical services for the delivery of oral thin film strips containing active ingredients.
In addition, the company sells health and wellness products, consisting of nutraceuticals and infused soaps; and white label manufacturing, including oral thin film strips containing active ingredients under cannabis licensing, as well as provides licensing and consulting services.
Rapid Dose Therapeutics Corp. is headquartered in Burlington, Canada.",Data/company_logos_stock_analysis\Rapid_Dose_Therapeutics_Corp._logo.png,https://stockanalysis.com/quote/otc/RDTCF/,Canada,,Biotechnology,Healthcare,,Mark Upsdell,"1121 Walker's Line
Burlington, Ontario L7N 2G4
Canada",416 477 1052,rapid-dose.com,RDTCF,OTCMKTS,March - February,CAD,,,CA75339A1012,8731,,,,,
Next Science Limited,"Next Science Limited engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand.
It offers SURGX, an antimicrobial gel that conforms to the postoperative wound; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds.
The company was founded in 2012 and is headquartered in Sydney, Australia.",Data/company_logos_stock_analysis\Next_Science_Limited_logo.png,https://stockanalysis.com/quote/otc/NXSCF/,Australia,2012,Drug Manufacturers - Specialty & Generic,Healthcare,,Harry Hall,"Australia Square
Sydney, 2000
Australia",61 4 1229 2977,nextscience.com,NXSCF,OTCMKTS,January - December,USD,,,AU0000041329,3842,,,,,
"EOM Pharmaceuticals Holdings, Inc.","Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases.
Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis.
The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases.
Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.","Data/company_logos_stock_analysis\EOM_Pharmaceuticals_Holdings,_Inc._logo.png",https://stockanalysis.com/quote/otc/IMUC/,United States,2020,Biotechnology,Healthcare,4,Irach Taraporewala,"136 Summit Avenue
Montvale, 07645
United States",201 351 0605,eompharma.com,IMUC,OTCMKTS,January - December,USD,,,US4525364026,2834,,Common Stock,,,
"Charlotte's Web Holdings, Inc.","Charlotte's Web Holdings, Inc. is involved in the farming, manufacture, marketing, and sale of hemp-derived cannabidiol (CBD) wellness products.
The company’s products categories include hemp extract oil tinctures, such as liquid products; gummies; and capsules, CBD topical creams, and lotions, as well as products for pets under the Charlotte’s Web, ReCreate, CBD Medic, CBD Clinic, and Harmony Hemp brands.
Its products contain naturally occurring phytocannabinoids, including CBD, cannabichromene, cannabigerol, cannabinol, terpenes, flavonoids, and other beneficial hemp compounds.
The company distributes its products through retail outlets and health care practitioners, as well as online through its website.
It has a collaboration between its CW Labs science division and Colorado State University’s College of Agricultural Sciences; and scientific collaboration with McLean Hospital.
The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte’s Web Holdings, Inc. in July 2018.
The company was founded in 2013 and is headquartered in Louisville, Colorado.","Data/company_logos_stock_analysis\Charlotte's_Web_Holdings,_Inc._logo.png",https://stockanalysis.com/quote/otc/CWBHF/,Canada,2013,Drug Manufacturers - Specialty & Generic,Healthcare,164,William Morachnick,"700 Tech Court
Louisville, British Columbia 80027
United States",720 484 8930,charlottesweb.com,CWBHF,OTCMKTS,January - December,USD,,,CA16106R1091,2834,,,,,
Amplia Therapeutics Limited,"Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial.
It also develops AMP886, which is in preclinical trial for treating solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018.
Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.",Data/company_logos_stock_analysis\Amplia_Therapeutics_Limited_logo.png,https://stockanalysis.com/quote/otc/INNMF/,Australia,2000,Biotechnology,Healthcare,,Christopher Burns,"350 Queen Street
Melbourne, 3000
Australia",61 3 9123 1140,ampliatx.com,INNMF,OTCMKTS,April - March,AUD,,,AU0000023822,2836,,,,,
Hemogenyx Pharmaceuticals Plc,"Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer.
The company’s lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia.
It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation.
Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.",Data/company_logos_stock_analysis\Hemogenyx_Pharmaceuticals_Plc_logo.png,https://stockanalysis.com/quote/otc/HOPHF/,United Kingdom,2013,Biotechnology,Healthcare,17,Vladislav Sandler,"60 Gracechurch Street
London, EC3V 0HR
United Kingdom",,hemogenyx.com,HOPHF,OTCMKTS,January - December,GBP,,,GB00BYX3WZ24,2836,,,,,
Rubicon Organics Inc.,"Rubicon Organics Inc., together with its subsidiaries, engages in the production, processing, and sale of organic cannabis for the recreational and medical-use markets in Canada.
It offers cannabis products in jar, bag, pre-rolls, edible, poutine sauce mix, milled flower, relief stick, cool stick, and oil.
The company sells its products under the Simply Bare Organic, 1964 Supply Co, Homestead Cannabis Supply, LAB THEORY, and Wildflower brand names.
Rubicon Organics Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\Rubicon_Organics_Inc._logo.png,https://stockanalysis.com/quote/otc/ROMJF/,Canada,2015,Drug Manufacturers - Specialty & Generic,Healthcare,182,Margaret Brodie,"744 West Hastings Street
Vancouver, British Columbia V6C 1A5
Canada",604 288 5566,rubiconorganics.com,ROMJF,OTCMKTS,January - December,CAD,,,CA78112W1005,2834,,,,,
"Cell Source, Inc.","Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance.
Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses.
The company’s Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease; other non-malignant organ diseases through organ transplantation; and various cancers and non-malignant diseases.
Cell Source, Inc. is headquartered in New York, New York.","Data/company_logos_stock_analysis\Cell_Source,_Inc._logo.png",https://stockanalysis.com/quote/otc/CLCS/,United States,,Biotechnology,Healthcare,1,Itamar Shimrat,"57 West 57th Street
New York, Nevada 10019
United States",646 416 7896,cell-source.com,CLCS,OTCMKTS,January - December,USD,,,US15114L1044,2836,,,,,
Medigene AG,"Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer.
The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications.
Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications.
The company also develops MDG2011, MDG2021, MDG2012, MDG20XX, and MDG10xx to treat multiple solid tumors.
It has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors.
It has operations in Germany, the United States, and Asia. The company has research collaboration with WuXi Biologics to design and co-research TCR-guided T Cell engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors.
Medigene AG was founded in 1994 and is headquartered in Munich, Germany.",Data/company_logos_stock_analysis\Medigene_AG_logo.png,https://stockanalysis.com/quote/otc/MDGEF/,Germany,1994,Biotechnology,Healthcare,76,Selwyn Ho,"Lochhamer Strasse 11
Munich, 82152
Germany",49 89 2000 330,medigene.com,MDGEF,OTCMKTS,January - December,EUR,,,DE000A1X3W00,2836,,Common Stock,,,
IXICO plc,"IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, the Netherlands, Ireland, rest of Europe, and the United States.
Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study.
The company’s technologies comprise Assessa, an online digital platform for clinics; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer.
In addition, it focuses in therapeutic areas include Alzheimer's, Parkinson’s, Huntington’s, Multiple Sclerosis, and orphan and rare diseases.
Further, the company engages in the data collection and analysis of neurological disorders. Additionally, it offers drug development analytics, imaging operation, post marketing surveillance, and consultancy services; and end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway.
IXICO plc is based in London, the United Kingdom.",Data/company_logos_stock_analysis\IXICO_plc_logo.png,https://stockanalysis.com/quote/otc/PHYOF/,United Kingdom,1995,Biotechnology,Healthcare,81,Bram Goorden,"Griffin Court
London, EC1A 9PN
United Kingdom",44 20 3763 7499,ixico.com,PHYOF,OTCMKTS,October - September,GBP,,,GB00BFXR4C20,2833,,,,,
PharmaTher Holdings Ltd.,"PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes.
The company’s product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson’s disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia and procedural sedation.
It develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures.
In addition, the company offers PHARMAPATCH, a microneedle patch technology solution, which includes hydrogel-forming and gelatin methacryloyl delivery system for the treatment of psychedelics and infectious diseases.
Further, it has license agreement with BioRAE, Inc. for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle; and the University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS; as well as holds a patent and know-how license agreement with The Queen’s University of Belfast to develop and commercialize hydrogel-forming microneedle patch delivery technology.
The company was incorporated in 2019 and is headquartered in Toronto, Canada.",Data/company_logos_stock_analysis\PharmaTher_Holdings_Ltd._logo.png,https://stockanalysis.com/quote/otc/PHRRF/,Canada,2019,Biotechnology,Healthcare,,Fabio Chianelli,"82 Richmond Street East
Toronto, Ontario M5C 1P1
Canada",888-846-3171,pharmather.com,PHRRF,OTCMKTS,June - May,CAD,,,CA71716H1082,2834,,,,,
PreveCeutical Medical Inc.,"PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products.
Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; BSV Peptide Program that targets cancer progression; and Dual Gene Therapy for type 2 diabetes and obesity.
PreveCeutical Medical Inc. is headquartered in West Vancouver, Canada.",Data/company_logos_stock_analysis\PreveCeutical_Medical_Inc._logo.png,https://stockanalysis.com/quote/otc/PRVCF/,Canada,,Biotechnology,Healthcare,,Stephen Van Deventer,"5428 Marine Drive
West Vancouver, British Columbia V7W 2R2
Canada",,preveceutical.com,PRVCF,OTCMKTS,January - December,CAD,,,CA74141E1043,2834,,,,,
Cann Group Limited,"Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivating, manufacturing, and selling medicinal cannabis in Australia and Europe.
It also licenses to undertake research and to cultivate cannabis for human medicinal and research purposes.
The company was founded in 2014 and is based in Port Melbourne, Australia.",Data/company_logos_stock_analysis\Cann_Group_Limited_logo.png,https://stockanalysis.com/quote/otc/CNGGF/,Australia,2014,Drug Manufacturers - Specialty & Generic,Healthcare,,Jennifer Pilcher,"262-276 Lorimer Street
Port Melbourne, 3207
Australia",61 3 9095 7088,canngrouplimited.com,CNGGF,OTCMKTS,July - June,AUD,,,AU000000CAN2,2834,,,,,
Red Light Holland Corp.,"Red Light Holland Corp. engages in the production, growth, and sale of functional mushrooms and mushroom home grow kits to the recreational market in North America and Europe.
It is also involved in the selection, distribution, and export of truffles, cannabidiol products, cannabis seeds, headshop products, growshop goods, cannabis bake house muffins, cookies, and cakes.
The company sells its products under the iMicrodose, Maka, Happy Caps, and Mistercap’s brands through brick-and-mortar SmartShops, as well as through online stores.
Red Light Holland Corp. is based in Toronto, Canada.",Data/company_logos_stock_analysis\Red_Light_Holland_Corp._logo.png,https://stockanalysis.com/quote/otc/TRUFF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,104,Todd Shapiro,"1 Adelaide Street East
Toronto, Ontario M5C 2V9
Canada",647 204 7129,redlight.co,TRUFF,OTCMKTS,April - March,CAD,,,CA75671E1097,6211,,,,,
PharmaCielo Ltd.,"PharmaCielo Ltd., together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada.
Its products include medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol and cannabidiol medical cannabis, and other cannabis related products, as well as provides telemedicine software.
The company also exports its products. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies.
The company has strategic partnership with Benuvia Operations, LLC to produce cGMP pharmaceutical-grade CBD active pharmaceutical ingredients.
PharmaCielo Ltd. is headquartered in Toronto, Canada.",Data/company_logos_stock_analysis\PharmaCielo_Ltd._logo.png,https://stockanalysis.com/quote/otc/PCLOF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,,Marc Lustig,"82 Richmond Street East
Toronto, British Columbia M5C 1P1
Canada",,pharmacielo.com,PCLOF,OTCMKTS,January - December,CAD,,,CA71716K1012,2834,,,,,
"Inhibitor Therapeutics, Inc.","Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States.
The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.
It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019.
Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.","Data/company_logos_stock_analysis\Inhibitor_Therapeutics,_Inc._logo.png",https://stockanalysis.com/quote/otc/INTI/,United States,1992,Biotechnology,Healthcare,9,Francis O'Donnell,"900 West Platt St
Tampa, Delaware 33606-2173
United States",813-864-2562,inhibitortx.com,INTI,OTCMKTS,January - December,USD,,,US45720M1053,2836,,Common Stock,,,
"Enzon Pharmaceuticals, Inc.","Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations.
Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.
The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002.
Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.","Data/company_logos_stock_analysis\Enzon_Pharmaceuticals,_Inc._logo.png",https://stockanalysis.com/quote/otc/ENZN/,United States,1981,Biotechnology,Healthcare,1,Richard Feinstein,"20 Commerce Drive
Cranford, Delaware 07016
United States",732 980 4500,enzon.com,ENZN,OTCMKTS,January - December,USD,,,US2939041081,2836,,Common Stock,,,
Sirona Biochem Corp.,"Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France.
Its programs include cosmetic skin lightener and diabetes drug; and other projects comprise the development of an anti-aging/cell protection library, novel anti-wrinkle compound, and anti-viral program.
The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009.
Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\Sirona_Biochem_Corp._logo.png,https://stockanalysis.com/quote/otc/SRBCF/,Canada,2006,Biotechnology,Healthcare,,Howard Verrico,"595 Burrard Street
Vancouver, British Columbia V7X 1L4
Canada",604 641 4466,sironabiochem.com,SRBCF,OTCMKTS,November - October,CAD,,,CA82967M1005,2836,,,,,
"Nascent Biotech, Inc.","Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer.
It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation.
In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.","Data/company_logos_stock_analysis\Nascent_Biotech,_Inc._logo.png",https://stockanalysis.com/quote/otc/NBIO/,United States,,Biotechnology,Healthcare,,Sean Carrick,"631 US Hwy 1
North Palm Beach, Nevada 33408
United States",612 961 5656,nascentbiotech.com,NBIO,OTCMKTS,April - March,USD,,,US63108Q1013,2836,,Common Stock,,,
BetterLife Pharma Inc.,"BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada.
It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections.
The company’s products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders.
It is also developing MM-003, which has completed Phase II clinical trials for the treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream that has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia.
The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019.
BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\BetterLife_Pharma_Inc._logo.png,https://stockanalysis.com/quote/otc/BETRF/,Canada,2002,Biotechnology,Healthcare,7,Ahmad Doroudian,"1275 West 6th Avenue
Vancouver, British Columbia V6H 1A6
Canada",,abetterlifepharma.com,BETRF,OTCMKTS,February - January,CAD,,,CA08772P2026,2836,,Common Stock,,,
Kane Biotech Inc.,"Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally.
The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection.
Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.",Data/company_logos_stock_analysis\Kane_Biotech_Inc._logo.png,https://stockanalysis.com/quote/otc/KNBIF/,Canada,2001,Biotechnology,Healthcare,,Marc Edwards,"100 Innovation Drive
Winnipeg, R3T 6G2
Canada",204-453-1301,kanebiotech.com,KNBIF,OTCMKTS,January - December,CAD,,,CA4838092084,2836,,,,,
"Rafarma Pharmaceuticals, Inc.","Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia.
It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules.
The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders.
The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease.
Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012.
The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R.
& D. Biocogency Laboratories Inc. Ltd.","Data/company_logos_stock_analysis\Rafarma_Pharmaceuticals,_Inc._logo.png",https://stockanalysis.com/quote/otc/RAFA/,United States,,Drug Manufacturers - Specialty & Generic,Healthcare,,,"49 West 9000 South
Sandy, Wyoming 84070
United States",801-210-7135,rafarma.si,RAFA,OTCMKTS,April - March,USD,,,US75062C1009,6799,,Common Stock,,,
Resverlogix Corp.,"Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses.
The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions.
It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications.
The company is headquartered in Calgary, Canada.",Data/company_logos_stock_analysis\Resverlogix_Corp._logo.png,https://stockanalysis.com/quote/otc/RVXCF/,Canada,,Biotechnology,Healthcare,19,Donald McCaffrey,"4820 Richard Road SW
Calgary, Alberta T3E 6L1
Canada",403 254 9252,resverlogix.com,RVXCF,OTCMKTS,January - December,USD,,,CA76128M1086,2836,,,,,
"ProText Mobility, Inc.","ProText Mobility, Inc., a biotech company, engages in the development of pharmaceutical botanical medicines.
Its medicines are formulated with highly-bioavailable plant extracts. The company is based in Fort Lauderdale, Florida.
ProText Mobility, Inc. operates as a subsidiary of Plandaí Biotechnology, Inc.","Data/company_logos_stock_analysis\ProText_Mobility,_Inc._logo.png",https://stockanalysis.com/quote/otc/TXTM/,United States,,Biotechnology,Healthcare,,Roger Baylis-Duffield,"One West Las Olas Blvd.
Fort Lauderdale, 33301
United States",,protxtm.com,TXTM,OTCMKTS,,USD,,,US74371E2046,2836,,Common Stock,,,
"Integrated Cannabis Solutions, Inc.","Integrated Cannabis Solutions, Inc. focuses on the growing and processing of hemp or biomass in the United States.
The company intends to sell processed material in the form of Cannabidiol (CBD) or isolate to manufacturers or pharmaceutical companies for their manufacture, distribution, and sale of CBD related products, such as edibles for human consumption, vitamins, multi-vitamins, and topical products for human use comprises oils, tinctures, creams, oils and salves, and vaping liquids.
Further, it is planning to promote and assist in the establishment of a co-op with local farmers for establishing a consistent supply of biomass and enter into long term purchase contracts.
The company was formerly known as Integrated Parking Solutions, Inc. and changed its name to Integrated Cannabis Solutions, Inc. in April 2014.
Integrated Cannabis Solutions, Inc. was founded in 2003 and is headquartered in Coconut Creek, Florida.","Data/company_logos_stock_analysis\Integrated_Cannabis_Solutions,_Inc._logo.png",https://stockanalysis.com/quote/otc/IGPK/,United States,2003,Drug Manufacturers - Specialty & Generic,Healthcare,1,Eugene Caiazzo,"6810 North State Road 7
Coconut Creek, Nevada 33073
United States",954 906 0098,igpk.org,IGPK,OTCMKTS,January - December,USD,,,US45825Q1004,8700,,Common Stock,,,
Biotron Limited,"Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.
The company’s lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections.
Biotron Limited was incorporated in 1999 and is based in Sydney, Australia.",Data/company_logos_stock_analysis\Biotron_Limited_logo.png,https://stockanalysis.com/quote/otc/BITRF/,Australia,1999,Biotechnology,Healthcare,3,Michelle Miller,"56 Delhi Road
Sydney, 2113
Australia",61 2 9805 0488,biotron.com.au,BITRF,OTCMKTS,July - June,AUD,,,AU000000BIT4,2836,,,,,
4Front Ventures Corp.,"4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States.
The company operates through THC Cannabis and CBD Wellness segments. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services.
This segment sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties.
The CBD Wellness segment sells non-THC hemp derived products. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name.
4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.",Data/company_logos_stock_analysis\4Front_Ventures_Corp._logo.png,https://stockanalysis.com/quote/otc/FFNTF/,Canada,2011,Drug Manufacturers - Specialty & Generic,Healthcare,399,Andrew Thut,"7010 East Chauncey Lane
Phoenix, British Columbia 85054
United States",602 633 3067,4frontventures.com,FFNTF,OTCMKTS,January - December,USD,,,CA35086B2075,2834,,,,,
RIV Capital Inc.,"RIV Capital Inc., formerly known as Canopy Rivers Inc., is a venture capital firm.
The firm is a stage agnostic, with seed to sale, although it prefers to invest in series A to C rounds.
It prefers to make investments in cannabis sector with focus on burgeoning marijuana companies and sectors like agriculture and food sciences, production, processing, pharmaceuticals and biotechnology, software and data, hardware, consumer products and accessories, wellness products, retail and distribution, and media and content.
The firm also focuses on beverages, capsules and concentrates, edibles, dry flower / pre-rolls, vaporizers and hardware, pet products, and topicals.
In agriculture and food sciences firm focuses in invest plant science, soil science, food science, animal science and environmental science.
In production firm focuses in Indoor cultivation, greenhouse cultivation, outdoor cultivation, nursery cultivation and fermentation.
In processing firm focuses in harvesting, extraction and purification, packaging, food and beverage processing and laboratory testing services.
In pharmaceuticals and biotechnology firm focuses in pharmaceutical discovery and development, delivery method (ex: pill, soft gel, tincture), biosynthetic derived cannabinoids and other molecules, medical devices (ex: inhalers) and lab equipment.
In consumer products and accessories firm focuses in edibles, beverages, inhalable, cosmetics and cannabis consumption accessories.
In retail and distribution firm focuses in licensed brick and mortar retailers, pharmacies, online consumer marketplaces, delivery services, and others.
The firm invests in opportunities globally. The firm prefers to invest in check sizes have ranged from CA$1 million ($0.71 million) to CA$40 million ($28.45 million), but more typical investment range is between CA$5 million ($3.6 million) to CA$10 million ($7.1 million).
The firm is focused on making minority stake investments. Firm employ diverse investment structures including debt, preferred and common equity, and production-linked royalties.
RIV Capital Inc. was founded on 2017 and is based in Toronto, Canada.",Data/company_logos_stock_analysis\RIV_Capital_Inc._logo.png,https://stockanalysis.com/quote/otc/CNPOF/,Canada,2017,Drug Manufacturers - Specialty & Generic,Healthcare,,David Vautrin,"40 King Street West
Toronto, Ontario M5H 3Y2
Canada",416-583-5945,rivcapital.com,CNPOF,OTCMKTS,January - December,USD,,,CA7680141024,6799,,,,,
Orgenesis Inc.,"Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide.
It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals.
Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration.
The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services.
The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011.
Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.",Data/company_logos_stock_analysis\Orgenesis_Inc._logo.png,https://stockanalysis.com/quote/otc/ORGS/,United States,2008,Biotechnology,Healthcare,146,Vered Caplan,"20271 Goldenrod Lane
Germantown, Nevada 20876
United States",480 659 6404,orgenesis.com,ORGS,OTCMKTS,January - December,USD,,,US68619K2042,2836,,,,,
"Eagle Pharmaceuticals, Inc.","Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.
The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.
Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.
The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter.
It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas.
Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.","Data/company_logos_stock_analysis\Eagle_Pharmaceuticals,_Inc._logo.png",https://stockanalysis.com/quote/otc/EGRX/,United States,2007,Drug Manufacturers - Specialty & Generic,Healthcare,134,Michael Graves,"50 Tice Boulevard
Woodcliff Lake, Delaware 07677
United States",201 326 5300,eagleus.com,EGRX,OTCMKTS,January - December,USD,,,US2697961082,2834,,Common Stock,,,
"Bioxytran, Inc.","Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans.
The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.
It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19.
The company was founded in 2008 and is headquartered in Needham, Massachusetts.","Data/company_logos_stock_analysis\Bioxytran,_Inc._logo.png",https://stockanalysis.com/quote/otc/BIXT/,United States,2008,Biotechnology,Healthcare,3,David Platt,"75 2nd Avenue
Needham, Nevada 02494
United States",617 454 1199,bioxytraninc.com,BIXT,OTCMKTS,January - December,USD,,,US09075D1028,2836,,Common Stock,,,
Nextleaf Solutions Ltd.,"Nextleaf Solutions Ltd., a cannabis extraction technology company, engages in the manufacture and distribution of cannabinoid vapes, oils, and softgels in Canada.
The company is involved in the toll processing, such as extraction, distillation, and purification of CBD oils and THC cannabinoid ingredients, as well as engages in intellectual property licensing activities.
It sells its products under Glacial Gold and High Plains brands through government distributors and authorized retailers.
The company was formerly known as Legion Metals Corp. and changed its name to Nextleaf Solutions Ltd. Nextleaf Solutions Ltd. was founded in 2015 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\Nextleaf_Solutions_Ltd._logo.png,https://stockanalysis.com/quote/otc/OILFF/,Canada,2015,Drug Manufacturers - Specialty & Generic,Healthcare,,Emma Andrews,"68 Water Street
Vancouver, British Columbia V6B 1A4
Canada",604 283 2301,nextleafsolutions.com,OILFF,OTCMKTS,October - September,CAD,,,CA65347A1021,3559,,,,,
Crescita Therapeutics Inc.,"Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally.
The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services.
It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers and DuraPeel that supports the development of patented formulations that can deliver actives into or through the skin.
The company’s prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases.
Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments.
In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers.
The company has a commercialization license agreement with Cantabria Labs Inc.; a development and commercialization license agreement with Taro Pharmaceuticals Inc.; and a distribution and promotion agreement with FILLMED.
Crescita Therapeutics Inc. was founded in 2016 and is headquartered in Laval, Canada.",Data/company_logos_stock_analysis\Crescita_Therapeutics_Inc._logo.png,https://stockanalysis.com/quote/otc/CRRTF/,Canada,2016,Drug Manufacturers - Specialty & Generic,Healthcare,,Serge Verreault,"2805 Place Louis-R Renaud
Laval, Ontario H7V 0A3
Canada",800 361 0352,crescitatherapeutics.com,CRRTF,OTCMKTS,January - December,CAD,,,CA2258471028,2834,,,,,
Algorae Pharmaceuticals Limited,"Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand.
The company’s product pipeline includes AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient for the of treatment for dementia, including Alzheimer’s disease; NTCELL, an alginate coated capsule to target the treatment of Parkinson’s disease; and AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient to treat cardiovascular disease, including hypertension.
It is also developing AlgaraeOS in partnership with the University of New South Wales, an artificial intelligence platform for biopharmaceutical prediction of both fixed dose combination drug targets and repurposed drug targets agnostic to medical indication.
The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023.
Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.",Data/company_logos_stock_analysis\Algorae_Pharmaceuticals_Limited_logo.png,https://stockanalysis.com/quote/otc/LVCLF/,Australia,1987,Biotechnology,Healthcare,48,David Hainsworth,"Rialto South Tower
Melbourne, 3000
Australia",61 2 9698 5414,algoraepharma.com,LVCLF,OTCMKTS,July - June,AUD,,,AU0000296022,2836,,,,,
Willow Biosciences Inc.,"Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States.
The company has a collaboration agreement with SUANFARMA to develop anti-infective API through precision fermentation; and a multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients.
Willow Biosciences Inc. was founded in 2019 and is headquartered in Calgary, Canada.",Data/company_logos_stock_analysis\Willow_Biosciences_Inc._logo.png,https://stockanalysis.com/quote/otc/CANSF/,Canada,2019,Drug Manufacturers - Specialty & Generic,Healthcare,19,Chris Savile,"202, 1201-5th Street SW
Calgary, Alberta T2R 0Y6
Canada",403 910 5140,willowbio.com,CANSF,OTCMKTS,January - December,CAD,,,CA97111B4047,2836,,,,,
Ecofibre Limited,"Ecofibre Limited, together with its subsidiaries, engages in the polymer, health care, and hemp seed genetics businesses in the United States and Australia.
The company operates through Ecofibre Advanced Technologies, Ananda Health, Ecofibre Genetics, and EOF Bio segments.
It offers cannabinoid based health products for human and pet consumption. In addition, the company provides yarn, polymer textiles, and hemp related food products.
Further, it is involved in patient-centered cannabinoid-based drug activities. Ecofibre Limited was incorporated in 2009 and is based in Sydney, Australia.",Data/company_logos_stock_analysis\Ecofibre_Limited_logo.png,https://stockanalysis.com/quote/otc/EOFBF/,Australia,2009,Drug Manufacturers - Specialty & Generic,Healthcare,,Ulrich Tombuelt,"680 George Street
Sydney, 2000
Australia",61 7 3265 7630,ecofibre.com,EOFBF,OTCMKTS,July - June,AUD,,,AU0000040057,2834,,,,,
"Hempstract, Inc.","Hempstract, Inc. produces and sells cannabidiol (CBD) and cannabigerol solutions in the United States.
It offers CBD isolate powder and distillate oil. The company was formerly known as Riverdale Oil and Gas Corporation and changed its name to Hempstract, Inc. in November 2020.
Hempstract, Inc. is based in Warden, Washington.","Data/company_logos_stock_analysis\Hempstract,_Inc._logo.png",https://stockanalysis.com/quote/otc/HPST/,United States,,Drug Manufacturers - Specialty & Generic,Healthcare,3,Ronald Herzfeld,"PO Box 665
Warden, Nevada 98857-0665
United States",,hempstractlabs.com,HPST,OTCMKTS,January - December,USD,,,US42470Q1058,1311,,,,,
Australis Capital Inc.,"Australis Capital Inc. operates as a cannabis company.
It undertakes cannabis and non-cannabis, as well as horticulture projects in the United States, Canada, Denmark Finland, Iceland, Germany, the Netherlands, Bahrein, Kuwait, Southeast Asia, and Australia, as well as other jurisdictions.
The company was incorporated in 2015 and is headquartered in Las Vegas, Nevada.",Data/company_logos_stock_analysis\Australis_Capital_Inc._logo.png,https://stockanalysis.com/quote/otc/AUSAF/,Canada,2015,Drug Manufacturers - Specialty & Generic,Healthcare,,Terrance Booth,"376 East Warm Springs Road
Las Vegas, Alberta 89119
United States",800 898 0648,ausacap.com,AUSAF,OTCMKTS,April - March,CAD,,,CA05259R1073,6799,,,,,
"CV Sciences, Inc.","CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America.
The company offers its products under the PlusCBD, ProCBD, HappyLane, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-tailers.
It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction.
The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016.
CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.","Data/company_logos_stock_analysis\CV_Sciences,_Inc._logo.png",https://stockanalysis.com/quote/otc/CVSI/,United States,2010,Drug Manufacturers - Specialty & Generic,Healthcare,43,Joseph Dowling,"9530 Padgett Street
San Diego, Delaware 92126
United States",866 290 2157,cvsciences.com,CVSI,OTCMKTS,January - December,USD,,,US1266541028,2834,,Common Stock,,,
Mountain Valley MD Holdings Inc.,"Mountain Valley MD Holdings Inc., through its subsidiary, Mountain Valley MD Inc., operates as a health and wellness company in Canada.
The company offers Quicksome oral drug formulation and delivery technologies; and Quicksol solubility formulation and delivery technology.
It also provides licensed Agrarius, an agricultural plant signalling technology; and solubilized drugs to husbandry animal health.
Mountain Valley MD Holdings Inc.is headquartered in Concord, Canada.",Data/company_logos_stock_analysis\Mountain_Valley_MD_Holdings_Inc._logo.png,https://stockanalysis.com/quote/otc/MVMDF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,1,Dennis Hancock,"260 Edgeley Boulevard
Concord, British Columbia L4K 3Y4
Canada",647-725-9755,mountainvalleymd.com,MVMDF,OTCMKTS,April - March,CAD,,,CA62430M1014,2836,,,,,
Acrux Limited,"Acrux Limited, together with its subsidiaries, engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.
The company provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; Dapsone 5% and Dapsone 7.5% which are gels for the treatment of acne vulgaris; and Prilocaine 2.5% and Lidocaine 2.5%, a topical anaesthetic cream.
It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain caused by chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores.
The company was incorporated in 1998 and is based in West Melbourne, Australia.",Data/company_logos_stock_analysis\Acrux_Limited_logo.png,https://stockanalysis.com/quote/otc/ARUXF/,Australia,1998,Biotechnology,Healthcare,43,Michael Kotsanis,"103-113, Stanley Street
West Melbourne, Victoria 3003
Australia",61 3 8379 0100,acrux.com.au,ARUXF,OTCMKTS,July - June,AUD,,,AU000000ACR3,2834,,,,,
Medicure Inc.,"Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States.
The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction.
It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.",Data/company_logos_stock_analysis\Medicure_Inc._logo.png,https://stockanalysis.com/quote/otc/MCUJF/,Canada,1997,Drug Manufacturers - Specialty & Generic,Healthcare,38,Albert Friesen,"2-1250 Waverley Street
Winnipeg, R3T 6C6
Canada",204 487 7412,medicure.com,MCUJF,OTCMKTS,January - December,CAD,,,CA58469E4085,2836,,,,,
Elixinol Wellness Limited,"Elixinol Wellness Limited, through its subsidiaries, engages in the manufacture and distribution of hemp derived nutraceuticals, skincare, and food products in the Americas, Europe, and Australia.
It offers hemp derived cannabidiol and food products, dietary supplements, topicals, and skincare products.
The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021.
The company was incorporated in 2017 and is headquartered in Sydney, Australia.",Data/company_logos_stock_analysis\Elixinol_Wellness_Limited_logo.png,https://stockanalysis.com/quote/otc/ELLXF/,Australia,2017,Drug Manufacturers - Specialty & Generic,Healthcare,,,"680 George Street
Sydney, 2000
Australia",61 2 8280 7355,elixinolwellness.com,ELLXF,OTCMKTS,January - December,AUD,,,AU000000EXL4,2834,,,,,
"CLS Holdings USA, Inc.","CLS Holdings USA, Inc., a diversified cannabis company, focuses on the extraction and conversion of cannabinoids in the United States.
It extracts cannabinoids from the cannabis plants and converts into concentrates, that includes oils, waxes, edibles, and shatters; and provides toll processing services.
The company also sells organic medical cannabis to licensed retailers; recreational marijuana cannabis products to licensed distributors and retailers; extraction products, such as oils and waxes derived from in-house cannabis production; and offers processing and extraction services for licensed medical cannabis cultivators, as well as cannabis strains in the form of vegetative cuttings to licensed medical cannabis cultivators.
It offers its products under Oasis Cannabis and City Trees brand names. The company’s concentrates are used for pharmaceutical and other purposes.
CLS Holdings USA, Inc. was founded in 2014 and is based in Las Vegas, Nevada.","Data/company_logos_stock_analysis\CLS_Holdings_USA,_Inc._logo.png",https://stockanalysis.com/quote/otc/CLSH/,United States,2014,Drug Manufacturers - Specialty & Generic,Healthcare,2,Andrew Glashow,"516 South
Las Vegas, Nevada 89101
United States",416 922 4539,clsholdingsinc.com,CLSH,OTCMKTS,June - May,USD,,,US12565J1007,5912,,Common Stock,,,
"Burzynski Research Institute, Inc.","Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers.
The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name.
It also offers consulting services. The company was incorporated in 1984 and is headquartered in Houston, Texas.","Data/company_logos_stock_analysis\Burzynski_Research_Institute,_Inc._logo.png",https://stockanalysis.com/quote/otc/BZYR/,United States,1984,Biotechnology,Healthcare,1,Stanislaw Burzynski,"9432 Katy Freeway
Houston, Delaware 77055
United States",713 335 5697,burzynskiresearch.com,BZYR,OTCMKTS,March - February,USD,,,US1231591058,2836,,Common Stock,,,
Synairgen plc,"Synairgen plc discovers and develops drugs for respiratory diseases.
It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses.
Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.",Data/company_logos_stock_analysis\Synairgen_plc_logo.png,https://stockanalysis.com/quote/otc/SYGGF/,United Kingdom,2004,Biotechnology,Healthcare,36,Richard Marsden,"Mailpoint 810
Southampton, SO16 6YD
United Kingdom",44 23 8051 2800,synairgen.com,SYGGF,OTCMKTS,January - December,GBP,,,GB00B0381Z20,2836,,,,,
"Sigyn Therapeutics, Inc.","Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States.
Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats.
The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.
In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies.
Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Sigyn_Therapeutics,_Inc._logo.png",https://stockanalysis.com/quote/otc/SIGY/,United States,2019,Biotechnology,Healthcare,5,James Joyce,"2468 Historic Decatur Road
San Diego, Delaware 92106
United States",619 353 0800,sigyntherapeutics.com,SIGY,OTCMKTS,January - December,USD,,,US82674U1060,3841,,Common Stock,,,
Core One Labs Inc.,"Core One Labs Inc. operates as a psychedelic research and development company.
The company focuses on providing psychedelic medicines to novel delivery systems and psychedelic assisted psychotherapy; and intends to further develop and apply the technology to psychedelic compounds, such as psilocybin.
It also provides natural health products; news dissemination services; financing services; and operates medical clinics, as well as engages in micro cultivation.
The company was formerly known as Lifestyle Delivery Systems Inc. and changed its name to Core One Labs Inc. in September 2019.
Core One Labs Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\Core_One_Labs_Inc._logo.png,https://stockanalysis.com/quote/otc/CLABF/,Canada,2010,Biotechnology,Healthcare,,Joel Shacker,"1199 West Hastings Street
Vancouver, British Columbia V6E 3T5
Canada",888 452 6731,core1labs.com,CLABF,OTCMKTS,April - March,CAD,,,CA21872J3073,2834,,,,,
"Acreage Holdings, Inc.","Acreage Holdings, Inc., formerly High Street Capital Partners, is a principal investment firm specializing in cannabis industry. Acreage Holdings, Inc. was founded in 2014 and is based in New York, New York.","Data/company_logos_stock_analysis\Acreage_Holdings,_Inc._logo.png",https://stockanalysis.com/quote/otc/ACRDF/,United States,2011,Drug Manufacturers - Specialty & Generic,Healthcare,888,Dennis Curran,"366 Madison Avenue
New York, British Columbia British Columbia
United States",646 600 9181,,ACRDF,OTCMKTS,January - December,USD,,,CA00489Y7090,2834,,,,,
Endexx Corporation,"Endexx Corporation engages in the manufacturing and sale of cannabidiol (CBD)-based products for the health and wellness market.
The company provides oils, extracts, topicals, and pet products for supporting the relief of pain and inflammation for humans and pets through its e-commerce site cbdunlimited.com, as well as other online and in-store retailers.
It also offers hemp-derived oils, topical skin care for skin health, and beauty products, hemp-derived creams and balms, a premium line of hemp-derived health and beauty care products, and organic, plant-based, all-natural, zero-nicotine, tobacco-free vape products, as well as PhytoBites, a hemp-derived soft chews for animals.
The company was formerly known as CBD Unlimited, Inc. and changed its name to Endexx Corporation in May 2020.
Endexx Corporation is headquartered in Cave Creek, Arizona.",Data/company_logos_stock_analysis\Endexx_Corporation_logo.png,https://stockanalysis.com/quote/otc/EDXC/,United States,,Drug Manufacturers - Specialty & Generic,Healthcare,,Brad Listermann,"38246 North Hazelwood Circle
Cave Creek, Nevada 85331
United States",480 595 6900,endexx.com,EDXC,OTCMKTS,October - September,USD,,,US29259K1025,2834,,Common Stock,,,
"Stemsation International, Inc.","Stemsation International, Inc. researches, develops, manufactures, and sells canned and flavored oxygen products in the United States.
The company sells its products through business to business and direct to consumers channels. Stemsation International, Inc. was incorporated in 2006 and is headquartered in Plantation, Florida.","Data/company_logos_stock_analysis\Stemsation_International,_Inc._logo.png",https://stockanalysis.com/quote/otc/STSN/,United States,2006,Drug Manufacturers - Specialty & Generic,Healthcare,4,Ray Carter,"1537 NW 65th Avenue
Plantation, Florida 33313
United States",609-221-9200,stsninc.com,STSN,OTCMKTS,January - December,USD,,,US85859E1029,6500,,Common Stock,,,
Zelira Therapeutics Limited,"Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States.
It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia.
The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology.
In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019.
Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.",Data/company_logos_stock_analysis\Zelira_Therapeutics_Limited_logo.png,https://stockanalysis.com/quote/otc/ZLDAF/,Australia,2003,Biotechnology,Healthcare,,Oludare Odumosu,"101 St Georges Terrace
Perth, 6000
Australia",61 8 6558 0886,zeliratx.com,ZLDAF,OTCMKTS,July - June,AUD,,,AU000000ZLD1,2834,,,,,
Valeo Pharma Inc.,"Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada.
Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson’s disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma.
It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic.
In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions.
Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products.
The company was incorporated in 2003 and is based in Kirkland, Canada.",Data/company_logos_stock_analysis\Valeo_Pharma_Inc._logo.png,https://stockanalysis.com/quote/otc/VPHIF/,Canada,2003,Drug Manufacturers - Specialty & Generic,Healthcare,110,Al Moghaddam,"16667 Hymus Boulevard
Kirkland, Quebec H9H 4R9
Canada",514 694 0150,valeopharma.com,VPHIF,OTCMKTS,November - October,CAD,,,CA91915B1085,2834,,,,,Class A Shares
CordovaCann Corp.,"CordovaCann Corp. engages in identifying, funding, developing, and managing operations in the cannabis value chain business.
The company also operates retail stores under the Star Buds brand name. The company was formerly known as LiveReel Media Corporation and changed its name to CordovaCann Corp. in January 2018.
CordovaCann Corp. was founded in 1997 and is headquartered in Toronto, Canada.",Data/company_logos_stock_analysis\CordovaCann_Corp._logo.png,https://stockanalysis.com/quote/otc/LVRLF/,Canada,1997,Drug Manufacturers - Specialty & Generic,Healthcare,,Thomas Turner,"217 Queen Street West
Toronto, M5V 0R2
Canada",917 843 2169,cordovacann.com,LVRLF,OTCMKTS,July - June,CAD,,,CA21864T1075,2834,,,,,
Blueberries Medical Corp.,"Blueberries Medical Corp. engages in the growth, cultivation, and development of medicinal cannabis and related products in Colombia. It produces psychoactive and non-psychoactive cannabis by-products. The company is based in Vancouver, Canada.",Data/company_logos_stock_analysis\Blueberries_Medical_Corp._logo.png,https://stockanalysis.com/quote/otc/BBRRF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,,Facundo Garreton,"8500 West Georgia Street
Vancouver, British Columbia V6C 3E8
Canada",,blueberriesmed.com,BBRRF,OTCMKTS,January - December,CAD,,,CA09609Y1016,2834,,,,,
"ProtoKinetix, Incorporated","ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs).
The company’s AFGPs have commercial applications primarily in health care solutions, including ophthalmology, dermatology, transplants, and biomanufacturing.
It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003.
ProtoKinetix, Incorporated was incorporated in 1999 and is based in Dalton, Ohio.","Data/company_logos_stock_analysis\ProtoKinetix,_Incorporated_logo.png",https://stockanalysis.com/quote/otc/PKTX/,United States,1999,Biotechnology,Healthcare,5,Clarence Smith,"109 W Main St
Dalton, Nevada 44618
United States",330 455 4971,protokinetix.com,PKTX,OTCMKTS,January - December,USD,,,US7437221002,2836,,Common Stock,,,
Christina Lake Cannabis Corp.,"Christina Lake Cannabis Corp. engages in the research and development, cultivation, processing, production, and sale license of cannabis in British Columbia, Canada.
It offers distilled and winterized oils; kief; and other additional dried cannabis extracted products.
The company was formerly known as Cervantes Capital Corp. and changed its name to Christina Lake Cannabis Corp. in December 2018.
Christina Lake Cannabis Corp. was incorporated in 2014 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\Christina_Lake_Cannabis_Corp._logo.png,https://stockanalysis.com/quote/otc/CLCFF/,Canada,2014,Drug Manufacturers - Specialty & Generic,Healthcare,,Mark Aiken,"1075 West Georgia Street
Vancouver, British Columbia V6E 3C9
Canada",604 687 2038,christinalakecannabis.com,CLCFF,OTCMKTS,December - November,CAD,,,CA17104U1021,2833,,,,,
"CannaPharmaRX, Inc.","CannaPharmaRX, Inc. evaluates, negotiates, acquires, and develops various cannabis cultivation projects in Canada. The company is based in Calgary, Canada.","Data/company_logos_stock_analysis\CannaPharmaRX,_Inc._logo.png",https://stockanalysis.com/quote/otc/CPMD/,United States,,Drug Manufacturers - Specialty & Generic,Healthcare,21,Dean Medwid,"888 3rd Street SW
Calgary, Delaware T2P 5C5
Canada",403-637-0420,cannapharmarx.com,CPMD,OTCMKTS,January - December,USD,,,US13765D1090,2834,,Common Stock,,,
"CTT Pharmaceutical Holdings, Inc.","CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment.
It focuses on fast dissolving drug delivery systems. The company’s technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion.
Its principal asset is a patented orally administered wafer, an orally administrable wafer comprising at least one physiologically acceptable film forming agent.
The company was formerly known as Mindesta Inc. and changed its name to CTT Pharmaceutical Holdings, Inc. in July 2015.
The company is based in Ottawa, Canada.","Data/company_logos_stock_analysis\CTT_Pharmaceutical_Holdings,_Inc._logo.png",https://stockanalysis.com/quote/otc/CTTH/,United States,,Drug Manufacturers - Specialty & Generic,Healthcare,,Ryan Khouri,"429 Kent Street unit 112
Ottawa, Delaware K2P 2B4
Canada",613-241-9959,cttpharmaceuticals.com,CTTH,OTCMKTS,January - December,USD,,,US12651E1064,2834,,Common Stock,,,
"Vaccinex, Inc.","Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders.
The company’s lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.
It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer’s disease and has completed phase 2 study for treatment of Huntington’s disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer.
The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses.
It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children’s Hospital of Philadelphia; Emory University; Huntington Study Group; H.
Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.","Data/company_logos_stock_analysis\Vaccinex,_Inc._logo.png",https://stockanalysis.com/quote/otc/VCNX/,United States,2001,Biotechnology,Healthcare,40,Maurice Zauderer,"1895 Mount Hope Avenue
Rochester, Delaware 14620
United States",585 271 2700,vaccinex.com,VCNX,OTCMKTS,January - December,USD,,,US9186401033,2836,,Common Stock,,,
Appili Therapeutics Inc.,"Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada.
Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.
The company was incorporated in 2015 and is headquartered in Halifax, Canada.",Data/company_logos_stock_analysis\Appili_Therapeutics_Inc._logo.png,https://stockanalysis.com/quote/otc/APLIF/,Canada,2015,Biotechnology,Healthcare,9,Donald Cilla,"#21-1344 Summer Street
Halifax, Ontario B3H 0A8
Canada",902 442 4655,appilitherapeutics.com,APLIF,OTCMKTS,April - March,CAD,,,CA03783R1073,2834,,,,,Class A Shares
Revive Therapeutics Ltd.,"Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders.
It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.
The company also develops Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases.
Revive Therapeutics Ltd. is based in Toronto, Canada.",Data/company_logos_stock_analysis\Revive_Therapeutics_Ltd._logo.png,https://stockanalysis.com/quote/otc/RVVTF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,2,Michael Frank,"The Canadian Venture Building
Toronto, Ontario M5C 1P1
Canada",888-901-0036,revivethera.com,RVVTF,OTCMKTS,July - June,CAD,,,CA7615161030,2836,,,,,
TILT Holdings Inc.,"TILT Holdings Inc. operates in the cannabis industry in the United States, Canada, Israel, Mexico, South America, and the European Union.
The company operates through Cannabis, Accessories, and Other segments. It also produces, cultivates, and sells cannabis products.
In addition, the company manufactures and distributes electronic and non-nicotine devices and systems.
Further, it processes and provides medical cannabis products, including cannabis flowers, vape cartridges, concentrates, edibles, topicals, capsules, oil syringes, and tinctures.
TILT Holdings Inc. is based in Phoenix, Arizona.",Data/company_logos_stock_analysis\TILT_Holdings_Inc._logo.png,https://stockanalysis.com/quote/otc/TLLTF/,Canada,2018,Drug Manufacturers - Specialty & Generic,Healthcare,358,Tim Conder,"2801 E. Camelback Road
Phoenix, British Columbia 85016
United States",623 887 4990,tiltholdings.com,TLLTF,OTCMKTS,January - December,USD,,,CA88688R1047,2834,,,,,
Body and Mind Inc.,"Body and Mind Inc. cultivates, processes, distributes, and retails medical and recreational cannabis in Nevada, California, Arkansas, Ohio, Illinois, and New Jersey in the United States.
The company offers pre-rolled joints; packaged and grinded flower buds; concentrates; distillate oil; and vape cartridges.
It also produces and sells medical and adult¬use recreational marijuana products, such as cannabis flower, oil extracts, and edibles under the Body and Mind brand name.
In addition, the company operates San Diego BaM Body and Mind dispensary; manages BaM Body and Mind Long Beach dispensary; and owns and operates The Reef by Body and Mind retail dispensary.
Further, it produces marijuana extract products, such as distillate oils, shatters, and edibles. The company was formerly known as Deploy Technologies Inc. and changed its name to Body and Mind Inc. in November 2017.
Body and Mind Inc. was incorporated in 1998 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\Body_and_Mind_Inc._logo.png,https://stockanalysis.com/quote/otc/BMMJ/,United States,1998,Drug Manufacturers - Specialty & Generic,Healthcare,142,Michael Mills,"750 – 1095 West Pender Street
Vancouver, Nevada V6E 2M6
Canada",800 361 6312,bodyandmind.com,BMMJ,OTCMKTS,August - July,USD,,,US09689V1008,2834,,Common Stock,,,
"Galera Therapeutics, Inc.","Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer.
The company’s lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy.
It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer.
The company was incorporated in 2012 and is based in Malvern, Pennsylvania.","Data/company_logos_stock_analysis\Galera_Therapeutics,_Inc._logo.png",https://stockanalysis.com/quote/otc/GRTX/,United States,2012,Biotechnology,Healthcare,7,J. Sorensen,"P.O. Box 134
Malvern, Delaware 19355
United States",610 725 1500,galeratx.com,GRTX,OTCMKTS,January - December,USD,,,US36338D1081,2836,,Common Stock,,,
THC Biomed Intl Ltd.,"THC Biomed Intl Ltd. produces and sells medical and recreational cannabis in Canada.
It offers cannabis beverage shots, gummies, and biscuits under the THC KISS brand names, as well as pure cannabis sticks.
The company was founded in 2012 and is headquartered in Kelowna, Canada.",Data/company_logos_stock_analysis\THC_Biomed_Intl_Ltd._logo.png,https://stockanalysis.com/quote/otc/THCBF/,Canada,2012,Drug Manufacturers - Specialty & Generic,Healthcare,35,John Miller,"2550 Acland Road
Kelowna, British Columbia V1X 7L4
Canada",,thcbiomed.com,THCBF,OTCMKTS,August - July,CAD,,,CA87243W1032,2834,,,,,
City View Green Holdings Inc.,"City View Green Holdings Inc., a consumer-packaged goods company, formulates, produces, and sells cannabis edibles and related products in Canada.
The company offers cannabis infused edibles, including baked goods, chews/gummies, and chocolate products.
City View Green Holdings Inc. is based in Toronto, Canada.",Data/company_logos_stock_analysis\City_View_Green_Holdings_Inc._logo.png,https://stockanalysis.com/quote/otc/CVGRF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,,Roberto Fia,"345 Danforth Avenue
Toronto, British Columbia M4K 1N7
Canada",,cityviewgreen.ca,CVGRF,OTCMKTS,January - December,CAD,,,CA1787181025,2834,,,,,
"Anything Technologies Media, Inc.","Anything Technologies Media, Inc. engages in manufacturing, distribution, and sale of CBD health products.
It procures and produces hemp seeds, smokable hemp flower, hemp biomass, distillates, and isolates, as well as products, such as vape, lotions, salves, and hemp beverage.
The company was formerly known as Exchange Mobile Telecommunications Corp. and changed its name to Anything Technologies Media, Inc. in September 2010.
Anything Technologies Media, Inc. was incorporated in 1997 and is based in Carson City, Nevada.","Data/company_logos_stock_analysis\Anything_Technologies_Media,_Inc._logo.png",https://stockanalysis.com/quote/otc/EXMT/,United States,1997,Drug Manufacturers - Specialty & Generic,Healthcare,,Lee Katterman,"800 E. College Parkway
Carson City, Nevada 89706
United States",650 222 2863,anythingtechnologiesmedia.com,EXMT,OTCMKTS,July - June,USD,,,US0373551045,7812,,Common Stock,,,
"Medical Marijuana, Inc.","Medical Marijuana, Inc., an investment holding company, operates in the cannabinoid-based nutraceutical industry.
It focuses on the development, sale, and distribution of hemp oil that contains naturally occurring cannabinoids, including cannabidiol (CBD) and other products containing CBD-rich hemp oil; treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products; and nonpsychoactive cannabidiol products.
The company is also involved in the research and development of new therapeutic agents that are designed to reduce oxidative stress and act as immuno-modulators and neuroprotectants; dietary supplements, skin care products, and prescription-based hemp oil under the Kannaway and HempMeds brands; and proprietary testing, genetics, labeling and packaging, tracking, and production and standardization methods for the medicinal cannabinoid industry.
In addition, it offers RSHO oil for the treatment of various illnesses and conditions; and plant-based, non-GMO pet products for health and wellness, play and wear, and environmentally-friendly supplies.
Medical Marijuana, Inc. was incorporated in 2005 and is based in Vista, California.","Data/company_logos_stock_analysis\Medical_Marijuana,_Inc._logo.png",https://stockanalysis.com/quote/otc/MJNA/,United States,2005,Drug Manufacturers - Specialty & Generic,Healthcare,91,Timothy Scott,"2384 La Mirada Drive
Vista, Oregon 92081
United States",866 273 8502,medicalmarijuanainc.com,MJNA,OTCMKTS,January - December,USD,,,US58463A1051,2834,,Common Stock,,,
AREV Life Sciences Global Corp.,"AREV Life Sciences Global Corp. operates as an early-stage life science discovery company in Canada.
It is involved in the extraction of compounds for consumption and topical use; clinical nutrition business; and Medicine Merchant, a technology platform.
The company’s pipeline products include SUS-TAINN, a superior utility supplementation therapeutic agent for indicated nutritional needs; and RES-TORE, a product based on organic plant nutrition for patients with overt clinical need for rational enhanced caloric intake and micronutrient supplementation.
It also develops edible oils, moringa, hops, cannabis sativa, pharma, sea cucumber, ginseng, and functional fungi ingredients; and anti-virals and phytomedicinalization.
In addition, the company flash-freezes active ingredients, oils, and oleoresins for use as ingredients in food, nutraceuticals, and other consumer products.
The company was formerly known as AREV NanoTec Brands Inc. and changed its name to AREV Life Sciences Global Corp. in August 2021.
AREV Life Sciences Global Corp. is based in Coquitlam, Canada.",Data/company_logos_stock_analysis\AREV_Life_Sciences_Global_Corp._logo.png,https://stockanalysis.com/quote/otc/AREVF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,2,Michael Withrow,"18 - 91 Golden Drive
Coquitlam, British Columbia V3K 6R2
Canada",604 803 8439,arevlifesciences.com,AREVF,OTCMKTS,January - December,CAD,,,CA04019J1093,2834,,,,,
"American Green, Inc.","American Green, Inc. operates as a technology company in the medical cannabis industry in the United States.
It develops retail, brand, and commercial cultivating solutions in partnership with licensed retail medical marijuana dispensaries operated under the American Green brand name.
The company operates ZaZZZ, a consumer operated marijuana vending machine for automated, age-verifying dispensing of cannabis-based medicines.
It also offers Jurassic Water for cannabis plants; truth lighting, a LED lighting solution; and OG tea nutrients, a specialty fertilizer product, as well as hemp creams and hemp lip balms through e-commerce.
It has collaboration agreement with Endexx Corporation to develop the Access Control Identification and Verification Vending Platform.
The company was formerly known as Tranzbyte Corporation and changed its name to American Green, Inc. in May 2014.
American Green, Inc. was incorporated in 1998 and is headquartered in Phoenix, Arizona.","Data/company_logos_stock_analysis\American_Green,_Inc._logo.png",https://stockanalysis.com/quote/otc/ERBB/,United States,1998,Drug Manufacturers - Specialty & Generic,Healthcare,1,,"2902 West Virginia Ave
Phoenix, Nevada 85009
United States",480 443 1600,americangreen.com,ERBB,OTCMKTS,July - June,USD,,,US02640N2009,5912,,Common Stock,,,
"One World Products, Inc.","One World Products, Inc. intends to produce raw cannabis and hemp plant ingredients for medical and industrial uses.
It focuses on cultivating, processing, and supplying of crude cannabis oil. The company was founded in 2018 and is headquartered in Las Vegas, Nevada.","Data/company_logos_stock_analysis\One_World_Products,_Inc._logo.png",https://stockanalysis.com/quote/otc/OWPC/,United States,2018,Drug Manufacturers - Specialty & Generic,Healthcare,10,Isiah Thomas,"6605 Grand Montecito Pkwy
Las Vegas, Nevada 89149
United States",800 605 3210,oneworldproducts.com,OWPC,OTCMKTS,January - December,USD,,,US68248W1080,2834,,Common Stock,,,
"Panbela Therapeutics, Inc.","Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs.
The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin.
The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020.
Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.","Data/company_logos_stock_analysis\Panbela_Therapeutics,_Inc._logo.png",https://stockanalysis.com/quote/otc/PBLA/,United States,2011,Biotechnology,Healthcare,8,Jennifer Simpson,"712 Vista Boulevard
Waconia, Delaware 55387
United States",952 479 1196,panbela.com,PBLA,OTCMKTS,January - December,USD,,,US69833W1071,2836,,Common Stock,,,
1933 Industries Inc.,"1933 Industries Inc., together with its subsidiaries, engages in the cultivation and production of cannabis products in the United States.
It operates in three segments: the Medical Segment, the Recreational Segment, and the CBD-Infused Products Segment.
The company produces, packages, and markets cannabidiol (CBD)-infused products, including tinctures, vape pens and cartridges, lotions, pain creams, gummies, and capsules under the Canna Hemp and Canna Hemp X brand names.
It also offers craft-style cannabis, infused pre-rolls, full spectrum oils, distillates, terpenes, and vaporizer products; and boutique concentrates, such as shatters, crumbles, batters, sugar waxes, diamonds, and cured and live resins under the AMA and Level X brand names.
The company offers its products through retail dispensaries and retail outlets, as well as through its e-commerce platform.
The company was formerly known as Friday Night Inc. and changed its name to 1933 Industries Inc. in September 2018.
1933 Industries Inc. is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\1933_Industries_Inc._logo.png,https://stockanalysis.com/quote/otc/TGIFF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,87,Paul Rosen,"1055 West Hastings Street
Vancouver, British Columbia V6E 2E9
Canada",604 728 4407,1933industries.com,TGIFF,OTCMKTS,August - July,CAD,,,CA65442F1053,2834,,,,,
"Helix BioMedix, Inc.","Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States.
It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections.
The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington.","Data/company_logos_stock_analysis\Helix_BioMedix,_Inc._logo.png",https://stockanalysis.com/quote/otc/HXBM/,United States,1988,Biotechnology,Healthcare,8,Robin Carmichael,"22121-17th Avenue SE
Bothell, Delaware 98021
United States",425-402-8400,helixbiomedix.com,HXBM,OTCMKTS,January - December,USD,,,US4232875074,2836,,Common Stock,,,
"SOHM, Inc.","SOHM, Inc. develops, manufactures, markets, and distributes generic and private label pharmaceutical products in the United States.
The company offers analgesics, antibiotics, anti-cold, and anti-inflammatory drugs, as well as over-the-counter, cosmeceuticals, and nutraceutical products.
It also exports its products. The company has collaboration agreement with Coastar Therapeutics to advance in the field of genome editing using red blood cell membrane derived carriers and genome editing technology.
SOHM, Inc. was founded in 2005 and is based in Corona, California.","Data/company_logos_stock_analysis\SOHM,_Inc._logo.png",https://stockanalysis.com/quote/otc/SHMN/,United States,2005,Drug Manufacturers - Specialty & Generic,Healthcare,145,Shailesh Shah,"4740 Green River Road
Corona, Nevada 92880
United States",714-522-6700,sohm.com,SHMN,OTCMKTS,January - December,USD,,,US83408P1084,5169,,Common Stock,,,
"Trevena, Inc.","Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.
Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.","Data/company_logos_stock_analysis\Trevena,_Inc._logo.png",https://stockanalysis.com/quote/otc/TRVN/,United States,2007,Biotechnology,Healthcare,23,Carrie Bourdow,"955 Chesterbrook Boulevard
Chesterbrook, Delaware 19087
United States",610 354 8840,trevena.com,TRVN,OTCMKTS,January - December,USD,,,US89532E1091,2836,,Common Stock,,,
"LiveWire Ergogenics, Inc.","LiveWire Ergogenics Inc. focuses on acquiring, managing, and licensing special purpose real estate properties to produce handcrafted and organically grown cannabis products for medical and recreational adult-use in California.
The company is based in Anaheim, California.","Data/company_logos_stock_analysis\LiveWire_Ergogenics,_Inc._logo.png",https://stockanalysis.com/quote/otc/LVVV/,United States,2007,Drug Manufacturers - Specialty & Generic,Healthcare,3,William Hodson,"1600 North Kraemer Boulevard
Anaheim, Nevada 92806
United States",714 740 5144,livewireergogenics.com,LVVV,OTCMKTS,January - December,USD,,,US53838A1043,2834,,Common Stock,,,
"GB Sciences, Inc.","GB Sciences, Inc., a plant-based research and biopharmaceutical drug development company.
The company offers cannabis inspired medicines and complex therapeutic mixtures for the prescription drug market.
Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson’s disease, neuropathic pain, chronic pain, cytokine release syndrome, stress/anxiety/depression, and cardiovascular therapeutic programs.
The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016.
GB Sciences, Inc. is based in Las Vegas, Nevada.","Data/company_logos_stock_analysis\GB_Sciences,_Inc._logo.png",https://stockanalysis.com/quote/otc/GBLX/,United States,2001,Biotechnology,Healthcare,2,,"9205 W. Russell Road
Las Vegas, Nevada 89148
United States",866 721 0297,gbsciences.com,GBLX,OTCMKTS,April - March,USD,,,US3615441090,2834,,Common Stock,,,
"Kiromic BioPharma, Inc.","Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors.
The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.
It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L.
The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019.
Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.","Data/company_logos_stock_analysis\Kiromic_BioPharma,_Inc._logo.png",https://stockanalysis.com/quote/otc/KRBP/,United States,2006,Biotechnology,Healthcare,35,Pietro Bersani,"7707 Fannin Street
Houston, Delaware 77054
United States",832 968 4888,kiromic.com,KRBP,OTCMKTS,January - December,USD,,,US4976341051,2836,,Common Stock,,,
"4Cable TV International, Inc.","4Cable TV International, Inc. provides specialty solutions to the cable television sector.
It offers a suite of products comprising RF to Fiber (RF2F), a proprietary line of coax-to-fiber taps that enables cable operators to reach homes within their franchise authorized area; PowerMiser, a circuitry, which allows a low current 1 GHz amplifier and/or line extender to be constructed with a decrease in current power requirements; RF over Glass (RFoG) signal distribution technology that combines the existing cable TV infrastructure with fiber optics to reach the home; and Node+0 application, which combines the RFoG technology platform with its PowerMiser engineering to take fiber signal.
The company also provides SOLAR-CATV that utilizes solar power and helps the operator extend service to areas not presently served without adding power sources; and Dynamically Scalable Return technology, which allows nodes, R-ONU’s (RFoG optical network units) to adjust their return bandwidth by changing the channel lineup at the head end, as well as repair, testing, and upgrade services.
It markets and sells its products through a network of dealers in the United States and Canada primarily to independent cable TV operators, as well as to multiple system operators.
4Cable TV International, Inc. was incorporated in 2007 and is based in Conway, South Carolina.","Data/company_logos_stock_analysis\4Cable_TV_International,_Inc._logo.png",https://stockanalysis.com/quote/otc/CATV/,United States,2007,Drug Manufacturers - Specialty & Generic,Healthcare,15,Steven Richey,"1248 Highway 501 Business
Conway, Nevada 29526
United States",843-347-4933,4cable.tv,CATV,OTCMKTS,January - December,USD,,,US3510381045,3669,,,,,
CENTR Brands Corp.,"CENTR Brands Corp. engages in the develops, markets, and sells Cannabidiol (CBD) beverage products in the United States.
It offers CENTR CBD sparkling water, a non-alcoholic CBD-infused functional beverage; CENTR instant ready-to-mix with CBD and adaptogen powder; CENTR Enhanced, a citrus, zero calorie, nootropic and adaptogen sparkling water; and CENTR CBD drinking recipes.
The company was founded in 2012 and is based in Vancouver, Canada.",Data/company_logos_stock_analysis\CENTR_Brands_Corp._logo.png,https://stockanalysis.com/quote/otc/CNTRF/,Canada,2012,Drug Manufacturers - Specialty & Generic,Healthcare,,Robert W. Becher,"507-837 West Hasting Street
Vancouver, British Columbia V6C 396
Canada",888-527-3251,findyourcentr.com,CNTRF,OTCMKTS,June - May,CAD,,,CA15234A1030,2086,,,,,
Algernon Pharmaceuticals Inc.,"Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia.
The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program.
It pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries.
The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015.
Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\Algernon_Pharmaceuticals_Inc._logo.png,https://stockanalysis.com/quote/otc/AGNPF/,Canada,2015,Biotechnology,Healthcare,,Christopher Moreau,"601 West Broadway
Vancouver, British Columbia V5Z 4C2
Canada",604 398 4175,algernonpharmaceuticals.com,AGNPF,OTCMKTS,September - August,CAD,,,CA01559R4008,2834,,,,,
"Kona Gold Beverage, Inc.","NuVibe, Inc., a lifestyle company, develops and sells hemp and cannabidiol (CBD) products in the functional beverage and fitness markets in the United States.
It offers hemp energy drinks and CBD energy water; and alkaline waters, beverages for kids, energy drinks, fruit-flavored sodas, low-carb lemonade, healthy aloe juice drinks, snack products, and CBD-infused jellybeans.
The company also sells shirts, tanks, hats, and towels. It sells its products to beverage distributors and resellers, retail grocery, smoke shops and specialty stores, wholesalers, merchandisers, vape shops, and convenience stores; and provides beverage services.
The company was formerly known as Kona Gold Beverage, Inc. and changed its name to NuVibe, Inc. in April 2024.
NuVibe, Inc. was incorporated in 1997 and is headquartered in Rockledge, Florida.","Data/company_logos_stock_analysis\Kona_Gold_Beverage,_Inc._logo.png",https://stockanalysis.com/quote/otc/KGKG/,United States,1997,Drug Manufacturers - Specialty & Generic,Healthcare,21,Jared Fisher,"5585 Schenck Ave
Rockledge, Delaware 32955
United States",844 714 2224,konagoldbeverage.com,KGKG,OTCMKTS,January - December,USD,,,US50049K1034,2086,,Common Stock,,,
"CohBar, Inc.","CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases.
It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases.
CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.","Data/company_logos_stock_analysis\CohBar,_Inc._logo.png",https://stockanalysis.com/quote/otc/CWBR/,United States,2007,Biotechnology,Healthcare,10,,"1455 Adams Drive
Menlo Park, Delaware 94025
United States",650 446 7888,cohbar.com,CWBR,OTCMKTS,January - December,USD,,,US19249J1097,2836,,Common Stock,,,
Western Sierra Resource Corporation,"Western Sierra Resource Corporation operates as a gold and silver mining company with projects in Arizona, Nevada, California, and Mexico.
The company primarily owns six precious metal reserves in Arizona and one in Nevada. It also manages the company's mineral resource projects covering precious metals, helium, and natural gas properties located in the Southwestern United States; and water and infrastructure assets in Northwest CO for implementation of industrial hemp irrigation, processing, and manufacture of hemp-based building materials for construction of on-site affordable housing in resort area.
The company was formerly known as Western Sierra Mining Corp. and changed its name to Western Sierra Resource Corporation in September 2018.
Western Sierra Resource Corporation was founded in 1907 and is based in Edmond, Oklahoma.",Data/company_logos_stock_analysis\Western_Sierra_Resource_Corporation_logo.png,https://stockanalysis.com/quote/otc/WSRC/,United States,1907,Drug Manufacturers - Specialty & Generic,Healthcare,2,Roger Johnson,"6175 Plumtree Lane
Edmond, Utah 73034
United States",928 680 5513,westernsierraresource.com,WSRC,OTCMKTS,January - December,USD,,,US95952L2007,2834,,Common Stock,,,
"Bespoke Extracts, Inc.","Bespoke Extracts, Inc., together with its subsidiary, Bespoke Extracts Colorado, LLC, produces and sells pre-rolled marijuana cigarettes in the United States.
The company owns, manufactures, and distributes a portfolio of cannabis consumer packaged goods under the Fresh Joints, Box-O-Joints, and Wee Joints brand names; and operates a marijuana infused products production facility.
It serves licensed marijuana dispensaries. The company was formerly known as DiMi Telematics International, Inc. and changed its name to Bespoke Extracts, Inc. in March 2017.
Bespoke Extracts, Inc. was founded in 1988 and is headquartered in Aurora, Colorado.","Data/company_logos_stock_analysis\Bespoke_Extracts,_Inc._logo.png",https://stockanalysis.com/quote/otc/BSPK/,United States,1988,Drug Manufacturers - Specialty & Generic,Healthcare,2,Michael Feinsod,"12001 E. 33rd Avenue
Aurora, Nevada 80010
United States",720 949 1143,bespokeextracts.com,BSPK,OTCMKTS,January - December,USD,,,US08634Q1094,2834,,Common Stock,,,
"Evofem Biosciences, Inc.","Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health.
Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis.
Evofem Biosciences, Inc. is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Evofem_Biosciences,_Inc._logo.png",https://stockanalysis.com/quote/otc/EVFM/,United States,,Biotechnology,Healthcare,38,Saundra Pelletier,"7770 Regents Roas
San Diego, Delaware 92122
United States",858 550 1900,evofem.com,EVFM,OTCMKTS,January - December,USD,,,US30048L2034,2834,,Common Stock,,,
Pharmadrug Inc.,"Pharmadrug Inc. operates as a specialty pharmaceutical company.
It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally derived approved drugs.
The company also engages in the researching and reformulating of established natural medicines; development of synthetic formulations of existing drugs for potential commercialization and distribution; development of cepharanthine, a drug for the treatment of infectious disease and rare cancers; and research and development activities in the psychedelics space for the treatment of non-neuropsychiatric conditions.
It has a license agreement with Southwest Research Institute. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019.
Pharmadrug Inc. is based in Toronto, Canada.",Data/company_logos_stock_analysis\Pharmadrug_Inc._logo.png,https://stockanalysis.com/quote/otc/LMLLF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,,Robert Steen,"77 King Street West
Toronto, Ontario M5K 1H1
Canada",647 202 1824,pharmadrug.ca,LMLLF,OTCMKTS,January - December,CAD,,,CA71716W2040,5122,,,,,
New Leaf Ventures Inc,"New Leaf Ventures Inc. engages in processing, packaging, marketing, and distributing cannabis and related products.
The company offers its products under the DAMA and Goodies brand names. It also provides consulting, real property and equipment leasing, intellectual property licensing, and management services.
New Leaf Ventures Inc. was incorporated in 2018 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\New_Leaf_Ventures_Inc_logo.png,https://stockanalysis.com/quote/otc/NLVVF/,Canada,2018,Drug Manufacturers - Specialty & Generic,Healthcare,,,"1910 - 1030 West Georgia Street
Vancouver, British Columbia V6E 2Y3
Canada",604-862-2793,newleafventuresinc.com,NLVVF,OTCMKTS,January - December,CAD,,,CA64639M3049,2833,,,,,
"Regen BioPharma, Inc.","Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States.
It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease.
The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6.
The company was incorporated in 2012 and is based in La Mesa, California.","Data/company_logos_stock_analysis\Regen_BioPharma,_Inc._logo.png",https://stockanalysis.com/quote/otc/RGBP/,United States,2012,Biotechnology,Healthcare,1,David Koos,"4700 Spring Street
La Mesa, Nevada 91942
United States",619 722 5505,regenbiopharmainc.com,RGBP,OTCMKTS,October - September,USD,,,US75886M1027,2836,,Common Stock,,,
Target Group Inc.,"Target Group Inc. cultivates, processes, and distributes curated cannabis products for the medical and adult-use recreational cannabis market in Canada and the United States.
Its products include cannabis flower and extract pods for vaporizer use, cannabis pre-rolls, k-cup infused coffee and tea pods, infused cannabis beverages and edibles, infused topical products, and CBD wellness products.
The company also offers Wisp, a single-use pre-measured pod and vaporizer system for consumers involved in vaporizing natural herbs, including cannabis.
It has a collaboration agreement with cGreen, Inc for manufacturing and distributing the patent-pending THC antidote True Focus in the United States, Europe, and the Caribbean; and distribution, collaboration, and licensing agreement with Serious Seeds B.V.
The company was formerly known as Chess Supersite Corporation and changed its name to Target Group Inc. in July 2018.
Target Group Inc. was incorporated in 2013 and is based in Hamilton, Canada.",Data/company_logos_stock_analysis\Target_Group_Inc._logo.png,https://stockanalysis.com/quote/otc/CBDY/,United States,2013,Drug Manufacturers - Specialty & Generic,Healthcare,49,Anthony Zarcone,"20 Hempstead Drive
Hamilton, Delaware L8W 2E7
Canada",905 541 3833,targetgroupinc.ca,CBDY,OTCMKTS,January - December,USD,,,US87614W1045,2834,,Common Stock,,,
Maple Leaf Green World Inc.,"Maple Leaf Green World Inc., does not have significant operations.
previously, the company engaged in the medical hemp business in Canada and the United States. The company was formerly known as Maple Leaf Reforestation Inc. and changed its name to Maple Leaf Green World Inc. in October 2012.
Maple Leaf Green World Inc. is headquartered in Calgary, Canada.",Data/company_logos_stock_analysis\Maple_Leaf_Green_World_Inc._logo.png,https://stockanalysis.com/quote/otc/MGWFF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,1,Raymond Lai,"1222- 11th Avenue SW
Calgary, Alberta T3C 0M4
Canada",403-618-6186,mlgreenworld.com,MGWFF,OTCMKTS,January - December,CAD,,,CA5652973069,2834,,,,,
Ovation Science Inc.,"Ovation Science Inc. engages in the production, sub-licensing, and sale of cannabis or hemp products in Canada and the United States.
The company sublicenses product formulations through Invisicare, a patented drug delivery technology to produce topical and transdermal cannabis products under the Ovation name.
It also offers cannabidiol health and wellness solutions under the Invibe MD name; skincare solutions under the ARLO CBD name; and topical and transdermal creams and lotions with CBD, THC, and combinations, as well as hemp seed oil.
Ovation Science Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\Ovation_Science_Inc._logo.png,https://stockanalysis.com/quote/otc/OVATF/,Canada,2017,Drug Manufacturers - Specialty & Generic,Healthcare,,Terry Howlett,"1166 Alberni Street
Vancouver, British Columbia V6E 3Z3
Canada",604 982 5700,ovationscience.com,OVATF,OTCMKTS,January - December,CAD,,,CA69016D1087,2834,,,,,
International Stem Cell Corporation,"International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally.
It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson’s disease, as well as for treating stroke, traumatic brain injury, and Alzheimer’s disease.
The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner.
In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening.
Its human cell culture products also consists of adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells.
International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.",Data/company_logos_stock_analysis\International_Stem_Cell_Corporation_logo.png,https://stockanalysis.com/quote/otc/ISCO/,United States,2001,Biotechnology,Healthcare,29,Andrey Semechkin,"9745 Businesspark Avenue
San Diego, Delaware 92131
United States",760 940 6383,internationalstemcell.com,ISCO,OTCMKTS,January - December,USD,,,US4603782016,2836,,Common Stock,,,
"WOWI, Inc.","WOWI, Inc., an early-stage company, engages in the business of licensing technology and intellectual property to operators and businesses in the legal cannabis industry in the United States.
The company also provides packaging and labeling, as well as equipment and real property leasing services to various companies.
In addition, it offers a plethora of consulting services, including proper business structure and management services in the legal cannabis space serving cultivations, growers, extractors, and dispensaries that operate legally in states that has legal medicinal and/or recreational legislation.
The company is headquartered in Centennial, Colorado.","Data/company_logos_stock_analysis\WOWI,_Inc._logo.png",https://stockanalysis.com/quote/otc/WOWU/,United States,,Drug Manufacturers - Specialty & Generic,Healthcare,,Anthony Russo,"6770 South Yosemite Street
Centennial, Florida 80112
United States",720-482-6257,worldofweedinc.com,WOWU,OTCMKTS,October - September,USD,,,US92940M1018,2834,,,,,
GelStat Corp.,"GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products.
Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms.
The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers.
GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.",Data/company_logos_stock_analysis\GelStat_Corp._logo.png,https://stockanalysis.com/quote/otc/GSAC/,United States,2002,Drug Manufacturers - Specialty & Generic,Healthcare,2,Javier Acosta,"3557 SW Corporate Parkway
Palm City, Delaware 34990
United States",772-283-0020,gelstat.com,GSAC,OTCMKTS,January - December,USD,,,US3685331056,2834,,Common Stock,,,
"Emmaus Life Sciences, Inc.","Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.
The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Its pipeline products include ELS001/ELS007, a pharmaceutical grade L-glutamine, which has completed phase 3 clinical trial to treat sickle cell disease; ELS004, a pharmaceutical grade L-glutamine which has completed phase 1 clinical study to treat diverticulosis; ELS005 in preclinical study for the use and combination of KM10544 to treat blood cancers; ELS003, a lab device/research tool in preclinical study to measure transmittance of cell sheet; and ELS002, a chondrocyte cell sheet technology to replace knee cartilage replacement or to treat osteoarthritis is in preclinical study.
It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor (KM10544) for the treatment of cancers.
The company was founded in 2000 and is headquartered in Torrance, California.","Data/company_logos_stock_analysis\Emmaus_Life_Sciences,_Inc._logo.png",https://stockanalysis.com/quote/otc/EMMA/,United States,2000,Biotechnology,Healthcare,55,Willis Lee,"21250 Hawthorne Boulevard
Torrance, Delaware 90503
United States",310 214 0065,emmausmedical.com,EMMA,OTCMKTS,January - December,USD,,,US29137T1016,2834,,Common Stock,,,
"Nexien BioPharma, Inc.","Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions in the United States.
The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018.
Nexien BioPharma, Inc. is based in Glendale, Colorado.","Data/company_logos_stock_analysis\Nexien_BioPharma,_Inc._logo.png",https://stockanalysis.com/quote/otc/NXEN/,United States,,Drug Manufacturers - Specialty & Generic,Healthcare,,Richard Greenberg,"4340 East Kentucky Avenue
Glendale, Delaware 80246
United States",303 495 7583,nexienbiopharma.com,NXEN,OTCMKTS,July - June,USD,,,US65343D1000,2834,,Common Stock,,,
RespireRx Pharmaceuticals Inc.,"RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders.
It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors.
The company’s lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea.
It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications.
It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders.
The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015.
RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.",Data/company_logos_stock_analysis\RespireRx_Pharmaceuticals_Inc._logo.png,https://stockanalysis.com/quote/otc/RSPI/,United States,1987,Biotechnology,Healthcare,2,Arnold Lippa,"126 Valley Road
Glen Rock, Delaware 07452
United States",201 444 4947,respirerx.com,RSPI,OTCMKTS,January - December,USD,,,US7612273059,2836,,Common Stock,,,
"Arch Therapeutics, Inc.","Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States.
It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease.
The company’s flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds.
It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body.
The company was founded in 2006 and is based in Framingham, Massachusetts.","Data/company_logos_stock_analysis\Arch_Therapeutics,_Inc._logo.png",https://stockanalysis.com/quote/otc/ARTH/,United States,2006,Biotechnology,Healthcare,8,Terrence Norchi,"235 Walnut Street
Framingham, Nevada 01702
United States",617 431 2313,archtherapeutics.com,ARTH,OTCMKTS,October - September,USD,,,US03939W1099,2836,,,,,
Global Roundtable Corporation,"Global Roundtable Corporation operates in the health and wellness business.
It also provides products and ancillary services in the mental wellness segment and optical-vision medical care.
The company was formerly known as Green Cures & Botanical Distribution Inc. and changed its name to Global Roundtable Corporation in May 2023.
Global Roundtable Corporation was incorporated in 1986 and is based in Denver, Colorado.",Data/company_logos_stock_analysis\Global_Roundtable_Corporation_logo.png,https://stockanalysis.com/quote/otc/GRCU/,United States,1986,Drug Manufacturers - Specialty & Generic,Healthcare,20,Rich Thomas,"7535 East Avenue
Denver, Colorado 80231
United States",,,GRCU,OTCMKTS,January - December,USD,,,US3930072083,2834,,Common Stock,,,
"The Greater Cannabis Company, Inc.","The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics.
It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body.
The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease, and other neuropsychiatric disorders.
The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.","Data/company_logos_stock_analysis\The_Greater_Cannabis_Company,_Inc._logo.png",https://stockanalysis.com/quote/otc/GCAN/,United States,2014,Drug Manufacturers - Specialty & Generic,Healthcare,1,Aitan Zacharin,"2833 Smith Avenue
Baltimore, Florida 21209
United States",443 738 4051,gcanrx.com,GCAN,OTCMKTS,January - December,USD,,,US3916571033,2833,,Common Stock,,,
Nutra Pharma Corp.,"Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States.
The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, non–narcotic, non–addictive, and over–the–counter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and anti–inflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses.
It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain.
The company was incorporated in 2000 and is based in Plantation, Florida.",Data/company_logos_stock_analysis\Nutra_Pharma_Corp._logo.png,https://stockanalysis.com/quote/otc/NPHC/,United States,2000,Drug Manufacturers - Specialty & Generic,Healthcare,4,Michael Flax,"1537 NW 65th Avenue
Plantation, California 33313
United States",954 509 0911,nutrapharma.com,NPHC,OTCMKTS,January - December,USD,,,US67060U2087,2836,,Common Stock,,,
Neutra Corp.,"Neutra Corp. researches, develops, and provides hemp-derived products in the nutraceutical space in the United States.
The company sells hemp-derived products, including products containing delta-8-THC and other cannabinoids, CBD sports creams, and other products.
Neutra Corp. was incorporated in 2011 and is based in Houston, Texas.",Data/company_logos_stock_analysis\Neutra_Corp._logo.png,https://stockanalysis.com/quote/otc/NTRR/,United States,2011,Drug Manufacturers - Specialty & Generic,Healthcare,15,Sydney Jim,"2500 CityWest Boulevard
Houston, Wyoming 77042
United States",307 228 1488,neutrainc.com,NTRR,OTCMKTS,February - January,USD,,,US64129C3034,2833,,Common Stock,,,
"Premier Biomedical, Inc.","Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases.
It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors.
It is also developing hemp oil products, including anti-pain patch, roll-on topical products, sprays, ointments, tincture drop product, a hemp oil capsule, and pet product; sequential-dialysis technique for cancer, Alzheimer’s disease, ALS, blood sepsis, leukemia, and other life-threatening cancers; and Feldetrex drug candidate for the treatment of multiple sclerosis, fibromyalgia, neuropathic pain, and traumatic brain injuries.
Premier Biomedical, Inc. was founded in 2010 and is headquartered in Jackson Center, Pennsylvania.","Data/company_logos_stock_analysis\Premier_Biomedical,_Inc._logo.png",https://stockanalysis.com/quote/otc/BIEI/,United States,2010,Drug Manufacturers - Specialty & Generic,Healthcare,4,,"PO Box 25
Jackson Center, Nevada 16133
United States",724 633 7033,premierbiomedical.com,BIEI,OTCMKTS,January - December,USD,,,US74048K2033,2836,,Common Stock,,,
NeutriSci International Inc.,"NeutriSci International Inc. develops and markets nutraceutical products in Canada, Germany, and Japan.
It offers neuenergy, an energy tab designed to deliver enhanced focus and mental clarity. The company sells its products through a distribution network of retail storefront and online markets.
NeutriSci International Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\NeutriSci_International_Inc._logo.png,https://stockanalysis.com/quote/otc/NRXCF/,Canada,2009,Drug Manufacturers - Specialty & Generic,Healthcare,,Glen Rehman,"1600 – 609 Granville Street
Vancouver, British Columbia V7Y 1C3
Canada",403 264 6320,neutrisci.com,NRXCF,OTCMKTS,January - December,CAD,,,CA64129Y1079,2834,,,,,
HAVN Life Sciences Inc.,"HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi.
The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp.
mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds.
The company was incorporated in 2020 and is based in Port Moody, Canada.",Data/company_logos_stock_analysis\HAVN_Life_Sciences_Inc._logo.png,https://stockanalysis.com/quote/otc/HAVLF/,Canada,2020,Biotechnology,Healthcare,,Tim Moore,"605 - 130 Brew Street
Port Moody, British Columbia V3H 0E3
Canada",604 370 9520,havnlife.com,HAVLF,OTCMKTS,May - April,CAD,,,CA4196213058,2836,,,,,
Itoco Inc.,"Itoco Inc. engages in the processing, production, and distribution of medical cannabis products. The company was formerly known as Itoco Mining Corporation and changed its name to Itoco Inc. in May 2018. Itoco Inc. is based in Reno, Nevada.",Data/company_logos_stock_analysis\Itoco_Inc._logo.png,https://stockanalysis.com/quote/otc/ITMC/,United States,,Biotechnology,Healthcare,,,"880-50 West Liberty Street
Reno, Nevada 89501
United States",905-829-5000,itoco.net,ITMC,OTCMKTS,January - December,USD,,,US4657212076,2833,,Common Stock,,,
"AXIM Biotechnologies, Inc.","AXIM Biotechnologies, Inc. engages in the development and sale of diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases.
The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests.
It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring.
The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014.
AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.","Data/company_logos_stock_analysis\AXIM_Biotechnologies,_Inc._logo.png",https://stockanalysis.com/quote/otc/AXIM/,United States,2010,Biotechnology,Healthcare,7,John Huemoeller,"6191 Cornerstone Court, East
San Diego, Nevada 92121
United States",858 923 4422,aximbiotech.com,AXIM,OTCMKTS,January - December,USD,,,US05463V1008,2835,,,,,
"Marizyme, Inc.","Marizyme, Inc., a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health.
It’s product portfolio includes DuraGraft, a first-in-class, De Novo granted and CE marked intra-operative vascular graft storage and flushing solution used during coronary artery bypass graft (CABG) surgeries; MATLOC, a point-of-care, lab-on-chip technology platform, developed for quantitative chronic kidney disease assessment; and Krillase, a protein enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, dental care and thrombosi.
The company also engages in the development of MAR-FG-001, a fat grafting technology for the use during fat grafting procedures.
Marizyme, Inc. was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018.
The company was incorporated in 2007 and is based in Jupiter, Florida.","Data/company_logos_stock_analysis\Marizyme,_Inc._logo.png",https://stockanalysis.com/quote/otc/MRZM/,United States,2007,Biotechnology,Healthcare,13,David Barthel,"555 Heritage Drive
Jupiter, Nevada 33458
United States",(561) 935-9955,marizyme.com,MRZM,OTCMKTS,January - December,USD,,,US5703721028,2836,,,,,
"Cannabis Global, Inc.","Cannabis Global, Inc. focuses on the creating and commercialization of engineered technologies to deliver hemp extracts and cannabinoids to the human body.
The company offers cannabis flower packaged, pre-rolls, and edible products to cannabis retailers and distributors; and Comply Bag, a solution for cannabis storage, transport, and tracking.
It also provides managerial services in areas of the regulated hemp and cannabis industries. The company was formerly known as MCTC Holdings, Inc. and changed its name to Cannabis Global, Inc. in December 2019.
Cannabis Global, Inc. was incorporated in 2005 and is headquartered in Los Angeles, California.","Data/company_logos_stock_analysis\Cannabis_Global,_Inc._logo.png",https://stockanalysis.com/quote/otc/CBGL/,United States,2005,Drug Manufacturers - Specialty & Generic,Healthcare,3,Edward Manolos,"520 South Grand Avenue
Los Angeles, Nevada 90071
United States",310 986 4929,cannabisglobalinc.com,CBGL,OTCMKTS,September - August,USD,,,US13767G1004,2834,,Common Stock,,,
CanaQuest Medical Corp.,"CanaQuest Medical Corp. develops health products and pharmaceuticals that utilize hemps, cannabis, and algae oils.
The company was formerly known as Algae Dynamics Corp. and changed its name to CanaQuest Medical Corp. in January 2019.
CanaQuest Medical Corp. was founded in 2008 and is based in Mississauga, Canada.",Data/company_logos_stock_analysis\CanaQuest_Medical_Corp._logo.png,https://stockanalysis.com/quote/otc/CANQF/,Canada,2008,Drug Manufacturers - Specialty & Generic,Healthcare,,Paul Ramsay,"4120 Ridgeway Drive
Mississauga, Ontario L5L 5S9
Canada",416-704-3040,canaquest.com,CANQF,OTCMKTS,April - March,CAD,,,CA1372201097,2833,,Common Stock,,,
Branded Legacy Inc,"Branded Legacy Inc engages in the commercial development of hemp and cannabinoid-infused beverages in Central Florida.
It provides CBD topicals and tinctures, and hemp coffees and teas. The company was formerly known as Elev8 Brands, Inc. and changed its name to Branded Legacy Inc in May 2020.
Branded Legacy Inc. was incorporated in 1981 and is headquartered in Melbourne, Florida.",Data/company_logos_stock_analysis\Branded_Legacy_Inc_logo.png,https://stockanalysis.com/quote/otc/BLEG/,United States,1981,Drug Manufacturers - Specialty & Generic,Healthcare,3,David Oswald,"746 North Drive
Melbourne, Utah 32934
United States",321 345 3565,brandedlegacy.com,BLEG,OTCMKTS,January - December,USD,,,US10528L1052,2080,,Common Stock,,,
Global Hemp Group Inc.,"Global Hemp Group Inc. engages in health and wellness, and industrial hemp businesses.
The Industrial Hemp division primarily focuses on the environmental uses of hemp for construction and bio-energy sources for carbon-negative footprint.
The Health and Wellness Division focuses on the acquisition of exclusive licensing of patents and IP for the commercialization of hemp formulations that have been independently pre-clinically tested.
The company was formerly known as Arris Holdings Inc. and changed its name to Global Hemp Group Inc. in March 2014.
Global Hemp Group Inc. was incorporated in 2009 and is headquartered in North Vancouver, Canada.",Data/company_logos_stock_analysis\Global_Hemp_Group_Inc._logo.png,https://stockanalysis.com/quote/otc/GBHPF/,Canada,2009,Drug Manufacturers - Specialty & Generic,Healthcare,,Curtis Ralph Huber,"#106 – 1169 Mt. Seymour Road
North Vancouver, British Columbia V7H 2Y4
Canada",778 726 2900,globalhempgroup.com,GBHPF,OTCMKTS,October - September,CAD,,,CA37953Y2033,2834,,,,,Class A Shares
"Sorrento Therapeutics, Inc.","Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain.
It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.
Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease.
The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia.
It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia.
It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma.
The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
The plan was later approved as Chapter 11 liquidation on November 30, 2023.","Data/company_logos_stock_analysis\Sorrento_Therapeutics,_Inc._logo.png",https://stockanalysis.com/quote/otc/SRNE/,United States,2006,Biotechnology,Healthcare,949,Henry Ji,"4955 Directors Place
San Diego, Delaware 92121
United States",858 203 4100,sorrentotherapeutics.com,SRNE,OTCMKTS,January - December,USD,,,US83587F2020,2836,,Common Stock,,,
"Resonate Blends, Inc.","Resonate Blends, Inc. engages in the discovery, development, and marketing of products designed to mankind.
The company focuses on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual’s ability to mobilize their own adult stem cells from their bone marrow.
It also has a license to market a dual acting all natural diet aid designed to help control hunger through normal body signals to the brain and stomach.
In addition, the company engages in the research and development activities center on exploring other areas, such as Secretogues that can naturally enhance a person’s own growth hormone production and similar all natural bioactive formulations to enhance human performance safely, ethically, and legally; and utilizing known body mechanisms without the use of drugs.
Resonate Blends, Inc. is based in North Bergen, New Jersey.","Data/company_logos_stock_analysis\Resonate_Blends,_Inc._logo.png",https://stockanalysis.com/quote/otc/KOAN/,United States,,Drug Manufacturers - Specialty & Generic,Healthcare,,,"One Marine Plaza
North Bergen, Nevada 04047
United States",(786) 369-9696,resonateblends.com,KOAN,OTCMKTS,January - December,USD,,,US76090M1027,2833,,Common Stock,,,
"Propanc Biopharma, Inc.","Propanc Biopharma, Inc., a biopharmaceutical company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia.
Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.
The company has a research collaboration with University of Jaén to carry out a research project aimed at the synthetic development of PRP and its subsequent validation; and a joint research and drug discovery program with Universities of Jaén and Granada for the POP1 program to investigate the changes in genetic and protein expression that occur in cancer cells.
The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017.
Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.","Data/company_logos_stock_analysis\Propanc_Biopharma,_Inc._logo.png",https://stockanalysis.com/quote/otc/PPCB/,United States,2007,Biotechnology,Healthcare,2,James Nathanielsz,"302, 6 Butler Street
Camberwell, Delaware 3124
Australia",61 3 9882 0780,propanc.com,PPCB,OTCMKTS,July - June,USD,,,US74346N4043,2836,,Common Stock,,,
CNBX Pharmaceuticals Inc.,"CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer.
Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome.
The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer.
In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test.
The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022.
CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland.",Data/company_logos_stock_analysis\CNBX_Pharmaceuticals_Inc._logo.png,https://stockanalysis.com/quote/otc/CNBX/,United States,2004,Biotechnology,Healthcare,2,Eyal Barad,"#3 Bethesda Metro Center
Bethesda, Nevada 20814
United States",877 424 2429,cnbxpharma.com,CNBX,OTCMKTS,September - August,USD,,,US13764M1009,2834,,Common Stock,,,
"Molecular Templates, Inc.","Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States.
The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors.
The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets.
Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.","Data/company_logos_stock_analysis\Molecular_Templates,_Inc._logo.png",https://stockanalysis.com/quote/otc/MTEM/,United States,2001,Biotechnology,Healthcare,62,Eric Poma,"9301 Amberglen Boulevard
Austin, Delaware 78729
United States",512 869 1555,mtem.com,MTEM,OTCMKTS,January - December,USD,,,US6085501095,2836,,,,,
"Veritas Farms, Inc.","Veritas Farms, Inc. focuses on growing, producing, marketing, and distributing hemp oils and extracts containing phytocannabinoids.
The company’s products include capsules, gummies, tinctures, lotions, salves, cream, balm sticks, lip balms, and pet chews.
It markets and sells its products under the Veritas Farms brand name, as well as through bulk, white label and private label custom formulations for distributors and retailers.
The company was formerly known as SanSal Wellness Holdings, Inc. and changed its name to Veritas Farms, Inc. in February 2019.
Veritas Farms, Inc. is based in Fort Lauderdale, Florida.","Data/company_logos_stock_analysis\Veritas_Farms,_Inc._logo.png",https://stockanalysis.com/quote/otc/VFRM/,United States,,Drug Manufacturers - Specialty & Generic,Healthcare,17,Thomas Vickers,"401 E. Las Olas Boulevard
Fort Lauderdale, Nevada 33301
United States",833 691 4367,theveritasfarms.com,VFRM,OTCMKTS,January - December,USD,,,US92347N2071,2833,,Common Stock,,,
"Bellerophon Therapeutics, Inc.","Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States.
Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness.
The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014.
Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.","Data/company_logos_stock_analysis\Bellerophon_Therapeutics,_Inc._logo.png",https://stockanalysis.com/quote/otc/BLPH/,United States,2009,Biotechnology,Healthcare,18,Craig Jalbert,"20 Independence Boulevard
Warren, Delaware 07059
United States",908 574 4770,bellerophon.com,BLPH,OTCMKTS,January - December,USD,,,US0787713009,2836,,,,,
"U.S. Stem Cell, Inc.","U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States.
The company’s lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells or cells from a patient’s body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia.
Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients.
The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure.
In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases.
The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015.
U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.","Data/company_logos_stock_analysis\U.S._Stem_Cell,_Inc._logo.png",https://stockanalysis.com/quote/otc/USRM/,United States,1999,Biotechnology,Healthcare,11,Michael Tomas,"1560 Sawgrass Corporate Parkway
Sunrise, Florida 33323
United States",954 835 1500,us-stemcell.com,USRM,OTCMKTS,January - December,USD,,,US90350U1007,2836,,Common Stock,,,
"Hemp, Inc","Hemp, Inc. provides industrial hemp in the United States.
The company offers pre-roll blends, fortified pre-rolls; Bubba Kush hemp; caviar/moon rocks; and diamonds and crumbles.
It is also involved in the processing and farming industrial hemp; extracting hemp CBD oil; and provides education seminar for farmers and entrepreneurs, as well as provides research and development, and hemp consulting.
In addition, the company sells its products under the King of Hemp brand. The company was formerly known as Marijuana, Inc. and changed its name to Hemp, Inc. in June 2012.
Hemp, Inc. was incorporated in 2008 and is based in Las Vegas, Nevada.","Data/company_logos_stock_analysis\Hemp,_Inc_logo.png",https://stockanalysis.com/quote/otc/HEMP/,United States,2008,Drug Manufacturers - Specialty & Generic,Healthcare,4,Gary Perlowin,"7380 South Eastern Avenue
Las Vegas, Colorado 89123
United States",855 436 7688,hempinc.com,HEMP,OTCMKTS,January - December,USD,,,US4237032069,7370,,Common Stock,,,
"Marijuana Company of America, Inc.","Marijuana Company of America, Inc., together with its subsidiaries, develops, produces, and distributes cannabis and cannabidiol (CBD) products under the hempSMART brand name in the United States.
The company offers hempSMART products comprising hempSMART Brain, a patented and formulated personal care consumer product for brain wellness; hempSMART Pain capsules for temporary relief of minor discomfort with physical activity; hempSMART Pain Cream to reduce minor discomfort and promote muscle relaxation; hempSMART Drops, a hemp CBD oil tincture drops; hempSMART Pet Drops for cats and dogs; hempSMART Face, a facial moisturizer; and hempSMART drink mix, an industrial hemp based powderized CBD drink through its web site and affiliate marketing programs.
It also distributes hemp and CBD products, such as smoke and vape shop related products to wholesalers, c-stores, specialty retailers, and consumers through www.cdistro.com.
The company was formerly known as Converge Global, Inc. and changed its name to Marijuana Company of America, Inc. in December 2015.
Marijuana Company of America, Inc. was incorporated in 1985 and is based in Los Angeles, California.","Data/company_logos_stock_analysis\Marijuana_Company_of_America,_Inc._logo.png",https://stockanalysis.com/quote/otc/MCOA/,United States,1985,Drug Manufacturers - Specialty & Generic,Healthcare,7,Jesus Quintero,"633 West 5th Street
Los Angeles, Utah 90071
United States",888 777 4362,marijuanacompanyofamerica.com,MCOA,OTCMKTS,January - December,USD,,,US56782E2046,7370,,Common Stock,,,
Zenith Capital Corp.,"Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs.
The company’s lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer, as well as advanced or metastatic triple negative breast cancer in collaboration with Pfizer Inc. It has research and development collaboration agreement with National Cancer Institute, and licensing agreement with Newsoara to develop ZEN-3694, as well as with University of California.
The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016.
Zenith Capital Corp. was incorporated in 2013 and is headquartered in Calgary, Canada.",Data/company_logos_stock_analysis\Zenith_Capital_Corp._logo.png,https://stockanalysis.com/quote/otc/ZHCLF/,Canada,2013,Biotechnology,Healthcare,,Donald McCaffrey,"4820 Richard Road SW
Calgary, Alberta T3E 6L1
Canada",587 390 7865,zenithepigenetics.com,ZHCLF,OTCMKTS,May - April,USD,,,CA98935N1033,2836,,Common Stock,,,
Innovation Pharmaceuticals Inc.,"Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective.
Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19.
The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017.
Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.",Data/company_logos_stock_analysis\Innovation_Pharmaceuticals_Inc._logo.png,https://stockanalysis.com/quote/otc/IPIX/,United States,2005,Biotechnology,Healthcare,4,Leo Ehrlich,"301 Edgewater Place
Wakefield, Nevada 01880
United States",978 921 4125,ipharminc.com,IPIX,OTCMKTS,July - June,USD,,,US45782D1000,2836,,Common Stock,,,Class A Shares
Scopus BioPharma Inc.,"Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs.
It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses.
The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein.
Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem.
The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017.
Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.",Data/company_logos_stock_analysis\Scopus_BioPharma_Inc._logo.png,https://stockanalysis.com/quote/otc/SCPS/,United States,2017,Biotechnology,Healthcare,13,,"420 Lexington Avenue
New York, Delaware 10170
United States",212 479 2513,scopusbiopharma.com,SCPS,OTCMKTS,January - December,USD,,,US8091711015,2836,,Common Stock,,,
NovAccess Global Inc.,"NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States.
It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer.
The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.",Data/company_logos_stock_analysis\NovAccess_Global_Inc._logo.png,https://stockanalysis.com/quote/otc/XSNX/,United States,1997,Biotechnology,Healthcare,3,Dwain Morris-Irvin,"8584, Washington Street
Chagrin Falls, Colorado 44023
United States",213 642 9268,novaccessglobal.com,XSNX,OTCMKTS,October - September,USD,,,US67001N1072,2836,,Common Stock,,,
"Evelo Biosciences, Inc.","Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects.
It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis.
The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology.
Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Evelo_Biosciences,_Inc._logo.png",https://stockanalysis.com/quote/otc/EVLO/,United States,2014,Biotechnology,Healthcare,66,,"620 Memorial Drive
Cambridge, Delaware 02139
United States",617 577 0300,evelobio.com,EVLO,OTCMKTS,January - December,USD,,,US2997341035,2836,,Common Stock,,,
"Navidea Biopharmaceuticals, Inc.","Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics.
It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.
It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints.
The company is also developing Tc99m tilmanocept for cardiovascular, kaposi’s sarcoma, tuberculosis, and other immunotherapeutic applications.
The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012.
Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.","Data/company_logos_stock_analysis\Navidea_Biopharmaceuticals,_Inc._logo.png",https://stockanalysis.com/quote/otc/NAVB/,United States,1983,Biotechnology,Healthcare,13,,"4995 Bradenton Avenue
Dublin, Delaware 43017-3552
United States",614 793 7500,navidea.com,NAVB,OTCMKTS,January - December,USD,,,US63937X2027,2835,,Common Stock,,,
"Ampio Pharmaceuticals, Inc.","Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States.
The company develops OA-201, a small molecule formulation for the treatment of OAK pain. Ampio Pharmaceuticals, Inc. is based in Englewood, Colorado.","Data/company_logos_stock_analysis\Ampio_Pharmaceuticals,_Inc._logo.png",https://stockanalysis.com/quote/otc/AMPE/,United States,,Biotechnology,Healthcare,6,Michael Martino,"9800 Mount Pyramid Court
Englewood, Delaware 80112
United States",720 437 6500,ampiopharma.com,AMPE,OTCMKTS,January - December,USD,,,US03209T1097,2834,,Common Stock,,,
"RegeneRx Biopharmaceuticals, Inc.","RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration.
The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue.
It has strategic partnerships with Lee’s Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000.
RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.","Data/company_logos_stock_analysis\RegeneRx_Biopharmaceuticals,_Inc._logo.png",https://stockanalysis.com/quote/otc/RGRX/,United States,1982,Biotechnology,Healthcare,3,J. Finkelstein,"15245 Shady Grove Road
Rockville, Delaware 20850
United States",301 208 9191,regenerx.com,RGRX,OTCMKTS,January - December,USD,,,US75886X1081,2834,,Common Stock,,,
"Calithera Biosciences, Inc.","Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023.
Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business.
Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Calithera_Biosciences,_Inc._logo.png",https://stockanalysis.com/quote/otc/CALA/,United States,2010,Biotechnology,Healthcare,9,,"343 Oyster Point Boulevard
South San Francisco, Delaware 94080
United States",650 870 1000,calithera.com,CALA,OTCMKTS,January - December,USD,,,US13089P5070,2836,,Common Stock,,,
BioELife Corp.,"BioELife Corp. operates in cannabinoid market. It offers cannabinoid products, such as combo adult gummies with chirorub, combo tincture with chirorub, intensive relief rub, tinctures, adult gummies, premium pre-rolls, and flowers.
The company was formerly known as US Lithium Corp. and changed its name to BioELife Corp. in March 2020.
The company was founded in 2006 and is based in Seal Beach, California.",Data/company_logos_stock_analysis\BioELife_Corp._logo.png,https://stockanalysis.com/quote/otc/LITH/,United States,2006,Drug Manufacturers - Specialty & Generic,Healthcare,1,Gregory Rotelli,"12340 Seal Beach Boulevard
Seal Beach, Nevada 90740
United States",702-866-2500,bioelife.com,LITH,OTCMKTS,January - December,USD,,,US90351E2046,2833,,Common Stock,,,
"Tengion, Inc.","Tengion, Inc. operates as a regenerative medicine company.
The company focuses on discovering, developing, manufacturing, and commercializing a range of neo-organs or products composed of living cells with or without synthetic or natural materials that are implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.
Its product portfolio includes Neo-Kidney Augment to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease; and Neo-Urinary Conduit, which is in Phase I clinical trial and used to replace the use of bowel tissue in bladder cancer patients requiring a non-continent urinary diversion after bladder removal surgery.
The company has a license agreement with Children’s Medical Center Corporation (CMCC) for the license of certain patent rights and intellectual property rights owned or controlled by CMCC related to tissue engineering technology.
Tengion, Inc. was founded in 2003 and is headquartered in Winston-Salem, North Carolina. On December 29, 2014, Tengion, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.","Data/company_logos_stock_analysis\Tengion,_Inc._logo.png",https://stockanalysis.com/quote/otc/TNGNQ/,United States,2003,Biotechnology,Healthcare,26,,"3929 Westpoint Boulevard
Winston-Salem, Delaware 27103
United States",336-722-5855,,TNGNQ,OTCMKTS,January - December,USD,,,US88034G2084,2836,,,,,
Clever Leaves Holdings Inc.,"Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries.
The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally.
The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States.
It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers.
The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.",Data/company_logos_stock_analysis\Clever_Leaves_Holdings_Inc._logo.png,https://stockanalysis.com/quote/otc/CLVR/,Canada,2017,Drug Manufacturers - Specialty & Generic,Healthcare,296,Andres Fajardo,"Bodega 19-B, Parque Ind. Tibitoc P.H
Tocancipá, British Columbia 251017
Colombia",561 634 7430,cleverleaves.com,CLVR,OTCMKTS,January - December,USD,,,CA1867601041,2833,,,,,
Bhang Inc.,"Bhang Inc. operates as a cannabis consumer packaged goods company.
It offers cannabis; hempderived cannabidiol; and terpene products, including chocolates, pre-rolls, vapes, gums, beverages, and gummies.
Its portfolio of products includes milk chocolate, ice milk chocolate, caramel mocha milk chocolate, cherries and cream milk chocolate, caramel dark chocolate, dark chocolate, fire dark chocolate, blueberry dark chocolate, fried chicken and cola dark chocolate, toffee and salt dark chocolate, italian espresso dark chocolate, cookies and cream white chocolate, and white toast white chocolate bars.
The company produces and distributes cannabis-infused products through partners and licensees that are distributed worldwide.
Bhang Inc. is based in Toronto, Canada.",Data/company_logos_stock_analysis\Bhang_Inc._logo.png,https://stockanalysis.com/quote/otc/BHNGF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,,John Simmonds,"40 King Street West
Toronto, Ontario M5H 3S1
Canada",,bhangnation.com,BHNGF,OTCMKTS,January - December,USD,,,CA08862K1057,2834,,,,,
Q BioMed Inc.,"Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.
The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain.
It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer.
Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others.
The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015.
Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.",Data/company_logos_stock_analysis\Q_BioMed_Inc._logo.png,https://stockanalysis.com/quote/otc/QBIO/,United States,2013,Biotechnology,Healthcare,,Denis Corin,"366 Madison Avenue
New York, Nevada 10017
United States",212 588 0022,qbiomed.com,QBIO,OTCMKTS,December - November,USD,,,US74736N1054,2836,,Common Stock,,,
"Stem Holdings, Inc.","Stem Holdings, Inc. does not have significant operations.
Previously, the company operated as a vertically-integrated cannabis products and technology company.
Its brands include TJ’s Gardens, TravisxJames, and Yerba Buena flower and extracts; Cannavor edible confections; and e-commerce delivery platforms provided direct-to consumer proprietary logistics and an omnichannel UX (user experience)/CX (customer experience).
The company was incorporated in 2016 and is headquartered in Boca Raton, Florida.","Data/company_logos_stock_analysis\Stem_Holdings,_Inc._logo.png",https://stockanalysis.com/quote/otc/STMH/,United States,2016,Drug Manufacturers - Specialty & Generic,Healthcare,75,Matthew Cohen,"2201 NW Corporate Boulevard
Boca Raton, Nevada 33431
United States",561 948 5410,stemholdings.com,STMH,OTCMKTS,October - September,USD,,,US85858U1079,6512,,Common Stock,,,
"Kaleido Biosciences, Inc.","Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies.
The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease.
It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases.
The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen.
Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.","Data/company_logos_stock_analysis\Kaleido_Biosciences,_Inc._logo.png",https://stockanalysis.com/quote/otc/KLDO/,United States,2015,Biotechnology,Healthcare,76,,"65 Hayden Avenue
Lexington, Delaware 02421
United States",617 674 9000,kaleido.com,KLDO,OTCMKTS,January - December,USD,,,US4833471000,2836,,Common Stock,,,
"Anthera Pharmaceuticals, Inc.","Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs.
It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.
The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.","Data/company_logos_stock_analysis\Anthera_Pharmaceuticals,_Inc._logo.png",https://stockanalysis.com/quote/otc/ANTH/,United States,2004,Biotechnology,Healthcare,21,John Thompson,"The Pennzoil Building
Houston, Delaware 77002
United States",410 350 1839,anthera.com,ANTH,OTCMKTS,January - December,USD,,,US03674U3005,2836,,Common Stock,,,
TetraLogic Pharmaceuticals Corporation,"TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases.
It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells.
SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma.
TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease.
The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006.
TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.",Data/company_logos_stock_analysis\TetraLogic_Pharmaceuticals_Corporation_logo.png,https://stockanalysis.com/quote/otc/TLOG/,United States,2001,Biotechnology,Healthcare,30,,"343 Phoenixville Pike
Malvern, Delaware 19355
United States",610 889 9900,tetralogicpharma.com,TLOG,OTCMKTS,January - December,USD,,,US88165U1097,2836,,,,,
"Eloxx Pharmaceuticals, Inc.","Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases.
Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.
The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology.
Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.","Data/company_logos_stock_analysis\Eloxx_Pharmaceuticals,_Inc._logo.png",https://stockanalysis.com/quote/otc/ELOX/,United States,2013,Biotechnology,Healthcare,18,Sumit Aggarwal,"480 Arsenal Way
Watertown, Delaware 02472
United States",781 577 5300,eloxxpharma.com,ELOX,OTCMKTS,January - December,USD,,,US29014R1032,2836,,,,,
"Poniard Pharmaceuticals, Inc.","Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics.
Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers.
The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors.
The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006.
Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.","Data/company_logos_stock_analysis\Poniard_Pharmaceuticals,_Inc._logo.png",https://stockanalysis.com/quote/otc/PARD/,United States,1984,Biotechnology,Healthcare,8,,"300 Elliott Avenue West
Seattle, Washington 98119
United States",206 281 7001,,PARD,OTCMKTS,January - December,USD,,,US7324494001,2835,,,,,
CannAmerica Brands Corp.,"CannAmerica Brands Corp. owns a portfolio of brands of medical cannabis and recreational cannabis products.
The company primarily builds and maximizes the value of its brands by promoting, marketing, and licensing brands through various distribution channels, including dispensaries, wholesalers, and distributors in the states of Colorado, Nevada, Oklahoma, and Massachusetts.
It offers cannabis infused gummy products, disposable vape pens, distillate droppers, and shatter and wax concentrate products under the CannAmerica brand.
The company is headquartered in Vancouver, Canada.",Data/company_logos_stock_analysis\CannAmerica_Brands_Corp._logo.png,https://stockanalysis.com/quote/otc/CNNXF/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,,,"595 Howe Street
Vancouver, British Columbia V6C 2T5
Canada",,cannamericabrands.com,CNNXF,OTCMKTS,April - March,CAD,,,CA13766C1005,2833,,,,,
"Acreage Holdings, Inc.","Acreage Holdings, Inc. operates in cannabis industry in the United States.
It cultivates and processes cannabis plants; manufactures branded consumer products; distributes cannabis flower and manufactured products; and retails dosable cannabis products to consumers.
The company serves medical and adult recreational use customers in Connecticut, Illinois, Maine, Massachusetts, New Jersey, New York, Ohio, and Pennsylvania under the The Botanist, Prime, and Superflux brands.
Acreage Holdings, Inc. was founded in 2011 and is headquartered in New York, New York.","Data/company_logos_stock_analysis\Acreage_Holdings,_Inc._logo.png",https://stockanalysis.com/quote/otc/ACRHF/,Canada,2011,Drug Manufacturers - Specialty & Generic,Healthcare,888,Dennis Curran,"366 Madison Avenue
New York, British Columbia 10017
United States",646 600 9181,acreageholdings.com,ACRHF,OTCMKTS,January - December,USD,,,CA00489Y6001,2834,,,,,
Eli Lilly and Company,"Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache.
Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis.
It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain.
It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes.
The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",Data/company_logos_stock_analysis\Eli_Lilly_and_Company_logo.svg,https://stockanalysis.com/stocks/lly/,United States,1876,Drug Manufacturers - General,Healthcare,"43,000",David Ricks,"Lilly Corporate Center
Indianapolis, Indiana 46285
United States",317 276 2000,lilly.com,LLY,NYSE,January - December,USD,0000059478,532457108,US5324571083,2834,,Common Stock,35-0470950,,
Novo Nordisk A/S,"Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application.
The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases; and with Valo Health, Inc. to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease.
Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",,https://stockanalysis.com/stocks/nvo/,Denmark,1923,Drug Manufacturers - General,Healthcare,"64,319",Lars Jorgensen,"Novo Alle 1
Bagsvaerd, 2880
Denmark",45 44 44 88 88,novonordisk.com,NVO,NYSE,January - December,DKK,0000353278,670100205,US6701002056,2834,,,,,
Johnson & Johnson,"Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.
The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke.
this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery.
It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics.
The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis.
Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",Data/company_logos_stock_analysis\Johnson_&_Johnson_logo.svg,https://stockanalysis.com/stocks/jnj/,United States,1886,Drug Manufacturers - General,Healthcare,"131,900",Joaquin Duato,"One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
United States",732 524 0400,jnj.com,JNJ,NYSE,January - December,USD,0000200406,478160104,US4781601046,2834,"Sep 24, 1944",Common Stock,22-1024240,,
AbbVie Inc.,"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products.
Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism.
It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP.
The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.",Data/company_logos_stock_analysis\AbbVie_Inc._logo.svg,https://stockanalysis.com/stocks/abbv/,United States,2012,Drug Manufacturers - General,Healthcare,"50,000",Robert Michael,"1 North Waukegan Road
North Chicago, Illinois 60064-6400
United States",847 932 7900,abbvie.com,ABBV,NYSE,January - December,USD,0001551152,00287Y109,US00287Y1091,2834,,Common Stock,32-0375147,,
AstraZeneca PLC,"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.
The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.
It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",Data/company_logos_stock_analysis\AstraZeneca_PLC_logo.svg,https://stockanalysis.com/stocks/azn/,United Kingdom,1992,Drug Manufacturers - General,Healthcare,"89,900",Pascal Soriot,"1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge, CB2 0AA
United Kingdom",44 20 3749 5000,astrazeneca.com,AZN,NASDAQ,January - December,USD,0000901832,046353108,US0463531089,2834,"May 12, 1993",,,,
Novartis AG,"Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.
It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria.
It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies.
The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",Data/company_logos_stock_analysis\Novartis_AG_logo.svg,https://stockanalysis.com/stocks/nvs/,Switzerland,1895,Drug Manufacturers - General,Healthcare,"76,057",Vasant Narasimhan,"Lichtstrasse 35
Basel, 4056
Switzerland",41 61 324 1111,novartis.com,NVS,NYSE,January - December,USD,0001114448,66987V109,US66987V1098,2834,"Nov 18, 1991",,,,
"Merck & Co., Inc.","Merck & Co., Inc. operates as a healthcare company worldwide.
It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.
vIt has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications.
It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.
The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.","Data/company_logos_stock_analysis\Merck_&_Co.,_Inc._logo.svg",https://stockanalysis.com/stocks/mrk/,United States,2000,Drug Manufacturers - General,Healthcare,"72,000",Robert Davis,"126 East Lincoln Avenue
Rahway, New Jersey 07065
United States",908 740 4000,merck.com,MRK,NYSE,January - December,USD,0000310158,58933Y105,US58933Y1055,2834,,Common Stock,22-1918501,,
Pfizer Inc.,"Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally.
The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands.
In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems.
The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",Data/company_logos_stock_analysis\Pfizer_Inc._logo.svg,https://stockanalysis.com/stocks/pfe/,United States,1849,Drug Manufacturers - General,Healthcare,"88,000",Albert Bourla,"66 Hudson Boulevard East
New York, New York 10001-2192
United States",212 733 2323,pfizer.com,PFE,NYSE,January - December,USD,0000078003,717081103,US7170811035,2834,,Common Stock,13-5315170,,
Bristol-Myers Squibb Company,"Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases.
The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis.
In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer.
It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.",Data/company_logos_stock_analysis\Bristol-Myers_Squibb_Company_logo.svg,https://stockanalysis.com/stocks/bmy/,United States,1887,Drug Manufacturers - General,Healthcare,"34,100",Christopher Boerner,"Route 206 & Province Line Road
Princeton, New Jersey 08543
United States",609 252 4621,bms.com,BMY,NYSE,January - December,USD,0000014272,110122108,US1101221083,2834,,Common Stock,22-0790350,,
Amgen Inc.,"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.
The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels.
The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development.
Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",Data/company_logos_stock_analysis\Amgen_Inc._logo.svg,https://stockanalysis.com/stocks/amgn/,United States,1980,Drug Manufacturers - General,Healthcare,"26,700",Robert Bradway,"One Amgen Center Drive
Thousand Oaks, California 91320-1799
United States",805 447 1000,amgen.com,AMGN,NASDAQ,January - December,USD,0000318154,031162100,US0311621009,2836,,Common Stock,95-3540776,,
Sanofi,"Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.
It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines.
The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema.
Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer.
Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies.
It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab.
The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",Data/company_logos_stock_analysis\Sanofi_logo.svg,https://stockanalysis.com/stocks/sny/,France,1994,Drug Manufacturers - General,Healthcare,"86,088",Paul Hudson,"46, avenue de la Grande Armée,
Paris, 75017
France",33 1 53 77 40 00,sanofi.com,SNY,NASDAQ,January - December,EUR,0001121404,80105N105,US80105N1054,2834,,,13-3529324,,
"Gilead Sciences, Inc.","Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies.
The company was incorporated in 1987 and is headquartered in Foster City, California.","Data/company_logos_stock_analysis\Gilead_Sciences,_Inc._logo.svg",https://stockanalysis.com/stocks/gild/,United States,1987,Drug Manufacturers - General,Healthcare,"18,000",Daniel P. O'Day,"333 Lakeside Drive
Foster City, California 94404
United States",650 574 3000,gilead.com,GILD,NASDAQ,January - December,USD,0000882095,375558103,US3755581036,2836,"Jan 22, 1992",Common Stock,94-3047598,,
GSK plc,"GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.
It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson’s disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines.
The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.",Data/company_logos_stock_analysis\GSK_plc_logo.svg,https://stockanalysis.com/stocks/gsk/,United Kingdom,1715,Drug Manufacturers - General,Healthcare,"70,212",Emma Walmsley,"980 Great West Road, Middlesex
Brentford, TW8 9GS
United Kingdom",44 20 8047 5000,gsk.com,GSK,NYSE,January - December,GBP,0001131399,37733W204,US37733W2044,2834,,,,,
Organon & Co.,"Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally.
Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
The company’s biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.
It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis.
The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss.
It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions.
The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.",Data/company_logos_stock_analysis\Organon_&_Co._logo.svg,https://stockanalysis.com/stocks/ogn/,United States,1923,Drug Manufacturers - General,Healthcare,"10,000",Kevin Ali,"30 Hudson Street, Floor 33
Jersey City, New Jersey 07302
United States",551 430 6900,organon.com,OGN,NYSE,January - December,USD,0001821825,68622V106,US68622V1061,2834,,Common Stock,46-4838035,,
"Grifols, S.A.","Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.
It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development.
Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG.
It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies.
The company was founded in 1909 and is headquartered in Barcelona, Spain.","Data/company_logos_stock_analysis\Grifols,_S.A._logo.svg",https://stockanalysis.com/stocks/grfs/,Spain,1940,Drug Manufacturers - General,Healthcare,"23,737",Jose Ignacio Abia Buenache,"Avinguda de la Generalitat, 152, Parc empresarial Can Sant Joan
Barcelona, 08174
Spain",34 935 712 200,grifols.com,GRFS,NASDAQ,January - December,EUR,0001438569,398438408,US3984384087,2834,"May 17, 2006",,,,
Biogen Inc.,"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.
In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development.
It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain.
The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Biogen_Inc._logo.svg,https://stockanalysis.com/stocks/biib/,United States,1978,Drug Manufacturers - General,Healthcare,"7,570",Christopher Viehbacher,"225 Binney Street
Cambridge, Massachusetts 02142
United States",617 679 2000,biogen.com,BIIB,NASDAQ,January - December,USD,0000875045,09062X103,US09062X1037,2836,"Sep 16, 1991",Common Stock,33-0112644,,
Amarin Corporation plc,"Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates.
The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa.
The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999.
Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.",Data/company_logos_stock_analysis\Amarin_Corporation_plc_logo.svg,https://stockanalysis.com/stocks/amrn/,Ireland,1989,Drug Manufacturers - General,Healthcare,275,Aaron Berg,"Iconic Offices, The Greenway, Block C Ardilaun Court
Dublin, 112-114
Ireland",353 0 166 99020,amarincorp.com,AMRN,NASDAQ,January - December,USD,0000897448,023111206,US0231112063,2834,"Apr 1, 1993",,,,
Scilex Holding Company,"Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia.
The company has a collaboration with ACEA Therapeutics to Support the Expansion of ZTlido program. Scilex Holding Company is headquartered in Palo Alto, California.",Data/company_logos_stock_analysis\Scilex_Holding_Company_logo.svg,https://stockanalysis.com/stocks/sclx/,United States,2011,Drug Manufacturers - General,Healthcare,105,Jaisim Shah,"960 San Antonio Road
Palo Alto, California 94303
United States",650 516 4310,scilexholding.com,SCLX,NASDAQ,January - December,USD,0001820190,80880W106,US80880W1062,2836,,Common Stock,,,
"MIRA Pharmaceuticals, Inc.","MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.
In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.","Data/company_logos_stock_analysis\MIRA_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/mira/,United States,2020,Drug Manufacturers - General,Healthcare,3,Erez Aminov,"1200 Brickell Avenue, Suite 1950 #1183
Miami, Florida 32183
United States",786 432 9792,mirapharmaceuticals.com,MIRA,NASDAQ,January - December,USD,0001904286,60458C104,US60458C1045,2834,"Aug 3, 2023",Common Stock,85-3354547,$7.00,
